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Abstract 
Bipolar disorder (BD) is a common highly heritable disorder. The calcium channel 
gene family has been widely implicated in BD aetiology and these genes include 
CACNA1C, and CACNG4. The association signal for CACNA1C with BD is located in 
the middle of the third intron of the gene. CACNG4 encodes a transmembrane 
AMPA receptor regulator that is involved in trafficking AMPA receptors to the 
neuronal post-synaptic density.  
High-resolution melting curve (HRM) analysis and whole genome sequencing 
(WGS) methods were used to identify functional variants in calcium channels 
genes in the UCL BD cohort. Variants that were predicted to impact gene 
regulation, transcription or to be damaging to protein structure were genotyped in 
the larger UCL BD and control cohort. 
HRM analysis identified 26 calcium channel gene variants. These included two 
non-synonymous CACNG4 variants that were associated with mental illness 
(rs371128228, p=1.05x10-4, OR=4.39 and 17:65026851 (C/T), p=5x10-4, OR=9.52). 
Fluorescent activated cell sorting analysis was used to determine the effect of 
rs371128228 on trafficking of GluR1 and GluR2 to the cell surface. This analysis 
demonstrated that the risk allele of rs371128228 significantly decreased cell 
surface trafficking of GluR1 (p=0.026) but no effect was observed on GluR2 
trafficking. 
WGS analysis of CACNA1C intron 3 identified two BD associated (p=0.015, 
OR=1.15) variants 105bp apart that were in complete LD. Both variants are 
predicted to create YY1 transcription factor binding sites. Luciferase reporter 
assays show a significant decrease in gene expression in the presence of both 
variants (p=0.004). Protein-DNA complex assays of the CACNA1C variants 
demonstrate increased nuclear proteins binding affinity for the variant alleles. 
If these calcium channel variants are confirmed to be important risk factors for BD 
they could be used as markers for personalised treatment or in the identification of 
genetic subtypes of BD or other psychiatric illness. 
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 Introduction Chapter 1
1.1 BIPOLAR DISORDER 
1.1.1 OVERVIEW  
Over the past decade there has been an effort to accurately estimate the frequency 
of mental disorders and their global burden. Calculations by the World Health 
Organisation (WHO) have identified BD as one of the top ten leading causes of 
work lost due to mental disability [1]. The European profile of prevention and 
promotion of mental health study (EuroPoPP-MH) states that there is a three-fold 
increase in the number of days lost at work if an individual suffers from a mental 
health disorder compared to a healthy individual [2]. Therefore mental disorders 
should be considered a high priority health challenge for the 21st century [3, 4]. 
Wittchen et al. state in their 2010 report, entitled ‘The size and burden of mental 
disorders and other disorders of the brain in Europe 2010’, that each year 38.2% 
of adults in the European population (18-65 years old) suffer from a mental health 
disorder [4]. This places a cost of approximately €798 billion on the European 
economy [5]. Identification of factors which modulate an individual’s disease risk 
provides a platform from which to better understand individual predisposition, 
and design specialised and preventative treatments, extending as far as targeting 
individuals prior to the manifestation of mental health disorders. 
Bipolar Affective Disorder (BD) is fundamentally a disorder of mood, with a 
lifetime prevalence of approximately 1% in the general population [6]. The term 
BD encompasses the central concept of the disorder, in which there is a fluctuation 
between euthymic states, mania and depression. Diagnosis of BD depends on the 
occurrence of two or more episodes of mania or hypomania [7]. The presence of 
depressive episodes is not a pre-requisite for BD diagnoses. Nevertheless, the 
majority of people with BD do experience depressive episodes during the course of 
their illness. The peak age of onset for the disorder is 25, with onset after the age of 
18 being considered typical. However, cases of early onset BD (13-18 years of age) 
and very early onset of below 13 years of age have been reported [8]. 
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Bipolar disorder encompasses a number of different cognitive, behavioural and 
affective symptoms (Figure 1). Mania is defined as an elevated or irritable mood 
that is prominent and sustained for a period of one week or more [7]. Symptoms of 
mania are not restricted to mood swings but encompass cognitive, physiological 
and behavioural changes. Manic symptoms can include an increase in energy and 
activity, rapid speech, racing thoughts, impaired judgement, insomnia and feelings 
of elation and grandiosity. Psychotic symptoms such as grandiose delusions and 
paranoid ideation are often part of manic episodes. The features of mania can 
severely affect an individual’s ability to function on a daily basis. Hypomania is a 
less severe form of mania, which lasts for a period of four days or more resulting in 
some interference to an individual’s daily life [7]. Depending on the classification 
system used, BD can be diagnosed by the occurrence of two or more episodes of 
mania/hypomania as mentioned previously. However, the usual course of BD is 
one of recurrent swings of mood between mania and depressive states, broken by 
periods of euthymia [6]. While mania may be the defining symptom of BD disorder, 
depression is the concept that is more widely known and understood. Depressive 
episodes are defined as persistent low moods lasting for a period of more than two 
weeks. During these episodes individuals may experience a loss of interest or 
pleasure in normal activities. Symptoms can include inability to sleep, a sense of 
hopelessness, suicidal ideation, fatigue, reduced self-confidence and social 
impairment [7]. While this list is not exhaustive, it incorporates the main features 
of a depressive episode (Figure 1). The full list of the International Classification 
Diseases-10 (ICD-10) criteria used to diagnose the different types of BD is given in 
Appendix I. 
The presence of psychotic symptoms represents a severe manifestation of BD and 
these are classified as being either mood congruent or mood incongruent. Mood 
congruency occurs when the symptoms are consistent with the individual’s 
current mood. Mania with mood congruent psychosis may present itself in 
symptoms such as grandiose delusions or hearing voices telling the subject that 
they have special powers. Mania with mood incongruent psychosis can be defined 
as the delusions not reflecting the manic state, such as hearing voices describing  
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Figure 1. Common symptoms of Bipolar Disorder. 
There are three categories of symptoms which occur during the course of BD, 
these are affective, behavioural and cognitive.  
neutral topics or delusions of reference [7]. Examples of mood congruent 
depressive psychosis are delusions of guilt, nihilistic delusions and delusions of 
bodily decay, also known as Cotard’s delusion [9]. Depressive episodes with mood 
incongruent psychosis manifest when the hallucinations do not exhibit affective 
content [7].  
Individuals suffering from BD often have comorbid alcohol or substance misuse 
disorders [10, 11]. It is not known if this association is secondary to the mood state 
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(ie. a coping mechanism in depression and/or decreased self-control during manic 
episodes), or due to shared etiological factors (including shared genetic risk). 
1.1.2 HISTORY AND CLASSIFICATION 
Descriptions of people suffering from psychiatric illnesses, and the familial nature 
of these disorders date back as far as Hippocrates (460-337 BCE) and the 
Hippocrates-Galen Humoral Theory [12]. This theory proposed that imbalance in 
bodily fluids, resulted in specific bodily disease. Imbalance of Hippocrates four 
‘humours’, yellow bile, black bile, phlegm and blood, was proposed as the cause of 
mood disorders and other illnesses. It can be argued that Hippocrates was the first 
individual to classify mental health disorders by differentiating the disorders 
melancholia and mania. 
The link between mania and melancholia was first made by the Greek physician 
Artaeus of Cappadocia (c. 30-90CE). Arteaus was a strong follower of Hippocrates’ 
teachings, and a member of a group called the ‘Eclectics’ [12]. Eclectics were 
defined by the multiple approaches they took to defining a disorder from both the 
observation of the disorder and application of philosophical theories. Artaeus 
produced very careful descriptions of mental health disorders in his books ‘On the 
Aetiology and Symptomatology of Chronic Diseases’ and ‘The Treatment of Chronic 
Diseases’ [13]. He described mania and melancholy as two distinct entities of the 
same disorder, as below. 
‘‘ ... I think that melancholia is the beginning and a part of mania...The development of 
a mania is really a worsening of the disease (melancholia) rather than a change into 
another disease...In most of them (melancholics) the sadness became better after 
various lengths of time and changed into happiness; the patients then developed a 
mania’’. Aretaeus of Cappadocia (30-90 CE) 
Artaeus, in agreement with Hipprocrates, stated that the disorders were biological 
in nature and were a result of disturbances in the mind and other organs. His 
classifications, albeit broader than today’s classification, were the first model for 
bipolarity. Artaeus was also the first to make the distinction between depression 
which was a result of innate biological imbalance, ‘melancholia’, and depression 
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which resulted from negative life experiences. In the second century, Alexander of 
Tralles (525-605 CE) first described the transition that can occur from melancholia 
to mania and stated that mania is a worse form of melancholia. He also linked 
melancholia to suicidality and homicidality [14]. 
Other descriptions of mood disorders can be found in both Chinese and Ayurvedic 
medical books [15]. One of the most influential books in Ayurvedic medicine; the 
Charaka Samhita, devotes a chapter to the discussion of insanity. In the 12th 
century BCE a description of Kuang, a disease which is characterised by irritable 
raving can be found. This is later linked to Dian, the disease of worry, withdrawal 
and depression in the medical text Classics of Difficulties and Spiritual Axis [16]. 
The delineation of BD as an independent disorder, separate from other depressive 
disorders and schizophrenia (SCZ), has its origins in the 19th century. In 1854 Jules 
Baillarger (1809-1890) and Jean Pierre Falret (1794-1870), independently 
introduced the idea of a “la folie á double forme” (madness dual form) or “folie 
circular” (circular madness) to the French Imperial Academy of Medicine in Paris 
[17]. These terms arose from the observation of patients in asylums who 
presented with alternating episodes of melancholy and mania. This pattern of 
variation in patients’ moods differentiated their illness quite distinctly from 
individuals suffering from depression alone. The idea, that mania and depression 
were two distinct states within one unitary disorder, echoed the ideas of Alexander 
of Tralles and Artaeus of Cappadoccia described centuries previously.  
The differentiation of BD from schizophrenia stems from Emil Kraepelin’s (1856-
1926) study and classification of psychiatric illnesses. During his lifetime Kraepelin 
published four editions of the Compendium der Psychiatrie in which he proposed 
that psychiatry was a branch of medical science and the manner by which 
psychiatric disorders were studied should be akin to the approach taken by the 
natural sciences. Studying the clinical course and manifestation of BD, Kraepelin 
noted that, unlike SCZ, the disorder was punctuated by periods of relative 
normality and symptom free intervals [18]. This led to the formation of what is 
known as the Kraepelin Dichotomy which denotes BD and SCZ as two separate 
disorders, each with their own disease progression and symptoms [19]. In 1899, 
Kraepelin coined the term manic depressive illness. The description of the 
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different disorders and the manner by which Kraepelin approached the study of 
such disorders paved the way for modern psychiatry. 
In 1953, Karl Kleist, a German neurologist and psychiatrist, coined the terms 
bipolar and unipolar. Kleist had similar views to Kraepelin and considered both 
bipolar and unipolar to be part of the same disorder. In 1957 Karl Lenord, Kleist’s 
student, proposed that unipolar and bipolar disorder were in fact separate entities. 
The definition of BD has continued to evolve and subtypes of BD have been 
proposed. 
Hypomania was originally described in 1881 by Erich Mendel but in the latter part 
of the 20th century it came to be seen as the defining feature of a milder form of BD. 
In 1976 Dunner proposed the subdivision of BD and its milder form, Bipolar type II 
(BD-II) [12]. 
1.1.3 DIAGNOSTIC CRITERIA 
Two main diagnostic classification systems are currently used in psychiatry. These 
are the ICD-10 from the WHO [7] and the Diagnostic and Statistical Manual of 
Mental Disorders, 5th edition, (DSM-V) from the American Psychiatric Association 
(APA) [20]. A third system is currently under development, the Research Domain 
Criteria from the National Institute of Mental Health (NIMH) [21].  
Jacques Bertillion (1851-1922), of the International Statistical Institute, devised a 
classification system based on causes of death, called the Bertillon Classification of 
Causes of Death [22]. Bertillion’s classification system contained three lists of 44, 
99 and 161 conditions upon which the categorisation of causes of deaths and other 
maladies could be made. This system was adopted by numerous countries for 
disease and death classification. It became known as the ICD in later years and was 
revised every ten years. Several changes occurred over these years including the 
expansion of disease classification. The sixth revision of the ICD document (ICD-6) 
was undertaken by the WHO and was published in 1948. The ICD-6 was expanded 
into two books and for the first time contained separate sections for the 
classifications of mental health disorders. The current edition of the ICD, is the 
ICD-10 [7]. 
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The second system which is primarily used in North America is the DSM. The DSM 
was first published in 1952 by the APA and incorporated a number of different 
classifications from the ICD-6. The DSM-I expanded on the categories established 
in the ICD-6 and aimed to provide a classification system of clinical utility 
(http://www.psychiatry.org/practice/dsm/dsm-history-of-the-manual). The 
following example shows how the classification system has evolved according to 
the contemporary aetiological theory. The term ‘reaction’ was used in the DSM-I, as 
mental health disorders were often thought to arise in response to life events. This 
term ‘reaction’ was omitted from the DSM-II, when more biological theories of 
aetiology held sway. There have been many revisions of the DSM, and the current 
edition is DSM-V, which was released by the APA in May of 2013. The next 
publication of the DSM is expected in 2017, in which revision of the classification 
system based on genetic and neuroscience findings are planned. 
In relation to BD, there are differences in the diagnostic criteria between the ICD-
10 and the DSM-V. The DSM is a United States based classification system, whereas 
the ICD is a core function of the WHO which has been ratified by all 193 WHO 
member countries. DSM-V makes the distinction between BD-I and BD-II whereas 
no such distinction is seen in the ICD-10. In the DSM-V classification, at least one 
manic episode is required for the diagnosis of BD-I, whereas at least one episode of 
hypomania and a major depressive episode is required for a BD-II diagnosis [20]. 
In ICD-10 a distinction between mania and hypomania is made, but BD is not 
divided into BD-I and BD-II. ICD-10 tends to be employed in more varied 
environments than the DSM, which is utilised primarily by professional groups and 
highly trained individuals [21].  
As mentioned previously, the presence of a manic episode is an important criterion 
for BD diagnosis. Approximately 40% of individuals with BD are initially diagnosed 
with unipolar depression, as it is quite common for an individual to suffer many 
depressive episodes prior to their first manic episode [23].  
The third classification system is currently under development. Since 2009, the 
NIMH has been creating a new system to “Develop, for research purposes, new 
ways of classifying mental disorders based on behavioural dimensions and 
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neurobiological measures.” [21]. This has been termed the Research Domain 
Criteria (RDoc).  
The RDoc will focus on incorporating findings from scientific research in a manner 
that will allow for a higher degree of sub classification, and less reliance on 
clinically derived symptom clusters. The RDoc aims to facilitate the elucidation of 
pathological mechanisms underlying mental disorders. Specifically, the RDoc aims 
to map disorders to neural circuits for specific behavioural functions [21]. 
Cuthbert et al. set out the four main challenges that need to be addressed to 
achieve the RDoc.  
1. The bringing together of experts from various specialised fields in order to 
accurately identify “fundamental behavioural components” that underlie 
mental health disorders. 
2. Create methods to determine how far the disruption to these fundamental 
behavioural components extends, and what can be considered as atypical 
and what will be considered as pathological. 
3. Develop methods to accurately measure these disruptions for clinical 
diagnoses. 
4. Integrate research from a variety of fields including genetics and 
neuroscience which contribute to these genetic disorders. 
The RDoc is not intended to be used, at least initially, for routine clinical diagnoses 
but rather as a classification system for research. It is the first system to attempt to 
fully incorporate biological research into classification. The DSM-V has made a 
move towards doing this, but only to a limited extent [24]. Currently the ICD-10 
and DSM-V do not map well onto genetic, system biology or neuroscience findings 
[21].  
Revisions to disease classification systems can have a large impact on patient 
diagnosis. Given the breadth and heterogeneity of symptoms associated with BD, 
until the formalisation of the bipolar-unipolar distinction in the DSM-III, many 
individuals were misdiagnosed and not identified until later in life as suffering 
from BD [7]. Stoll et al., conducted a study from 1972 until late 1988 which looked 
at discharge diagnoses for individuals in six psychiatric treatment centres in the 
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Figure 2. Weighted mean for discharge diagnoses in 6 psychiatric treatment 
centres in the United States between 1972-1988.  
Image taken from [25]. 
United States [25]. During this period, the DSM-III was released, which contained 
changes to disorder classifications. In addition to the formalised distinction 
between unipolar disorder and bipolar disorder, the broad category of 
schizophrenia was further refined. The results from this study illustrate the impact 
of the changes to the diagnostic criteria on the incidence of the two disorders 
(Figure 2). The refining of the SCZ disorder classification led to a drop in the 
number of individuals diagnosed with SCZ. Conversely, there was a large increase 
in the incidence of major affective disorders.  
The pathology of BD and other psychiatric illnesses have proved elusive. The study 
of genetic effects in psychiatry is helping to shed light on the underlying 
mechanisms of the disease. The shift from basing diagnoses on clinical criteria to 
diagnoses based on underlying biological pathology has the potential to provide 
more accurate diagnoses for patients.  
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1.1.4 BIPOLAR DISORDER SUBTYPES 
As discussed in the section above, there are two main subtypes of Bipolar Disorder. 
These are Bipolar Disorder type 1 (BD-I) and Bipolar Disorder type 2 (BD-II). For 
an individual to be diagnosed with BD-I under the DSM-V system, they must meet 
the criteria of presenting with a prominent manic episode sustained for a period of 
seven days of more. BD-II is characterised by depressive episodes and less extreme 
periods of mania, referred to as hypomania. These can occur more frequently than 
manic episodes but are not as severe (Figure 3). Less common subtypes of BD 
include rapid cycling BD, more than four depressive episodes per year, and mixed 
affective disorder [26].  
Risk of suicide in BD is greatly elevated during depressive periods and has a higher 
prevalence during disease course in BD-II (24%) than in BD-I (17%) [27]. In 2007, 
it was reported that whilst the international population average for suicide was 
0.017%, the annual number of individuals with BD who attempted suicide was 23-
fold higher than this (around 0.4%) [28].  
The Standardised Mortality Ratio (SMR) has been used in estimates for BD. SMR is 
used in epidemiology to measure the increase or decrease in the mortality of a 
study cohort. The SMR, for suicide alone, measures the ratio of expected numbers 
of suicides versus observed suicides in the study cohort. SMR for BD is 15.0 
(males) and 22.4 (females) for individuals who had been previously hospitalised 
[29, 30]. A recent meta-analysis, conducted by the International Society for Bipolar 
Disorders Task Force on Suicide [31], looked at a number of the variables in people 
with BD who had attempted suicide and died by suicide. Some of the key risk 
factors identified were depressive polarity of first episode and depressive polarity 
of last or more recent episode, earlier age of illness onset, and any co-morbid 
substance abuse. Given the criteria for BD, as defined in the ICD-10, it is likely that 
there will be a delay in diagnosis if the first mood disturbance is depressive. This 
lag time between diagnosis of BD and prescription of mood stabilising treatment 
could be responsible for the increased risk of suicide associated with the initial 
depressive episode. A study conducted by Angst et al., followed an initial cohort of 
406 individuals suffering from BD over a period of 34-38 years in order to assess 
the SMR of BD [32]. They were followed prospectively for 22 years after which 
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Figure 3. Mood changes in BD-I and BD-II over time. 
Fluctuations between moods occurs more frequently in BD-II but has a less severe 
impact on an individual’s daily functioning than the manic episodes in BD-I. M, 
mania, HM, Hypomania, D, Depression. Image adapted from [33]. 
mortality was assessed for 99% of the cohort, at this stage 76% of participants had 
died. The cohort consisted of individuals whom had been hospitalised, 
representing a group of individuals suffering from a more severe form of BD. These 
therefore may not be indicative of the general population of individuals with BD. 
Angst et al. showed that patients who received long term treatment were less 
likely to commit suicide. In addition to this they showed that suicide mortality 
(SMR=18.04) was similar to the SMR described previously [29, 30]. 
Depressive episodes and manic episodes both have a marked effect on the quality 
of life of an individual suffering from BD. Manic episodes often result in the forced 
hospitalisation of individuals [34]. Depressive episodes have been linked to rates 
of suicide in individuals with BD which are increased compared to the general 
population [35]. These results strongly reinforce the idea that delineation of 
disorder mechanisms and early diagnoses is of paramount importance in the field 
of psychiatric illness. 
1.1.4.1 DISEASE AETIOLOGY 
BD is a complex disorder the aetiology of which is far from being fully delineated. 
The nature of this complexity holds true for the underpinnings of the disorder. The 
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aim of this section is to provide a brief summary of our aetiological understanding 
of BD. I will discuss risk factors and pathological associations from the 
demographic down to the molecular. Three main topics will be covered in this 
section, environmental risk factors, neuropathological features and biochemical 
changes.  
There has long been the argument between geneticists and other fields of study 
about whether the cause of the disorder results more from environmental stresses 
than genetics. Genetic effects are not fully penetrant as 100% concordance rates 
are not seen between monozygotic twins [36]. Current evidence points towards a 
joint effect where some environmental stress factors, combined with genetic 
variation result in disease manifestation. 
1.1.4.2 ENVIRONMENT RISK FACTORS FOR BIPOLAR DISORDER 
Environmental impacts and stresses that occur during an individual’s lifetime can 
have resounding effects on their life. Reported risk factors for BD include, prenatal 
stress (infection), perinatal stress (hypoxia), childhood maltreatment, traumatic 
life events and environmental toxins such as drug use. 
Bipolar Disorder and SCZ share a number of similarities in terms of cognitive 
dysfunction [37], anatomical changes [38], and genetic risk factors [39]. 
Increasingly SCZ is coming to be conceptualised as a neurodevelopmental disorder. 
Prenatal and perinatal factors have been shown to be associated with an increased 
risk of developing SCZ [40]. The similarities between BD and SCZ have led to the 
suggestion that BD may also be considered as a neurodevelopmental disorder [41]. 
While evidence for the association between BD and prenatal and perinatal stress is 
less consistent than with SCZ, a number of epidemiological studies proposed that 
pre- and peri-natal stresses may contribute an increased risk of developing BD. 
Some of these early life environmental risk factors include season of birth [42], 
specific obstetric complications [43] and inadequate prenatal nutrition [44]. 
Consistent evidence from multiple studies has implicated preterm birth as a risk 
factor for BD [45]. A study conducted by Nosarti et al. demonstrated that 
individuals with a gestational age of between 32 to 36 weeks were 2.7 (95% CI, 
1.6-4.5) times more likely to be diagnosed with BD in adulthood and individuals 
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born prior to 32 weeks were 7.4 (95% CI, 2.7-20.6) times more likely to develop 
BD compared with term births (37-41 weeks) [46]. Adverse experiences during 
childhood also comprise an environmental risk factor that is associated with the 
risk of BD, its severity and the age of illness onset. The most consistent forms of 
traumas experienced within a cohort of early onset BD are that of physical and 
sexual abuse. A correlation has been observed between severity of abuse and the 
complexity of psychopathological manifestation such as lifetime suicide attempt 
(OR 1.466, 95% 1.095-1.964) and rapid cycling (OR 1.476, 95% CI 1.073-2.030) 
[47]. Verbal abuse, including that from parents and social peers in the form of 
bullying has also been implicated in the development and progression of BD [48]. 
Substance abuse is common in individuals with psychiatric disorders. Alcohol 
dependence syndrome (ADS) and BD are often co-morbid. While the directionally 
remains uncertain, study estimates show co-morbid rates of BD and ADS to be 
between 6-69%, with an average rate of 30% per study [49]. Cassidy et al. who 
studied substance abuse histories of 392 patients hospitalised following manic or 
mixed episodes of BD, reported comorbidity rates of 14-60% for drug abuse, with a 
higher rate of substance abuse observed in males with BD versus females. The rate 
of alcohol abuse was 59.7% in males and 37.8% in females with BD. In a similar 
manner the rate of drug abuse for males with BD was 54.5% versus 33.8% in 
females with BD [49]. Substance abuse prior to onset of disease is associated with 
a higher risk of BD. A bi-directional association between cannabis use and the 
presence of BD has recently been studied by Feingold et al. [50]. They report an 
association between frequent use of cannabis (from once weekly to daily/almost 
daily) and incidence of BD, but not a correlation between increased incidence of 
episodes in BD. 
Both environmental risk factors and genetic risks will be mediated through 
biological substrates which will be discussed in the following sections. 
1.1.4.3 NEUROPATHOLOGY 
Neuropsychological impairments and alterations to brain structure have been long 
associated with BD. The onset of BD, peaking after adolescence, closely correlates 
with brain development during this period [51]. During adolescence brain 
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development slows and the brain undergoes goes high rates of synaptic pruning. 
There have been a number of cognitive studies undertaken on BD to determine the 
extent of neuropsychological impairment on executive function. Cognitive function 
tests cover seven domains of executive functioning in the brain including 
processing speed, verbal comprehension, working memory, verbal learning and 
memory, reasoning and problem solving and verbal comprehension. 
Deficits have been reported in individuals with BD in executive functioning, 
processing speed and memory [52]. Pre-morbid studies on BD cognitive 
impairment have reported significantly lower effect sizes than seen in SCZ. Effect 
sizes between -1.0 and 1.5 are typically observed in SCZ, while lower effect sizes in 
BD are estimated to be between -0.5 and -0.7 [52, 53]. Premorbid testing of 
childhood cognition demonstrates subtle differences between children who later 
develop BD and healthy controls. These subtle differences show that 
approximately 23% of children who later develop BD have neuropsychological 
impairment, defined as achieving scores below the 10th percentile [54].  
In BD, a more severe level of cognitive dysfunction has been found in patients who 
have a history of psychosis [55]. This level of impairment is closer to the levels 
exhibited by those individuals with SCZ than BD patients who exhibit no psychotic 
features. Cognitive impairment in individuals with SCZ is virtually 
indistinguishable to those found in people with psychotic BD [37, 56]. The similar 
cognitive signatures in SCZ and BD indicate that in both groups of patients the 
same underlying cognitive systems are perturbed. 
The natural history of cognitive impairment following first manic or depressive 
episode of BD has also been studied. Emerging evidence suggests that unlike SCZ, 
where impairment is more severe and pervasive throughout the course of an 
individual’s lifetime, cognitive impairment in BD is less severe. The deterioration is 
more pronounced in individuals who have a history of psychotic symptoms [57]. 
Dickerson et al. report deficits in overall cognitive abilities and executive 
functioning in 60 BD patients in the two years following disease onset [58]. 
Additionally, Zanelli et al. [57] describe an observable difference in verbal fluency 
and verbal memory between BD patients and healthy volunteers with no history of 
psychiatric illness. Following illness onset there is a marked difference between 
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the course of cognitive impairment in individuals who have a history of psychosis 
versus those where psychosis is absent [37].  
1.1.4.4 NEUROANATOMICAL  
The first volumetric association between brain regions and bipolar disorder came 
from a report by Rieder et al. in 1983 [59]. This computed topographic study 
showed a significant correlation between age and ventricular to brain ratios in a 
group of BD patients when compared to individuals with schizophrenia and schizo-
affective disorder. MRI studies have shown differences in the size of the lateral 
ventricle volumes in BD patients compared to healthy controls [60]. The 
alterations in size also differ in and between age matched BD patients. Those who 
have had multiple episodes present with increased ventricular volume compared 
to individuals who have had one episode [61]. Functional magnetic resonance 
imaging studies have identified structural and functional variation in regions 
associated with emotional processing in bipolar patients compared to healthy 
volunteer subjects. Evidence points towards limbic hyperactivation and frontal 
hypoactivation during emotion processing tasks, principally in manic individuals, 
but these activation states were present to a lesser degree in euthymic and 
depressed subjects [60]. Reduction in the volume of the prefrontal and cingulate 
brain regions have been noted in studies involving youths with BD [62]. 
Hyperintensities in the deep white matter and subcortical grey matter have been 
shown to be associated with BD [63]. Hyperintense lesions in magnetic resonance 
imaging (MRI) studies denote areas of damage in the brain such as axon/nerve 
loss, focal demyelination and ischaemic damage [63]. 
A number of meta-analyses have identified regional alterations in brain regions. 
These include: prefrontal lobe reduction and globus pallidus enlargement. 
Hallahan et al. [64] performed a mega analysis between 321 individuals with BD-I 
and 442 healthy controls, reporting an inverse correlation between illness 
duration and total cerebral volume. They further report differences in 
hippocampal and amygdala volume between patients who were being treated with 
lithium and unmedicated BD patients, who hadn’t taken psychotropic medication 
for a period of two weeks prior to, and lithium for a period of a month prior to the 
MRI [65, 66]. An increase in volume in both brain regions in lithium treated 
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patients was reported. Decreased activity in specific brain regions has also been 
detected by multiple studies. Reduced activation detected in the rostral and lateral 
orbiotofrontal cortext subregions has been reported during manic episodes with a 
corresponding change seen during depressive episodes [67].  
Although some of the findings above are well replicated, there is a lack of 
longitudinal studies to explore the natural history of neurocognitive and 
neuroanatomical changes in BD. A further drawback of many of the studies is that 
they only include euthymic or medicated patients for practical reasons. While the 
study of euthymic BD subjects can elucidate stable trait changes it is difficult to 
study functional changes associated with manic episodes. The influence of 
antipsychotics and the drugs used to ameliorate BD episodes impacts cognitive 
processes and this must be taken into account during studies trying to delineate 
the underlying mechanisms of the disorder. There is some evidence to suggest that 
lithium treatment increase brain volumes in individuals with BD [64, 68]. No 
impact has been seen with other treatments for BD on brain structure.  
Neuroimaging studies looking at neural circuits and brain structure can help define 
clinical outcomes and potentially redefine bipolar disorder diagnostic criteria if 
implicated appropriately. Cognitive testing is an important tool for examining 
executive functions in determining the cognitive deficits present during periods of 
mood disturbances and in euthymic periods [69]. 
1.1.5 BIOCHEMICAL PATHWAYS IMPLICATED IN BIPOLAR DISORDER  
1.1.5.1 NEUROTRANSMITTERS 
A number of biochemical pathways have been implicated in BD. Given the episodic 
nature of BD it seems reasonable to look for biochemical changes which correlate 
with affective changes. Neurochemical and neuronal receptor changes have been 
reported in individuals with BD. A number of biological processes and pathways 
that are likely to be involved in BD have been discovered as a result of patient’s 
responses to psychoactive agents. Neurotransmitters such as epinephrine, 
norepinephrine, serotonin, and dopamine and their pathways have been 
implicated in the pathology of BD. 
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In 1972 the hypothesis of a “balanced adrenergic-cholinergic system” underlying 
different affective states was proposed by Janowsky et al. [70]. The central tenet of 
this hypothesis is that relatively high adrenergic activity results in mania, whereas 
relatively high cholinergic activity results in depression. Evidence for the 
involvement of the central nervous system (CNS) acetylcholine neurotransmitter 
came from observations that a number of cholinergic agonist and 
acetylcholinesterase inhibitors induced severe depression [71].  
At the time of the proposal for a balanced adrenergic-cholinergic system, little was 
known about dopamine function, composition, or its contribution to the 
development of mania. There are four major neurocircuits where dopamine 
neurotransmission predominates. These are the tuberoinfundibularm, the 
nigrostriatal, the mesocortical, and the mesolimbic pathways [72]. Dopamine 
signalling is largely mediated through G coupled protein receptors, modulating fast 
synaptic transmission in glutaminergic and GABAergic neurons [73]. 
A comprehensive review conducted by Van Enkhuizen in 2014 conclude that there 
is more evidence for a catecholaminergic–cholinergic balanced hypothesis in BD 
[74]. Evidence for the involvement of catecholamines (dopamine and 
norepinephrine) in the etiology of BD has been growing over past decades. Rare 
increases in both dopamine and norepinephrine, caused by drugs used to treat 
depression, have been shown to cause a switch in individuals from a state of 
depression to mania [75]. Generally, antidepressants impact multiple 
neurotransmitter systems, for example many increase extracellular levels of 
serotonin in the brain [76]. The method of action for drugs used to treat 
depression and mania will be discussed in section 1.1.6 of this thesis. 
The mood stabilising drugs, lithium and sodium valproate, have an impact on the 
dopamine signalling pathway. Valproate has been shown to increase dopamine 
reuptake transporter (DAT) gene expression in a time and dose dependent manner 
[77] through interaction with the Sp family of transcription factors. Agents such as 
L-dopa, used in the treatment of Parkinsons disease and a precursor to dopamine, 
can result in hallucinations. Other dopamine agonists can exacerbate mania [72], 
further implicating the dopamine pathway in BD. Haloperidol, an antipsychotic 
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drug used as treatment for BD, decreases dopamergic transmission and is an 
effective treatment for mania [78]. 
Lower dopamine type 1 (D1-type) receptor densities could reflect a higher synaptic 
dopamine concentration. These findings are consistent with the 
hyperdopaminergic state hypothesis. Lower concentrations of D1-type receptor 
levels has been observed in the frontal cortex of patients with BD in comparison to 
healthy volunteers as measured by positron emission tomography [79].  
Imbalances in both dopaminergic and glutamatergic pathways have been 
demonstrated post-mortem in the brains of BD patients [80]. Increased 
glutamate/glutamine ratio and reduced levels of N-methyl-D-aspartate (NMDA) 
receptor subunits are reported in post-mortem brains from BD patients [81]. 
Observations of changes in glutamate levels have also been found in the serum, 
plasma and the CNS of individuals with BD [82]. There is some doubt as to whether 
these changes reported by multiple groups could be influenced by medication 
exposure or post-mortem effects on the brain. Studies which have controlled for 
some of these variables have found increased levels of glutamate in the frontal 
cortex of patients with BD [83]. Glutamate is a major neurotransmitter in the 
cortex and mediates fast synaptic excitatory signalling. This evidence suggests a 
potential role for dysfunction in the glutamatergic neurotransmission in the 
pathophysiology of BD. 
1.1.5.2 CELLULAR CHANGES 
At a cellular level disruption of calcium (Ca2+) homeostasis and oxidative stress is 
implicated in the pathophysiology of BD I. Dysregulation of intracellular Ca2+ has 
been shown in lymphocytes and platelets of patients with BD [84]. Increased levels 
of glutamate may result in excitoxicity following calcium influx [85]. The glutamate 
pathway is implicated in the regulation of calcium influx and an imbalance in the 
glutamatergic pathway may lead to calcium dysregulation. 
Serotonin or 5-hydroxytryptamine (5-HT) is another neurotransmitter that has 
been robustly associated with mood disorders. In the brain 5-HT production is 
found localised in the raphe nuclei. These are moderately sized nuclei that are 
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located in the brain stem; their axonal projections extend throughout the brain 
[86]. 
Studies reportnig reductions in the levels of serotonin have led to a monoamine 
deficiency hypothesis for the cause of BD [87, 88]. Selective serotonin reuptake 
inhibitor (SSRI) drugs target the serotonin transporter (SERT) and serotonergic 
neurotransmission that are widely recognised as playing an important role in 
depression. The monoamine hypothesis is based on the observation that reduced 
monoamines neurotransmitters in the CNS result in depression [89]. This 
hypothesis is based largely on the observation that drugs that increase monoamine 
levels are effective antidepressants such as the SSRI fluoxetine, or the monoamine 
oxidase inhibitor tranylcypromine [89]. While more recent discoveries of potent 
antidepressants have indicated that the hypothesis of monoamine deficiency is not 
sufficient to explain depression, there is nonetheless a strong body of evidence that 
suggesting it plays a leading role in regulating mood and depression.  
The Ca2+ signalling pathway has been implicated in BD as well as SCZ [90-92]. The 
Ca2+ pathway, is a key modulator in many of the processes that regulate neuronal 
excitability, information processing and cognition. The Ca2+ pathway is involved in 
the regulation of neurotransmitter release from the presynaptic terminals and in a 
variety of postsynaptic processes. Alterations to these calcium signalling pathways 
may result in a functional switch in either excitatory or inhibitory neurons. 
Excitation or inhibition of neurons commences a downstream activation of 
signalling pathways that modify the level of neuronal activity responsible for 
controlling brain rhythms [91]. Membrane depolarisation that occurs in response 
to the activation of these excitatory and inhibitory neurons is also known as the 
tonic excitatory drive [93]. Alterations to brain rhythms may be connected to 
physiological processes, such as control of sleep/wake patterns, that are 
experienced in both depressive and manic episodes of bipolar disorder [94]. As 
membrane depolarisation occurs sodium (Na+) flows into the cells while potassium 
(K+) current activity is depressed [95]. An example of the tonic excitatory drive is 
the hydrolysis of the membrane phospholipid phosphatidylinositol 4,5-
bisphosphate (PtdIns4,5P2), leading to inactivation of K channels responsible for 
M1 current [96], which depolarises the membrane to increase neuronal activity. 
When PtdIns4,5P2 hydrolysis occurs inositol 1,4,5-triphosphate (InsP3+) is formed, 
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stimulating the opening of Ca2+-activated non-selective cation (CAN) channels. 
These CAN channels can also be activated by Ca2+ flux into the cell through voltage 
dependent calcium channel (VDCC) genes [93]. Mutations in genes that are 
members of the VDCC family have been implicated in multiple genetic studies of 
BD and will be discussed in depth later in this thesis. 
A number of other processes and pathways have been implicated in BD. These 
include inflammation, and the hypothalamic-pituitary-adrenal (HPA) axis. 
Inflammation has been reported to play a role in both the periphery of the brain 
and the CNS for BD [97]. Inflammation has also been reported to have a role in the 
pathophysiology of BD as well as a bidirectional link being postulated for mood 
symptoms and inflammation [98, 99]. The HPA axis has been shown to be 
dysfunctional in patients suffering from BD [100]. Molecular abnormalities of the 
two main brain corticosteroids receptors, glucocorticoid and mineralocorticoid, 
essential for the HPA function have been found in post-mortem studies of BD 
brains [101]. Immune responses in the body result in the release of cytokines by 
macrophages [98]. Cytokine release can have an effect on the HPA-axis as well as 
microglial activation and brain structure [102].  
This brief overview shows that a wide variety of neurochemicals have been 
implicated in perturbing mood state. While the effect of exogenous 
pharmacological agents on neurotransmitter systems is often clear, identifying 
endogenous susceptibility to BD in neurotransmitter pathways has proved to be a 
challenge. 
1.1.6 TREATMENT OF BIPOLAR DISORDER 
Currently the main type of treatment for BD is pharmacological. Pharmacological 
treatments for BD can be divided into two categories. The first is treatments for 
acute mood disturbances (depression and mania) and the second is prophylactic 
treatment against both manic and depressive episodes. Often combinations of 
treatments are used for the treatment of acute phases of illness and for 
prophylaxis. Several medications are licenced for the treatment of BD and other 
medicines are prescribed off label. 
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 One major issue in the pharmacological treatment of BD is the significant number 
of side effects, some of which are both medically and psychologically severe. These 
range from weight gain, diarrhoea and fatigue, to extrapyramidal symptoms such 
as parkinsonism, akathisia and tremors [103]. While medications prescribed for 
BD are effective (eg. Lithium use for BD prophylaxis), these are not completely 
effective for everyone. A meta-analysis of six studies, focusing on the use of lithium 
in the treatment of acute mania has reported a response rate of 47% in BD patients 
versus 32% in controls [104]. Some individuals have a heightened response to the 
drug than others, while some individuals are treatment resistant for lithium [103]. 
There are also a number of psychological therapies used in the treatment for BD 
which will be touched on briefly in this section. 
The obstacle to the development of disorder specific pharmaceutical treatments 
results is our current limited understanding of the pathophysiology of BD. As has 
been shown in the previous section there are multiple facets to the BD phenotype 
including mood disturbance, cognitive impairment, psychotic features, and 
disturbances in various physiological functions. 
1.1.6.1 MOOD STABILISERS 
Lithium is the first line medication used to treat BD. Lithium has been used for the 
past 60 years but its mechanism of action is not well understood [105]. There are 
currently two main hypotheses of lithium action. The first is the “inositol depletion 
theory” [93] and the second is the “neurogenesis” hypothesis [68]. The inositol 
depletion theory focuses on the deficits seen in the excitatory and inhibitory 
neurons, whereas the neurogenesis theory incorporates cellular decline in 
progenitor cell populations [106].  
Acetylcholine acting through through the muscarine 1 (M1) channel catalyses the 
hydrolysis of PtdIns4,5P2 into InsP3. This hydrolysis leads to the activation of InsP3 
receptors located in the endoplasmic reticulum (ER) releasing Ca2+ ions which 
stimulate the tonic excitatory drive as described in 1.1.5.2 and as shown in Figure 
4. InsP3 is then recycled through the inositol pathway and converted into inositol 
by IMPase providing a basis for the formation of PtdIns. Lithium impacts on the  
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Figure 4. Effect of Lithium and Valproate on the inositol synthesis pathway.  
The presence of lithium reduces the supply of inositol and in turn levels of 
PtdIns4,5P2. Lithium decreases the amount of PtdIns4,5P2 present in the system by 
inhibiting the lithium-sensitive inositol monophosphate (IMPase) which recycles 
InsP1 into inositol. This lowers the intracellular levels of Ca2+. Valproate may 
improve inositol reduction by 1. Lowering the amount of PtdIns4P available to be 
converted to PtdINS4,5P2 and then hydrolysed to InsP3. 2. Inhibiting Glucose-6-
Phosphate synthesis into novel InsP1. Image based on [93]. 
inositol pathway by blocking IMPase function and reducing the amount of free 
inositol present for the conversion to PtdIns. 
Sodium valproate, originally used as an anticonvulsant, is often used in the course 
of treatment for BD. This drug is also thought to deplete inositol. Valproate may 
prevent the production of de novo inositol from glucose-6-phosphate (6-G-PO4) 
[107, 108]. Valproate use also reduces the amount of PtdIns4P and PtdIns4P,5P2 
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[109, 110] which is depicted in Figure 4. This action occurs by blocking of inositol 
synthase and PtdIns4P. 
Lithium and valproate are both thought to increase synaptic plasticity stability, 
through inositol depletion. Increased synaptic formation, secondary to the 
reduction of membrane phophoinositides, has been demonstrated in cultured rat 
hippocampal neuron after four hours of lithium treatment [111]. Lithium’s 
therapeutic benefits are normally seen after one to two weeks when administered 
for psychosis; however synaptic formation has been previously shown to occur at a 
faster rate in vitro than in vivo [112].  
Another mechanism of action for lithium has shown to occur through the Glycogen 
synthase kinase-3β (GSK-3β)/wnt/β-catenin pathway. In 1997 Hedgepeth et al. 
showed that lithium activates the wnt signalling pathway through inhibition of 
GSK-3 [113]. The activation of the wnt signalling pathway leads to an accumulation 
of β-catenin protein. This protein is important for activating expression of 
neuroprotective genes such as BCL-2 in addition to promoting nuclear 
transcription of IGF-I,IGF-II, BDNF and VEGF [114]. In the adult and developing 
brain IGF-I acts to promotes neuroplasticity, neurogenesis and angiogenesis [115].  
Valproate has also been shown to increase mRNA levels of the molecular 
chaperone, glucose related protein (GRP78), in C6 glioma cells in culture [116]. 
GRP78 is an endoplasmic reticulum chaperone protein that regulates intracellular 
levels of Ca2+. This sequestering of excess Ca2+ ions prevents excitoxicity in 
neurons. 
The neurogenesis theory of lithium action has been mainly born out of imaging 
studies. A meta-analysis conducted by Hafeman et al. in 2012 describes the effects 
of lithium on the brain as measured by structural magnetic resonance imaging 
(sMRI), function MRI (fMRI) and diffusion tensor imaging (DTI) [68]. Structural 
MRI studies show that lithium increases or normalises grey matter volumes in 
several brain regions where deficits were seen prior to treatment, including the 
amygdala, hippocampus, anterior and subgenal cingulate [68]. Robust correlations 
have also been observed between the increases in grey matter volume and 
treatment response [117, 118]. Moore et al. reported a significant increase in 
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prefrontal cortex grey matter in lithium responsive patients compared to non-
responders (p=0.003). Long term potentiation (LTP) of CA1 pyramidal cells has 
also been shown to occur following four weeks of treatment with lithium. This 
suggests lithium is promoting synaptic plasticity [119]. Lithium has additionally 
been shown to have a robust effect on neuronal circuits, decreasing neuronal death 
[120, 121] and facilitating neurogenesis [122, 123]. This mode of action is 
important as it may facilitate the repair of impaired neuronal communication that 
have been proposed as an underlying mechanism for BD [124].  
Studies have demonstrated that taking lithium reduces suicide risk in BD patients 
[125]. This is clearly an important outcome of lithium action, given that the annual 
prevalence of suicide attempt in individuals with BD is 23-fold higher than in the 
general population (0.017%).  
There has been interest in the use of memantine for the treatment of BD. 
Memantine is one of the four drugs licenced for the treatment of Alzheimer’s 
dementia [126]. Memantine acts primarily on NMDA receptors, antagonising the 
action of glutamate. Memantine blocks the sensitisation of dopamine D2 receptors 
in mice, where a cyclic condition mirroring BD had been induced via imipramine 
administration. Following the discontinuation of imipramine administration many 
of the animals demonstrated depressive like symptoms. Depressive symptoms 
were ameliorated by the administration of memantine. Serra et al. have reported 
enhanced mood stabilisation for at least three years in patients who were 
previously treatment resistant to the standard antipsychotic agents used for BD. 
Studies suggest that memantine increases hippocampal volume euthymic BD 
patients [126].  
While mania may be the defining characteristic of BD, bipolar depression occurs 
three times more frequently [127] and causes greater impairment both socially 
and cognitively [14]. A number of different antidepressants are prescribed, many 
of which target the biochemical systems which are altered in BD, including SSRIs 
such as sertraline, monoamine oxidase inhibitors (MAOI), such as moclobemide, 
noradrenaline reuptake inhibitors including reboxetine and serotonin-
noradrenaline reuptake inhibitors such as venlafaxine and duloxetine. SSRI’s are 
some of the most commonly prescribed drugs used to target depression in both BD 
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and major depressive disorder. SSRIs function by targeting the serotoninergic 
pathway, activating serotonin transmission and blocking SERT transport of 
serotonin to receptors [128]. Other common mood stabilising drugs used for the 
treatment of BD are carbamazepine, gabapentine, and lamotrigine. 
However antidepressant treatment brings with it the risk of manic susceptibility 
therefore antidepressants should be prescribed in combination with an anti-manic 
agent. Many treatments have anti-manic properties; these include mood-
stabilisation treatments discussed above, anti-psychotic drugs, and calcium 
channel blockers [129]. The three main antipsychotics used in the treatment of BD 
are olanzapine, haloperidol and risperidone. These have rapid onsets of action and 
all have been found to be effective in the treatment of mania [130]. Shim et al., 
investigated the role of olanzapine in synaptic plasticity following a four week 
course of treatment. Olanzapine was not associated with an increase in LTP in 
hippocampal CA1 pyramidal cells, but did increase synaptic transmissions. 
The UK National Institute for Health and Care Excellence (NICE) publishes 
guidelines on the assessment and treatment of BD [127]. Lithium is recommended 
as the first time prophylactic treatment for individuals with BD. Additionally 
lamotrigine or olanzapine monotherapy is suggested. The antipsychotics, 
haloperidol, olanzapine, quetiapine or risperidone, are recommended for first line 
agents in the treatment of mania. For bipolar depression NICE recommends the 
use of one of the following treatment regimes in combination with lithium: 
fluoxetine, fluoxetine combined with olanzapine or quetiapine.  
Psychological treatments are also recommended for the treatment of BD. These 
include cognitive behavioural therapy (CBT) [131] and interpersonal therapy 
(IPT). In addition to cognitive therapy, psychoeducation is recommended for 
overall management of BD. These psychological sessions are aimed at the 
education and personalisation of treatment, focusing on identifying early warning 
symptoms that may be indicators of a relapse into depression. It has been shown 
that the introduction of coping mechanisms, and plans to follow post treatment in 
addition to the afore mentioned CBT and IPT strategies confer prophylactic effects 
on BD relapse, and result in improvements in residual or subsyndromal symptoms 
[127]. 
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There has been little recent progress in the pharmacological treatment of BD. It is 
hoped that the elucidation of the specific underlying pathological defect in 
individuals with BD will eventually enable personalised interventions. Elucidation 
of the underlying genetic risk factors, alongside work being conducted on neural 
pathway disruptions is essential to these ends. 
1.2 GENETICS OF BIPOLAR DISORDER 
In this section I will focus on the evidence for a major genetic contribution to the 
aetiology of BD. I will give an overview of the different molecular genetic 
methodologies that have been utilised to delineate the genetic underpinnings of 
BD. These will be discussed in five sections covering linkage studies, candidate 
gene studies, genome-wide association studies (GWAS), pathway analysis and 
whole genome sequencing studies. 
1.2.1 HERITABILITY OF BIPOLAR DISORDER 
The tendency of both depression and psychosis to run in families has long been 
observed. Heritability, as a statistical measure, is the proportion of phenotypic 
variance attributable to genetic variance. It estimates the contribution genetic 
impact has to a specific phenotype, but provides no information pertaining to the 
genes involved in a specific phenotype [132]. Lifetime risk in BD, based on 
heritability estimates, is shown in Figure 5 with respect of the relatedness to a 
proband with BD. The general population risk of BD ranges from 0.5-1%; the 
lifetime risk for a first degree relative of an individual with BD is 5-10% higher 
compared to an unrelated person in the general population [36]. This increase in 
risk has been observed in numerous studies despite the use of different diagnostic 
criteria. Concordance rates between monozygotic (MZ) and dizygotic (DZ) twins 
have been estimated to be 40-70% and 15-20% respectively.  
1.2.1.1 FAMILY STUDIES 
Family studies of mood disorders have not always distinguished between unipolar 
depression (UPD) and BD. The differentiation of the two disorders into separate 
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Figure 5. Estimates of the lifetime risk of developing bipolar disorder.  
These estimates show the risk of developing BD based on an individual’s 
relatedness to a BD proband. Image based on [133]. 
entities has only been established in the past 60 years. While studies including 
both BD and UPD individuals are not specific to disease type, they did show disease 
aggregation in families [134]. This provides evidence for shared underlying genetic 
risk factors.  
Family studies have reinforced the role of a genetic contribution to BD and other 
psychiatric illnesses. It is apparent from heritability estimates that the risk of 
developing a mental illness increases with an increasing relatedness to affected 
probands with a mental illness diagnoses. Increasing risk of UPD and 
schizoaffective disorder, has been reported in siblings and family members with 
BD [135]. The rate at which UPD and schizoaffective disorder segregate in relatives 
of people affected by a psychiatric illness is twice the rate of the general population 
[136]. This provides evidence for shared underlying risk factors. 
The lifetime risk of developing UPD is estimated to be between 15-20% higher in 
first-degree relatives of individuals with BD than in the general public. UPD has 
been proposed to be a more prevalent disease diagnoses in first degree relatives of 
individuals with BD than any other psychiatric illness, including BD [137].  
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A recent Swedish study that investigated the relationship of BD and other 
psychiatric illnesses estimate co-occurrence rates of relative risk between 9.7-22.9 
in a total of 54,723 BD patients and their extended families [138]. Heritability for 
this population in 4,149,748 nuclear families and their offspring is calculated as 
58%. In addition to this a study conducted by Lichtenstein et al. in 2009 reported 
on common genetic variants in SCZ and BD from the Swedish multigenerational 
records. This study included 35,985 first degree relatives of SCZ probands and 
40,487 first degree relatives of BD probands from over 2 million nuclear families 
identified on the Swedish register [139]. The heritability for BD in this study was 
estimated to be 59%. The co-occurrence between BD and SCZ was 63% adding to 
the evidence for additive genetic variation which is common between the two 
disorders. Another study, conducted by Wray and Gottesman, in 2012 showed 
heritability estimates of 62% for BD in data from >2.6 million individuals from 
Denmark [140]. This estimate is lower than previously reported from other family 
studies and could arise through diverse environmental impacts, such as diagnostic 
interpretation, between national registry data and family and twin studies. 
Studies investigating the genetic relationship between BD-I and BD-II have shown 
no apparent difference in the risk of developing either BD-I (3.6%) or BD-II (3.5%) 
to the relatives of an individual with BD-I [141]. However, evidence suggests that 
relatives of BD-II probands are at a greater risk of developing BD-II (6.1%) rather 
than BD-I (1.8%) [141-143]. The difference between the disorders may suggest a 
diluted effect of specific genes affecting pathways that lead to full manic episodes. 
Early onset BD has been reported to have a strong familial link, suggesting that 
early-onset cases are more genetically homogeneous in nature [144]. 
In the past shared underlying genetic predisposition in different psychiatric 
illnesses has often been overlooked but with the development of the Psychiatric 
Genomics Consortium (PGC) cross disorder group it has become possible to study 
the shared underlying genetic variation between psychiatric disorders [145, 146]. 
While each disorder can be classified individually and separately, a common 
genetic background may result in some of the abnormal phenotypic symptoms 
which are similar between disorders. 
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1.2.1.2 TWIN STUDIES 
The contribution of genetic and environmental factors on the heritability of a 
disease or disorder is often measured using concordance rates from twin studies 
that have used MZ and DZ twin populations. Concordance is usually measured 
between MZ and DZ twins to determine the level of underlying genetic component 
as twins often share a common environment and either all of their genes (MZ) or 
half of their genes (DZ). Measurements of concordance rates are similar to that of 
lifetime risk estimates. The measurement reflects the presence or absence of the 
same characteristics or in this case presence of bipolar disorder between 
individuals. Concordance estimates in MZ twins are higher than those seen in DZ 
twins [36]. If one assumes that the shared environmental factors are the same 
between the MZ and DZ sets of twins then these higher levels of concordance rates 
reflect the actions of genes. 
Twin studies in BD have estimated that inherited genetic variation could account 
for 60-85% of variance in disease risk [4, 5]. Additionally, heritability estimates 
from twin studies based in the UK, including 67 twin pairs and in a Finnish 
population based analysis of 19,124 same-sex twin pairs, born from 1940-1957, 
report heritability estimates of 89% and 93% respectively [6, 7]. BD is estimated to 
be one of the most heritable psychiatric conditions (Figure 6) second only to 
autism whose heritability has been estimated as greater than 90% in MZ twins 
[147]. 
In relation to the above studies the estimations of concordance rates for MZ and DZ 
twins in the UK study were 67% and 19% [148] and in the Finnish population was 
43% (MZ) and 6% (DZ) [149].  
Another form of twin study reporting on concordance rates has focused on the 
differences observed between the spectrums of the different BD diagnoses. 
Edvardsen et al. (2008) looked at MZ and DZ twin concordance rates between BD-
I, BD-II and cyclothymia in 303 individuals from the Danish population [150]. 
Cyclothymia is viewed as a less severe form of BD where individuals experience 
low and high mood elevations, but not severe enough to result in hospitalisation. It 
sometimes can progress into a diagnosis of BD later in life. Higher concordance  
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Figure 6. Heritability estimates for a number of Psychiatric Illnesses. 
BD has the second highest estimate of heritability amongst psychiatric (0.85) and 
psychological disorders after autism whose heritability estimates are >0.9. Figure 
adapted from [151]. 
rates observed between MZ twins compared to DZ twins followed the trends 
previously mentioned between BD and other psychiatric illnesses. Half of the MZ 
twins had either BD-I, BD-II or cyclothymia. This is significantly less than the 10% 
of DZ twins presenting with one of the disorders (Fishers Exact p=0.047). The 
difference in MZ and DZ concordance rates and the diminishing levels of relative 
risk between individuals genetically further away from the proband reflect the 
true action of genetic influence on BD. 
1.2.2 MOLECULAR GENETIC STUDIES OF BIPOLAR DISORDER 
1.2.2.1 LINKAGE STUDIES 
Linkage analysis is a statistical method which aims to detect regions of the 
chromosome which harbour variants that effect the risk of human disease. For 
Mendelian disorders, linkage analysis has been quite successful in discerning 
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which genes segregate with disease phenotypes. One of the earliest and most 
successful examples of linkage analysis of Mendelian disorders was the 
identification of a CF locus on chromosome 7.q31 where a specific deletion of 3 
base pairs accounts for 70% of mutations seen in cystic fibrosis patients [152]. 
During this period the markers utilised for linkage analysis were restriction 
fragment length polymorphisms (RFLP) and this progressed on to the use of 
microsatellite markers, repeating sequences of 2-5 base pairs which are found 
throughout the genome. 
Linkage analysis can locate a susceptibility locus to a region of the genome with a 
resolution of approximately 20-30 centimorgans (cM) [153]. In physical distance 
this is in the region of 20-30 million base pairs. Fine mapping is then usually 
employed to investigate the region of interest. Thus linkage analysis was often the 
first step to gene mapping, and followed by linkage disequilibrium analysis. 
Linkage provides a powerful tool to detecting variants with an odds ratio (OR) of 
three or greater [154]. Some of the earliest linkage studies in BD conducted by 
Reich et al. reported linkage of the X chromosome with the disorder. Linkage 
studies pointed towards the Xq28 region, in individuals with BD [155] using colour 
blindness, blood group Xg and G-6-PO4 deficiency as phenotypic markers [156]. 
Subsequent studies have found evidence for association of the X chromosome with 
BD from pedigrees in different populations including eight Belgian pedigrees 
[157], an Iranian pedigree [158], two Sardinian pedigrees [159] and a north 
American pedigree [160]. However other studies failed to find linkage between BD 
and the X chromosome [161-163]. Many of the studies published on X linkage and 
BD were scrutinised over the decades following these publications. There was a 
serious doubt as to the actual evidence and biases that may have arisen as a result 
of publishing only pedigrees where X-linked transmission appeared to be 
observed. Both markers are at a significant difference from each other on the X 
chromosome. The Xg blood group marker is located at Xq22.3 and the marker for 
colour blindness is located at Xq28 making the chances of co-linkage unlikely 
[156]. As is evident from above no one marker appear to be directly linked to BD 
with conflicting results reported between linkage of markers and BD in different 
pedigrees. 
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One of the first linkage analysis studies to use DNA markers was conducted on an 
old order Amish family, by Egeland et al. in 1987. The old order Amish population 
can be regarded as a defined population in isolate. This linkage study found linkage 
of BD to chromosome 11p in one pedigree [164]. However the evidence of linkage 
to 11p disappeared as the family was extended laterally.  
Although replicated linkage was found for a few regions, linkage findings in BD 
have generally been inconsistent. Comparative meta-analyses have been 
conducted on linkage study results using two different techniques. The meta-
analysis approach is a method for combining results from a number of different 
studies which have similar research methods in an attempt to increase power. 
Strict inclusion criteria must be used to prevent study bias. 
 Two meta-analytic methods have been applied to linkage studies in BD. The first 
method is a multiple scan probability (MSP) method and the second is a genome 
scan meta-analysis (GSMA). The MSP method modifies a meta-analysis of Fisher to 
allow for regional P values instead of single locus P values and was proposed by 
Gershon and Badner in 2001 as a novel approach for investigating results from 
linkage studies [165, 166]. Using whole genome linkage data, from eleven 
published studies, they reported evidence for susceptibility loci at 13q (p<6x10-6) 
and 22q (p<1x10-6) for BD [167]. MSP detection focuses on the effect size of a 
variant in a smaller number of individuals. 
The GSMA method was described first in 3 separate papers in 2003. The first 
publication was used to determine whether GSMA could suitably detect linkage 
across multiple genome scans [168], the second study focused on meta-analysis of 
genome-wide linkage studies for SCZ [169], and the third paper focused on BD 
[170]. Eighteen BD data sets, with greater than 20 affected individuals, were 
incorporated for this study in an effort to identify linkage association. GSMA was 
proposed as a method to identify regions which consistently harbour one or more 
disease related locus. 
No significant region of linkage was observed in BD, although some chromosomal 
regions showed suggestive evidence of linkage (9p22, 10q11.21-22.1 and 14q24.1-
32.12) [170]. The use of the GSMA method on data from SCZ linkage studies 
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identified a significant association on chromosomal region 2q (p<0.000417) [169]. 
Compared to the SCZ cohort size (1200 pedigrees) the BD cohort was still 
underpowered (347 pedigrees). This might account for the resulting lack of 
linkages seen in the BD GSMA study.  
The lack of linkage findings is not exclusive to the study of psychiatric genetics but 
to the field of complex disorders in general. The inability to detect regions of the 
genome linked with complex disorders may have been arisen from false negative 
results due to inadequate power, but even linkage studies incorporating large BD 
datasets proved unable to detect regions conferring relative risk scores of less than 
1.5 [154, 171]. Inability to replicate true BD linkage findings may stem from locus 
heterogeneity. Alternatively, false-positive associations may be reported from 
studies due to multiple model testing [170]. For complex disorders many of the 
original linkage studies focused on family pedigrees from populations that were 
considered to be isolates. This prevents the dilution of linkage evidence that may 
be experienced if some families have a different gene linked to a common disease 
phenotype. BD has complex underlying mechanisms and interplay between genetic 
variants and other risk factors. Linkage analysis has not proved to be extremely 
effective in delineating the involvement of any one particular gene.  
1.2.2.2 CANDIDATE GENE STUDIES 
In the wake of gene linkage studies and the findings of putatively associated 
chromosomal regions using DNA markers, the focus turned towards identifying 
genes located in these regions which may harbour variants which influence disease 
susceptibility. These progressions coincided with advances in technology and 
development of software which enabled higher throughput sample analyses. 
Hundreds of samples could be genotyped for one or multiple variants 
simultaneously, providing an increased production in data available to 
researchers. Many of the early candidate gene studies focused on genes involved in 
the pathways for which there was some evidence of disturbance, for example the 
aforementioned serotonin and dopamine pathways. The original proposed 
hypotheses of the balanced adrenergic-cholinergic system and a balanced 
catecholaminergic-cholinergic system, led to a focus on genes which play roles in 
these systems and other related neurological pathways. In this section I will 
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provide a summary of some of the main candidate genes which were investigated 
following linkage studies. 
One gene that was investigated in the early days of candidate gene studies was 
brain derived neurotrophic factor gene (BDNF) [172]. BDNF is oriented in the 
reverse direction on chromosome 11p13 and encodes a precursor peptide which, 
when cleaved, forms the mature protein. It is a member of the neurotrophin 
superfamily. BDNF plays a key role in axonal development, including the 
promotion and modification of growth alongside the development and survival of 
neuronal populations [173]. The gene is strongly conserved and only one frequent 
non-synonymous variant is reported in the gene at codon 66, resulting in a valine 
to methionine change. Three family based association studies reported 
overtransmission of the valine amino acid in individuals with BD [174-176]. Four 
case-control association studies were also conducted which showed no evidence 
for allelic or genotypic association between BD and this variant [177-180]. A UK 
case-control association study found no overall association between the BDNF 
variant and BD. However, they reported a significant association between rapid 
cycling in individuals with BD and the valine amino acid. More recently, reports 
have stated that individuals with BD have significantly higher circulating levels of 
BDNF in their plasma compared to controls (p=0.001) [181].  
Another gene focused on following the era of linkage studies was DAOA. Five 
independent linkage studies reported evidence for variant association at the 
DAOA/G30 locus on chromosome 13q [173]. The gene in this region was named 
DAOA as its protein product was believed to initiate the enzyme D-amino acid 
oxidase. This region was originally associated with SCZ [182]. Linkage 
disequilibrium was found in two US families with BD and was replicated in three 
additional studies [183-186]. No single pathogenic variant was identified in these 
studies, instead evidence for linkage disequilibrium came from multiple single 
nucleotide variants and multilocus haplotypes [173]. Genetic variation at two loci 
in the DAOA gene, M23 and M24, have been linked to decreased grey matter 
volumes in the temporal pole and amygdala areas of the brain [187]. 
Early linkage studies led to the suggestion that some susceptibility genes are 
common to both BD and SCZ [188]. A number of linkage studies identified a region 
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associated with BD on chromosome 22q11 [189-191]. This region contains a 
microdeletion which incorporates a number of genes [192]. One of the genes in 
this region was the catechol-o-methyltransderase (COMT) gene, which encodes an 
enzyme involved in the degradation of catecholamines such as dopamine, 
epinephrine and norepinephrine [193]. Several studies testing the association of a 
methionine/valine amino acid change with BD reported negative findings [194-
196] while others report an association between the methionine and rapid cycling 
within BD [197, 198]. Studies focusing on associations with variants in COMT and 
SCZ reported three variant allele associations and two haplotype associations 
[199]. These variants were additionally studied in a BD case-control cohort. Two of 
the allelic variants and the three haplotypes were associated with BD [200].  
The monoamine oxidase A gene (MAOA) is located on chromosome Xp11 [201] and 
encodes a protein which has similar functions to that of COMT. Its protein product 
is involved in the degradation of neurotransmitters ephinpherine, 
norephinephrine, serotonin and dopamine [202]. The first report of MAOA variants 
associated with psychiatric illness was in 1993. Brunner et al. demonstrated that 
individuals with disturbed monoamine metabolism and X-linked mental 
retardation had a behavioural phenotype which bore a resemblance to a manic 
syndrome [203]. Studies of association between the MAOA gene and BD have 
identified three variants in this gene. The first is a dinucleotide CA repeat [204], 
the second was a variable number tandem repeat [205, 206], and the third variant 
was a single nucleotide polymorphism [206]. Associations for the three variants 
have been reported in BD case control cohorts from the UK [207, 208] a Japanese 
study [209] and an Iranian study [210]. However other candidate gene studies 
focusing on the MAOA gene did not report associations [211-213] 
Members of the serotonin receptors (5-HT) have been investigated as a result of 
findings implicating abnormal serotonergic neurotransmission in BD [214-216]. 
Allelic variation in the serotonin transporter gene (5-HTT) was hypothesised to be 
involved in the prophylactic response to lithium in BD patients. Currently 
researchers propose conflicting results as to whether the short form (S) or the long 
form (L) of the gene show a higher benefit from lithium prophylaxis [217]. The S 
form of 5-HTTLPR, located in the promoter region of the Solute Carrier Family 6 
Member 4 gene (SLC6A4), is associated with depression in response to childhood 
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maltreatment [218]. Individuals who experience childhood maltreatment are likely 
to develop persistent depressive episodes later in life. The 5-HTTLPR 
polymorphism is also associated with cognitive impairment [219].  
Other genetic variations which have been investigated in the study of BD are copy 
number variants (CNV). CNVs are structural genetic variation that are more than 
1kb in size and consist of deletions, duplications, insertions or inversion of part of 
the chromosomes [220]. Large, rare CNVs have been associated with an increased 
risk of developing SCZ. Given the evidence for a shared underlying genetic 
architecture between BD and SCZ there have been a number of studies conducted 
in individuals with BD in an attempt to investigate CNVs. Studies report that the 
frequency of singleton deletions more than 100kb in length are more common in 
BD [221, 222]. Additionally, certain subtypes of BD, such as early-onset BD, have a 
higher frequency of CNVs [223] and of de novo CNVs [224]. Most studies conducted 
on CNVs however suggest that CNVs have a more prominent role in SCZ than in BD, 
with many researchers reporting no significant frequency difference observed 
between CNVs in BD and healthy controls [225-227].  
As further evidence was produced to support heterogeneity at the level of genetic 
variation for BD, different methods of statistical approaches were improved upon 
to account for disease modelling. As was discussed in relation to the meta-analyses 
conducted on genome-wide linkage data, disease modelling and modes of 
inheritance have an important role in experimental design. Evidently, if common 
variation with low effect size played a role in disease manifestation in individuals, 
then focusing solely on familial pedigrees would not identify these regions. Instead 
larger samples of unrelated individuals would provide a platform for investigating 
variation that would have been previously missed due to the limitations of linkage 
analysis. Candidate gene studies were plagued by an inability to replicate 
associations. Variant associations in one cohort did not map well on to other 
population cohorts. Candidate genes studies did not really prove effective until the 
facilitation of GWAS by high throughput genotyping. Results from GWAS studies 
will be further discussed in the following section of this thesis, but suffice to say 
currently numerous candidate genes of interest are emerging. 
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1.2.2.3 GENOME-WIDE ASSOCIATION STUDIES 
The completion of the Human Genome Project (HGP) in 2001 was a turning point 
for genetic studies. It has opened up the genome for more comprehensive 
investigations during the past 15 years. Genome-wide association studies (GWAS) 
genotype hundreds of thousand single nucleotide polymorphisms (SNPs) across 
the genome in multiple people. GWASs prove a highly attractive approach to the 
investigation of variance observed in complex disorders. Compared to linkage 
studies they are capable of detecting multiple loci that have expected smaller effect 
sizes than would be possible in linkage studies with the same sample size. 
Additionally, there is a higher probability of defining potential candidate genes 
located in regions of association than basing candidate gene choice on the potential 
genes involved in pathogenesis. Similar to the approach taken in whole genome 
linkage studies, many meta-analyses have been conducted between genotyping 
data which is present from previously conducted BD GWAS to infer greater 
evidence for regions of association. GWAS studies are defined as an unbiased, 
hypothesis free approach to determining regions of the genome which may be 
involved in genetic risk to disease as there is no predilection for specific genes or 
candidate regions [228, 229]. To date 18 GWASs in BD have been completed [230-
247] and numerous meta-analyses undertaken. The GWASs are outlined in Table 1. 
Genes involved in ion channels, lithium response and neuronal networks were 
among the first sets of associated regions reported in BD GWASs.  
The first BD GWAS was conducted by Baum et al. in 2007. The study implicated a 
SNP located in the first intron of the diacylglycerol kinase eta (DGKH) gene 
(p=1.5x10-8, OR=1.59). DGKH is a gene involved in the lithium sensitive 
phosphatidyl inositol pathway. This study is an example of a pooled GWAS. Baum 
et al., genotyped 550,000 SNPs in two separate cohorts and then followed up SNPs 
of interest with individual genotyping. This proved to be a cost effective manner to 
identify associated genes. 
The Wellcome Trust Case Control Consortium (WTCCC) conducted a GWAS for 
seven common disorders, of which BD was one [231]. For each of the disorders 
2,000 individuals were collected for analysis and a control sample of 3,000 healthy 
volunteers was used for the study. 
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Study Year Journal Population Cases Controls Genome-wide 
significant genes 
Implicated genes 
Baum  2007 Mol Psychiatry [230] NIMH and German 461 & 772 563 & 876 _____________ DGKH 
WTCCC  2007 Nature [231] WTCCC 1,868 3,000 _____________ KCNC2, GABRB1, GRM7, SYN3 
Ferreira  2008 Nature Genetics [232] STEP-BD & UK & Ireland 4,387 6,209 CACNA1C, ANK3 
 Sklar  2008 Mol Psychiatry [233] STEP-BD 1,461 2,008 _____________ MYO5B, TSPAN8, EGFR 
Schulze 2009 Mol Psychiatry [248] 
NIMH wave 5 & Meta-
Analysis 466 212 ANK3 
 
Smith  2009 Mol Psychiatry [235] GAIN 1,001 & 345 1,033 & 670 _____________ NAP5, DPY19L3, NTRK2 
Scott 2009 PNAS [236]  
NIMH/Pritzker & GSK 
GWAS 1,177 & 899 722 &904 _____________ CPS1, NEK7, ATP6V1G3 
Hattori 2009 Am J Med Genet B [237] Japanese 107 & 395 107 & 409 _____________ 
 
Djurovic  2010 
Jour of Affective Disorders 
[238]  Norwegian, Icelandic 194 & 435 336 & 10,258 _____________ 
DLEU2, GUCY1B2, PKIA, CCL2, 
DPP10, CNTNAP5, FBN1 
PGC-BD 2011 Nature Genetics [239] PGC-BD 7,481 & 4,496 9,250 & 42,542 CACNA1C, ODZ4 
 Smith 2011 PLoS Genetics [240] BiGS 2,191 1,434 _____________  Yosifova 2011 Gene Brain Behav [241] Bulgarian 188 & 122 376 & 328 _____________ GRIK5, PARD6B, CTSH 
Cichon 2011 AJHG [242] MooDS (German) 6,030 31,749 NCAN 
 
Lee 2011 Mol Psychiatry [244] Han Chinese 1,000 & 409 1,000 & 1,000 _____________ SP8, ST8SIA2, KCTD12, CACNB2 
Chen 2013 Mol Psychiatry [245] meta-analysis 6,658 & 484 8,187 & 1,823 TRANK1 
 
Kuo 2014 
Prog. Neuro-Psychopharm 
[249] 
Taiwanese, multistage 
GWAS 200 & 351 200 & 341 _____________ KCNH7, MYST4, NRXN, SEMA3D 
Mühleisen 2014 
Nature Communications 
[246] PGC-BD & MooDS 9,747 14,278 
ANK3, ODZ4, TRANK1, 
ADCY2 
 Xu 2014 BMC Med Genet [247] Canadian and UK 950 950  
SYNE1 , ZNF659, CNTNAP5, CDH 
Table 1. Summary of all the GWAS studies of BD to date 
Summary includes the number of samples involved in each study and lists of genes which reached genome-wide significance or came close to the 
threshold cut off for whole genome-wide significance. Some of the studies conducted meta-analyses in addition to the original GWAS; if no 
associations were observed prior to meta-analysis then the results from the meta-analysis are included. NIMH (National Institute of Mental Health), 
WTCCC (Welcome Trust Case Control Consortium), STEP-BD (Systematic Treatment Enhancement Program for Bipolar Disorder), GAIN (Genetic 
Association Information Network), GSK (GlaxoSmithKline), BiGS (Bipolar Genome Study), PGC-BD (Psychiatric Genomics Consortium Bipolar 
Disorder), MooDS (Systematic Investigation of the Molecular Causes of Major Mood Disorders and Schizophrenia)
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The highest association signal for BD in the WTCCC GWAS was detected on 
chromosome 16p12 (p=6.3x10-8). This association disappeared in the expanded 
reference group analysis (p=5.41x10-6, Supplementary Table 8 [231]) which 
included individuals from the 1958 birth control cohort, and UK blood services 
controls. Other genes of interested implicated in the Wellcome Trust GWAS were 
KCNC2, encoding a potassium voltage-gated channel (p=2.2x10-7), GABRB1, GABA A 
receptor β1 subunit responsible for encoding a ligand gated ion channel (p=6.2x10-
5), glutamate neurotransmitter receptor GRM7 (p=9.7x10-5) and finally SYN3, 
encoding synpasin-3 a neuronal phosphoprotein (p=7.2x10-5). 
Genome-wide tests look at the correlation between a SNP and a particular disease 
or trait. A standard GWAS association threshold of p=5x10-8 is used to adjust for 
the multiple tests conducted on the data [250] explaining why the variants from 
the WTCCC do not classify as genome-wide significant loci in this study. This 
adjustment is used to control for false positive results. GWASs have the ability to 
accurately identify variants with an MAF of >5% through improved imputation 
methodologies, provided the reference panel is matched for population structure 
[251, 252]. Rare variants are more difficult to identify as they are often not 
included on the reference panel. In order to address the issue of false negatives 
arising from GWASs two strategies are used. The first involves the generation of a 
weight sum of contribution, or polygenic risk score, of variants above nominal 
significance in a discovery sample and then determining whether they are 
predictive of phenotype in a second cohort [253]. The second method involves the 
use of multiple regression to evaluate the genetic variance explained by all SNPs 
[254].  
Sklar et al. (2008) conducted a GWAS using the STEP-BD (Edinburgh-Dublin-
Systematic Treatment Enhancement Programme 2) and UCL samples and 
investigated whether previously implicated SNPs from both the WTCCC and the 
Baum study replicated [233]. No SNP reach genome-wide significance in the study 
with the highest P-value seen in the MYO5B gene, located on chromosome 18, (p= 
1.66x10-7, OR=1.51). MYO5B encodes a Ca2+ sensitive motor which partners with 
recycling endosomes (REs) upon calcium influx into the cell following the insertion 
of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-R) 
[255]. It is involved in spine recruitment in neurons during long term potentiation. 
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Sklar et al. did not find an association with the previously reported CACNA1C 
variant rs1006737 (p=3.15x10-6) [231]. However, a number of SNPs in a region of 
linkage disequilibrium (LD) located in the third intron of the CACNA1C, also 
including the rs1006737 mutation were associated, but not at a genome-wide 
significant level. Another gene which showed association with BD in the Sklar et al. 
GWAS was tetraspanin eight TSPAN8 (p=6.11x10-7). Haplotype analysis further 
strengthened associations with these genes, MYO5B p=2.4x10-8, and TSPAN8 
p=7.57x10-7, and also implicated the epidermal growth factor receptor (EGFR) 
p=8.36x10-8. 
Ferreira et al. conducted a meta-analysis of the WTCCC GWAS, STEP-UCL and ED-
DUB-STEP2 in 2008 and reported an association with rs1006737 (p=7.2x10-8) 
located in the third intron of the CACNA1C gene, encoding the L-type α1C subunit 
of the voltage gated calcium channel gene family. They further reported an 
association with rs10994336 located in Ankyrin-3 (ANK3), p=9.1×10-9. A meta-
analysis conducted by Schluze et al. [248] shows association evidence for the 
previously implicated variant in ANK3 rs10994336 (p=1.7×10−5, OR=1.54). This 
meta-analysis contained more data, primarily from the National Institute of Mental 
Health (NIMH) BD cohort than that included in the Ferreira et al. study. 
Scott et al. (2009) conducted a GWAS on approximately 2,100 bipolar samples and 
1,700 control samples all of which had European ancestry from the NIMH 
repository, Pritzker repository and samples from the UK and Canada which were 
part of a GlaxoSmithKline sample [236]. Each of the sample cohorts were 
genotyped using the Illumina HumanHap 550K chip and a fixed effects meta-
analysis was conducted. Neither of the individual GWAS studies found associations 
reaching the genome-wide significant threshold, although three genes showed 
nominal significance. The first, CPS1, encodes a mitrochondrial enzyme involved in 
synthesis of carbamoyl phosphate (p=7.6x10-7, OR 1.34), the variant rs2813164 
(p=8.3x10-7, OR 1.31) is located between NEK7 (never in mitosis-related gene 7) 
and ATP6V1G3 encoding ATPase, H+ Transporting, Lysosomal V1 subunit. To 
increase the power of this study Scott et al. added in genotype data from the 
WTCCC study mentioned previously. Following quality control they report further 
evidence for the implicated genes (CPS1, NEK7 and ATP6V1G3) but their analysis of 
the combined sample data did not reach genome-wide significance. The strongest 
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association from the meta-analyses was found in an intron of the MCTP1 gene 
(p=1.8x10-7, OR=1.21). A number of non-synonymous SNPs in ITIH1, encoding the 
heavy chain 1 of the Inter-α trypsin inhibitor (33 variants p<10=6) also shows 
association in the meta-analysis. Regions on chromosome 1p32.1 and chromosome 
3p21 were implicated in this study. The membrane protein encoded by MCTP1 has 
a high affinity for binding Ca2+ ions in the absence of phospholipids and is highly 
expressed in the brain [256]. 
Genes implicated in the first series of GWAS reports and meta-analyses include a 
number of genes which are involved in neuronal excitability through the formation 
of ion channels such as CACNA1C, GABRB1, KCNC2 and MCTP1. Other regions of 
association contained genes that are in the pathways where lithium may have 
some effect such as DGKH.  
It is clear from such studies that combining samples for meta-analysis further 
benefited the number of results seen and strengthened the evidence for certain 
genes, while other associations disappeared and did not replicate across sample 
cohorts. These studies proved more sensitive in detecting variants with small 
effect sizes than linkage analysis, and some of the early studies showed replicated 
associations in a number of the same genes. However, given the evidence for the 
modes of genetic transmissions not enough candidate genes were seen if the 
hypothesis of polygenic inheritance was to be supported. 
In 2011, the Psychiatric Genomics Consortium for Bipolar Disorder (PGC-BD) 
published results from one of the largest BD GWAS studies to date. They conducted 
the GWAS on 7,481 BD samples, and 9,250 healthy volunteer samples. SNPs 
associated with BD at a genome-wide significance level were then tested in an 
independent sample of 4,496 BD cases and 42,422 controls to determine whether 
replicated associations with BD could be demonstrated. Further analysis was 
conducted on the dataset, and a combined GWAS of both BD and SCZ was 
conducted to determine common underlying associations. One standard quality 
control method that is used for GWAS studies is genomic control (GC). This method 
follows the concept that only a small number of variants should show true 
associations with a phenotype [257-259]. It corrects for the number of false 
positives which may occur due to population heterogeneity. The genomic control 
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inflation for the PGC-BD GWAS was calculated to be 1.148 providing evidence that 
BD will have a large number of underlying variants each with a small effect size. 
For the primary GWAS the cut off threshold for association was p≤5x10-8. 
Imputation was performed to address missing genotypes using the programme 
BEAGLE [260]. Association of the previously reported ANK3 variant rs10994397 
(p=7.1×10−9, OR= 1.35) was confirmed. A variant in the SYNE1 gene, located on 
chromosome 6q25 showed association with BD (p=4.3x10-8, OR=1.15). A variant in 
the TENM4 gene (encoding a human homolog of the Drosophila pair-rule gene ten-
m), rs12576775 was nominally associated at p=2.1x10-7, OR=1.18 as it did not pass 
the cut off threshold for genome-wide association at p=5x10-8. Thirty four SNPs 
which had a P value of less than 10-5 were tested in the second sample to see if 
their associations followed the same direction of effect. Associations were found 
with more SNPs than was to be expected by chance. Two SNPs remained genome-
wide significant following correction for multiple testing in the replication sample, 
rs10896135 located in C11orf80, and another variant present in the CACNA1C 
gene, rs4765913 (p=1.60×10−4, OR=1.13) which has been shown by Green et al. to 
be in moderate LD with the top GWAS hit rs1006737 [261]. These variants did not 
reach genome-wide significance in the primary GWAS. Additionally a combined 
analysis conducted with the PGC-BD cohort and the PGC-SCZ samples reports a 
stronger association with the CACNA1C variant rs4765913 (praw=7.7 × 10−8) 
compared to BD alone (praw=1.35 × 10−6). 
In the combined GWAS and replication analysis other members of the L-type 
family of calcium channel genes showed nominal association. These include 
CACNB3 (p=2.51x10-6, OR=0.86) encoding the β3 subunit of the VDCC gene family 
and CACNA1D, (p=3.73x10-5) which encodes for the 1D α pore of the VDCC family. 
The study showed the effect that larger sample sizes can have on the number of 
loci reaching the genome-wide threshold of significance (5x10-8) [250]. This 
suggests that greater GWAS sample numbers are required to identify all the 
genetic variants contributing to the risk of developing BD. 
Since the publication of the 2011 PGC GWAS BD study, there have been three 
further GWAS publications [242, 245, 246]. Cichon et al. report an associated 
variant, rs1064395, located in the Neurocan NCAN gene (p= 3.02x10-8, OR=1.31). 
This finding was replicated in an independent sample. In a combined analysis of 
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both the replication and original GWAS rs1064395 was found to be associated with 
BD (p=2.14x10-9, OR=1.17). During early embryonic development NCAN is 
reported to be solely localised to the central nervous system. However evidence 
from RNA in situ hybridisation studies show expression in the cortical plate and 
subventricular zone of the neocortex at embryonic days 14.5-16.5 in rats. In the 
subventricular region transcripts were localised to the caudate region where the 
neurocan protein may be involved with axon guidance [262]. Expression was also 
reported in the hippocampus during development. Following birth NCAN’s general 
expression was found to be decreased. Analysis of NCAN expression in the human 
brain reports expression in the hippocampus. These brain regions are known to be 
involved in cognition and emotional processing which have previously been 
implicated in BD [41, 101, 111]. Mice who are NCAN deficient do not exhibit 
structural brain changes. However the loss of gene function or variation in the 
NCAN gene may have a more subtle impact such as an effect on LTP which in turn 
has been reported to be associated with impaired memory [263]. Verbal memory 
impairments have been reported in euthymic BD individuals [264, 265] 
Chen et al. conducted a meta-analysis on a combined sample of 14,000 individuals 
with European and Asian ancestry in 2013 [245]. An association between 
rs9834970 in TRANK1 (p=2.4x10-11) and BD was reported [245]. Two additional 
SNPs on chromosome 2q11 reached the genome-wide significance threshold of 
p<4x10-8, located near the LMAN2L gene. TRANK1 expression in a number of cell 
lines (HeLa, SH-SY5Y and HEK293) was also measured in response to commonly 
used mood stabilizers lithium and valproate. While no expression difference was 
detected in response to lithium, valproate increased expression of TRANK1 mRNA 
levels in all cell lines in both a -time and -dose dependent manner. No alteration in 
expression was noted when the cells used were exposed to corticosteroids which 
are reported to provoke mania in BD patients. The variant rs9834970 in TRANK1 
had also previously been reported in the WTCCC (p=4.50x10−7) [231] and a 
Brazilian family study (p=0.0025) [266]. 
Mühleisen conducted a GWAS combining unpublished data from the Systematic 
Investigation of the Molecular Causes of Major Mood Disorders and Schizophrenia 
(MooDs) PGC data cohort and the previously published PGC-BD samples [246]. The 
MooDs cohort consisted of 2,266 individuals with BD and 5,028 matched healthy 
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controls. Associations were found between ANK3, TRANK1, ODZ and BD, and two 
new susceptibility loci were also implicated. These were in the ADCY2 gene 
(p=9.89 × 10−9, OR=1.14) and a region on chromosome 6q21 between two genes 
MIR2113 and POU3F2. Only one variant in the previously reported BD 
susceptibility gene, CACNA1C, was reported as being nominally significance 
(rs4765913 p=9.69 × 10−6, OR=1.12). This variant did not pass the threshold for 
genome-wide significance in this cohort. The remaining SNPs in the CACNA1C were 
not associated with BD in the MooDs PGC cohort. 
Another GWAS study, conducted by Lee et al. in a Han Chinese population of BD-I 
samples, reports a number of suggestive associations. These were in SP8 
(p=4.48x10-7), ST8SIA2 (p=6.05x10-6), KCTD12 (p=9.4x10-6). Additionally they 
reported an association between rs11013860 in CACNB2, the β2 subunit of the 
calcium channel family of genes (rs11013860, p=5.15×10−5) [244]. Nominal 
association is additionally reported near ANK3 (rs1938526, p=5.15x10-5 and 
rs11720452, p=1.48x10-5). These results have yet to be replicated in any of the 
larger GWAS studies. Other studies conducted on different population cohorts have 
not reported differences between associations seen in individuals with Asian 
ancestry or European ancestry [245].  
A multi stage GWAS was also published in 2013 by Kuo et al. [249] starting with a 
primary study sample of 200 BD-I cases and 200 controls. From this 15 individual 
variants and eight genes were fine mapped in an extended cohort of 240 samples 
and 240 controls, followed by replication analysis in 351 cases and 341 controls. 
No gene reached genome-wide significance and the highest ranking SNP 
rs7619173 (p=2x10-5) was not in a gene coding region. SNPs located in four other 
genes showed nominal significance in this data KCNH7 (p=0.0047), NRXN 
(p=0.0095), SEMA3D (p=0.037) and MYST4 (p=0.0047).  
In 2014 Xu et al. conducted a GWAS on case and control samples from the UK and 
Canada. This was supplemented by analysis from 229 Canadian families, each with 
a BD proband [247]. Certain samples from the UK and Canadian cohorts have been 
previously included in GWAS meta-analysis reports from the PGC-BD GWAS [239] 
and the Scott et al. GWAS and meta-analysis [236]. In addition to this a subset of 
individuals from the UK sample were included in the WTCCC GWAS [231]. No 
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individual genes exceeded the genome-wide significant cut off threshold of 10-8, 
but a number of genes showed nominal significance in the preliminary data. 
Fourteen SNPs in SYNE1 were observed to have a P value of ≤10-6. This however 
could be due to the fact that the signal originated in the UK cohort that had 
previously been involved in the WTCCC and the Liu et al. meta-analysis between 
BD and depression so it cannot be described as in an independent signal in this 
study. A variant located in ZNF659 was among the top 68 SNPs p=3.25x10-4 and 
this gene had already been reported as being associated with BD [233]. 
The design of GWAS in psychiatric illness has evolved in recent years. Instead of 
conducting GWAS of single disease case-control samples, broader case definitions 
have been used in an attempt to investigate shared genetic susceptibility. 
Additionally, information from previous GWAS has been used by research group to 
target specific candidate genes for sequencing of genes of interest in an effort to 
determine variants which may lead to the signal seen in the GWAS. 
Pereira et al. used the UCL data from the GWAS conducted by Sklar et al. in 2008 to 
investigate the IGF1 gene [243]. The sample consisted of 506 BD-I samples and 510 
matched healthy controls. They identified ten SNPs from the 37 studied in the IGF1 
gene as having nominally significant P values. This gene was then sequenced in 
individuals who had a predefined haplotype, IGF1 susceptibility HAP, to determine 
whether any additional variation, potentially missed by the GWAS study, was 
present. Six additional single base changes were identified in these subjects 
alongside a CA tandem repeat. These seven variants were screened in an extended 
cohort sample of 937 individuals with BD and 990 healthy control individuals. 
These samples included the ones which had been previously undergone GWAS 
analysis. Of the seven variants found, three were reported to be associated with BD 
in the UK cohort, rs5742620 (p=0.0454), rs78352613 (p=0.006) and the CA 
microsatellite (p=0.0132). These variants were not previously covered by the 
GWAS study. This study provides an example of how focused sequencing of genes 
implicated through GWAS can identify other relevant variants. IGF1 mutations may 
play a role in the neurological deficits that are present in individuals with BD. An 
IGF1 knock out mouse was found to have neurodevelopment deficits indicating a 
role for IGF1 in myelination and axonal growth [267]. These results have not been 
replicated in any other GWAS to date. 
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The PGC cross disorder group has conducted a meta-analysis of five psychiatric 
disorders in an attempt to identify loci with shared effect between Autism 
Spectrum Disorder (ASD), Attention Deficiency-Hyperactivity Disorder (ADHD), 
BD, Major Depressive Disorder (MDD) and SCZ. The meta-analysis included a total 
of 33,332 cases and 27,888 controls [268]. In the primary analysis four loci passed 
the genome-wide significant threshold. These included two L-type calcium channel 
gene subunits CACAN1C (p=1.87x10-8) and CACNB2 (p=4·29x10-8, OR=1.08). Using 
the Bayesian information criterion (BIC) they determined the best-fit model for a 
variants effect on the five diseases. While CACNA1C had previously been associated 
in MDD, SCZ [269] and BD [270], the BIC model in this meta-analysis favoured a 
role for CACNA1C in BD and SCZ only. CACNB2 was shown by the BIC model to have 
a cross disorder effect. The strongest association signal in the meta-analysis came 
from rs2535629 in an intron of ITIH3 (p=2.54x10-12, OR 1.07). ITIH3 has been 
previously implicated in the PGC Bipolar GWAS in a combined analysis of SCZ and 
BD samples [236, 270]. The ITIH3 gene encodes the inter-α-inhibitor heavy chain 
3. The second highest association signal was found at rs11191454 in an intron of 
AS3MT (p=1.39x10-8, OR=1.13). The BIC model analyses for ITIH3 and AS3MT also 
found a shared effect between all five disorders. 
The PGC cross disorder group also applied polygenic risk profiling to the five 
disorders. One set of data was used as the discovery set and the other samples 
were used as target sets. Polygenic risk score analysis calculates the proportion of 
variation in the targets set using risk scores from the discovery set [39]. An overlap 
between the adult onset disorders, MDD, BD and SCZ was identified (P<10-5). The 
strongest overlap was seen between SCZ and BD. 
Curtis et al. [271] performed a meta-analysis on a cohort of 506 BD-I, 523 SCZ and 
505 controls from the UK described in chapter 3.1.1 of this thesis. An association 
signal from rs17645023 (p=10-6) was reported. This variant is located between 
two members of the γ family of subunits which interact with L type family of 
calcium channel genes, CACNG4 and CACNG5. This variant was not associated in 
either of the samples when they were analysed separately against healthy control 
populations. Mutations in the related CACNG2 gene are associated with epileptic 
seizures and ataxic gait in mice [272]. These genes encode transmembrane AMPA 
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receptor regulators which traffic AMPA receptors from the endoplasmic reticulum 
to the post-synaptic density. 
Many of the SNPs associated with BD through GWAS are localised in intronic or 
intragenic regions making it difficult to determine their functional effect. Studies 
focusing on identifying and annotating functional and regulatory regions in the 
genome have found that only 4.6% of variants associated in GWAS studies are 
located in coding regions [273]. For example one of the variant most strongly 
associated with BD is located in the third intron of CACNA1C gene. It may be that 
the most strongly associated variants are not the causative ones but rather they 
are in strong LD with causative variants. 
In addition to conducting a meta-analysis Chen et al. also investigated the potential 
risk loci that may be still be discoverable through GWAS using a method devised by 
Park et al. [274]. This method utilises previously published GWAS to determine the 
power and risk prediction of future studies. They estimate that there is a minimum 
of 105 additional susceptibility loci that can be determined for BD through GWAS 
studies but for this to happen the number of samples involved would need to be 
greater than 63,000 [245]. 
The most recent SCZ GWAS, conducted by the PGC, has identified 108 regions of 
association across the genome harbouring 128 independent associations in a large 
sample of 37,000 cases and 113,000 controls [275]. This is compared to the results 
from the original PGC mega analysis GWAS which identified 22 independent loci, 
13 of which were new, when the sample sizes were approximately 14,000 and 
18,500 cases and controls respectively [276]. 
This increase in sample numbers correlating to the number of resulting associated 
loci is depicted in Figure 7 from a review by Crowley and Sakamoto [277], looking 
into the advances from psychiatric genetics and the predicted outcomes for the 
next 5 years. It is hoped that an increasing jump in the number of associated loci 
for BD will follow the trend observed in SCZ. GWAS studies have proved successful 
in the identification of risk variants of small effect sizes which are associated with 
BD. A number of new technologies and methods have been developed to 
investigate the contribution rare variants may have on disease risk. 
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Figure 7. Relationship of associated loci in psychiatric illness and sample size. 
Progression of outcomes in genetic hits for a range of psychiatric illnesses 
compared to increases in sample sizes. Image taken from [277] 
The many constraints on large sample collection has meant that alternative 
pragmatic approaches to analysing GWAS data are beginning to be employed by 
researchers in the field of psychiatric genetics. Additionally, the data may harbour 
further associations which are not obvious following the primary GWAS analysis. 
The most consistent manner in approaching these large sets of data has been to 
begin to look at the data in a new manner and to apply different statistical tests to 
the data. Variants of small effect sizes may contribute to disease risk by the 
accumulation of multiple variants in a particular pathway or gene family. 
Investigation of the function of these variants through pathway analysis can 
provide further insight into the underlying genetic mechanisms of BD. 
1.2.2.4 PATHWAY ANALYSIS 
As the number of BD and control samples for which GWAS data is available has 
increase it has become possible to explore genetic associations at a pathway level 
in a meaningful way.  
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Pathways analysis was conducted on the data from the PGC-BD GWAS of 7,481 BD 
cases and 9,250 healthy controls [239]. Using the top 34 independent SNPs from 
the GWAS study (p>5x10-5) the PGC-BD group performed an analysis to determine 
whether there was an enrichment of any gene ontology (GO) pathways in the genes 
where these variants were located. The used an interval-based enrichment 
analysis (INRICH) which tests for an enrichment or burden of associated variants 
amongst predefined gene sets. They employed a permutation based approach to 
control for differences amongst genes. Controlling for gene size, SNP density and 
gene density is essential to avoid introducing bias to the analysis. The analysis was 
conducted by binning genes based on size and SNP density. An enrichment of 
nominally associated SNPs was found in GO:0015270 which contains eight genes, 
three of which belong to the L-type calcium channel family, CACNA1D, CACNA1C, 
and CACNB2 (p=2x10-5) [239]. 
INRICH pathway analysis has also been conducted on the data from the PGC five 
disorder meta-analysis and reported further evidence for pathways involving 
calcium channel genes. Associations in the calcium channel genes originated from 
the BD GWAS, however in the cross disorder group the removal of the BD cohort 
did not result in the calcium channel gene enrichment disappearing. This suggests 
that this family of voltage gated ion channels has an underlying role in a number of 
psychiatric illnesses [268]. 
INRICH is not the only pathway analysis software available to conduct gene 
enrichment analysis. Other methods include FORGE, ALIGATOR, SET-SCREEN and 
MAGENTA. These were compared in a recent study investigating pathways in 
psychiatric illness [278]. It is to be assumed that if one pathway is robustly 
associated using different methods it is more likely to signify a true result. A 
combined q value was devised to collate the p values from the different pathway 
analysis software. The q value is taken from the false discovery rate, where the q-
value of a test measures the proportion of false positives incurred when the test is 
called significant. Each of the gene sets were ranked by this value. The pathways 
were defined using five different databases GO, Kyoto Encyclopedia of Genes and 
Genomes (KEGG), Panther, Reactome, TargetScan. This study implicated a number 
of different pathways including histone methylation marks, neuronal signalling 
pathways and with genes involved at the postsynaptic density and the immune 
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system. The pathway most associated across adult psychiatric disorders (SCZ, 
MDD, and BD) was GO:51568, histone H3-H4 methylation (combined p=5.75×10−8, 
q=0.0003). The second strongest association was seen a pathway for histone 
methylation, GO=16571 (p=1.46x10-5, q=0.0362). It is not strange that pathways 
involved in gene regulation and translation may be involved in BD or other 
psychiatric illnesses. Recent assessment of the results from a number of GWAS 
studies has shown an abundance of enrichment with SNPs in the promoter, 5’UTR 
and the 3’UTR [279]. This may help to explain the GWAS association signals that 
occur outside protein coding regions. A nominal association for the calcium 
channel activity pathway GO:005262 was also seen amongst all five disorders 
(p=3.13x10-3) [278]. 
Pathway analysis was conducted on the GWAS data used in the Xu et al. publication 
[247]. The pathway analysis in the primary data set was performed based on a 
method devised by Beyene et al. [280]. SNPs that had a nominal association value 
of p<0.01 were chosen for pathway enrichment analysis; this included 5,111 SNPs 
from the discovery cohort in the study which mapped to 2,155 genes. These were 
the closest genes to each variant as defined using the Illumina SNP annotation file. 
The number of variants in each gene was used to calculate an aggregate summary 
measure [280]. The authors calculated the statistical significance of predefined 
pathway with Ingenuity Pathway Analysis software (IPA, version 11904312) using 
the aggregated summary measure. This used the Fisher’s exact test to calculate the 
level of association reported based on the number of genes annotated, the number 
of genes studied and representatives from the input data and the entire set of 
genes being assessed in the analysis. The threshold for association was set at 
p≤0.05 for pathway enrichment. Thirty pathways were found to be significantly 
enriched in the data presented in this study, a number of which show support for 
roles of genes already implicated through GWAS such as calcium signalling 
(Padj=0.003), glutamate receptor signalling (Padj=0.003), axonal guidance signalling 
(Padj=0.003), cyclic-AMP- response element (CRE)-binding protein (CREB) 
signalling in Neurons (Padj=0.0161). Other pathways implicated may reflect 
alternative disorders present in the cohorts, or other underlying mechanisms 
which may play small roles in BD but have not yet been implicated through GWAS 
studies such as the “molecular mechanisms of cancer” pathway (p=0.003). 
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Current results from pathway analyses have implicated pathways that would be 
expected to be involved in BD given previous evidence from GWAS studies. These 
include the calcium signalling pathway. Members of this pathway have been 
implicated through numerous GWAS. Other pathways of interest which could 
further our understanding of BD, which have not previously been implicated 
through GWAS or linkage studies, are the histone methylation pathways. These 
pathways are highly involved in the regulation of gene expression and 
transcription. In addition to these results, these analyses have highlighted 
pathways previously not implicated in BD such as cancer pathways which appear 
to have no direct impact on the phenotypes observed in individuals with BD but 
genes in this category may have an impact on signal cascade pathways. 
1.2.2.5 NEXT GENERATION SEQUENCING IN BIPOLAR DISORDER 
Next generation sequencing (NGS) is essential for all fields of biological research. 
In the past decade it has become increasingly more affordable for researchers and 
collaborations to invest in both whole exome sequencing and whole genome 
sequencing (WGS). Sanger sequencing has been utilised to investigate genetic 
variation in the genome using capillary electrophoresis, however, this method is 
not suited to high through put screening of the genome. NGS works in a highly 
parallel fashion across the genome concurrently. Genomic DNA is cut into small 
uniform DNA fragments which allow parallel sequencing reactions to occur (Figure 
8). Each of the small fragments of DNA is screened and bases identified from the 
signal emitted as each fragment is resynthesized. These are then aligned with 
either a reference genome or they undergo novel reconstruction to produce de 
novo sequence alignments. All of the aligned reads allows for the genomic 
sequence to be read accurately. Most genomic bases are read more than once, and 
this is described as sequencing read depth, or coverage. High coverage can be used 
to determine whether the base that is observed at a specific position in the genome 
has been accurately called and to determine whether the call is likely to be 
accurate. 
Figure 9 shows a timeline, taken from a review by Lehner, Senthil and Addington 
[281], marking the progress that has occurred in the field of psychiatric genetics 
during the past 26 years. The number of biosamples stored by the NIMH  
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Figure 8. Concept of Next Generation Sequencing through parallel sequencing of genomic DNA.  
Genomic DNA is fragmented into short reads which facilitates the concurrent parallel sequencing reactions. DNA alignment shows how sections are 
read multiple times and the DNA sequence is read from the base which occurs in the majority of reads. In some reads where a common SNP may be 
present this will show in the vcf output file from the sequencing reaction. These sequences are then aligned to produce an entire whole genome 
sequencing output file. 
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Repository and Genomics Resources (NRGR) shows an accompanying increase in 
the technology available to analyse the data and to handle the samples (green 
circles). There are also an increasing number of policies which have been created 
to promote the sharing of data and depositing both human and non-human 
genomic data in repositories (Orange). There are two different sample repositories 
currently available for depositing such data, the NRGR and the Database of 
Genotypes and Phenotypes (dbGAP) (Purple Circles). Additionally in Europe there 
is a repository called the European Genome-phenome archive (EGA) that is a 
repository for the WTCCC data, which is not shown in this figure 
(https://www.ebi.ac.uk/ega/home). There are a growing number of large-scale 
collaborations that have greatly facilitated genetic research into psychiatric 
illnesses, providing additional samples and resources for a combined approach to 
understanding genetics. This originally started with the HGP, aimed at producing a 
reference human genome and was completed in 2001. The establishment of the 
PGC has been previously discussed in this thesis and has had a previously unseen 
impact on delineating genetic underpinnings in psychiatric illness. The Autism 
Sequencing Collaboration (ASC) formed in early 2010 and involves over 20 
research groups working together to exome sequence 20,000 Autism patients 
(Light Blue circles).  
To date there have seven next generation sequencing studies conducted in cohorts 
of patients with BD (Table 2). Four of these were exome sequencing studies 
conducted on BD case control samples and family pedigrees [282-285]. In addition 
to this two whole genome sequencing studies have been published [286, 287]. Two 
of these studies have been conducted on the large Amish pedigree that was 
originally used to investigate linkage in BD [164] (see section 1.2.2.1). 
There are advantages and disadvantages associated with both whole genome and 
exome sequencing. The deciding factor for many researchers arises from cost 
benefit analysis; exome sequencing is cheaper so a greater number of samples can 
be sequenced with a higher depth of coverage achieved for the same price as a 
fewer number of samples and lower coverage at a whole genome level. With GWAS 
studies pushing the mind-sets of researchers to the “greater number of samples 
coincides with increased number of loci” resolve, it is understandable why this 
appears an attractive option.   
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Figure 9 Timeline of progress in psychiatric genetics from 1989-2013. 
This graph depicts advances that have been made in the field of psychiatric genetic 
studies since 1989. New technologies, such as SNP arrays, are depicted by green 
circles. Sample repositories such as dbGAP and the NIMH Repository and 
Genomics Resource (NRGR) are depicted in purple. Data sharing policies which 
have been implemented over the past 26 years are denoted by orange circles. 
Large scale collaborations such as the Psychiatric Genomics Consortium (PGC) and 
the Human Genome Project (HGP) are denoted by light blue circles. Finally pivotal 
findings such as de novo variation in autism spectrum disorder and the first BD 
GWAS are denoted by red circles. Image [281] 
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Study Year Journal Population Study Design NGS 
             N 
Genes Implicated 
Cases Controls Families 
Chen 2013 PLoS Genetics 
[282] 
Unknown Case-Control Exome 191 107 _______________ Seven genes sets 
nominally associated 
Cruceanu 2013 Genome [283] Canadian Large Pedigree Exome   250 samples from 25 
families 
ZNF259,segregation of a 
rare allele among affected 
individuals 
Kerner 2013 Front. Psychiatry 
[284] 
NIMH* Single Family Exome 3 1 One family consisting 
3 affected daughters 
and 1 unaffected son 
IQUB, JMJD1C, GADD45A, 
GOLGB1, PLSCR5, VRK2, 
MESDC2, FGGY 
      
Georgi 2014 PLoS Genetics 
[286] 
ASMAD** Large Pedigree Whole Genome 
Sequencing 
combined with 
Linkage 
analysis 
50  Originating from one 
pedigree with 497 
individuals 
Some rare deleterious 
mutations found but these 
may be results of founder 
effects 
       
       
       
Strauss 2014 Hum. Mol. 
Genetics [285] 
ASMAD Large Pedigree Exome 7  Originating from four 
families 
KCNH7 
        
Fiorentino 2014 Bipolar Disorders 
[287] 
UK UCL Case Only Whole Genome 99  _______________ CACNA1C, ANK3 
Ament 2015 PNAS European Large Pedigree Whole Genome 
combined with 
resequencing 
and genotyping 
200  Originating from 41 
families 
GABRA6, ANK3, CACNA1B, 
CACNA1C, CACNA1D, 
CACNG2, CAMK2A, NGF 
          
Table 2. Next generation sequencing studies conducted on Bipolar Disorder.  
*National Institute of Mental Health sample set. **Amish Study of Major Affective Disorders. For some of the samples additional analysis was 
conducted following whole genome or whole exome sequencing. 
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On the flip side of the coin, an ability to investigate genetic variation present in all 
regions of the genome is potentially a bigger advantage given that GWAS points to 
numerous variants located in different regions outside of the classically defined 
protein coding regions of genes.  
In 2013 Chen et al. published a case control study focusing on exome sequencing 
from 191 BD cases and 207 controls [282] . In part, the main goal of their study 
was to investigate different methods of statistical analysis that can be employed to 
find variation present in exome sequence data for case control analyses. Using the 
Burden or Mutation point test (BOMP) method they searched for functional 
variants in a specific genomic region. This specific defined region can be in either a 
single gene, in a set of genes, in a defined region of a chromosome, or in a pathway 
of genes. The method is designed to allow for the inclusion of weightings for 
variants calculated by their bioinformatically determined functional impact. The 
authors identifyed pathways that were enriched for BD related variants. Seven 
pathways were nominally significantly associated with BD. The MAPK pathway 
was the most associated and after correction for multiple testing showed 
association with BD (p=0.0065). Of the 263 genes in the MAPK pathway, a number 
have been previously implicated in BD such as CACNA1C. The MAPK pathway is 
highly conserved and is thought to be involved in synaptic plasticity and cellular 
proliferation, migration and differentiation [288]. Additionally both lithium and 
sodium valproate activate the MAPK signalling cascade pathway, which may be 
involved in the anti-manic effects of these compounds [289]. 
Cruceanu et al. published an exome sequencing study that highlighted a rare 
missense mutation in ZNF259 which appears to be segregating in affected 
individuals in one pedigree [283]. The sample population included individuals 
where there was a high incidence of BD in the family pedigree and where probands 
showed good response to lithium monotherapy. Aside from the ZNF259 finding 
there were no other striking results or association seen in the sample 
Conflicting results were seen in the exome data published by Kerner et al. [284]. 
They investigated and sequenced a nuclear family in which three daughters were 
affected with BD and the fourth sibling was unaffected. There were no previous 
reports of psychiatric illness in this family on either the paternal or maternal side. 
Rare heterozygous mutations were found in eight brain expressed genes, which 
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occurred in protein coding regions of the gene, in the three individuals with BD but 
were absent in the remaining family members and 200 additional control 
individuals screened for the mutations in the general population. Of the eight 
mutations found, five were novel mutations and three had been previously 
described in some international studies but still were rare in healthy controls. All 
were rare variants and the genes in which they arose play a role in the both the 
ERK/MAPK and CREB cycle pathway which regulates gene expression and has 
been show to play a role in neuronal plasticity [290, 291]. While this study had 
only had three probands it was able to determine shared rare genetic variation. 
Additionally these variants were absent in unrelated individuals with the same 
ancestral background and in a large control population from an additional study. 
Two groups have focused on the Amish Study of Major Affective Disorders 
(ASMAD) cohort. Strauss et al. conducted exome sequencing in seven out of 
fourteen patients from four different Amish family pedigrees. Ten of the variants in 
this study were chosen for association analysis following sequencing. One variant, 
present in a potassium channel gene, KCNH7, was found in all fourteen of the 
individuals with exome sequencing data and was also associated in the wider 
pedigree. As previously discussed, mutations in potassium channels and ion 
channels have been implicated in the aetiology of BD. 
Georgi et al. conducted WGS on 50 individuals, including 23 with BD, from a single 
large Amish pedigree. They used linkage analysis to prioritise variants to genotype 
in 488 members of the extended pedigree. Several genomic regions showed a trend 
towards significance but none of these findings survived multiple correction. 
Fiorentino et al. conducted WGS on 99 BD individuals. This study was conducted in 
the Molecular Psychiatry lab in UCL and the results will be discussed in further 
detail in Chapter 6.2 [287]. 
Most recently, Ament et al. [292] conducted a next generation sequencing study on 
200 individuals with BD from 41 multiple affected BD pedigrees of European 
ancestry. The focus of their study was elucidating rare variants that may confer an 
increased susceptibility to individuals in the population and their risk of 
developing BD. From the families, two to seventeen individuals were sequenced 
per pedigree and each of the individuals were separated into one of three clusters. 
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The first consisted of closely related affected individuals. The second included 
affected individuals separated by multiple meiosis and the final group consisted of 
pairs of subjects who were discordant for BD. The reason for the multiple clusters 
was to test different genetic disease models such as rare variants with highly 
penetrant effects which may follow a monogenic pattern of inheritance or an 
oligogenic pattern were rare or uncommon variants may cluster in individuals and 
additively cause disorder symptoms. Three types of hypotheses were then 
employed to choose genes to further investigate. Genes located within 100kb from 
loci reaching significance (P<10-4) in the PGC BD GWAS [270]. Genes which are 
intrinsic for neuronal functions were also investigated to see whether they harbour 
an increased number of rare variants in individuals with BD. The last cohort of 
genes to be investigated originated from gene ontology pathway analysis. Variants 
with MAF < 0.05 present in coding or regulatory regions of the genome were also 
considered. Genotyping of rare variants was then conducted in a larger cohort of 
3,014 BD individuals (GAIN) [235] versus 1,717 healthy controls recruited from 
the Translational Genomics Research Institute [240]. Variant investigation 
highlighted a rare SNP, rs3811993 P=3x10-5, in the GABRA6 gene, which encodes 
the α6 subunit of one the main inhibitory neurotransmitter families, GABA 
receptor family, in the CNS. Resequencing of this variant in the additional case 
control sample further identified this variant in a further 7 BD cases and 1 single 
healthy control. 
Pathway analysis in the 200 WGS BD individuals and family members highlights an 
increased burden of rare and uncommon variants in their genome, specifically in 
genes involved in neuronal pathways (see Figure 10). These pathways include 
GABA pathway genes (P=1.5x10-5) and GTPase genes (P=6.8x10-3). Additionally 
voltage gated calcium channel genes (P=3.6x10-3) and calmodulin-dependent 
protein kinase genes (P=1.3x10-2) showed trends towards significance. 
Combined analysis of both the modelling approach and the pathway analysis 
suggested that rare variation in individuals affected with BD and their relatives is 
found predominantly in non-coding regions of the genome with 164 variants found 
outside exonic regions. Of these 88% were located in promoter regions in addition 
to the 5’ and 3’UTR.  
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Figure 10. Families of genes highlighted from pathway analysis in 200 WGS BD 
patients.  
A. The number of pedigrees which contain a fully or almost fully segregating 
variant from a coding or regulatory region in a gene which is defined as being a 
member of the GABA pathway in BD (Orange) and healthy controls (blue). B. The 
number of pedigrees which contain a fully or almost fully segregating variant from 
a coding or regulatory region in a gene which is defined as being a member of the 
Calcium channel pathway in BD (Orange) and healthy controls (blue). C. 
Segregation of rare coding or regulatory SNPs or indels in the GABRA4 gene from 
the GABA family. Each of the thick bars denote an exon, and the 5’ and 3’ UTR 
regions are denoted by the extended thick lines before and after the first and last 
exon respectively. D. The number of rare risk variants in each of the different 
cohorts, BD (orange), unaffected relations of a BD proband (light blue), healthy 
controls (dark blue) in the sample used for the Ament et al. study. Risk variants 
were defined as those with a P<0.001, SNPs from the mixed model disease type 
with P<0.05 and that had an odds ratio of great than 1. Image taken from [292]. 
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Ament et al. conducted further variant analysis by targeted sequencing of 26 genes, 
20 of which were implicated in their study (10 voltage gated calcium channel 
genes, 5 GABA receptor subunits and five camodulin-kinase signalling genes), and 
six others genes from the PGC GWAS association candidate loci (ANK3, TENM4, 
NTRK2, NTRK1, NGF, BDNF). This target resequencing focused primarily on the 
coding and regulatory regions of the genes, and found little evidence for coding 
variants in these genes with only ANK3 reaching significance in a model which 
supports the presence of only rare risk variants and the absence of protective 
variants. In contrast, significant associations were reported between rare variants 
located in enhancer and promoter regions, which have an impact on transcription 
factor binding sites. Analysis of the data using the sequence kernel association test 
(SKAT) [293] identified six genes, CACNA1C, CACNA1B, CACNA1D, CACNG2, 
CAMK2A and NGF that were significantly associated with BD. 
The dawn of the new era for genomic studies come with a need for more powerful 
and further developed statistical and informatics approaches. NGS data often 
produces thousands of novel variants which may impart a functional effect on 
disease susceptibility. Identifying the variants of interest and their association 
between phenotypes can be difficult given that some of these variants have small 
to moderate effect sizes. Increasingly powerful analytical methods are being 
devised in an attempt to address this issue. One of the common approaches to 
sorting through NGS data is to conduct burden analysis of variants in different 
genes and between gene sets [282]. Other approaches used to identify variants 
which may result in phenotypic changes are regression models [294] and over 
dispersion tests [295]. Both regression and over dispersion tests can analyse 
variants regardless of direction of effect and therefore these tests do not suffer 
from the loss of power that protective or neutral variants have on burden tests. 
Other approaches are starting to incorporate mixed models as well as using 
weighting of different types of genetic variants. 
NGS offers researchers the ability to select a sample cohort in which a more 
thorough investigation of genetic variation may be undertaken. The steps that 
follow after the initial data collection are where the integral approaches to analysis 
change. The investigators above have included resequencing of genes of interest in 
larger sample populations, using linkage analysis to investigate variation in the 
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NGS data, genotyping of variants in larger pedigrees, and using publically available 
data to determine variant frequency. 
1.3 CALCIUM CHANNEL GENES  
1.3.1 INTRODUCTION 
Bipolar disorder genome-wide association studies have identified a number of 
disease related genes and pathways. The L-type calcium channel gene family has 
been repeatedly implicated in BD. Calcium channels are formed from a 
combination of auxiliary subunits, based around a calcium selective α pore, first 
identified by their association with puriﬁed dihydropyridine [296, 297] (Figure 
11).  
Researchers have identified 26 genes with five different subunits, encoding ten α, 
four β, four α2δ and eight γ calcium channel subunits in the voltage dependent 
family of calcium channel genes (Table 3) [298]. The main alpha subunit forms a 
calcium selective pore in the membrane of the cell allowing the influx of Ca2+ ions 
into the cell while other auxiliary subunits interact directly with the α subunit to 
regulate channel gating in response to extracellular signals. The Ca2+ signalling 
pathway is a key component for initiating a multitude of different physiological 
changes in response to the influx of Ca2+ ions. This signalling pathway acts as a 
secondary messenger and launches a variety of signalling cascade pathways. 
Calcium channel pores are found in nearly all cells of the body and neurologically 
they participate in the mechanisms which are responsible for regulating neuronal 
excitability, information processing and cognition [93]. 
The role that calcium plays as a secondary messenger is an integral part of the 
biochemical transduction of synaptic signals and this in turn impacts gene 
regulation and expression [299]. The allosteric nature of calcium as a divalent 
cation makes it suitable for its vital role in biological systems. Its large radius and 
electron shell configuration make it suitable for interacting with large biological 
molecules, and the size and radius offers Ca2+ ions a flexibility that other smaller  
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Figure 11. Formation of the Voltage-Gated Calcium Channel in the cell membrane.  
The main α1 subunit forms a pore in the cell membrane allowing Ca2+ influx into 
the cell following membrane depolarization. The other auxiliary subunits control 
the voltage gating and influx of Ca2+ into the cell. Each of the protein subunits 
interact via various domains. The α1 subunit interacts with β subunits via an α 
interacting domain (AID) and β interacting domain (BID). The α2 and δ subunits 
bind via proteolysis disulphide bridge formation. Other binding motifs such as the, 
post synaptic density protein (PSD95), Drosophila disc large tumour suppressor 
(Dlg1), and zonula occludens-1 protein (zo-1) (PDZ) domain allow the auxiliary 
subunits to scaffold to the post synaptic density. The SRC homology 3 (SH3) 
domain controls the biophysical properties of the calcium channel activity and 
inactivation . GK, Guanylate kinase-like domain is essential for plasma membrane 
expression of β subunits of the calcium channel family of genes [300].  Image based 
on [301].  
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Gene Name Type 
Chromosomal 
Location 
CACNA1A  P/Q type, alpha 1A subunit 19p13 
CACNA1B  N type, alpha 1B subunit 9q34 
CACNA1C  L type, alpha 1C subunit 12p13.3 
CACNA1D  L type, alpha 1D subunit 3p14.3 
CACNA1E  R type, alpha 1E subunit 1q25.3 
CACNA1F  L type, alpha 1F subunit Xp11.23 
CACNA1G  T type, alpha 1G subunit 17q22 
CACNA1H  T type, alpha 1H subunit 16p13.3 
CACNA1I  T type, alpha 1I subunit 22q13.1 
CACNA1S  L type, alpha 1S subunit 1q32 
CACNA2D1  alpha 2/delta subunit 1 7q21-q22 
CACNA2D2  alpha 2/delta subunit 2 3p21.3 
CACNA2D3  alpha 2/delta subunit 3 3p21.1 
CACNA2D4  alpha 2/delta subunit 4 12p13.33 
CACNB1  beta 1 subunit 17q21-q22 
CACNB2  beta 2 subunit 10p12 
CACNB3  beta 3 subunit 12q13 
CACNB4  beta 4 subunit 2q22-q23 
CACNG1  gamma subunit 1 17q24 
CACNG2  gamma subunit 2 22q13.1 
CACNG3  gamma subunit 3 16p12.1 
CACNG4  gamma subunit 4 17q24 
CACNG5  gamma subunit 5 17q24 
CACNG6  gamma subunit 6 19q13.4 
CACNG7  gamma subunit 7 19q13.4 
CACNG8  gamma subunit 8 19q13.4 
Table 3. Calcium channel genes. 
Calcium channel alpha pores and their chromosomal locations in the human 
genome 
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divalent cations such as magnesium do not have. Intercellular calcium 
concentration is regulated through a number of specific mechanisms to maintain a 
low cytosolic level. A calcium gradient is formed across the cell membrane by a 
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump that removes calcium 
from the cytosol, and places it into internal stores in the endoplasmic reticulum 
(ER) membrane. This gradient allows calcium entry into the neurons through the 
voltage dependent calcium channel located on the plasma membranes. 
Additionally calcium can be released from the ER stores through InsP3 receptors 
[302] which will be further explained below (Figure 12).  Influx of calcium through 
ion channels occurs in response to excitatory neurotransmitters signals. Calcium 
can enter the cell through either VDCCs, or ligand gated channels such as (N-
methyl- D-aspartate)-type glutamate receptors (NMDARs) and α-amino-3-
hydroxy-5-methyl-4-isoxazolepropinonic acid receptors (AMPA-R). In addition to 
this, calcium entry may be instigated via neuronal inputs stimulating G protein 
coupled receptors (GPCRs). Both of these mechanisms create intracellular and 
nuclear calcium channel transients for further downstream signalling (Figure 13) 
[303].  
The mechanism of membrane depolarisation, that lead to the opening of VDCCs 
and the influx of Ca2+ ions, occurs through the stimulationof excitatory 
postsynaptic potentials (EPSP). EPSPs induce action potentials that propagate 
actively through the axon and then back through the dendrite [304], leading to 
plasma membrane depolarisation and opening of L-type VDCCs. L-type calcium 
channels are ubiquitously expressed in the somatic and perisomatic area [305] and 
allow for a high influx of Ca2+ ions. This occurs through synaptic input stimulating 
NMDA and AMPA-R on the postsynaptic density. 
The second mechanism that leads to increased nuclear and intracellular calcium 
transients occurs through the coupling of GPCRs on the postsynaptic density. The 
coupling of the GPCRs leads to the activation of phospholipase C (PLC), that results 
in cleavage of phosphatidylinositol 4,5, biphosphate which in turn leads to the 
formation of InsP3 [306]. InsP3 generation causes the opening of InsP3 receptor 
pumps which are located on the ER and Golgi apparatus allowing the efflux of Ca2+ 
into the cytosol and then into the nuclear pore complex.  
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Figure 12. Mechanisms by which neuronal activity generates increased levels of 
intercellular and nuclear calcium transients.  
A. (1) Excitatory neuronal signals activate both (2) NMDA and AMPA receptors in 
the post-synaptic density. (3) Upon activation of these ligand gated channels 
excitatory postsynaptic potentials (EPSP) are invoked (4) firing action potentials 
in the neurons. (5) These action potentials disseminate back through the dendrites 
causing membrane depolarisation. (6) Depolarisation of the membrane results in 
the opening of VDCC, allowing for calcium influx into the neuron. B. (1) Input from 
excitatory neuronal signals activates (2) G protein coupled receptors (GPCRs) 
which lead to the (3) activation of phospholipase C (PLC). (4) The activation of PLC 
results in the production of inositol 3 phosphate (IP3). (5) When IP3 is produced 
IP3 receptors are activate and lead to the release of Ca2+ from intracellular stores 
in the neuron. (6) Release of intracellular Ca2+ results in an intercellular 
propagating calcium wave. (7) Further amplification of the calcium signal is 
achieved through release of calcium from the endoplasmic reticulum or golgi 
through ryanodine receptors. Image taken from [303].  
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Figure 13. Processes activated following the influx of Ca2+ ions.  
Calcium can enter the cell through a number of different mechanisms and activates 
an assortment of signal transduction pathways. These processes act at different 
cellular levels, stimulating tissue contraction in muscles, allowing communication 
between cells through the transport and movement of chemicals such as hormones 
and cellular signalling both by secretion and through synaptic signalling. At a 
protein level, enzyme regulation is controlled and protein phosphorylation can be 
instigated. At the genetic level the control of gene transcription is influenced by the 
influx of Ca2+ ions. Image taken from [307]. 
Calcium’s control of gene expression can occur through a number of mechanisms. 
Upon influx of calcium through the calcium pore the Ras-MAPK cascade signalling 
pathway is initiated, leading to the phosphorylation of serine residue 133 in CREB. 
Cell depolarisation, resulting from the influx of calcium into the cell, can lead to the 
alternative splicing of pre-mRNAs impacting on gene expression [308]. Crucially, 
Ca2+ influx plays a vital role in gene regulation through transcriptional initiation. 
The role of nuclear calcium in transcriptional regulation was first reported by 
Hardingham et al. in 1997 following studies conducted on a mouse pituitary cell 
line [309]. Transcriptional activation initiated by the CREB transcription factor 
was completely blocked following injection of the cell nucleus with BAPTA, a 
calcium chelator. BAPTA was fused to a large 70-kDA carbohydrate, dextran, which 
prevented the diffusion of the chelator through the nuclear membrane, preventing 
the chelator interaction with cytosolic calcium. In addition, the presence of dextran  
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Figure 14. Activation of gene transcription by the influx of calcium through plasma 
membrane calcium channels. 
As calcium enters cells through α pores on the plasma membrane it initiates the 
Ras-MAPK signalling pathway. The binding of calmodulin to the IQ domain in the 
carboxy terminus of the α1C subunit allows for the activation of the Ras-MAPK 
signal transduction pathway. Activation of this pathway leads to the 
phosphorylation of Ser133 in CREB. Image from [310]. 
did not interfere with membrane depolarisation which results in the influx of Ca2+ 
ions through VDCC, on the cell membrane, as described previously. Transcriptional 
activation initiated through other pathways such as the serum response element 
(SRE) [309], were not blocked by BAPTA. The ERK/MAP kinase pathway targets 
SRE following an increase in concentration of calcium in the submebranous space 
which is located close to the calcium channels in the membrane [311-313]. 
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Ca2+ influx through different channels mediate different responses. L-type VDCCs 
are highly associated with activation of the CREB cycle through phosphorylation of 
CREB at Ser133 [312, 314]. This phosphorylation at Ser133, and other serine 
residues in the CREB protein enhance initiation of transcriptional activation and 
activity [315]. This occurs through the action of calmodulin-dependent protein 
kinase IV (CaMKIV), a tyrosine/serine kinase which is located in the cell nucleus 
[316]. The effect of phosphorylation is thought to recruit the transcriptional 
coactivator CREB-binding protein (CREBBP) to the phosphorylated Ser133 residue 
[317, 318]. Phosphorylation of other serine residues in the CREB protein occurs in 
response to specific neuronal activity [319], stimulated solely through the 
phosphorylation of Ser133 in CREB. Activation of CPB, by CaMKIV and nuclear 
calcium, is a requirement for the initiation of gene transcription in the nucleus 
[320]. It is proposed that CBP acts to initiate transcription by increasing the 
acetylation of histones bound to target genes in the nucleus [318]. 
In addition to commencing the downstream cascades of signalling pathways, the 
influx of calcium ions into cells is directly monitored by a family of proteins called 
neuronal calcium sensors (NCS) [321]. One member of the NCS family is the 
downstream response element (DRE)-antagonist modulator (DREAM) which binds 
directly to calcium through its EF-hand calcium binding motif [322, 323]. The EF- 
hand is a helix-loop-helix motif that has high affinity for binding calcium, and with 
a lower affinity, magnesium [324]. DREAM can block transcription by binding to 
the downstream response element (DRE) (TACCGACAT) located in many genes 
[325]. As calcium concentration increases in the nucleus it interacts with DREAM, 
binding to the EF hands and allowing transcription to occur.  
Changes in cytoplasmic calcium levels mediated by entry through L-type VDCCs 
regulate transcription through the initiation of the Ras-MAPK (mitogen-activated 
protein kinase) pathway (Figure 14) [310]. This initiation of transcription is highly 
coupled to a calmodulin-binding isoleucine-glutamine (IQ) domain in the carboxy 
terminus of the CACNA1C α pore [326]. As calmodulin binds to L-type VDCCs in the 
plasma membrane, it stimulates prolonged Ras-MAPK dependent phosphorylation 
of Ser133 in the CREB transcription factor. Calmodulin binds to L-type VDCCs in a 
calcium dependent manner and activates the Ras-MAPK pathway through 
localisation of the signalling pathway. 
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1.3.1.1 ALPHA SUBUNITS 
The α1 subunit of voltage gated calcium channels is the main pore which allows 
the influx of Ca2+ in and out of the cell [298]. Ten genes encode the calcium channel 
alpha pores (Table 4). The general structure of the α pore consists of four repeat 
domains, each of which contains six transmembrane segments. This subunit can 
function independently to allow calcium influx in the cell. Under normal 
physiological situations it is associated with auxiliary subunits which control the 
opening and closing of the transmembrane pore, and trafficking of the pore from 
the ER.  
There are five different types of voltage dependent calcium channel α pores, N-
type, P/Q-type, T-type, R-type and L-type. These are grouped into three different 
categories, Cav1, Cav2 and Cav3, depending on their function. The Cav1 subgroup is 
involved in excitation and contraction in cardiac, skeletal and smooth muscle cells, 
transcriptional regulation, enzyme activity, and neuronal Ca2+ transients in 
dendrites and cell bodies. Ca2+ transients occur when calcium enters the cell 
through membrane depolarisation-activated calcium channels as inward calcium 
currents. Cav2 types are involved in neurotransmitter release and the Cav3 types 
are involved in cardiac pace making and repetitive firing [307]. 
The classification system for the different types of calcium channel pores 
originates from their different physiological and pharmacological channel 
properties. L-type VDCC are characterised by high voltage activation with large 
single channel conductance, slowed voltage dependent inactivation, up-regulation 
marked by cAMP-dependent phosphorylation pathways and inhibition by Ca2+ 
blockers [327, 328]. T-type VDCCs are so named as a result of their transient 
nature, are activated at a much lower negative membrane potential than the L-type 
family of VDCCs. Additionally they have small single channel currents, are 
inactivated rapidly and deactivate slowly [329]. N-type calcium channels were 
originally distinguished by their intermediate voltage dependence activation rate 
which is between that of the L- and T- types. They have a more negative and faster 
rate of inactivation than the L-type of VDCC and but in contrast have a more 
positive and slower rate of inactivation than that of the T-channels.  
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Channel 
Name 
Channel 
Subtype 
Gene Subunit Location Tissue Associated Disorders 
L-Type 
Cav1.1 CACNA1S α
1
 pore 1q32 Skeleton Hypokalemic periodic paralysis; Malignant Hyperthermia; 
Thyrotoxic periodic paralysis, susceptibility 
 
Cav1.2 CACNA1C α
1
 pore 12p13.3 Cardiac cells, Endocrine System, 
Neurons 
Timothy Syndrome; Brugada syndrome 3 
 
    
 
Cav1.3 CACNA1D α
1
 pore 3p14.3 Endocrine System, Cochlea, Cardiac 
cells, Neurons 
Primary aldosteronism, seizures, and neurologic 
abnormalities; Sinoatrial node dysfunction and deafness 
 
    
 
Cav1.4 CACNA1F α
1
 pore Xp11.23 Retina X-linked cone-rod dystrophy type 1; X-linked congenital 
stationary night blindness type 2 
 
    
N-Type Cav2.2 CACNA1B α1 pore 9q34 Neurons Neuropathic pain; Myoclonus-Dystonia syndrome 
P/Q type Cav2.1 CACNA1A α1 pore 19p13 Neurons Episodic ataxia; Familial Hemiplegic Migraine; Spinocerebellar 
Ataxia type 6; Sporadic Hemiplegic migraine 
 
     
R-Type Cav2.3 CACNA1E α1 pore 1q25.3 Neurons - 
T-Type Cav3.1 CACNA1G α1 pore 17q22 Neurons and Heart Abberantly methylated can result in Primary Tumour Growth 
 
     
 
Cav3.2 CACNA1H α
1
 pore 16p13.3 Neurons, Heart, Kidney, Liver Epilepsy, Childhood Absence, Idiopathic generalisation 
 
Cav3.3 CACNA1I α
1
 pore 22q13.1 Neurons - 
Table 4. Classification of the alpha pores of the calcium channel family  
There are ten genes which encode α pore subunits of the VDCC. Here the localisation of gene expression is shown and disorders which are 
associated with dysfunction in the α pore are listed. 
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The N-type calcium channel genes are found predominantly in the presynaptic 
termini and participate in the transmission of neurotransmitters upon 
depolarization [330].  
The current is extremely variable in different neurons and N-type channels are 
largely distinguished through their insensitivity to organic L-type Ca2+ blockers but 
sensitivity to the ω-conotoxin GVIA from the cone snail [331, 332]. Several other 
types of calcium channels were identified through the effects of peptide toxins. 
The P/Q type channels are separate entities but there is little to distinguish 
between them. The P-type channel is highly sensitive to the spider toxin ω-
agatoxin IVA [333], while the Q type channels are blocked with a lower affinity 
than the P type [334]. The R-type VDCC are resistant to most typical calcium 
channel blockers [334]. While the N, P/Q and R type VDCCs appear to be 
predominantly expressed in neurons, T- and L-type Ca2+ currents are found in a 
wide number of cells. 
1.3.1.2 BETA SUBUNITS 
For L-type VDCC and other types of high-voltage-activated calcium channels, the β 
subunit is specifically required for plasma membrane expression and correct 
gating [335]. The four different members of the β subunit family share a conserved 
31 amino acid sequence known as the β interacting domain (BID) [336]. The -N 
and -C termini of all four members are variable, and there are a number of 
different splicing isoforms of each variant. The β subunit binds with high affinity to 
the α pore of the calcium channel via a specific 18 amino acid anchoring domain in 
the cytoplasmic linker found between the first two homologous repeats in the α 
subunit (I-II linker), also known as the α interaction domain (AID) [337-339]. 
Studies have shown that the β subunits are important for surface expression, 
degradation and promoting the gating of VDCC. Binding of the β subunit prevents 
the degradation of the α subunit, and exposes the ER exporting signals on the α 
pore to facilitate trafficking to the cell membrane. Additionally the β subunits play 
a protective role in trafficking of the voltage gated calcium channels to the cell 
membrane by preventing degradation by proteases and promotes the correct 
92 
folding of these proteins [340] [341]. They also play a role in regulation of the 
VDCC by lipids, G coupled proteins, kinases and other signalling proteins [342].  
1.3.1.3 ALPHA-2-DELTA SUBUNITS 
Currently four members of the α2δ family of subunits have been cloned, 
CACNA2D1, CACNA2D2, CACNA2D3, and CACNA2D4. These subunits are expressed 
in a variety of tissues including CNS expression of CACNA2D1, CACNA2D2, and 
CACNA2D3 [343]. CACNA2D4 is expressed in the retina and endocrine tissue [344]. 
Molecular studies investigating the composure of the α2δ subunit have shown that, 
following disulphide bridge reduction, the α2 subunit is 150kDa, and the δ subunit 
is between 17-25kDa [345]. Post translational proteolytic cleavage occurs on the C 
terminus of a pre-protein which forms the δ subunit [345]. Sulphide bond 
formation normally occurs co-translationally in the lumen of the ER and it is not 
yet known which protease causes the proteolytic cleavage that result in disulphide 
bond formation. However there is the suggestion that this occurs during trafficking 
of the α2δ protein [346]. The native α2δ protein is anchored to the extracellular 
membrane, with the α2 in the extracellular space, and the δ subunit anchored to 
the membrane as can be seen in Figure 11. Some of the functions of the α2δ 
subunits depend on expression of the β subunit of the calcium channel gene family 
[347].  
The α2δ subunit contains a Von Willebrand factor-A domain (VWA) which binds to 
a variety of cell adhesion and extracellular proteins [348] through its metal ion 
adhesion domain, this interacts with a number of proteins to promote trafficking 
and to increase the density and expression of the α pore from L, N, P/Q and R-type 
calcium channels at the plasma membrane [349].  
1.3.1.4 GAMMA SUBUNITS 
The γ family of calcium channel subunits are comprised of eight different 
members. The γ-subunits are expressed in different VDCCs and can be clustered 
into three separate groups, (Figure 15), γ1 and γ6 subunits are mainly expressed in 
skeletal muscle tissue and lack the PSD-95/DLG/ZO-1 (PDZ)-binding motif 
characteristic of the rest of the γ family [350]. Additionally γ6 is expressed in  
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Figure 15. TARP Phylogenetic tree 
Phylogenetic tree showing the relationship between calcium channel γ subunits 
and TARPs and the closely related claudin tight junction proteins. Image based on 
[351]. 
cardiac myocytes, where it is found in two alternative isoforms, the only γ-subunit 
to have an alternative isoform. 
Both γ1 and γ6 stabilise L-type VDCC in an inactive state. Studies have shown that 
γ2 (stargazin) has a similar inhibitive effect on the VDCC by stabilizing the 
interaction between another auxiliary subunit of the calcium channel, α2δ [352], 
while γ5 regulates Ca2+ permeability via AMPA-R assembly. Additionally, γ7 
expression has an effect on calcium channel activity, but rather than promoting 
this effect via subunit interaction [353], it does so through alterations on mRNA 
stability [354]. While originally classified as a VDCC subunit studies have shown 
stargazin’s main function is in synaptic signalling in the central nervous system 
where it, and the other members of the γ family of subunits, are tightly associated 
with AMPA-R regulation and localisation [355]. γ2, γ3, γ4 and γ8 are classified as 
type-I transmembrane AMPA receptor regulators (TARPs) and are intrinsically 
involved in the control of both the trafficking of AMPA-R to the cell surface as 
auxiliary subunits. They are also involved in channel gating and mediating fast 
synaptic transmission in the CNS in specific brain regions [351], [356]. 
γ8 
γ4 
γ6 
γ1 
 
γ7 
γ5 
 
γ3 γ2 
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Figure 16. Trafficking of AMPA-R to the postsynaptic density through TARP 
interaction. 
ER, Endoplasmic Reticulum, PSD-95, Post-synaptic Density Protein 95  
They are expressed neuronally and play a role in the localisation and regulation of 
gating of AMPA-R at the post-synaptic density (PSD) (Figure 16) [357, 358]. γ5 and 
γ7 (type-II TARPS) are more closely related to the type-I TARPs, than γ6 and γ1 and 
the claudin family of proteins. The type-II TARPs are specifically enriched in 
specific neuronal areas, with the highest expression of γ7 occurring in the Purkinje 
cells and γ5 being found associated with AMPA-R in the cerebellum, and 
expression of the protein found to a lesser extent in the kidneys [359].  
Research into the main functions of TARPs have shown them to play an integral 
role in mediating fast excitatory transmission in the CNS, where post translational 
modifications occur to the specific glutamate receptors resulting in long-term 
Nucleus
ER
Golgi Apparatus
P
P P
PSD-95
Post Synaptic Density
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potential or long-term depression [360]. Alterations to the transport of these 
receptors could alter CNS plasticity resulting in abnormal synaptic connections 
forming. The role of TARPs in establishing connections during development is 
another potential hypothesis for how variation in these subunits may lead to an 
increased susceptibility to psychiatric illnesses. 
Association of TARPs and AMPA-R in the endoplasmic recticulum facilitates 
trafficking from the ER to the plasma membrane [361]. Following this binding of 
the TARP, through the C terminus, to PSD-95, it localises and secures the AMPA-R 
to the postsynaptic membrane. Trafficking of AMPA-R to the postsynaptic 
membrane is differentially regulated depending on which TARP it is bound too. 
Type-I TARPs binding to AMPA-R type I (GluR1) slows the desensitization and 
deactivation of the glutamate channels and prolongs their activation following the 
removal of glutamate [362]. This binding forms a specific complex between the 
TARPs and AMPA-R. Binding of TARPs to AMPA-R allows the AMPA-R to leave the 
ER and be trafficked to the postsynaptic density. Here they are anchored by 
scaffolding proteins through PDZ-95 binding domain. 
1.3.2 GENETIC VARIATION IN CALCIUM CHANNEL GENES 
There are a number of studies which have shown that variation in calcium channel 
gene subunits plays a prominent role in the manifestation of severe psychiatric 
disorders and phenotypes. 
As previously discussed, clear evidence pointing to abnormalities in calcium levels 
has been seen in patients suffering from BD. Discerning whether mutations in 
these genes are having an effect on the assembly of the calcium channel subunit or 
controlling the activation of gating and calcium permeability into the cell would 
help researchers further understand the basis of the calcium imbalance found in 
BD.  
1.3.2.1 ALPHA SUBUNITS 
Genetic variation in CACNA1C leads to the manifestation of Timothy syndrome and 
Brugada syndrome. Missense mutations (p.G406R and p.G402S) in exon 8A of  
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Figure 17. Structure of the Alpha Pore of VDCC.  
The CACNA1C α pore subunit is comprised of four repeat domain which have 6 
transmembrane domains each. Variants which are associated with Brugada 
syndrome are represented by red circles. The variants associated with Timothy 
syndrome are represented by the green circles. All of the variants are located in 
intracellular loops of the α pore. 
CACNA1C, an alternatively spliced exon, are responsible for the rare disorder, 
Timothy syndrome (TS) [363] (Figure 17). This disorder is characterised by 
developmental delays and autism, in addition to severe cardiac manifestations. The 
two mutations were originally reported first in 2004 by Splawski and colleagues 
showing links with autism and cardiac arrhythmia [363].  
In vitro studies have shown that iPS stem cells, derived from patients with TS, 
which were used to develop cortical neuronal precursor cells, displayed aberrant 
development and differentiation. Defects in Ca2+ signalling and decreased 
expression of genes in brain regions, such as the lower cortical layers, are 
additionally observed in these neurons [364]. In the same publication Pasca et al., 
showed that tyrosine hydroxylase is abnormally expressed and there is increased 
production of both dopamine and norepinephrine. This can be corrected through 
the use of roscovitine, which in addition to acting as a cyclin-dependent kinase, 
functions as a L-type calcium channel blocker [365]. Calcium channel blockers are 
also used in the treatment of bipolar disorder and may function in a similar 
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manner to the method by which the aberrant gene expressions in TS are 
ameliorated.  
Additionally, variants known to cause Brugada Syndrome (BrS) a severe 
cardiovascular disease are found in CACNA1C (Figure 17). Individuals suffering 
from BD have been consistently associated with an elevated risk for cardiovascular 
disease [366]. A Danish study following 5.5 million individuals, from 1978 to 2001, 
reports that of the 11,648 people diagnosed BD, 3,669 had passed away when the 
study was complete. Estimates of the standard mortality rate (SMR) of 
cardiovascular disorder on the cohort show an elevated risk of 1.59 in men and 
1.47 in women compared to that of the general population [367]. Estimates of 
cardiovascular SMR in a Swedish study report similar values of 1.9 for men and 2.6 
for women [29]. BrS is a serious cardiovascular disease which can cause sudden 
cardiac death [368]. Variants in the CACNA1C and CACNB2B genes lead to a 
reduced peak calcium current in Brugada syndrome which results in the loss of 
gene function [369, 370].  
Variants in the P/Q type alpha subunit, CACNA1A, have been shown to result in a 
number of autosomal dominant neurological defects such as familial hemiplegic 
migraines, episodic ataxia type-2 and spinocerebellar ataxia [371]. 
One of the top association signals in BD comes from rs1006737 (P= 7.0 × 10-8) 
[232, 233], lying in the third intron of CACNA1C. Another two SNPs located in this 
intronic region, rs4765913 (p= 1.52 × 10−8) [232] and rs1024582 (p= 1.7 × 10-7) 
[270], are also strongly associated with BD. GWAS results across five different 
psychiatric illnesses further implicates rs1024582 in susceptibility to both BD and 
SCZ [268]. 
Research shows that that the presence of rs1006737 CACNA1C BD risk variant 
leads to alterations in certain brain activities. One study showed that the 
rs1006737 risk allele in healthy males is associated with lower extraversion, trait 
anxiety, paranoid ideation and higher harm avoidance [372]. The rs1006737 risk 
variant has been shown by many MRI studies to modulate amygdala functioning 
during emotional processing, the enhancement of such activation leads to impaired 
facial emotion recognition in BD patients [268, 373-376]. There has been 
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conflicting evidence as to whether the presence of the CACNA1C variant results in 
brain volumetric alteration, with reports stating this SNP has been associated with 
brainstem alterations, increased grey matter density as well as a cortical volume 
increase [377-379], while a recent study looking at multiple variants did not find 
any association between this SNP and brain volumetric alterations [380]. 
CACNA1B has been reported to show evidence for association with SCZ (p=0.002) 
in genome-wide analyses of genome-wide association datasets [381]. A recent 
study by Ament et al. [292] has shown that there are rare variation in four genes 
that are members of the calcium channel family of genes, CACNA1B, CACNA1D, and 
CACNG2, associated with BD. 
1.3.2.2 BETA SUBUNITS 
Gene ontology enrichment analysis of 34 SNPs reaching a genome-wide significant 
association (P ≤ 5 × 10−8) in a large-scale genome BD association study have found 
enrichment in the GO: 0015270, dihydropyridine-sensitive calcium channel 
activity. Of the eight genes in this category, 3 are members of the VDCC family, 
CACNA1C, CACNA1D and CACNB3 [239]. Other genes encoding calcium channel 
subunits have shown association in BD and other neurological disorders. In 
addition to the associations seen in the PGC GWAS for CACNB3, null β3 mice show 
impaired working memory, coinciding with increased aggression and a decrease in 
anxiety [382]. A case-control study focused on patients with epilepsy has identified 
3 mutations in CACNB4 found only in people suffering from epilepsy and none in 
healthy volunteers [383]. CACNB2 has been found to be associated with BD in the 
Han Chinese population (rs11013860, P=5.15 × 10-5) [244]. Jan et al. have shown 
support for an association between the same variant, rs11013860 in CACNB2, and 
BD-I in a homogenous Taiwanese cohort [384]. 
1.3.2.3 ALPHA-2-DELTA-4 SUBUNITS 
A rare deletion in CACNA2D4 has been found in two unrelated late onset bipolar I 
patients and one control, all of the break points of these deletions caused the 
removal of CACHE domain, which is involved in small molecule recognition in a 
wide range of proteins [385]. Linkage disequilibrium contrast analysis between 
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SNPs in cases and controls has shown association between SNPs in CACNA2D4 in 
BD (LD-contrast test, p=4.6x10-14) [386]. 
1.3.2.4 GAMMA SUBUNITS 
Mutations in stargazin (CACNG2) were first identified in stargazer mice [387]. The 
genetic variation in CACNG2 leads to the loss of AMPA-Rs at excitatory synpases 
[388]. These mice suffer from recurrent epileptic seizures, cerebellar ataxia and 
ataxic gait [389].  
A combined burden analysis of non-synonymous variation in CACNG5 has shown 
an association with SCZ (p=1.46x10-8). This data also reports that four variants in 
the CACNG5 gene result in decreased cell surface expression of the AMPA-R2 [390]. 
A case-case study between BD and SCZ has identified an association between 
rs17645023 and both disorders (p=1x10-6.1) which lies between CACNG4 and 
CACNG5 [271]. Studies focusing on SCZ have shown TARP dysregulation at a both 
transcript and protein level, with γ-3 and γ-5 protein levels increasing and γ-4, γ-7 
and γ-8 protein levels decreasing in the anterior cingulate cortex [391].  
1.4 INTRONIC GENETIC VARIATION  
1.4.1 INTRODUCTION 
It is clear and evident from the above descriptions of the genetic models proposed 
for BD that while variants located in exonic regions may have a role to play in 
increasing disease risk, it is also likely that many other risk variants in regulatory 
regions have an important role to play in disease susceptibility. These regulatory 
domains will include regions such as the promoter, the 5’UTR and the 3’UTR and 
specific regions of the introns. These intronic regions may have a functional impact 
on transcription factor binding sites and gene expression. A large proportion of 
GWAS candidate hits occur in introns (such as with the CACNA1C gene) or in 
regions of the genome where there is no gene present. In the past these results 
have been dismissed because it has been difficult to functionally implicate these 
variants in disease risk. Fortunately, in the past five years, there has been a 
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significant move in improving the resources and databases available for such 
investigation, primarily starting with the ENCyclopaedia of DNA Elements project 
(ENCODE). In addition to this large scale project additional online resources and 
software are becoming increasing available, facilitating stronger research and 
experiment design. 
1.4.2 ENCODE DATA 
The aim of the ENCODE project is to characterise all functional variants in the 
human genome [392]. In the first phase of publications the consortium targeted 
1% of the genome to determine techniques and methods which would accurately 
identify functional elements [393]. The second phase, resulting in a co-ordinated 
set of 34 publications in 2012, targeted technologies which had been used in phase 
one, to improve techniques used to identify genomic elements. The second phase 
covered 147 different cell lines and tissues, resulting in 1640 data sets. Phase two 
cell lines where divided into three different tiers 
(http://genome.ucsc.edu/ENCODE/cellTypes.html). Tier 1 included three cell 
lines; K652, a leukaemia cell line, GM12878, an immortalized B lymphocyte 
Epstein-Barr line and H1-hESC, a human embryonic cell line. Tier 2 was comprised 
of 15 different tissues and cell types. There are two neuronal cell lines in tier two, 
H1-neurons derived from human embryonic stem cells and SK-N-SH cells from a 
neuroblastoma. Tier 3 included another 338 cell lines and tissue samples. Of these 
18 were related to the central nervous system, 14 from brain tissue, one from the 
cerebellum, one from the frontal cerebrum tissue, one from the frontal cortex and 
one from the pons. 
Functional elements include RNA transcribed sites, protein-coding regions, 
transcription factor binding sites (TFBS), open chromatin and histone 
modifications, and DNA methylation sites [392]. Evidence strongly points to over 
80.4% of the genome containing functional genomic elements in at least one cell 
type.  
Regions of accessible chromatin provide researchers with a baseline map of areas 
of possible transcription in the genome. Regions of open chromatin are marked by 
the presence of DNAse-hypersensitivity sites (DHSs), indicating regulatory active 
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regions [394, 395]. Of the 7 million peaks found, approximately 40% were located 
within 2.5kb of previously categorised transcriptional start site (TSS). Chromatin 
immunoprecipitation followed by sequencing, (ChIP-seq) was generated for 119 
different TF over the main cell lines [396]. ChIP-seq is used to identify TFBS and 
histone modifications [397]. Histone marks combined with DHSs can be used to 
identify putative functional elements involved in transcriptional regulation, such 
as promoters or enhancers (Table 5) [398]. Transcription factor binding sites play 
an important role in activation of transcription. Mutations in TFBS, located in ChIP-
seq peaks, were introduced into cells to determine whether the proposed regions 
were functionally active or just putative elements. Over 70% of the reported TFBS 
showed altered function in functional reporter assays in the ENCODE data [396]. It 
was noted that affinity for TF binding at specific genome regions was allele 
specific, with reduced functionality seen in the presence of novel SNPs. Use of 
these data provides a novel method for determining functionality of novel SNPs 
found in non-coding regions of the genome which have no previous genotyping 
data. 
The National Human Genome Resources Institute has a catalogue of all SNPs found 
by GWAS. Approximately 93% of SNP-phenotype associations lie in non-coding 
regions [399], making it difficult for researchers to infer biological impact for these 
findings. SNPs with novel functional data found using the ENCODE methods show 
strong enrichment for GWAS disease associations. Maurano et al. looked at the 
localisation of disease associated variants and their results show that 76.6% of 
these non-coding GWAS SNPs are present in DHSs (2,931 SNPs) or are in complete 
LD (r2=1) with SNPs in neighbouring DHS [399]. Individual analysis showed 
enrichment of GWAS variants in TFBS modulated chromatin structure, as 
previously mentioned. 
Characterising the potential etiological function of previously annotated SNPs 
associated with disease could implicate new genes underlying certain disorders 
highlighting novel therapeutic and treatment pathways. The ENCODE data set 
encompasses a large range of variants which have a vast range of non-coding 
functions. Currently it has the potential to add novel functional data to genomic 
regions which were previously uncharacterised.  
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Histone modification Putative Functions 
H2A.Z 
Variant of H2A Histone protein. Enriched at insulators (with CTCF), and upstream and 
downstream of TSS [400] 
H3K4me1 
Enriched at enhancers and is a mark of regulatory elements associated with enhancers. Enriched 
downstream of TSS [401] 
H3K4me2 Mark of regulatory elements associated with promoters and enhancers [402] 
H3K4me3 Mark of regulatory elements at active promoter sites and transcription starts [402] 
H3K9ac Mark of active regulatory regions with a preference for promoters [403] 
H3K9me1  Unknown, preference for 5' end of gene [404] 
H3K9me3 
Mark of transcriptional repression associated with constitutive heterochromatin and repetitive 
elements 
H3K27me3 
Mark of active regulatory elements which may distinguish active promoters and enhancers from 
their inactive counterparts 
H3K36me3 Mark of actively transcribed regions found predominantly near exons [402] 
H3K79me2 Transcription-associated mark with a preference for the 5' of genes [404] 
H4K20me1 Unknown, preference for 5' end of gene [404] 
Table 5. Histone Markers in the Genome 
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1.4.3 UTILISING DATA SETS SUCH AS ENCODE TO INVESTIGATE NGS 
ENCODE data provide a rich resource for researchers investigating variation that is 
located outside protein coding regions. Prior to its publication researchers 
depended on bioinformatic extrapolation from TFBS prediction software and 
conducting extensive research to determine whether these findings were real or 
not. Even then the evidence may not have conclusively defined the regulatory 
effect that variants may have been having. The accessible nature of the ENCODE 
data provides a platform for researchers to tailor their experiments to specific 
regulatory functions. The range of cell types investigated is extensive but a number 
of cell types, as described previously, are over represented in the data release. 
Projects such as ENCODE have led to a paradigm shift in the idea that intragenic 
and intergenic regions once classified as containing “junk” DNA, now represent a 
treasure trove of biological structures which may be extremely important for 
disease studies. As such the ENCODE data provide an exemplary model for the 
effects a collaboration can have on instigating alternative approaches to research.  
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 Aims of Thesis Chapter 2
The main aim of this thesis was to investigate members of the L-type group of 
calcium channel genes, and genes encoding auxiliary subunits of the calcium 
channel family to elucidate genetic variation that may increase the susceptibility of 
an individual to develop bipolar disorder.  
The specific aims of the thesis were: 
 To screen calcium channel genes, previously implicated in GWAS studies, 
for de novo or rare mutations using a method called High-resolution 
Melting Curve Analysis to identify variation conferring disease 
susceptibility to individuals with bipolar disorder. 
 To investigate variation detected using High-resolution Melting Curve 
Analysis that is present in promoter regions, 3’ and 5’UTR regions because 
these are commonly missing from exome capture sequence data. 
 To genotype variants of interest in the UCL extended case control cohort. 
 To investigate variation present in any of the calcium channel genes from 
whole genome sequencing data of 99 individuals with bipolar disorder. To 
follow up any potentially interesting mutations using genotyping in a larger 
expanded case control cohort. 
 To screen the third intron of CACNA1C for mutations which may be giving 
rise to the strongest association signal which has been implicated through 
multiple GWAS studies and determine if these mutations are located in a 
functional region as denoted by ENCODE data. 
 To determine the potential role of any base pair changes found to be 
associated with bipolar disorder in the calcium channel family of genes in 
this study utilising functional assays. 
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 Material and Methods Chapter 3
3.1 GENERAL METHODS 
In this section all of the materials and methods used for the different experiments 
will be outlined and discussed. Methods which were specific to both the high-
resolution melting curve analysis and the next generation sequencing analysis will 
be discussed separately.  
3.1.1 UCL RESEARCH SUBJECTS 
3.1.1.1 BIPOLAR SAMPLE 
This study included 1,890 affected BD research subjects. These were sampled in 
three cohorts. The first cohort, UCL1, includes 506 BD-I research subjects defined 
by the presence of mania and hospitalisation according to research diagnostic 
criteria (RDC) [232, 233]. The second and the third cohorts, UCL2 and UCL3, 
consist of 593 and 791 subjects respectively with classifications of BD-I or BD-II, 
described in the introduction. Ancestry screening was used as a selection criterion 
for the inclusion of cases. Samples were included if at least three out of four 
grandparents were English, Irish, Scottish or Welsh and if the fourth grandparent 
was non-Jewish European, before the EU enlargement in 2004. All participants 
provided signed consent and National Health Service (NHS) multicentre research 
ethics was obtained. 
BD research subjects had been given a clinical diagnosis by the International 
Statistical Classification of Diseases and Related Health Problems 10th Revision 
(ICD-10) of BD and then needed to fulfil the criteria for the lifetime version of the 
Schizophrenia and Affective Disorder Schedule (SADS-L) [405]. They were 
additionally rated with the Operational Criteria Checklist (OPCRIT) [406], which 
provides DSM–III-R (1987) 3rd ed [407]. 
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3.1.1.2 SCHIZOPHRENIA SAMPLE 
The schizophrenia sample cohort consists of 605 SCZ samples which had 
previously fulfilled the ICD10 criteria for SCZ made by NHS psychiatrists and 
needed to fulfil the criteria for SCZ (SADS-L) [405]. Ancestral requirements for 
samples were the same as those described previously for the BD cohort. Samples 
were further rated with the OPCRIT [406] provided by the DSM–III-R (1987) 3rd 
ed [407]. NHS multicentre research ethics approval was obtained. All participants 
provided signed consent. 
3.1.1.3 ALCOHOL DEPENDENCE SYNDROME SAMPLE 
The UCL Alcohol dependence syndrome sample consisted of 1225 case samples, 
recruited as part of the UK-COGA (United Kingdom Collaborative Study on the 
Genetics of Alcoholism) study [408]. Diagnosis was conducted using a modified 
version of the Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA-
I) questionnaire for the United Kingdom. These samples met the diagnostic criteria 
according to the DSM-IV and ICD-10 and were of UK or Irish ancestry as defined 
previously 3.1.1.1 .These samples were additionally rated using the OPCRIT [406] 
provided by the DSM–III (1980) 3rd ed [407]. NHS multicentre research ethics 
approval was obtained. All participants provided signed consent. 
3.1.1.4 CONTROL SAMPLES 
The sample of 1095 controls comprised 614 screened subjects who had no first 
degree family or personal history of psychiatric illness and an additional 480 
unscreened normal British subjects obtained from the European Collection of 
Animal Cell Cultures (ECACC). National Health Service multicentre research ethics 
approval was obtained. All participants provided signed consent. Controls were 
screened using the SADS-L to ensure they did not meet the criteria for any 
psychiatric illness were included if they had no family or personal history of 
mental illness and additionally if they met the ancestry criteria as defined above 
(3.1.1.1) [409]. 
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3.1.1.5 OTHER DATASETS 
A number of data sets were used in this thesis to determine the allelic frequency of 
variants in healthy controls in the general population and two other SCZ datasets. 
Three control datasets were used; the exome variant server (EVS) 
(http://evs.gs.washington.edu/EVS/), the 1000 Genome dataset 
(http://www.1000genomes.org/) and data from the Exome Aggregation 
Consortium (ExAC) (http://exac.broadinstitute.org)  
The EVS is part of the National Heart, Lung, and Blood Institute GO Exome 
Sequencing Project (ESP). It contains exome sequencing data on 6503 unrelated 
individuals with heart, lung and blood disorders from a number of different 
populations. This dataset contains information on 2203 African-Americans and 
4300 European-Americans. The 1000 Genomes project dataset contains whole 
genome sequencing information on 2577 individuals, including 503 unrelated 
individuals with European ancestry. The ExAC comprises exome sequencing data 
of 60,706 unrelated individuals. The European cohort in the ExAC consisted of 
33,370 individuals [410]. 
Two SCZ datasets were used in this study. These were the UK10K SCZ cohort that 
contains exome sequencing data for 1390 individuals and the Swedish 
schizophrenia cohort comprising of 2,536 individuals [411]. The ExAC dataset 
contains data from Swedish SCZ and BD studies (12119); these include the 2453 
individuals from the previously mentioned Swedish exome cohort. Where possible 
the 2453 individuals were removed from the overall control sample to ensure no 
overlap occurred as the sequence calls for each individual was previously known. 
3.1.2 GENOMIC DNA EXTRACTIONS 
DNA samples were collected from blood samples from the UCL1 cohort, saliva 
samples for the UCL2 cohort and a mixture of both blood and saliva for the UCL3 
samples. DNA was obtained from samples in UCL1 and UCL3 from blood samples 
using a modified Puregene protocol in a two part process. DNA from UCL2 and 
UCL3 was extracted from saliva samples following the Oragene protocol for DNA 
extraction (DNA Genotek, Ottowa, Canada). 
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3.1.2.1 GENOMIC DNA EXTRACTIONS FROM BLOOD 
The blood samples, stored at -20°C, were defrosted in a water bath at 37°C over a 
period of 30 minutes to one hour. This is done over a short period of time to 
prevent cellular damage and the release of enzymes that may interfere with the 
quality of DNA. The defrosted blood was transferred to a 50ml Falcon tube, to 
which 30ml of 1x red blood cell lysis buffer solution [100mM NaCl, 100mM EDTA] 
(Appendix II, II.I) was added. The blood lysis mixture was incubated at room 
temperature (RT) for five minutes, inverting three times during this period to 
ensure mixing occurred. The lysis solution breaks down the erythrocytes (red 
blood cells) and leaves the white blood cells, containing the DNA, intact. The blood 
lysis mixture was then centrifuged at 3,000rpm for 5 minutes at 4°C. The 
supernatant was discarded and 20mls of 1x red cell lysis buffer was used to 
resuspend the pellet. The incubation and centrifugation steps were repeated a final 
time with 10mls of 1x red cell lysis solution. The addition of three separate 
volumes of red blood cell lysis buffer aids the removal of excess proteins and other 
contaminants that may be found in the blood. When a clear white blood cell pellet 
was left at the bottom of the tube, 15ul of Proteinase K was added to the pellet and 
the sample was vortexed until it was homogeneous. Proteinase K is a broad 
spectrum serine protease that digests any proteins that may be remaining in the 
solution (Appendix II, II.I). Additionally proteinase k limits the activity of 
intracellular DNAse that could degrade the DNA. Following the addition of 
Proteinase K, 10mls of cell lysis buffer [10 mM Tris-HCl pH 8.0, 25 mM EDTA, 0.5% 
SDS] (Appendix II, II.I) was added and the samples were incubated in a water bath 
at 55°C for one hour (the optimum temperature for the protease activity of 
Proteinase K is 65°C). After one hour the samples were removed and placed 
directly on ice. At RT 3.33mls of protein precipitation solution [5M Ammonium 
Acetate] was then added. The samples were left to cool for 10-15 minutes on ice, 
vortexing intermittently. The main component of the protein precipitation solution 
is Ammonium Acetate (NH4OAc) (Appendix II, II.I). Addition of NH4OAc increases 
the protein-protein interactions that occur in solution. The increase of salt 
concentration causes proteins to aggregate and precipitate out of solution. Samples 
were then spun at 3000rpm for ten minutes at 4°C. Following the spin the 
supernatant was removed using a sterile pipette and transferred to 10mls of 
isopropanol. Each tube was gently inverted a number of times until the DNA in 
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solution precipitated out. The samples were then centrifuged for five minutes at 
3000rpm. This ensures that any DNA that has precipitated out is tightly pelleted on 
the bottom of the tube. The isopropanol is then removed from the tubes and the 
DNA washed using 10mls of 70% ethanol. The samples were centrifuged again for 
five minutes at 3000rpm. The ethanol was carefully poured off and the Falcon 
tubes were inverted on tissue paper to remove any remaining ethanol. Samples 
were left to air dry for 15-20 minutes until all of the ethanol was removed. Low 
tris-EDTA [Tris-Cl (1 M, pH7.5-8), EDTA (0.5 M, pH 8.0)] (TE) (Appendix II, II.I) 
buffer solution was added to rehydrate the DNA and samples were left shaking 
overnight at RT. Once the DNA was dissolved samples were quantified using the 
procedure described in 3.1.3. DNA samples were normalised to form stock 
solutions of between 50ng/μl 500ng/μl and working aliquots were created by 
diluting samples to 25ng/μl. 
3.1.2.2 GENOMIC DNA EXTRACTION FROM SALIVA 
DNA was collected from some participants using the Oragene DNA Self-Collection 
Kit (DNA Genotek). The Oragene Self-Collection Kit is a non-invasive manner of 
sample collection, which increases the ease at which samples may be collected 
from participants that are not able to comply with blood collection. Upon collection 
of the sample and closure of the tube a DNA stabiliser is released and mixed with 
the sample. The samples are stable at RT for up to 5 years from collection. DNA 
from the saliva samples was extracted as per the directions detailed in the 
manufacturer’s instructions. The saliva samples containers were incubated at 50˚C 
for a minimum of one hour. The purpose of the incubation is to ensure that 
nucleases present in the sample are permanently inactivated to prevent any DNA 
degradation. Samples were transferred to a 15ml centrifuge tube and the volume 
of each sample was noted. Impurities were removed from the sample by adding 
1/25th volume of prepIT-L2P (DNA Genotek), vortexing the samples for a few 
seconds, and incubating each tube on ice for ten minutes. Samples were 
centrifuged at 3000rpm at RT for ten minutess. The supernatant was then 
transferred to a clean 15ml tube and the pellet was discarded. This step ensures 
that the majority of the contaminants are removed from solution. DNA was 
precipitated from the supernatant by adding 1.2x volume of 100% ethanol to the 
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solution and the tubes were mixed by inversion. The samples were left to stand for 
ten minutes at RT. Lower temperatures are not recommended as impurities may 
co-precipitate with the DNA. The tubes were centrifuged at 3000rpm for ten 
minutes to pellet the DNA. Following centrifugation the supernatant was removed 
from the tubes and the DNA was washed with 1ml of 70% ethanol. Samples were 
left for one minute at RT and the ethanol was completely removed after this time. 
The DNA was rehydrated using between 200-500ul of TE buffer solution 
depending on the amount of DNA that precipitated in the tube. Samples were left 
shaking for a minimum of one hour at 50°C and overnight at RT to ensure the DNA 
dissolved in the TE buffer. Once the DNA was dissolved samples were quantified 
using the procedure described in 3.1.3. DNA samples were normalised to form 
stock solutions of between 50ng/μl 500ng/μl and working aliquots were created 
by diluting samples to 25ng/μl. 
3.1.3 DNA QUANTIFICATIONS 
All DNA samples were quantified by the Qubit® 2.0 Fluorimeter (Invitrogen, UK) 
using the dsDNA BR (broad range) kit, which is highly selective for double 
stranded DNA over RNA. The Fluorimeter was calibrated using two standards 
provided by the manufacturer: 0ng/μl and 100ng/μl. 1ul of each sample was added 
to a master mix containing 199ul of Qubit® dsDNA BR buffer and 1ul of Qubit® 
dsDNA BR reagent. Samples were then incubated in the master mix for two 
minutes to allow the assay to reach maximum fluorescence and read using the 
fluorimeter. Each sample was read twice and samples were quantified in duplicate 
to ensure the average readings did not cross a standard error threshold of 5. 
Samples which passed the standard error cut off threshold were requantified 
following further shaking of the sample tubes. The reason for aberrant 
concentration readings is often due to undissolved DNA. 
 
In addition to the use of the Qubit, the NanoDrop 2000 spectrophotometer 
(Thermo Scientific, UK) was used for quantifying DNA when there were lower 
sample numbers and the purity of the DNA sample needed to be checked. This 
works on low volumes of DNA and outputs DNA concentration per μl using 260nm 
absorbance rate. DNA purity is measured using the 260/280nm, and 260/230nm 
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outputs. For DNA the 260/280 ratio should be around 1.8 and for pure DNA the 
260/230 ratio should be between 2.0-2.2. Deviation in these ratios generally 
reflects contamination in the DNA sample or degradation of the DNA. 
3.1.4 POLYMERASE CHAIN REACTION 
Polymerase chain reaction (PCR) is an in vitro technique that enables researchers 
to clone a specific region of DNA from small amounts of starting product. It is 
inexpensive and efficient and allows specific targeting of regions of interest. PCR 
consists of three steps that are vital for the appropriate region to be amplified: 
DNA denaturation, primer annealing and polymerase strand elongation. 
Denaturation of the sample causes the two strands of DNA to separate; this is done 
by heating the DNA to 95°C for two minutes. PCR buffers provide an optimal pH for 
the reaction and contain cations such as K+, which aids stabilization of primer 
annealing by binding to the phosphate groups on the backbone of DNA. Another 
important cation present, NH4+, can destabilise the hydrogen bonds between 
mismatch DNA bases by interactions during thermocycling, which increases the 
ratio of specific: unspecific final product. 
Longer denaturation time can be used if the region of interest has a high GC 
content. Primer hybridisation occurs when assay of DNA, primers, dNTPs and 
polymerase are incubated at an optimal annealing temperature, generally 5°C 
lower than the primer template melting temperature. Polymerase elongation time 
is calculated based on one minute per kilobase (kb) of DNA to be amplified. The 
ratio of specific product to unspecific product increases exponentially as the PCR 
reaction progresses. 
3.1.4.1 PRIMER DESIGN FOR PCR 
Primers were designed for PCR and real-time PCR using a number of guidelines. 
Primers should be between 18-22bp long, each having a melting temperature (Tm) 
between 42-65°C. The Tm of the primer pairs should not differ by more than 5°C 
and the GC content of each primer should be in the range of 40- 60%. Primer 
design should be avoided in genomic regions where repeats, or a run of 3 or more 
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bases are present. Primers should contain a C or G base at the 5’ or 3’ end: this aids 
specific binding due to the stronger bonding of G and C bases.  
The specificity and concentration of the primers designed are essential for 
maximum efficiency and targeting the specific region of interest. If the 
concentration of the primers is too high it raises the probability of the primers 
misaligning or annealing to regions other than the sequence of interest resulting in 
a number of spurious PCR products. Similarly, primer concentrations below a 
certain threshold will also have adverse effects on the PCR amplified as it restricts 
the amount of primer template available to anneal to the single stranded DNA. The 
final concentration for PCR primers should be between 0.05-1μM for the final 
reaction, with typically 0.1-0.5μM of each primer. 
Additionally some primers were designed using Primer3 online software 
(http://primer3.ut.ee/) [412, 413]. The region of DNA to be amplified is used as an 
input file and the primers are designed in the adjacent regions, defined using 
square brackets [ ]. An example of the output from Primer3 is shown in Figure 18. 
Following their design, primers were analysed using NetPrimer (Premier Biosoft, 
http://www.premierbiosoft.com/NetPrimer/AnalyzePrimer.jsp). This analysis 
covers a number of primer properties such as determining the primers propensity 
for the formation of secondary structures such as hairpin loops or dimers, -3’ and -
5’ end stability and repeats and runs. Secondary structures often result in poor or 
no yield of the targeted amplicon as they reduce the amount of primer that is 
available to anneal to the target DNA sequence 
3.1.4.2 PCR OPTIMISATION 
Optimisation for the PCR assay was conducted using four previously established 
conditions. These were the primary conditions used when starting an optimisation. 
If a genomic region appeared difficult to amplify using the standard optimisation 
conditions other conditions were tried and tested that specifically targeted the 
problem encountered in this region, such as high GC content. GC-rich genomic 
regions are refractory to amplification as they have a higher probability of forming 
secondary structures due to the stronger nature of the bonds present between the 
cytosine and guanine base. DMSO lowers the Tm of the DNA by binding to the  
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Figure 18. Primer 3 results for primers in the intronic region of CACNA1C.  
Information pertaining to hairpin loops, secondary structures, GC% is also given 
by the software.  
cytosine residue changing DNA conformation; this change in conformation 
facilitates the annealing of primers to the amplicon region and enhances the 
amplification of the region of interest. 
The addition of 7-deaza-dGTP has been reported to weaken the bonds in base-base 
interactions, lowering the melting temperature required for the PCR [414]. Aside 
from the above mentioned exceptions, the conditions used for standard PCR 
optimisation varied the concentration of MgCl2 present in the reaction, and the 
addition or absence of betaine. The addition of Mg2+ ions is essential as they form 
soluble complexes with the dNTP mixtures removing the beta and gamma  
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Volume (μl) 
2.0 mM MgCl2   2.5 mM MgCl2 
5 M Betaine No Betaine   5 M Betaine No Betaine 
10x Buffer 2.5 2.5 
 
2.5 2.5 
Betaine (5M) 5 0 
 
5 0 
MgCl2 (50mM) 1 1 
 
1.25 1.25 
dNTPs (25mM) 0.2 0.2 
 
0.2 0.2 
F oligo (10μM) 1 1 
 
1 1 
R oligo (10μM) 1 1 
 
1 1 
Water 11.8 16.8 
 
11.55 16.55 
Taq 0.5 0.5 
 
0.5 0.5 
DNA (12.5ng/μl) 2 2 
 
2 2 
Total 25 25   25 25 
Table 6. Standardised PCR reactions mixes for optimisations.  
 
Step Temperature (˚C) Time Cycles 
Denaturation 94 5 mins 1 
Denaturation 94 30 sec 
35 Annealing  60 30 sec 
Extension 72 30 sec 
Hold 72 10 mins 1 
Table 7. PCR conditions used for primer optimisation 
 
phosphates from the dNTPs allowing for the reaction to continue. The four primary 
conditions used for primer optimisation are listed in Table 6 and the PCR 
thermocycling conditions used are presented in Table 7. 
3.1.5 AGAROSE GEL ELECTROPHORESIS 
For simple and efficient detection of PCR products following PCR amplification 
agarose gels are used. Agarose is a natural polymer, extracted from seaweed, 
which upon heating and cooling in a buffer forms a gel through hydrogen bonds. 
Agarose gels are porous in nature and allow for the DNA to run through the gel 
when an electric current is applied. We used a continuous buffer to prepare the gel 
and allow for the migration of DNA along the gel. Continuous buffer systems are 
ones where the concentration of the buffer is the same in both the gel and the tank. 
PH of the buffer is essential for the electrophoretic mobility; a 1x Tris-Borate-
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EDTA [TBE, 90mM Tris, 90mM Boric, 2mM EDTA, pH 8.0] (Appendix II, II.II)  was 
used for these experiements. Optimal agarose concentration is dependent solely on 
the size of the band that is being run. The lower the concentration of agarose, the 
faster the DNA will travel through the gel. For PCR products >1kb it is 
recommended to use a 0.8% gel, and for products <1kb it is essential to use a 1% 
gel. This ensures the adequate separation of the bands, allowing for accurate 
detection of the specific PCR product. If there are a number of small bands 
presents and the agarose concentration is too low, these will cluster together 
making it difficult to discern whether the correct band is present.  
For the every gel 0.9g of agarose was added to a conical flask (1% w/v) and 
sufficient 90ml of 1xTBE buffer was added to the flask (Appendix II, II.II). The 
amount of agarose and TBE buffer depends solely on the size of the gel needed. The 
agarose was left to hydrate for a minute and then boiled for over one minute to 
ensure all of the agarose powder had dissolved in the buffer and cooled until the 
temperature was 50-60°C. Ethidium Bromide (EtBr) was prepared at 10mg/ml 
and added to the gel prior to casting, at a final concentration of 5ug/ml (Appendix 
II, II.II). EtBr is an intercalating agent that fluoresces under UV lights and is used to 
visualise the DNA at the end of the gel run. The gel was then poured into a casting 
tray which had combs placed to form wells and left to set for 30-45 minutes. After 
the gel had fully solidified it was placed in the electrophoresis gel tank and the 
buffer was added until it is 3-5mm above the gel.  
Five μl of PCR products were mixed with 1μl of 5x loading buffer (Bioline UK) prior 
to the addition of the DNA to the wells in the gel. The loading buffer contains 
glycogen or sucrose and adds density to the DNA allowing it to remain in the gel 
well rather than diffuse in the buffer. The buffer additionally adds a visible colour 
allowing for the progress of DNA migration to be seen on the gel. Specific 
molecular markers, Hyperladder markers I and IV (Bioline UK) were added to 
determine the size of the bands seen as they ran in tandem. 5μl of the PCR product 
and the molecular marker were pipetted into separate wells. The electrophoresis 
tank was then assembled fully and connected to the power supply. Gels were 
primarily run for 30 minutes at 120V; this differed depending on the size of the 
bands of DNA (the bigger the molecular weight of the product the slower it moves 
through the gel). Following sufficient separation of the bands the gel was 
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visualised using a UV transilluminator (UVP Gel-doc-it Imaging systems, UK) to 
determine the correct amount of PCR product was present. This image was 
captured using an internal camera. 
3.1.6 MAMMALIAN CELL CULTURE 
To investigate the effect variation in specific genes may have on a cellular system, 
or gene expression we used the human embryonic kidney 293 transformed cell 
line (HEK293) that were a kind gift from Josef Kittler (UCL) to transfect in DNA. 
These cells line were first characterised by Graham, Smiley, Russell, and Nairn 
[415] following transformation of a cell line using human adenovirus type 5. 
HEK293 cells have been widely used for recombination protein experiments since 
the cell line’s first description. A versatile cell line, its cellular machinery is capable 
of generating mature functioning proteins, allowing for biological evaluation of 
cellular trafficking and expression can be studies in tandem. Some speculation 
around the origin of these cells has persisted, while they have been obtained from 
the kidney, researchers such as Van der Eb predict that they may be neuronally 
derived given the expression of some mRNA and other expressed proteins that are 
normally found in neuronal lineages [415]. 
3.1.6.1 SUBCULTURING OF HEK293 CELLS 
HEK293 cells were cultured as mono layers in a plastic tissue culture flask at 37°C 
in 10ml of DMEM (Dulbecco’s Modified Eagle Media), 10% FBS (Fetal Bovine 
Serum), 1% Penicillin (50U/ml)/Streptomycin (50μg/ml) (Appendix II, II.III). The 
media is buffered by biocarbonate and must be kept in an atmosphere of 95% O2 
and 5% CO2 and is pH sensitive. Cells were grown in Nunc T-75 sterile filter cap 
flasks (Thermo Scientific, UK) until they were between 80-90% confluent. When 
they reached an appropriately confluent stage they were split into the required 
number of flasks. Cells were split in a class II microbiological safety hoods to 
prevent contamination. All surfaces and anything placed inside the hood were 
sprayed with 70% ethanol prior to the introduction of the cells to the hood to 
further prevent contamination. Cells were removed from the incubator and the 
DMEM culture media was removed. The cells were washed using 5ml of PBS  
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Figure 19. Neubauer-Improved Haemocytometer.  
A. The grid pattern of the counting chamber of the haemocytometer is divided into 
specific sections of known dimensions. Each of the small squares are 1mm in 
height, and 0.2mm in width. This allows for the accurate measurement of the 
number of cells in solution by the counting the cells in the specific squares [source: 
www.peqlab.de, Neubauer grid] B. The construction of the Neubauer 
Haemocytometer showing the counting chamber and the cover slip. 
(Phosphate Buffered Saline) to remove any remaining culture media as foetal calf 
serum contains protease inhibitors (Appendix II, II.III). Trypsin is an active 
protease and the cells were treated with trypsin to remove the monolayer of cell 
growth from the bottom of the T-75 flask. Five ml of Trypsin was then added and 
cells were left in the incubator for 5 minutes. 
Following the incubation period the flask was removed from the incubator, the 
flask was gently tapped to ensure the full detachment of cells. The flask was 
checked under the microscope to ensure all cells had detached fully and 
trypsinization was stopped by the addition of 5ml of DMEM, 10% FBS, 1% 
Pen/Strep. The mixture was then removed from the flask and placed in a 15ml 
Falcon tube and spun for 5 minutes at 1000rpm to pellet the cells. The supernatant 
was discarded and the cells were resuspended in 10ml of DMEM, 10% FBS, 1% 
Pen/Strep. Various volumes were then added to newly prepared T75 flasks 
containing an appropriate volume of DMEM, for example a 1:10 dilution would 
involve 9ml of DMEM in the T75 flask and the addition of 1ml from the 
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resuspended cells. The remaining unused cells were disposed of in a 4% Virkon 
solution (RMS, UK). 
3.1.6.2 COUNTING OF CELLS 
Prior to preparation of cells for transfection cell counting was undertaken using a 
Neubauer-Improved haemocytometer (Marienfeld, Germany) (Figure 19). The 
haemocytometer is a modified glass slide with indentations and line markings 
around a specific region of known area and depth that facilitates the counting of 
cells. As the specific measurements are known, the amount of cells in a volume of 
liquid can be deduced by taking an average count of cells found in specific areas. 
The gridded area of the haemocytometer consists of nine 1mm2 squares. These are 
further divided up so that the central square results in 0.0025mm2 squares.  
The distance between the cover slip and the counting chamber is 0.1mm2. The 
haemocytometer and the cover slip were washed prior to use with 70% ethanol. 
The cover slip was moistened and pressed down gently on top of the chamber until 
it was aligned and fixed. Cells were prepared following the protocol for 
subculturing, as outlined in 3.1.6.1, but following the centrifugation step, cells were 
resuspended in 5ml DMEM, 10% FBS and 1% Pen/Strep. The cellular suspension 
was mixed gently to ensure the suspension was homogeneous and 10μl of cell 
suspension was applied to the edge of the cover slip and enters each of the 
counting chambers through capillary action. Cells were counted four times using 
the centre square (Figure 19) to estimate the average number of cells in the 10ul 
added. A hand counter was used to count the number of cells in the selected area. 
The average number of cells counted was determined by dividing the total number 
of cells counted by 4. The number of cells in the area is equivalent to the number of 
the cells per square x104/ml. The volume needed to achieve the appropriate 
number of confluent cells was then determined for seeding of the cells into 6-well 
plates. 
3.1.6.3 SEEDING OF CELLS 
Twenty four hours before transfection, HEK293 cells were seeded into 6 well 
plates at approximately 5 x 105 cells per well in 3ml of DMEM, 10% FBS and 1% 
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Penicillin/Streptomycin. Cells were left for 24 hours in the incubator at 37°C and 
5% CO2.  
3.1.6.4 CATIONIC LIPID MEDIATED CELLULAR TRANSFECTION 
Lipofectamine was used to transfect the created plasmid DNA vectors into the 
HEK293 cells (Appendix II, II.IV). Lipofectamine is a cationic liposome that 
mediates the introduction of DNA into the cell with higher efficiency then 
previously used methods such as calcium phosphate coprecipitation, which can 
result in low transfection yields and cell toxicity. The cationic lipids consist of a 
positively charged head group with a number of hydrocarbon chains. This attribute 
of the lipid is responsible for mediating interaction between the cationic lipid and 
the phosphate backbone of the nucleic acid. It also instigates DNA condensation for 
complex formation. The negatively charged DNA binds spontaneously to the 
positively charged head of the cationic lipid. Not much is known about the exact 
entry of the DNA-lipid complex into the cells but it is thought that the positively 
charged head interacts with the negatively charged cell membrane and the 
transfection complex enter the cells through endocytosis. Cells were plated so that 
they reached 70-90% confluency at time of transfection. To prepare the cells for 
transfection the growth media was removed and the cells were washed with 1ml of 
PBS to ensure the removal of any antibiotic, as this can interfere with transfection 
efficiency. Growth media was then replaced with 1.2ml of Opti-MEM® reduced 
media serum (Life technologies, UK), which is a modified Eagle’s Minimum 
Essential Media suitable for cationic lipid transfections. Due to its higher 
concentration of HEPES (2-[4-(2-hydroxyethyl) piperazin-1-yl] ethanesulfonic 
acid) and sodium bicarbonate in the buffer it is more suitable for transfecting cells 
when creating DNA complexes. Media such as DMEM, when supplemented with 
antibiotics and FBS, can negatively affect transfection efficiency in wide variety of 
cell lines. Opti-MEM reduced media serum is also supplemented with L-glutamine, 
hypoxanthine, thymidine, sodium pyruvate, trace elements and growth factors and 
was used during the transfection period to facilitate greater transfection efficiency. 
Transfections were performed using Lipofectamine 2000® (Life Technologies). In 
an eppendorf tube 150µl of Opti-MEM media was mixed with 4µl of Lipofectamine 
2000® and the mixture was left to incubate for 10 minutes. In a second eppendorf 
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tube 150µl of Opti-MEM was combined with 500ng of the DNA of interest. 
Following the lipofectamine and Opti-MEM incubation period the solution was 
added to the DNA/Opti-MEM mixture and Lipofectamine/Opti-MEM mixture were 
incubated for 20 minutes at RT. The transfection complex was added into each 
well, one drop at a time, and the plate was left in the incubator. After four hours 
the Opti-MEM media was removed and replaced with DMEM, 10% FBS and 1% 
Pencillin/Streptomycin. 
3.2 METHODS FOR RESULTS CHAPTER 4 AND 5: HIGH-RESOLUTION 
MELTING CURVE ANALYSIS IN CALCIUM CHANNEL GENES 
3.2.1 RESEARCH SAMPLES 
High-resolution melting (HRM) curve analysis was conducted on the first 1000 
individuals collected for the UCL BD sample as described in section 3.1.1.1. Follow 
up KASPar genotyping of variants was conducted using the BD sample and the 
initial control sample as described in section 3.1.1.4 Additional BD samples, 
following the ancestry classifications previously established, and control DNA 
samples were collected following the primary HRM analyses and were included in 
the KASPar genotyping analysis. The SCZ and ADS samples, described in sections 
3.1.1.2 and 3.1.1.3 respectively, were used for follow-up genotyping. Additional 
databases were used to determine variant frequency. These include the 1000 
Genomes project, the Exome Aggregation Consortium cohort, the Exome variant 
server database, the UK10K SCZ sample and the Swedish SCZ Exome sample. 
3.2.2 HIGH-RESOLUTION MELTING 
HRM is a fluorescent PCR technique that allows for the rapid high-throughput 
analysis of genomic regions for the presence of variants. HRM is used a priori to 
sequencing to allow for the rapid screening of multiple cases and control samples, 
thus reducing cost and time and effort in identifying novel and previously 
identified variation in the genome. HRM is a real time PCR technique that amplifies 
the region of interest using standardised PCR techniques, as mentioned in (3.1.4), 
in the presence of an intercalating fluorescent dye. There are a number of dyes that 
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can be used in for the HRM analyses, we utilised a saturating dye. These dyes do 
not interfere with the melting temperature (Tm) of the amplicon, or inhibit 
polymerase activity. In addition to this saturated dyes can be used at higher 
concentrations than unsaturated dyes. This ensures a higher rate of incorporation 
of the dye into dsDNA. The fluorescence measure is indicative of the DNA state, 
with high fluorescence seen when the dye is incorporated in dsDNA, and low levels 
of fluorescence when it is unbound. In conjunction with the fluorescent dyes the 
PCR was carried out using a LightCycler 480 (Roche, UK) thermal cycle. Optimal 
PCR conditions were determined using the conditions in Table 8. Each fluorophore 
has a specific wavelength which is emitted when it is excited and the incorporation 
of the dye into the DNA and whether it is bound can be measured using 
quantitative PCR. 
Following the amplification step, the product was slowly denatured in incremental 
temperatures producing a characteristic melting curve profile. For HRM, the 
temperature increments increase each cycle by between 0.008 - 0.2 °C increments. 
This slight decrease in temperature increases the resolution of the melting profile, 
making it easier to discern differences in the DNA sequence. Unlike low resolution 
melting curve analysis, which is viewed as the derivative of fluorescence vs 
temperature (–
𝑑𝐹
𝑑𝑇
) against T, the data derived from HRM must be analysed using 
the data in the raw form. A comparison is done between the pre-melt temperature 
and the post-melt temperatures, which is normalised to identify mutations (Figure 
20) [416]. 
3.2.3 PURIFICATION OF SAMPLES 
Purification of PCR products ensures the elimination of PCR fragments and probes 
prior to downstream experiments. Purification of the DNA was completed using 
the ethanol/EDTA precipitation method. Following PCR it is likely that an excess of 
salts, the presence of PCR primers, primer-dimers, reaction buffers or dNTPs, could 
interfere with sequencing or other experiments. MicroCLEAN (Microzone Limited, 
UK) is a DNA clean up reagent that concentrates the PCR product and removes the 
previously mentioned reagents (Appendix II, II.V). 
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Reagents 
Sensi 
MgCl2 
3mM 
Sensi 
MgCl2 
4mM 
Sensi  
MgCl2 
4.5mM 
Sensi  
MgCl2 
5mM 
300nM 
Quanta 
400nM 
Quanta 
SensiMix HRM 2 2 2 2 0 0 
50mM MgCl2 0.3 0.4 0.45 0.5 0 0 
EvaGreen Dye 0.16 0.16 0.16 0.16 0 0 
F Oligo(10mM) 0.08 0.08 0.08 0.08 0.15 0.2 
R Oligo(10mM) 0.08 0.08 0.08 0.08 0.15 0.2 
Accumelt 0 0 0 0 2 2 
DNA (12.5ng/μl) 1 1 1 1 1 1 
Water 1.38 1.28 1.23 1.18 1.7 1.6 
Total  5 5 5 5 5 5 
Table 8. Optimisation condition for HRM assays. 
Standard conditions used to optimise HRM primers for the specific amplicon of 
choice. The main changes between the conditions lie in the increased in the MgCl2 
 
Figure 20. HRM melt curve analysis. 
HRM melt curve analysis of CACNA1D Exon 1 after normalization. Curve A and C 
(Red and Green) represent the presence of the wildtype allele. Curve B (Blue) is a 
different shape and Curve group D show a shift to the right. These are samples 
which were choosen to follow up by Sanger sequencing. 
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3.2.3.1 MICROCLEAN OF PCR PRODUCTS FOR PURIFICATION IN 96-WELL PLATES 
An equal volume of microCLEAN e.g. 10μl of Microclean for 10μl of PCR reaction, was 
added to the DNA sample and the plate was shaken using a Mixmate (Eppendorf, 
Germany) to mix the solution. The plate was placed in a centrifuge at 4000rpm for one 
hour. To remove the supernatant, plates were overturned on a tissue and the plate was 
spun in the centrifuge at 1000rpm for one minute. The pellet was then resuspended in 
5μl of pre-PCR water (Sigma-Aldrich, UK) and allowed to rehydrate at RT. 
3.2.3.2 MICROCLEAN OF PCR PRODUCTS PURIFICATION IN TUBES 
An equal amount of microCLEAN reagent was added to the DNA sample and mixed 
by pipetting. Following five minutes incubation at RT, the tubes were spun in a 
bench top centrifuge at 13,000rpm for seven minutes. The supernatant was 
aspirated and spun again for one minute to remove any dregs that may be still 
present in the tube. The pellet was then resuspended in 5μl of pre-PCR water 
(Sigma-Aldrich, UK) and allowed to rehydrate at RT. 
3.2.4 SANGER SEQUENCING 
DNA sequencing was used to validate and confirm the presence of mutations that 
may have been identified using HRM analysis and genotyping, or created via site 
directed mutagenesis. DNA samples to be sequenced were tagged with fluorescent 
dye using BigDye1.3 (Life Technologies) reagents. Each of these fluorescent 
markers was incorporated into the DNA sequence via thermo cycling (Table 10). 
Thermo cycling allows for the dyes to be incorporated and creates and amplifies 
the sequencing extension products, each of which are terminated by one of the 
four genetic bases (Figure 21) Each of the fluorescent dyes emits a specific 
wavelength when excited by light making it possible to discern the presence of a 
specific base at the 3’ terminal dideoxynucleotide as A, C, T or G. 
The forward and reverse primers used to sequence the region of interest were 
designed as previously described in section 3.1.4.1 and the region of amplicon to 
be sequenced was amplified under optimum conditions.  
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Figure 21. BigDye reaction for Terminator Cycle Sequencing. 
 
Reagents Volume (μl) 
Big Dye v3.1 1  
Buffer x5 1.5 
Primer F/R 0.32 
Water 6.18 
PCR Product 1 
Total 10 
Table 9. Big Dye v3.2 Reaction Mix for sequencing 
 
 
 
Step Temperature (°C) Time Cycles 
Denaturation 94 5 mins 1 
Denaturation 96°C 10 sec 
25 Annealing 50°C 5 sec 
Extension 60°C 4 min 
Table 10. Big Dye v3.1 Thermocycling conditions 
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3.2.4.1 BIG DYE THERMOCYCLING 
PCR for the sequencing reaction was conducted using amplified product according 
to the manufacturer’s protocol (Table 9) using the resuspended PCR product 
which had been cleaned using Microclean (3.2.3). One forward and one reverse 
condition was done for each sample to ensure adequate coverage of the genetic 
region was achieved as fidelity to the true sequence somewhat deteriorates as the 
amplicon gets longer. Having a forward and reverse sample alleviates this issue. 
Purification and precipitation of the DNA for sequencing was done using 
EDTA/Ethanol precipitation. 2.5μl of EDTA [125mM] and 30μl of 100% ethanol 
were added to the 10μl of extension reaction from the Big Dye v3.1 PCR reaction. 
The precipitation reaction was left at RT for ten mins and was then spun in a 
centrifuge for one hour at 4000 rpm. To remove the supernatant the samples were 
spun upside down at 1000g for 10 mins. Samples were then washed with 30μl of 
70% ethanol and spun for ten minutes at 4000g. The supernatant was removed 
again using the procedure previously described. Samples were left at RT for 15 
minutes to ensure that all of the ethanol was completely removed. Following this, 
15μl of Hi-Di™ formamide was added to each of the wells on the plate to be 
sequenced or to the individual tubes. Sequencing was conducted using the ABI 
3730xl (Applied Biosystems, UK) at a number of locations including North Thomas 
Regional Genetics Lab, Queen Square, Wolfson Institute, UCL and Source 
BioScience, Cambridge. 
3.2.4.2 SEQUENCING ANALYSIS 
DNA sequencing analysis was conducted using the Staden Package [417]. The 
package assembles the DNA, covering the most essential requisites for sequencing 
analysis. The Staden package contains two programmes gap4 and pregap4. Gap4 
performs the assembly of the sequence files, joins contigs, allows for pattern 
recognition, read pair analysis and allows for the visualisation of all contigs 
present in the sequencing of samples. Pregap4 provides a graphical interface 
where the user can conduct quality control on each individual sample. It is then 
possible, following the input of the sequencing files, to investigate whether 
variation is present in the sequence which would deviate from the reference 
sequence obtained from the UCSC genome browser (Figure 22). 
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Figure 22. Staden Trace display of a CACNG4 variant. 
The staden package assembles all of the sequencing files inputs and creates contigs 
through which the user can search for variation in the sequence. Figure 22 shows 
the presence of a heterozygous mutation G/A in an individual in the fourth exon of 
the CACNG4 gene 
3.2.5 VARIANT SELECTION FOR KASPAR GENOTYPING 
Following HRM screening of variants and sequencing analysis each sample was 
investigated to determine whether there were mutations present in the genomic 
regions of interest. Only a minority of samples were chosen to send for sequencing 
to determine whether variation was present. To investigate allele frequencies in 
the entire BD and control cohorts the variants need to be genotyped. To qualify for 
the following genotyping, variants needed to satisfy a number of criteria which are 
outlined below. 
3.2.5.1 BIOINFORMATIC FUNCTIONAL PREDICTION 
Bioinformatic prediction software tools are used to infer functionality of variants 
present in the genome. Different predictive software can produce conflicting 
results, as the characteristic of the variant analysed are not the same.  
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For variants present in exons, PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/) and Sort Intolerant from Tolerant 
(SIFT) (http://sift.jcvi.org/) were used to predict whether these variants could be 
deleterious, or benign. PolyPhen-2 calculates a variant’s impact on the structure of 
the resulting protein by contrasting conservation of the wild-type base with the 
frequency with which the substitution is seen in the family of related homologous 
proteins. It also measures the number of structural impacts a non-synonymous 
variant could have on the protein structure and secondary structure. This is 
achieved by determining the nature of the amino acid change, polar to non-polar, 
and whether the inserted amino acid is spatially different in the structure, altering 
necessary regions in the protein structure such as hydrophobic bonds. 
SIFT on the other hand purely focuses on the conservation of a specific base pair, 
utilising sequence alignment data closely related sequence data using Position-
Specific Iterated Basic Local Alignment Search Tool (PSI-BLAST).  
The promoter, 5’UTR, and 3’UTR variants were investigated using Transcription 
Element Search System (TESS) (http://www.cbil.upenn.edu/) [418] and 
Alibaba2.1 (http://www.gene-
regulation.com/pub/programs/alibaba2/index.html). These programmes examine 
whether variants may have an impact on transcription factor binding sites (TFBS) 
which are predicted from the DNA sequence. Often a base change may not result in 
a change of TFBS, but sometimes it may result in a loss of the TFBS and/or the 
creation of a new one. 
3.2.6 SNV GENOTYPING WITH KASPAR 
Following variant validation, using sequencing in the genes of interest, and 
preliminary investigation using the above mentioned software, the single 
nucleotide variants (SNVs) where further investigated in the complete cohorts of 
interest. HRM is a useful tool for determining whether variation is present but does 
not offer the researcher complete information on the frequency of the SNV in that 
population. The main reason for this is often the variant does not have a significant 
enough effect on the change of the melting curve to distinctly set apart all of the 
individuals that carry the variant. As the control cohorts are also not screened 
128 
using HRM analysis, genotyping is the perfect way to get a complete overview of 
the frequency of the variant in both case and control populations.  
KASPar (KBiosciences Competitive Allele-Specific Polymerase Chain reaction) 
genotyping is a simple, rapid, cost effective way to determine allele frequencies in 
a sample set. KASPar is a homogeneous, FRET based, endpoint genotyping 
technology consisting of two main components. The first component is the KASPar 
assay mix, which consists of competing, non-fluorescently labelled, forward 
primers targeting the variant of choice, and one common reverse primer. The 
second component is the KASPar master mix, which contains the FRET cassette 
and Taq polymerase in an optimised buffer solution. The two forward competing 
primers, targeting the wild-type allele and variant allele, contain complementary 
sequences to the FAM and HEX dye respectively, which are present in the master 
mix. During PCR one of the allele-specific primers matches the genomic region and 
the target region is amplified with the common reverse primer. As PCR progresses 
the level of allele specific tails increase and the fluor labelled part of the FRET 
cassette releasing the fluor from the 3’ end quencher to produce a fluorescent 
signal (Figure 23). 
3.2.6.1 KASPAR PROTOCOL 
Primers were designed to target the desired variant using Primer Picker (K 
Bioscience, UK) software. This primer designing software creates two specific 
forward primers which target either the wild-type or the variant, and two reverse 
primers. Only one of the reverse primers is used for the actual genotyping 
procedure which is determined using optimisation. Optimisation of genotyping 
conditions was done using both specific forward primers and one of the two 
common reverse primers. The volumes for the allele mixtures are described in 
Table 11 and the six different master mixes used for the genotyping optimisation 
are outlined in Table 12. Optimisation was carried out using a DNA sample that 
contained the variant of interest and a wild-type control DNA sample. The 
optimised conditions were used to carry out case-control genotyping on previously 
prepared DNA samples. The samples were previously aliquoted onto 384-well PCR 
plates and dried down. Prior to the addition of the optimised master mix for the 
PCR procedure the positive control samples (12.5ng/μl) were added to the plate  
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Figure 23. Diagrammatic representation of the mechanisms underlying KASPar 
Chemistry.  
Image taken from LGC KASP genotyping chemistry user guide 
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Conditions 
Concentration 
in Assay Mix  
Volume in 1X 
Assay Mix (μl) 
Allele Specific Primer 1 (100μM) 12 12 
Allele Specific Primer 2 (100μM) 12 12 
Common (reverse) Primer 
(100μM) 30 30 
Water/TrisHCl (10mM,pH8.3) 
 
46 
Total volume 
 
100 
Table 11. Allele Mix for KASPar Assay 
 
Reagents 
  
A B C D E F 
1.8mM 
MgCl2 
2.2mM 
MgCl2 
2.5mM 
MgCl2 
2.8mM 
MgCl2 
5% 
DMSO 
10% 
DMSO 
DNA (12.5ng/μl) 1 1 1 1 1 1 
2X Rxn mix (+KTAQ) 2 2 2 2 2 2 
Assay mix 1/2 0.11 0.11 0.11 0.11 0.11 0.11 
MgCl2 1:10 0 0.32 0.56 0.8 0 0 
Water 0.89 0.57 0.33 0.09 0.69 0.5 
Total 4 4 4 4 4 4 
DMSO 0 0 0 0 0.2 0.4 
Table 12. Optimisation Conditions for KASPar Genotyping 
 
and dried at 50°C. The master mix for the PCR procedure was dispensed into each 
well of the plate using an Epmotion 5075 (Eppendorf, UK). The plate was then 
mixed using a Mixmate and spun in a centrifuge at 1500rpm for 1 minute before 
loading into the LightCycler 480 (Roche Diagnostics, UK). The thermal cycling 
conditions for the endpoint genotyping are outlined in Table 13. During the PCR 
the readings for the PCR were read three different times, as some readings 
provided better separation than others. Only one optimal reading was used for 
each of the analyses. For all SNPs genotyped, 17% of samples were duplicated to 
detect error and confirm reproducibility of genotypes on a cross check plate 
consisting of case and control duplicates. All the data were analysed to confirm 
Hardy-Weinberg equilibrium (HWE). Additionally rare variants present in a low 
number of samples were sequenced from stock DNA in all samples to confirm 
genotyping calls. 
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Figure 24. KASPar genotyping for CACNA1C. 
KASPar endpoint genotyping for one of the case-control plates for variant 
rs79398153, located in the third intron of CACNA1C. Wildtype alleles are 
represented by the blue triangles, heterozygous individuals are represented by the 
red triangles and individuals homozygous for the variant are represented by green 
triangles. Both the grey and pink circles are samples which have failed or are 
undefined and will be repeated on the following plate. 
3.2.6.1.1 ENDPOINT GENOTYPING 
Endpoint genotyping was conducted using LC480 software (see Figure 24). 
Genotyping data was taken from the whole amplification process and not the post- 
PCR melting step. Each fluorescent output was measured and samples were 
differentiation depending on the signal recorded, any variants which did not 
cluster closely were manually called as unknowns and were re genotyped on the 
cross check plate. Additionally samples which failed to amplify in the primary 
genotyping run were plated onto the cross check plate from a stock sample of 
25ng/μl and diluted to the working concentration of 3.33ng/μl. Genotype data was   
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Step Temperature (°C) Time Ramp Rate °C/s Cycles 
Hot Start Activation 94 15 min 4.8 1 
1
st 
Amplification 94 20 sec 2.5 
10 
 
65 1 min 2.5 
2
nd 
Amplification 94 20 sec 2.5 
26 
 
57 1 min 2.5 
Reading 37 1 sec 2.5 
1 
 
38 1 sec 0.06 
3
rd 
Amplification 94 20 sec 2.5 
3 
 
57 1 min 2.5 
Reading 1 37 1 sec 2.5 
1 
 
38 1 sec 0.06 
4
th 
Amplification 94 20 sec 4.8 
3 
 
57 1 min 2.5 
Reading 2 37 1 sec 2.5 
1 
 
38 1 sec 0.06 
Cooling 40 1 sec 2.5 1 
Table 13. Thermocycling conditions for KASPar Genotyping 
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accumulated and compiled to double check no differences were present between 
the original calls and the cross check plate. If such deviations were present 
samples were sequenced to verify calls. As to be expected for each SNP genotyped 
there was a number of samples which failed both the original and cross check 
genotyping. To ensure reliable assay mixes were used, runs which had less than 
98% of the samples called were re optimised. 
3.2.6.2 STATISTICAL ANALYSIS 
Allelic associations for SNPs were performed using the Chi-square test and the 
Fisher’s exact test. A cut-off significance value of  p< 0.05 was used 
3.2.7 PLASMID CONSTRUCTION 
Vectors are constructs of DNA that allow the insertion of genomic regions of 
interest by a number of different cloning techniques. There are several important 
benefits that arise from this procedure of construction vectors in molecular 
biology. Facilitation of in vitro experiments is the primary function of the 
construction of vector sequences. The introduction of genetic material into cells 
outside their normal biological location allows for easy manipulation of the newly 
created recombinant DNA. Diverse experimental conditions allow investigation of 
the effect that variants may have on gene expression, cell trafficking, localisation of 
specific proteins and much more. Construction of the vectors allows for the specific 
labelling of the recombinant DNA with fluorescent proteins such as green 
fluorescent protein. 
3.2.7.1 PREPARATION OF CACNAG4 TAGGED WITH RFP 
The cDNA for CACNG4 was obtained from Origene, USA. The CACNG4 open reading 
frame (ORF) was present in the pCMV6-XL4 vector (Figure 25). The pCMV6-XL4 
vector contains a CMV promoter for in vivo expression in mammalian cells and a 
T7 promoter for in vitro experiments. There are multiple restriction sites that can 
be used for the removal of the insert from the vector for cloning into the pTAG-RFP 
vector (Figure 26). 
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Figure 25. Vector sequence for pCMV6-XL4.  
CACNG4 was present in the multiple cloning site and was removed using 
restriction digestion.  
 
 
Figure 26. Vector Sequence for pTAG-RFP.  
CACNG4 was inserted into the multiple cloning site using restriction digestion. 
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3.2.7.2 GLUR1 
Two GluR1 constructs were used for this project. The first is GluR1 in the pGEM-T 
vector (Figure 27), which is cloned in using TA cloning and the second is pCI-SEP-
GluR1 plasmid which will be described later.  
The pGEM-T vector is 3kb in size, contains multiple cloning sites and is a high 
efficiency TA cloning vector. The plasmid was sent on a Whatman FTA elution card, 
containing 5-10μg of DNA, obtained from Sino Biological Inc Japan. The vector was 
isolated from the elution card by first cutting around the filter paper containing the 
vector and cutting the resulting circle into small pieces. The filter paper was 
transferred to a microcentrifuge tube and 200μl of sterile H2O was added. The 
mixture was briefly centrifuged to ensure all of the paper was in the water. The 
microcentrifuge tube was left to incubate at 95°C for 30 minutes in the water bath. 
The tube was vortexed gently every ten minutes. Following the incubation period 
the mixture was centrifuged for 30 seconds and 100μl of the supernatant was 
removed from and placed in a new clean tube. 10μl of the solution was run on a 1% 
agarose gel (EtBr) for two hours against hyperladder 1 (Bioline) to verify the 
presence of the vector (Figure 28). 
3.2.7.2.1 LIC CLONING 
Ligase independent cloning (LIC) is a fast and efficient way of creating vector 
insert clones that does not utilise DNA T4 ligase or need the presence of restriction 
sites to work as is common with cloning procedures. The protocol first described 
by Aslanidis and Jong in 1990 [419] uses specific complementary base overhangs 
of approximately 10-15 base pairs to insert the DNA fragments into the vector of 
choice. The method is based primarily on the 3’→5’ exonuclease nature of T4 DNA 
polymerase that creates the specific complementary base allowing non-covalent 
bi-molecular associations between the vector and the insert. The vector contains 
complementary overhangs to the insert but not to itself so that it cannot recirculize 
upon linearization.  
The vector is linearised using a single restriction site digestion and then is treated 
with dCTP (deoxycytidine triphosphate). This allows the 3’→5’ exonuclease nature  
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Figure 27. pGEM-T Vector 
The GluR1 insert was present in the TA cloning site and was removed using LIC 
cloning. Image taken from http://www.sinobiological.com/Vector-pGEM-T-a-
1636.html  
 
 
Figure 28. GluR1Elution 
The 10μl of eluted GluR1 cDNA run against Hyperladder 1 (Bioline). The observed 
pGEM-T vector and GluR1 should be approximately 5.7kb long. However, due to 
the supercoiled nature of the vector it is able to run faster on the gel giving the 
observed band of approximately 3.8kb. 
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of T4 DNA polymerase to remove all of the nucleotide bases until the first cytosine 
residue is reached. The result of this linearization followed by dCTP treatment 
results in the 10-12 base pair overhang allowing for the specific ligation 
independent annealing reaction to proceed. Similarly the insert is amplified using 
primers with complementary overhangs to the extra bases in the vector and is 
treated with dGTP to compliment the exonuclease activity seen in the vector. The 
vector and insert are then combined in a tube and the overhangs are long enough 
to provide very specific enzyme annealing between both the vector and insert. 
3.2.7.2.1.1 LINEARIZATION OF THE LIC VECTOR 
The pcDNA3 green fluorescent protein (GFP) Lic cloning vector (6D) was first 
linearised using SspI (Promega, UK). In a microfuge tube 5μl of Buffer E (Promega, 
UK) 2.5μl of BSAI (10 units/μl), and 5μg of plasmid DNA were mixed together. 
Following a short vortex, 1μl of SspI was added and pre-PCR water added to 
culminate in a final volume of 50μl. The digestion mixture was incubated at 50˚C 
for one hour. Following digestions the sample was run on a 0.8% agarose gel to 
ensure complete digestion and that linearization had occurred. As a positive 
control an undigested vector was run in the well beside the digested pcDNA3 GFP. 
The sample was added to 10μl of 5x loading buffer and hyperladder 1 was used as 
a marker to determine band size. The gel was run for one hour and 100V. The gel 
was analysed using the UV transilluminator (UVP Gel-doc-it, Imaging Systems, UK) 
as previously mentioned in section 3.1.5 and the linearised band of LIC vector was 
extracted. The plasmid DNA was purified from the gel using a QIAquick Gel 
Extraction Kit (Qiagen, UK) based on the manufacturers protocol. Quantification of 
the extraction sample was determined using a Nanodrop 2000 (Thermo, UK). 
3.2.7.2.1.2 PCR OF THE INSERT FOR LIC CLONING 
To prime the insert for inserting into the LIC cloning vector PCR was performed 
with specific primers. The primers used were F: 5’-
TACTTCCAATCCAATGCCACCATGCAGCACATTTTTGCCTTC-3’ and R: 5’-
CTCCCACTACCAATGCCCAATCCCGTGGCTCCCAAG-3’. The forward primer contains 
the complementary overhang, denoted by the underline, and 21 bases of the 
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beginning of GLUR1, including the start codon. The reverse primer contains the 
specific complementary overhangs, also denoted by the underline, but skips the 
stop codon at the end of GLUR1 to ensure correct read through of GFP is achieved. 
It is essential that both primers have a melting temperature of 60˚C. The insert was 
amplified using the high fidelity polymerase Pfx. An optimisation was run to 
determine the best optimizing conditions for the PCR reaction. The conditions are 
listed in Table 14 . The master mix for each optimisation was created and the PCR 
reaction undertaken Table 15. Following PCR, the amplified sample was run on an 
0.8% agarose gel at 100V for one hour. It is essential for the protocol to remove 
any free dNTPs in the reaction mixture. The sample was analysed as previously 
mentioned in section 3.1.5 and extracted from the gel using the QIAquick gel 
extraction kit according to the manufacturer’s instructions. 
3.2.7.2.1.3 T4 DNA TREATMENT OF BOTH LIC VECTOR AND PCR PRODUCT 
The LIC vector and PCR product were incubated in the presence of LIC-qualified 
T4-polyermase (EMD Millipore, USA) and dCTP and dGTP respectively. 0.2pmol of 
the insert was treated with dGTP to provide enough material for 10 annealing 
reactions. The formula used to calculate the amount of DNA to give 0.2pmol can be 
found below:  
𝐴 = 
𝐵 × 106
𝑁 × 660
 
Equation 1. Calculation of pmol of DNA 
Where A is the [pmol of DNA], N is the length of the DNA region in base pairs and B 
is the starting μg concentration of DNA length N. 660 is the approximate molecular 
weight of a DNA nucleotide pair. 
For the PCR product 2μl of T4-DNA polymerase buffer, 0.2pmol of PCR product, 
0.5μl dCTP, 1μl DTT (Dithiothreitol), 2μl 10x BSA and 0.4μl T4 DNA polymerase 
(3units/μl, Promega, UK) were mixed in a 1.5ml microfuge tube. Sterile water was 
added to a final volume of 20μl. The solution was vortexed briefly and then spun at 
13,000rpm for 1 minute. The reaction mix was incubated for 30 minutes at RT.  
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Step Time Temperature Cycles 
Denaturation 2 min 95˚C 1 
Denaturation 30 sec 95˚C 
30 Annealing  30 sec 56˚C 
Extension 3min* 72˚C 
Extension 10min 72˚C 1 
Hold 
 
4˚C 1 
 
Table 14. PCR conditions for LIC cloning.  
*1 minute per kb is used for Pfx polymerase 
Volume (μl) 
2.0 mM MgCl2 2.5 mM MgCl2 
A B C D E F 
5M 
Betaine 
No Betaine + 
No Enhancer 
No Betaine + 
Enhancer 
5 M 
Betaine 
No Betaine + 
No Enhancer 
No Betaine 
+ Enhancer 
10x Buffer 2.5 2.5 2.5 2.5 2.5 2.5 
10 x Enhancer 2.5 0 2.5 2.5 0 2.5 
5 M Betaine 5 0 0 5 0 0 
50 mM MgSO4 1 1 1 1.25 1.25 1.25 
25 mM dNTPs 0.2 0.2 0.2 0.2 0.2 0.2 
10 μM F oligo 1 1 1 1 1 1 
10 μM R oligo 1 1 1 1 1 1 
Taq 0.2 0.2 0.2 0.2 0.2 0.2 
DNA (25ng/ul) 0.5 0.5 0.5 0.5 0.5 0.5 
Water 11.1 18.6 16.1 10.85 18.35 15.85 
Total volume 25 25 25 25 25 25 
Table 15. pfx primer optimisation conditions. 
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Following the incubation period the enzyme was inactivated by incubation at 75˚C 
for 20 minutes and then spun at 13,000rpm for 1 minute. 
For the LIC vector 600ng of SspI digested vector was used, which is enough for 20 
annealing reactions. 2μl of T4-DNA polymerase buffer, 600ng of LIC vector, 0.5μl 
dGTP, 1μl DTT (dithiothreitol), 2μl 10x BSA and 0.4μl T4 DNA polymerase 
(3units/μl) were mixed in a 1.5ml microfuge tube. Sterile water was added to a 
final volume of 20μl. The solution was vortexed briefly and then spun at 
13,000rpm for 1 minute. The reaction mix was incubated for 30 minutes at RT. 
Following the incubation period the enzyme was inactivated by incubation for at 
75˚C for 20 minutes and then spun at 13,000rpm for 1 minute. 
3.2.7.2.1.4 ANNEALING OF THE LIC VECTOR AND PCR INSERT 
The insert and vector were annealed using the complementary base pair 
overhangs that had been generated using the procedures described previously. For 
this reaction, 0.02pmol of insert DNA, and 25-50ng of LIC prepared vector was 
used. The concentration of the vector varies depending on the vector: insert ratio, 
which is suggested to be 1:2.  
In a microfuge tube 3μl of LIC prepared vector was mixed with 3μl of LIC prepared 
insert and sterile water was added to a final volume of 20μl. The mixture was 
incubated at RT for 5-30 minutes. Annealing of the complexes generally occurs in 
first five minutes but the insert and vector can be incubated for up to one hour 
with equivalent results. 
3.2.7.2.1.5 E.COLI TRANSFORMATIONS 
Following the incubation, 6μl of annealing mixture was transformed into 900μl of 
Library Efficiency® DH5α™ Competent Cells (Life Technologies, UK). Cells were 
chilled on ice for 30 minutes. They were then placed in a water bath at 42°C for 45 
seconds before placing them on ice again for 2 minutes. The cells were then placed 
in super optimal broth (SOC, Life Technologies, UK) medium at 37°C for one hour 
and shaken at 225rpm (Appendix II, II.VI). To check transformation efficiency, a 
parallel transformation was done using the 0.1ng of pUC18 DNA. 
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Figure 29 PCR of E.coli single colonies for LIC insert.  
3.2.7.2.1.6 SELECTION OF E.COLI WITH INSERT 
Following overnight incubation a number of single colonies were removed A 
sterile single pipette tip was used to pick up each individual colony. The tip was 
then dipped into 5μl of pre-PCR sterile water. The tip was then placed in 500μl of 
Luria-Bertani broth (LB broth) [10g NaCl, 10g Trypton, 5g Yeast] with a vector 
specific antibiotic (Ampicillin (100μg/ml) or Kanamycin (50μg/ml)). The cells 
were shaken in LB Broth for 8 hours. DNA from the E.coli was extracted using a 
mini prep procedure (Qiagen) which is described below. In parallel a restriction 
digest was run on the 5μl of pre-PCR water, in which the tip used to pick single 
colonies was dipped. The digest was conducted using Xbal and HindIII. These two 
restriction sites are unique to the vector and flank the area in which the insert 
should anneal. In a microfuge tube 5μl of pre-PCR water containing the E.coli DNA, 
2μl of Promega Buffer E (Promega, UK), 2μl of BSA 10X, 1μl of Xbal and 1μl of 
HindIII were mixed together. Sterile water was added to make a final volume of 
20μl. The samples were incubated at 37°C for 4 hours. Following incubation 10μl 
of digested DNA was mixed with 2μl of 5x Loading Buffer (Bioline, UK) and run for 
2 hours at 100V on a 0.8% agarose gel. Following gel analysis, samples that 
contained the insert could be selected to grow up (Figure 29). 
3.2.7.2.2 MINI PREP 
DNA was isolated using the QIAprep® miniprep Kit (Qiagen, UK) from E.coli 
following the restriction digest in order to verify by sequencing that the insert was 
present. Samples which showed the presence of a correct band size were selected 
for mini-prep. Following the 8 hour incubation, 250μl of insert containing E.coli 
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was transferred into a 50ml falcon tube containing 5ml of LB Broth with 
appropriate antibiotic (Appendix II, II.VI). The cell solution was left shaking at 
37⁰C for >16 hour. Following overnight incubation, the E.coli was pelleted by 
centrifugation at 8000rpm for 5mins. The waste LB broth was discarded and the 
pellet was resuspended in 250μl of Buffer P1 and transferred to a microcentrifuge 
tube. 250μl of Buffer P2 was then added to the samples and each tube was invert 4-
6 times to mix the solutions. The samples were left to incubate at RT for five 
minutes for lysis of the bacterial cells to occur. 350μl of Buffer N3 was then added 
to terminate lysis and the samples were spun at 13,000rpm for 10mins to remove 
the cellular debris. The supernatant from this step is then removed by pipetting 
and added to a Qiaprep spin column. The samples were spun for 60seconds and 
the flow through was discarded. 500μl of Buffer PB was added to the spin column 
and the samples were spun for 60 seconds and the flow through was discarded. 
Finally 750μl of Buffer PB was added and the samples were spun for 60 seconds. 
The flow through was then discarded. 50μl of sterile water was added to the 
column and the samples were left for one minute at RT. The flow through was then 
collected and the samples were quantified using the Nanodrop as described in 
3.1.3. 
3.2.7.2.3 MIDI PREP 
To ensure an adequate volume of plasmid DNA was obtained prior to the onset of 
in vitro experiments a midi prep was done for each plasmid containing the insert.  
Samples which contained the correct insert were transformed into Library 
Efficiency® DH5α™ Competent Cells (Life Technologies, UK) (3.2.7.2.1.4) The 
plates were left overnight at 37⁰C and a single colony was taken and placed in 
500μl of Luria Bertani (LB) Broth with a vector specific antibiotic (Ampicillin 
(100μg/ml) or Kanamycin (50μg/ml)) (Appendix II, IV). The cells were shaken in 
LB Broth for 8 hours. Following this they were transferred into a 50ml Falcon tube 
containing 5ml of LB Broth with appropriate antibiotic. The cell solution was left 
shaking at 37⁰C for >16 hours. The following morning the sample was spun down 
in a centrifuge at 6000rpm, at 4⁰C for 15 minutes. The supernatant was disposed of 
and a 200μl pipette tip was dipped in the pellet of E.coli to make a preparation for 
the midi prep without having to first mini prep the DNA. 
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Following the incubation period the vector DNA was extracted according to the 
manufacturer’s protocol (Qiagen, UK). The 100ml of bacterial cell culture was split 
into two 50ml Falcon tubes. The cells were harvested by spinning at 6000rpm for 
fifteen minutes at 4⁰C. The bacterial pellet was then resuspended in 4ml of buffer 
P1, and the sample mixed vigorously to ensure it was completely homogenous. 
Four ml of buffer P2 and the sample was mixed by inverting the tube a number of 
times. The sample was incubated at RT for up to five minutes. Following the 
incubation period, four ml of pre-chilled buffer 3 was added and the sample was 
mixed to ensure the suspension was completely homogenous. Upon addition of 
buffer 3 a white fluffy lysate should form in the Falcon tube. The addition of chilled 
buffer 3 ensures the precipitation of proteins, cellular debris and even genomic 
DNA. The suspension is then added to a QIAfilter cartridge and the sample is left 
for 10 minutes for the lysate to rise to the top of the cartridge.  
During the ten minute incubation period the QIAGEN-tip was equilibrated by 
adding 4ml of buffer QBT and the column was allowed to empty via gravity. The 
clear liquid from the QIAfilter cartridge was filtered into the QIAGEN-tip using the 
syringe plunger. Once the sample was loaded onto the QIAGEN-tip, the tip was 
washed twice with 10ml of buffer QC twice. The first wash removes the majority of 
contaminants still residing in the sample. The DNA was then eluted from the 
QIAGEN-tip by adding 5ml of buffer QF. The elution was collected in a clean 50ml 
Falcon tube. DNA was precipitated by adding 3.5ml of room-temperature 
isopropanol and spun at 6000rpm at 4⁰C for one hour. The supernatant was 
discarded and the pellet was washed using 2ml of 70% ethanol. The sample was 
then spun at 6000rpm for twenty minutes. Following the spin the supernatant was 
carefully decanted and the tube was left inverted to ensure the removal of the 
majority of ethanol. The samples were then left open under a heat source for 5-10 
minutes to guarantee the removal of all of the ethanol. The DNA pellet was 
redissolved using pre-PCR water. 
Samples extracted, using the Qiagen midi prep kit, were quantified using the 
Nanodrop 2000 (Thermo Scientific, UK). A260/280 and A260/230 ratios were 
noted to ensure sample purity. A ratio of 1.8 for the A260/280 reading and 
between 2.0-2.2 for A260/230 reading is considered pure. 
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3.2.7.2.4 PCI-SEP-GLUR1/GLUR2 
The pCI-SEP-GluR1 (Figure 30) and GluR2 (Figure 31) vectors were provided from 
the Addgene repository from Robert Malinow (Plasmid 24002) [420]. The pCI 
mammalian vector contains the super-ecliptic pHluorin (SEP) coding sequence on 
the N-terminus of the GluR1/GluR2. The pCI-SEP vector contains a signalling 
peptide, at the extreme end of the N-terminus, which is essential for direction of 
the AMPA-Rs to the endoplasmic reticulum following translation [421, 422]. 
GFP proteins can be utilised in a number of different molecular biological 
techniques. Flow cytometry analysis was used to determine the expression of both 
GluR1 and GluR2 at the cell surface in the presence of the CACNG4 wild-type and 
mutant proteins. The ecliptic pHluorin is an enhanced pH sensitive variant of the 
GFP protein. Under normal conditions GFP has a major peak at 395nm and a minor 
peak at 475nm when measured with an emission maximum of 509nm. Ecliptic 
pHluorin is non-fluorescent in an acidic environment (pH>6.0) but becomes 
fluorescent under neutral conditions, enhancing both emission peaks [423]. SEP 
tagging has been used to measure AMPA-Rs surface expression previously [424]. 
The presence of the AMPA-R/SEP complex at the cell surface increases the 
fluorescence compared to that of normal GFP and ecliptic pHluorin. Additionally 
there is a 100-fold increase in the fluorescent signal when the SEP is present at the 
neutral cell surface, compared to the relatively acidic internal compartment [425]. 
3.2.7.3 SITE DIRECTED MUTAGENESIS 
Site directed mutagenesis was used to introduce the variants of interest into the 
wildtype vectors previously created using PCR and ligation. Site directed 
mutagenesis is a molecular biology technique involving a high fidelity DNA taq. 
This technique allows researchers to investigate the implications of a variant 
present in DNA sequence and create functional assays in vitro to determine 
whether it causes a change when present versus what would normally occur. 
Variants such as point variants, amino acid replacements and insertion of amino 
acids can be accomplished using this technique. Primers are designed to be 
complementary to the bases surrounding the region of interest, and contain the 
desired variant. During thermal cycling the primer directed replication of both 
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Figure 30. Circular map of the pCI-SEP-GluR1 vector. 
Image taken from https://www.addgene.org/24000/  
 
Figure 31. Circular vector map of the pCI-SEP-GluR2 vector. 
Image taken from https://www.addgene.org/24001/ 
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strands of the plasmid vector occurs. The replicated plasmid contains the mutated 
base and staggered nicks. As the parental plasmid DNA has been isolated from 
dam+ E.coli strains it is methylated and is susceptible to DpnI digestion. This 
technique is used to remove the parental plasmid DNA following temperature 
cycling. This ensures that only the plasmid containing the variant is transformed 
into the competent cells. 
Forward and reverse primers, complementary to both strands of the plasmid, were 
designed using the Agilent QuikChange Primer Design programme 
(www.agilent.com/genomics/qcpd). To ensure high fidelity annealing the primers 
were between 25-45 base pairs long with a melting temperature >78°C. HPLC 
purified primers were obtained from Sigma Aldrich, guaranteeing highly purified 
primers. Site directed mutagenesis was conducted using the QuikChange XL kit 
(Agilent). The reaction for the thermal cycling conditions was set up in a PCR plate. 
A control reaction was run in parallel using the pWhitescript 4.5kb control 
plasmid. The PCR reaction mixture is listed in Table 16 and the thermocycling 
conditions are listed in Table 17. 
These samples were then transformed into QuikChange XL Ultra competent cells 
by adding 2μl of DpnI digest DNA to 50μl of competent cells, to which 2μl β- 
mercaptoethanol had been added. Cells were incubated on ice for 30 mins and then 
placed in a water bath at 43˚C for 30 seconds. The samples were then placed back 
on ice for two minutes. 500ml of SOC media was added to the cells and they were 
left to shake for one hour before being 250μl of each sample was plated out onto 
an LB Agar plate containing appropriate antibiotic. These samples were left at 37˚C 
overnight. The following morning single E.coli colonies were picked from each 
plate and added to 500μl of LB Broth. If no colonies were observed the site 
directed PCR reaction was repeated with increasing concentrations of DNA. These 
concentrations ranged from 50ng/μl to 200ng/μl.  Colonies which were selected 
for growth were shaken at 37˚C for 8 hours. After 8 hours 250μl was added to 5ml 
of LB broth containing antibiotic and the samples were left overnight. DNA from 
these samples was isolated using the mini prep protocol described in 3.2.7.2.2. 
Once the DNA was extracted it was sent for sequencing to confirm the presence of 
the variants of interest. The samples which contained the variants were then 
prepared for midi prep 3.2.7.2.3.  
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Reagent μl 
10x Reaction Buffer 5 
dsDNA template (10ng/μl) 1 
Primer 1 (125 ng) 1.25 
Primer 2(125ng) 1.25 
dNTP mix 1 
Quik Solution 3 
ddH2O 37.5 
PfuUltra 1 
Total 50 
Table 16. PCR reaction mixture for site directed mutagenesis 
 
Step Temperature Cycles Time 
1 95 1 1 min 
2 
95 
18 
50 sec 
60 50 sec 
68 1 min/kb of plasmid length 
3 68 1 7 min 
Table 17. Thermocycling conditions for site directed mutagenesis 
3.2.8 CELLULAR TRANSFECTIONS 
The DNA transfection was done as previously described 3.1.6.3 and 3.1.6.4 . 500ng 
of GluR1 and CACNG4 were transfected into the cells 24 hours after seeding in 6 
well plates. Each time six samples were transfected and the pGL3-basic vector was 
used as a control for transfection in wells where co-transfection of GluR1 and 
GluR2 and CACNG4-wt/CACNG4-mutant were not added. Cells were seeded at a 
density of 0.3 x 106 so that they would reach 75-80% confluence in 24 hours. 
3.2.9 FLOW CYTOMETRY 
Hek293 cells were grown as described previously at 37˚C, 5% CO2 in DMEM 
supplemented with 10% FBS and 1% Penicillin/Streptomycin. Cells were 
transfected when they were 75-80% confluent. The constructs used for 
transfection were wild-type CACNG4-RFP, mutated CACNG4-RFP, GluR-1-SEP and 
GluR2-SEP. Co-transfections of wild-type CACNG4-RFP with either GluR-1 or GluR2 
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and mutated CACNG4-RFP with GluR1 or GluR2 was conducted. The pgl3-basic 
vector was used as a control for the co-transfections when only one of the main 
plasmids of interest was being transfected in. Twenty four hours after transfection 
all cells were trypsinised and collected. The cells were spun at 1500rp for five 
minutes to pellet the cells. The cells were washed using 1ml of PBS and spun again 
to remove any remaining DMEM and PBS. Cells were fixed in 4% 
paraformaldehyde for 15 minutes. The paraformaldehyde was removed and the 
cells were washed twice with PBS. They were resuspended in an appropriate 
volume of PBS and stored at 4˚C. 
Flow cytometry was conducted on fixed HEK293 cells using the BD LSRFortessa 
(Becton & Dickinson, New Jersey, USA) and collected using BD FACSDiva software 
(Becton & Dickinson, New Jersey, USA). Voltage settings for forward and side 
scatter were optimised and the same conditions were used across all samples. 
Where possible, 10,000 events were captured for each sample, and experiment run 
to generate enough data for further analysis. Further sample analysis was 
conducted using Flowjo software (Tree Star, USA). Cell populations were 
disseminated based on the negative control for each experiment using the forward 
scatter and side scatter parameters. These were then gated to control for 
background fluorescence which may arise from negative controls. The mean 
fluorescence intensity values were generated from the population positive for SEP 
fluorescence. The difference between wild-type CACNG4-GluR1/GluR2 and 
mutated CACNG4-GluR1/GluR2 was calculated using a two-tailed Student T-Test. 
The data is representative from a total of three independent replicate experiments. 
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3.3 METHODS FOR RESULTS CHAPTER 5: INVESTIGATION OF VARIANTS 
USING NEXT GENERATION SEQUENCING ANALYSIS 
3.3.1 RESEARCH SAMPLES FOR NEXT GENERATION SEQUENCING 
Whole-genome sequencing (WGS) was performed on 99 of the BD-I subjects who 
had a positive family history of bipolar disorder or bipolar spectrum disorder and 
a relatively early age of onset. A further four criteria were applied when selecting 
individuals for WGS; whether the individuals were lithium responsive or 
unresponsive and whether the cases were also alcohol dependent or not. Selection 
of the samples for whole genome sequencing, and variant calls were conducted 
prior to my commencement on this project. A list of the processes undertaken for 
the WGS project, from sample selection to genotyping of variants in the UCL 
cohort, is shown in Figure 32 These BD-I samples sent for WGS were selected by 
colleagues in the Molecular Psychiatry Laboratory, UCL. The WGS was conducted 
Illumina (Illumina, Inc. San Diego, CA, USA) and annoted by KNOME (Knome Inc, 
Boston, MA). Allele frequencies and comparisons to the 1000G allele frequencies, 
collated by genomic position, were conducted by a statistician at UCL (Dr. Curtis, 
UCL). The frequency cut off for variant selection, a minus log p (MLP) >1.3 for the 
Fisher’s exact test between the 99 BD subjects and 1000G, was decided by all 
individuals involved in variant selection. I was involved in selecting the remaining 
criteria including which region of interest in the CACNA1C intron 3 to investigate, 
the use of ENCODE marks, GERP scores and conservation marks and criteria for 
SNP selection in coding regions of the calcium channel family of genes. Once these 
variants were selected they KASPar genotyping was conducted in the BD case and 
healthy volunteer sample as described in sections 3.1.1.1 and 3.1.1.4 respectively. 
Additionally I decided to use externally available databases to investigate variant 
frequencies for alleles which were rare. 
3.3.2 NEXT GENERATION SEQUENCING AND ANALYSIS 
The genomic DNA was sequenced using one hundred base pair paired-end reads 
on a Hi-Seq 1000 (Illumina, Inc. San Diego, CA, USA). Sequence data alignment to 
the NCBI human reference genome 37.1 (hg19) and variant calling was performed  
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Figure 32. From Samples to variant genotyping. A stepwise depiction of the 
experiments involved in whole genome sequencing 
The white boxes denote steps which were performed either by colleagues at UCL 
or KNOME and the grey boxes denote processes which I conducted as part of the 
whole genome sequencing project in the lab.  
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using the CASSAVA pipeline at Illumina. The sequence data from these individuals 
was further analysed and annotated using kGAP (Knome Inc., Boston, MA). 
3.3.3 VARIANT SELECTION  
3.3.3.1 CACNA1C 
All variants present in the third intron of CACNA1C were pooled from the Knome 
VARIANTS software (Knome). Allele counts of each SNP in the BD samples were 
compared to those in the European cohort of the 1000 genomes (1000G) project. 
SNPs with a minus log p (MLP) >1.3 for the Fisher’s exact test between the 99 BD 
subjects and 1000G were chosen to be followed up by genotyping in the case-
control samples. Variants present in poly-base regions or insertions in repeat 
regions were excluded from genotyping.  
The variants were selected for genotyping in the UCL case-control cohort if they 
met the following four criteria: 
 Located in the third intron of CACNA1C between flanking higher 
recombination peaks (chr12:2,230,353-2,559,413 hg19); 
 Located in a putative functional site defined by being an ENCODE 
marked element [392]; 
 Located in a conserved non-coding sequence, determined using the 
mammalian conservation track on UCSC or by their GERP scores; 
 Not in a repeat region.  
3.3.3.2 OTHER CALCIUM CHANNEL GENES 
As evidence points towards calcium deregulation in individuals with BD, and 
pathway ontology analysis has shown that the calcium channel gene set is 
implicated with BD, variants present in the remaining calcium channel genes were 
investigated using KNOME software. The variants were selected for genotyping in 
the UCL case-control cohort if they met the following four criteria; Variants were 
non-synonymous; Genes have been previously implicated in Bipolar Disorders, 
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either through gene ontology analysis, pathway analysis, or have an association 
signal in the PGC1 BD data set; An MLP > 0.7. This indicates that there was one 
individual from the BD sample with the variant and no individuals in the 
1000Genome sample; PolyPhen-2 prediction of Damaging, or if the prediction was 
benign the variant was not present in the 1000G. 
3.3.4 KASPAR GENOTYPING 
3.3.4.1 CACNA1C 
Alignment software (KNOME) annotated one hundred and thirty four SNPs before 
filtering in the 99 BD 1 cases. After filtering, seven polymorphisms (two previously 
unreported SNPs and five that were on dbSNP) were selected to be followed up by 
genotyping analysis in the UCL sample. Each variant was validated by confirming 
the base pair call confidence using individual BAM files before genotyping. 
Bioinformatic analysis to determine potential function was carried out using the 
ENCODE track on the UCSC genome browser (http://genome.ucsc.edu/).  
3.3.4.2 OTHER CALCIUM CHANNEL GENES 
KNOME software predicted 26 non-synonymous variants in CACNA1S, CACNA1D, 
CACNA2D4, CACNA1C, CACNB1, and CACNB2. After filtering on the above mentioned 
criteria, 8 SNPs were selected to be followed up using KASPar genotyping. Each 
variant was validated using base pair call confidence using individual BAM files 
before genotyping.  
3.3.5 STATISTICAL ANALYSIS 
Allelic associations for SNPs were performed using the Chi-square test and the 
Fisher’s exact test. A cut-off significance value of P < 0.05 was used. 
  
153 
3.3.6 PLASMID CONSTRUCTION 
3.3.6.1 PJET1.2  
 
Figure 33. pJET1.2 Blunt End Cloning Vector 
 (http://www.thermoscientificbio.com/uploadedFiles/Resources/pJET1.2-blunt-
cloning-vector-map.pdf ) 
The pJET1.2 linearised cloning vector (Figure 33) is part of the CloneJET PCR 
cloning kit that allows blunt end cloning of PCR generated DNA fragments. The 
vector contains a lethal enzyme gene that is only removed upon the ligation of the 
DNA insert allowing for positive selection of the bacteria that contain the 
recombinant vector. E.coli containing the recircularised vector without the insert 
will express the lethal enzyme upon transformation preventing further colony 
formation. Blunt end PCR products were produced using high fidelity Pfu DNA 
polymerase and could be directly ligated into the pJET-1.2/blunt vector within 5 
minutes. 
3.3.6.1.1 BLUNT END LIGATION 
To determine whether the variants located in the third intron of CACNA1C have a 
functional effect on the regulation of gene expression we focused on a 729bp  
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Step Three-Step Cycling Time 
Denaturing 94⁰C 15 sec 
Annealing 55⁰C 30 sec 
Extension 68⁰C 1 min per kb 
Table 18. Pfx cycling conditions 
 
region that incorporates both SNPs and the regulatory regions as denoted by the 
ENCODE track on the UCSC genome browser. Both variants were identified during 
the analysis of the next generation sequencing data and are in complete LD in 
European populations as seen in the 1000 genomes (1000G), British in England 
and Scotland (GBR), Iberian population in Spain (IBS), and Toscani in Italy (TSI), 
but the T allele appears to be absent from the Finnish population (FIN). 
3.3.6.1.2 AMPLIFICATION OF THE THIRD INTRON OF CACNA1C 
The variants rs79398153 and rs116974827 located in the third intron of CACNA1C 
were amplified using F: 5’-cgctagcctgcaccacgtgtctttgcc-3’ and R: 5’-
gaagcttagtttgtctcacagaccctgacc-3’ (Sigma Aldrich, UK). The primers were originally 
created with NheI and HindIII restriction sites and a buffer of 6 bases before the 
restriction site. This allows the insert to be cloned directly into the pGL3-Basic 
vector using the method of double restriction digest. However, following the first 
transformation and sequence verification we found that the 6 bases found prior to 
the restriction site and the first base of the restriction site had not been cloned into 
the vector following transformation. We decided to use the blunt end cloning 
procedure to clone the insert into the pJET1.2/blunt vector and created the second 
set of primers noted above. Optimisation of the PCR conditions for the 
amplification of the insert was undertaken using the conditions described in Table 
15. The action of blunt end cloning relies primarily on the action of Pfx DNA 
polymerase (Lifetechnologies, USA). Pfx polymerase is a high fidelity thermostable 
enzyme which does not contain 5’-3’ exonuclease activity. It contains 3’-5’ 
proofreading activity, which proof reads the template produced ensuring high 
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fidelity output was used. To 0.5μl of DNA (25ng/μl), 2.5μl of pfx buffer, 2.5μl of 
Enhancer, 1μl of MgSO4 (50mM), 0.2μl of dNTPs (25mM) 1μl of both the forward 
and reverse primer (10uM), 0.2μl of Pfx DNA polymerase were added. Pre-PCR 
water (Sigma Aldrich, UK) was added to give a final volume of 25μl. The PCR was 
run under the conditions listed in Table 18. 
 
The samples were run on a 1% agarose gel to determine which condition was 
optimal (Appendix II, II.II). The insert was cloned into the pJET1.2/blunt vector as 
per the manufacturer’s protocol (Thermo Scientific, UK). The suggested 
concentration of DNA to use for the ligation is 500ng for a PCR product of length 
1000bp. The ligation reaction for the cloning of the 729bp insert into the blunt end 
vector was set up on ice. In a 1.5ml microcentrifuge tube 10μl of reaction buffer 
(2x), 1μl of DNA (500ng), 1μl of pJET1.2/blunt cloning vector (50ng/ul), pre-pcr 
water (Sigma Aldrich, UK) up to a volume of 19μl and 1μl of T4 DNA ligase. The 
sample was vortexed gently for 5 seconds. The ligation mixture was incubated at 
RT for 5 minutes. 
3.3.6.1.3 TRANSFORMATION OF VECTORS USING BLUNT END LIGATION 
The ligation mixture was transformed into the cells using heat shock 
transformation. Prior treatment of the competent cells by chilling in the presence 
of Ca2+ prepares the cell wall for the change in permeability Heat shock 
transformation is based on the principle that a sudden increase in temperature 
creates a pressure difference between the inside and the outside of the E.coli cells. 
This induces the formation of pores in the cell membrane, and returning the cells 
to a normal temperature returns the cell membrane to normal and allows for the 
cell to heal. Following the ligation 2.5μl of the mixture was added to 900μl of 
Library Efficiency® DH5α™ Competent Cells (Life Technologies, UK). Cells were 
chilled on ice for 30 minutes. They were then placed in a water bath at 42°C for 45 
seconds before placing them in ice again for 2 minutes. The cells were then placed 
in SOC medium at 37°C for one hour and shaken at 225rpm. To check 
transformation efficiency, a parallel transformation was done using the 0.1ng of 
pUC18 DNA. 
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Cells were plated on to agar plates containing ampicillin (10μg/ml) at different 
volumes. The volumes used were 50μl, 100μl (x2), 200μl and 500μl. This ensures 
that if there if the E.coli growth is slow, the plate with the highest volume of cells 
should contain some for selection and vice versa for a faster rate of growth. The 
cells were left in an incubator overnight at 37°C. Following overnight incubation a 
number of single colonies were removed and grown up for mini prep (Qiagen, UK). 
Each of the tips that picked the colony was dipped into 5μl of pre-PCR sterile water 
and PCR was conducted using the optimised primer conditions. Following PCR 
10μl of PCR DNA was mixed with 2μl of 5x Loading Buffer (Bioline, UK) and the 
samples were run for 2 hours at 100V on a 0.8% agarose gel. Following gel analysis 
the samples containing the correct samples were chosen to midi prep to create a 
working stock of the plasmid for the transfection. 
3.3.6.2 PGL3-BASIC VECTOR 
The pGL3 Luciferase Reporter Vectors are a series of vectors that can be used to 
determine whether putative regulatory regions in the genome have an effect on 
gene expression. As discussed above, studies such as the ENCODE study are 
identifying a plethora of genomic regions that could be functionally active at the 
level of gene expression regulation. The pGL3-Basic vector was obtained from 
promega (Figure 34) (Promega Corporation, USA). Due to the lack of eukaryotic 
promoter and enhancer sequences, it provides maximum flexibility for cloning 
numerous different putative functional elements. The luciferase expression is 
solely dependent on the insertion of a functional promoter upstream of the 
luciferase gene, although some basal level of luminescence may be seen. 
Following the insertion of the CACNA1C region into the pgl3-basic vector site 
directed mutagenesis (3.2.7.3) was used to create three different plasmid vectors. 
The first contained the rs79398153 variant, the second contained the 
rs116947827 variant and the third contained both variants. Stock solutions of all 
four plasmids were created using the mini and midi prep methods outlined 
previously (3.2.7.2.2 and 3.2.7.2.3). 
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Figure 34. pGL3-Basic Vector  
Image taken from the Promega pGL3 Luciferase Reporter Vectors technical manual  
 
Figure 35. pRL-SV40 Renilla Vector 
Image taken from the Promega pRL-SV40 technical manual  
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3.3.7 LUCIFERASE ASSAY 
The Dual-Luciferase® Reporter (DLR™) Assay System (Promega Corporation, USA) 
was used to measure luciferase expression following the transfection of the 
CACNA1C intronic vectors into HEK293 cells. As a dual reporter assay system the 
DLR™ assay from promega quantifies firefly and Renilla luminescence sequentially 
thus providing an internal control that measures for baseline response. The vector 
containing the gene responsible for Renilla luminescence is the pRL-SV40 (Figure 
35). This gene contains the SV40 enhancer and early promoter elements that 
ensure high levels of Renilla expression in co transfected cells.  This is an essential 
attribute of the kit as experimental variabilitys such as pipetting errors, cell lysis 
efficiency and assay efficiency can have an impact on number of cells producing 
luminance regardless of the amount originally seeded. The ratio of firefly to Renilla 
luminescence can be calculated giving a more accurate indication of whether the 
insert is effecting the expression of luciferase. The components of the DLR™ kit are 
listed in Table 19. 
3.3.7.1 PREPARATION OF CELLS FOR LUCIFERASE EXPRESSION MEASUREMENT 
Measurement of luciferase luminescence was done following the manufacturer’s 
protocol. Cells were co transfected with the pgl3-basic and prl-SV40 vectors and 
were left to grow for 48 hours. Prior to the addition of passive lysis buffer (PLB), 
DMEM was removed from each well and the cells were washed using 1ml of PBS. 
Following the addition of the PBS the plate was gently swirled to ensure all of the 
growth media was removed. To each well 500μl of PLB was added, which is 
sufficient to cover the cell monolayer in a 6 well plate. The plate was put on a 
shaker and left at RT for 15 minutes. The cell lysates are then removed and placed 
in a clean 1.5ml microcentrifuge tube and spun at 13,000rpm in a table top 
centrifuge for 30 seconds to remove the cellular debris. Following the spin the 
supernatant was placed in a new microcentrifuge tube. 
3.3.7.2 MEASUREMENT OF LUMINESCENCE 
Luminescence was measured on a Turbo 20/20 luminometer (Turbo Biosystems, 
UK). To the predispensed 100μl of the LAR-II solution 20μl of cell lysate was  
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Reagent Function 
Passive 
Lysis 
Buffer 
(PLB) 
Passive Lysis Buffer promotes rapid lysis of cultured mammalian cells 
without the need for scraping of adherent cells from the wells. In 
addition it is designed to stabilise the firefly and Renilla enzymes and 
maintains minimal autoluminescence 
Prior to use, the 5x PLB was diluted in 4 volumes of distilled water to 
create a 1x working stock solution. 
Luciferase 
Assay 
Reagent II 
(LAR II) 
The addition of the LAR II generates a stabilised luminescent signal 
from the firefly luciferase gene. The LAR II solution is prepared by 
resuspending the lyophilised Luciferase assay substrate in 10ml of 
Luciferase Assay Buffer. Aliquots of 1ml were made and the mixture 
was stored at -80°C. 
Stop & 
Glo®  
Stop & Glo® reagent simultaneously quenches the firefly luminescence 
while activating the Renilla luciferase expression and stabilises the 
Renilla luminescence signal. This reagent was freshly prepared prior to 
each experiment. One volume of Stop & Glo substrate was added to 50 
times Stop & Glo® buffer for the appropriate number of reactions. 
Table 19. Components of the Dual Luciferase Reporter Assay Kit 
 
added. The cell lysate-LAR II solution was mixed by pipetting once or twice. The 
sample is not vortexed as this can coat the sides of the tube preventing it mixing 
with Stop & Glo® once it is added in. The programme used to measure the reporter 
activity on the TURBO 20/20 was the Promega DLR II assay measurement 
programme. This programme incorporates a two second delay prior to reading and 
is followed by a ten second measurement period for each reporter assay sample. 
Following the reading of firefly luminescence, 100μl of Stop & Glo® reagent was 
added and the sample was vortexed briefly to ensure complete mixing of the LAR-
II reagent and the Stop & Glo® reagent. The tube was replaced in the Turbo 20/20 
machine and the Renilla luciferase activity measurement was taken over a period 
of ten seconds, and the final output and ratio was noted. To ensure reproducibility 
of the results the luciferase expression reporter assay was performed in triplicate 
each time and it was repeated three times. 
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Following the completion of all of the replications the results were analysed using 
an independent, two tailed T test using SPSS v.17. The two tail test was employed 
to discern whether there was an increase or decrease in the production of 
luciferase luminescence compared to the cells where there was no CACNA1C insert. 
3.3.8 ELECTROMOBILITY SHIFT ASSAY  
Electromobility shift (EMSA) assays are designed to detect the formation of protein 
complexes with nucleic acids [426]. EMSA assays are based on the principle that 
the formation of protein-nucleic acid complexes will move more slowly through 
the gel that free nucleic acid. It is used both as a qualitative and quantitative 
method for determining whether DNA binds to complexes using fluorescently 
labelled oligos. These are then used to perform a competition assay against 
unlabelled oligos. If the binding of the labelled DNA probe to the protein complex is 
specific, the visible band should completely disappear when an unlabelled oligo, 
with the same sequence as the labelled oligo, is added in excess. 
3.3.8.1 PREPARATION OF NUCELAR EXTRACTS FROM HEK293 CELLS 
HEK293 cells were grown in Nunc T-75 sterile filter cap flasks (Thermo Scientific, 
UK) to approximately 75-85% confluency in DMEM, 10% FBS, 1% Pen/Strep. The 
growth medium was removed from the flasks and the cells were washed with ice 
cold 1xPBS. Cytoplasmic lysis buffer was then added to the flasks and the cells 
were harvested into pre-chilled 1.5ml eppendorf tubes using cell scrapers (Thermo 
Scientific, UK) (Appendix II, II.VII). One millilitre of cells and cytoplasmic lysis 
buffer was placed in each tube. The cells were lysed by addition of 90μl of 10% NP-
40 solultion to each tube and cells. The homogenates were centrifuged in a table 
top centrifuge at 2000g for 10mins at 4˚C. Following centrifugation the 
supernatant containing the cytoplasmic proteins was removed and discarded. The 
nuclear pellets were suspended in 32μl of nuclear lysis buffer. Rapid freeze-thaw 
cycles in dry ice and ethanol were used to disrupt the nuclei. Cellular debris was 
removed by centrifuging the samples from 10 minutes at 13000g. Following 
centrifugation the supernatant from each tube was removed and mixed together. 
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The sample was gently pipetted to mix the nuclear lysate and then samples were 
stored in aliquots of 20μl at-80˚C. 
3.3.8.2 BRADFORD ASSAY 
 The Bradford assay quantification assay (Sigma-Aldrich, UK) was used to quantify 
protein concentration in the nuclear lysates according to the manufacturer’s 
instruction. The reagent contains Brilliant Blue G, a dye which forms a complex 
with the proteins in the nuclear lysate solution. The formation of these complex 
results in a shift to the absorption maximum that is proportional to the amount of 
protein bound. Using a protein standard, such as bovine albumin (BSA), allows for 
the quantifications of proteins of unknown concentration. 
The Bradford assay solution was brought to room temperature prior to performing 
the assay. BSA (10mg/ml) was diluted in nuclear to make protein standards of 1 
μg/ml, 2 μg/ml, 5 μg/ml, 10 μg/ml, 20 μg/ml and 50μg/ml. One part of the protein 
sample was mixed with 30 parts of the Bradford reagent in a disposable cuvette 
and incubated at room temperature for five minutes. Following the incubation 
period, sample absorbance was measured using a UV spectrophotometer (Pye 
Unicam PU8600 UV/VIS spectrophotometer, Philips) at 595nm. Each sample was 
performed in duplicate and a standard curve was created to determine the 
concentration of the nuclear lysate by plotting the absorbance at 595nm against 
the protein standard concentrations. 
3.3.8.3 PREPARATION OF THE 4% ACRYLAMIDE GEL 
In a 50ml falcon tube, 42.12ml of MilliQ H2O, 5ml of 40% polyacrylamide stock 
solution, 2.5ml of 10X TBE were added together (Appendix II, II.VII). The solution 
was mixed and then 300μl of 10% Ammonium Sulphate (APS) and 80μl of 
Tetramethylethylenediamine (TEMED) were added in. The addition of APS and 
TEMED initiates the polymerization of the acrylamide gel. The solution was 
thoroughly mixed and then poured between two 40cm gass plates with 0.75m2 
spacers and combs and allowed to set for one hour. 
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3.3.8.4 OLIGO PREPARATION 
Primers were designed for the CACNA1C intronic variants, rs79398153 (C/T) and 
rs116947827 (C/T). These oligonucleotides were 5’ end-labelled with infrared dye 
DY-682 (Eurofins MWG, Germany). Complementary primers and unlabelled 
primers targeting the wildtype and mutated alleles of both variants were designed 
as described previously in section 3.1.4.1. Generation of the dsDNA from the oligos 
was completed by denaturing aliquots of 5μl 20pmol/μl at 100˚C for three minutes. 
These complexes were then cooled to room temperature prior to use. 
3.3.8.5 BINDING REACTION 
The binding reaction for the EMSA was set up as described below in Table 20. 10μg 
of nuclear lysate was used per sample (Appendix II, II.VII). The use of Poly (dI.dC) 
in the reaction prevents non-specific binding of proteins in the nuclear extract 
leading to a reduction in background noise. The reaction was left in the dark at 
room temperature for 20 minutes for the binding reaction to proceed.  
3.3.8.6 ELECTROPHORESIS 
The 4% polyacrylamide gel was pre run for an hour on a LiCor 42000L sequencer 
(LiCor, Nebraska, USA). The gel was run at 10V/cm at 20˚C in 0.5xTBE buffer 
(Appendix II, II.VII). This pre run ensures that all traces of APS are removed and 
ensures the gel is at a constant temperature. Following the binding reaction 
incubation time, 1μl of Orange loading dye (10X) was added to the reaction 
mixture and the samples were mixed thoroughly. The samples were then resolved 
by electrophoresis on the 4% native polyacrylamide gel. The DNA-protein complex 
was detected using the LiCor 42000L.  
Competition assays were performed for both rs79398153 and rs116947827 to 
determine binding specificity and to determine binding efficiency. The labelled 
probes were outcompeted using varying amounts of unlabelled oligos (10x, 20x, 
50x, 100x and 200x). Ideally if the binding of the labelled probe is specific, the 
addition of the excess unlabelled for the same variant should result in the observed 
band disappearing. The principle behind the competition reaction is that excess  
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Reagents LP LP & NCL 
LP & NCL &  
10x ULP 
LP & NCL &  
20x ULP 
LP & NCL &  
50x ULP 
LP & NCL & 
100x ULP 
LP & NCL & 
200x ULP 
Parker Buffer 2 2 2 2 2 2 2 
2.5mM DTT 2 2 2 2 2 2 2 
MgCl2 (100mM) 1 1 1 1 1 1 1 
10% NP40 1 1 1 1 1 1 1 
Poly dI.dC 1 1 1 1 1 1 1 
Labelled Oligo 
(50fmol) 1 1 1 1 1 1 1 
Unlabelled 
Oligo (50fmol) 0 0 1 1 1 1 1 
H2O 12 11 10 10 10 10 10 
Nuclear Lysate 
(10 μg) 0 1 1 1 1 1 1 
Total Volume 20 20 20 20 20 20 20 
Table 20. EMSA Conditions 
Each EMSA shift assays used an increasing excess of unlabelled probe to determine the specificity of the binding seen on the gel. LP, labelled probe, 
NCL, nuclear cell lysate, 10x, 10-fold excess, ULP, Unlabelled probe. 
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Reagents LP LP & NCL 
LP & NCL &  
YY1 
Parker Buffer 2 2 2 
2.5mM DTT 2 2 2 
MgCl2 (100mM) 1 1 1 
10% NP40 1 1 1 
Poly dI.dC 1 1 1 
Labelled Oligo (50fmol) 1 1 1 
H2O 12 11 9 
Nuclear Lysate (10 μg) 0 1 1 
YY1 antibody (H-10) 0 0 1 
Total Volume 20 20 20 
Table 21. EMSA supershift reaction mixture. 
The EMSA reaction mixture was prepared for each of the variants labelled probes 
with nuclear cell lysate (NCL), Labelled probe (LP) and YY1 antibody. The antibody 
was incubated with NCL for 20 mins prior to the addition of the labelled probe. 
unlabelled DNA should compete for binding sites in the protein complex and 
eliminate the labelled oligo resulting in the removal of the observed band. Each of 
the competition reactions were conducted three times. 
3.3.9 EMSA SUPERSHIFT ASSAY 
EMSA supershift assays are slight modifications to the EMSA shift assay. In this 
assay antibodies specific to the putative transcription factor binding site are 
incubated with the nuclear cell lysate prior to the addition of the labelled probe. If 
the antibody recognises the protein in the nuclear cell lysate one of two results will 
be observed. If the antibody does not inhibit the binding of the labelled probe a 
super shift in the band will be observed due to the high molecular weight of the 
antibody. Secondly, the antibody could interfere with DNA and protein interactions 
and result in an absence of a band. YY1 Antibody (H-10) X (Santa Cruz 
Biotechnology) is a monoclonal mouse IgG1 representing the full length of YY1 of 
human origin and was used for the supershift assays. The EMSA supershift assay is 
listed in Table 21; the antibody was incubated with the nuclear cell lysate for 20 
minutes away from light prior to the addition of the labelled probe. The samples 
were then added to the gel as described in 3.3.8.6. The DNA-protein complex was 
detected using the LiCor 42000L.  
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   High-resolution melting Chapter 4
curve analysis of regulatory 
regions in Calcium Channel 
genes 
4.1 INTRODUCTION 
Calcium influx into cells plays a prominent role in our biological systems, from 
cardiac and skeletal muscles to neurons and the CNS, it acts as a secondary 
messenger, instigating cascade pathways and regulating transcription. Given 
calcium’s ubiquitous presence throughout the human body, and the physiological 
properties it contributes to our systems, it is not surprising that variants in calcium 
channel genes can have detrimental effects in vivo. Perhaps the best example of a 
susceptibility gene for psychiatric illness is CACNA1C which encodes the α pore of 
the L-type voltage dependent family of calcium channel genes (VDCC). As 
previously discussed in section 1.3.2, the CACNA1C variant rs1006737 has been 
repeatedly associated through genome-wide association studies in bipolar 
disorder. 
L-type calcium channels genes are expressed ubiquitously throughout the brain. 
They are highly associated with activation of the CREB cycle through 
phosphorylation leading to a role in transcriptional regulation and activation 
[315]. Additionally, L-type VDCC’s play a role in transcriptional regulation through 
calcium influx into the cytoplasm which initiates the Ras-MAPK pathway [310]. 
The Ras-MAPK pathway mediates the transfer of signals received on the cell 
surface to the nucleus of the cells through a protein cascade signalling pathway.  
L-type calcium channels are characterised by high voltage activation with large 
single channel conductance, slow voltage dependent inactivation, up-regulation 
marked by cAMP-dependent phosphorylation pathways and inhibition by Ca2+ 
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blockers [327, 328]. The CACNA1C alpha pore is expressed in a number of brain 
regions including the cerebellum and the hippocampus. Variants p.G406R and 
p.G402S in the CACNA1C gene lead to Timothy syndrome, a disorder characterised 
by developmental delay and autism [363]. 
One of the top association signals in BD comes from rs1006737 (P= 7.0 × 10-8) 
[232, 233], lying in the third intron of CACNA1C. Another two SNPs located in this 
intronic region, rs4765913 (p= 1.52 × 10−8) [232] and rs1024582 (p= 1.7 × 10-7) 
[270], are also strongly associated with BD. GWAS results across five different 
psychiatric illnesses further implicates rs1024582 in susceptibility to both BD and 
SCZ [268]. 
An accumulation of evidence has been building which suggests that some of the 
main variation associated with an increased susceptibility to BD is to be found in 
regions that are not currently being covered by exome sequencing. A recent study 
conducted by Ament et al. has identified a burden of variants in promoter, 5’ and 
3’UTR regions which are associated with BD [292]. GWAS studies, such as the 
study from the PGC-BD, show regions associated with BD but the top associated 
SNPs are often not thought to be causative or functional, and are located outside 
exonic regions [270]. Due to the heterogeneity and complex nature of BD, the 
ability of GWAS to identify causative genes is limited. In general, GWAS studies 
have reported robust association between disease or common traits and SNVs. 
Many of the associations explain only a fraction of the heritability estimated from 
family studies. It is hypothesised that rare variants contribute to the genetic 
variance of disease risk and quantitative trait variation. Current GWAS platforms 
are not designed to capture rare variants making it difficult to infer the association 
of rare variants using this method. Utilising data and results from GWAS studies 
allows variant investigation into SNVs located in regions such as the 5 and 3’UTR, 
and promoter regions. It can aid in the identification of regions where association 
signals are seen which may be arising as a result of LD. 
 
Gene ontology enrichment analysis of 34 SNPs reaching a genome-wide significant 
association (P ≤ 5 × 10−8) in a large-scale genome BD association study have found  
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Figure 36. Regional association plot of CACNB3. 
The regional association plot was obtained from 
http://www.broadinstitute.org/mpg/ricopili/. The data is from the PGC-BD GWAS 
[270]. One of the polymorphisms, rs11168751, shows nominal significance of 
P=4.43x10-6 but this does not reach the threshold level of genome-wide 
significance(P=5x10-8). The Y axis shows the –log10 of the P value.  
enrichment in the GO: 0015270, dihydropyridine-sensitive calcium channel 
activity. Of the eight genes in this category, 3 are members of the VDCC family, 
CACNA1C, CACNA1D and CACNB3 [239]. The regional association plot for CACNB3 is 
shown in Figure 36. No SNVs in this gene pass the threshold for genome-wide 
significance which is set at P=5x10-8 [250]. 
Numerous genome-wide association studies have shown consistent association 
signals originating from a SNP in the CACNA1C gene. The PGC-BD GWAS has found 
a large association peak in the third intron of CACNA1C (Figure 37). The group has 
also reported nominal association signals for the CACNA1D region (see Figure 38). 
The combined evidence of calcium channel gene associations from BD GWAS 
studies and the involvement of the calcium channels in neuronal networking 
pathways make this set of genes an appropriate candidate family to study in an 
attempt to identify variation that may increase an individual’s susceptibility to BD. 
   
 
Figure 37. Regional association plot of CACNA1C. 
 
 
 
Figure 38. Regional association plot of CACNA1D. 
The regional association plots for CACNA1D and CACNA1C were obtained from 
http://www.broadinstitute.org/mpg/ricopili/. The Data reflects the GWAS 
conducted by the PGC-BD [270]. The X axis shows the chromosome number and 
the position of the genetic region in kilobases. The Y axis shows the –log10 of the P 
value. In CACNA1C, one of the polymorphisms, rs1006737, in intron 3 reaches 
genome-wide significance (p=3x10-8). rs4765905 and rs4765913 have also been 
associated with SCZ (p=1x10-6) and BD (p=2x10-8) respectively. None of the or 
polymorphisms reach genome-wide significance in CACNA1D, however close to the 
3’ end of the gene there appear to be some variants with nominally significant 
levels of association.  
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4.2 HYPOTHESIS 
Members of the calcium channel family of genes have been associated with BD 
through GWAS, such as CACNA1C, or through gene pathway enrichment analysis 
such as CACNA1D and CACNB3. There is a certain limitation to the variants 
discoverable through GWAS as many rarer variants are not present on GWAS array 
platforms used to conduct these analyses. Current exome capture techniques often 
missed variants which are located in regulatory regions of the genome Figure 39. I 
focused on the afore mentioned genes in an attempt to identify polymorphisms in 
BD cases which were completely absent or present at a lower frequencies in 
ancestrally matched controls.  
Genetic variants located in regulatory regions can have a detrimental impact on the 
control and initiation of gene expression which would lead to aberrant expression 
of either the α subunits or the auxiliary subunits in the calcium channel gene 
family. It is possible that changes to expression of these genes could lead to 
disruption of intracellular calcium homeostasis and have an impact on 
downstream processes such as long term potentiation or synaptic plasticity in 
neurons.  
4.3 AIMS 
The aim of this study was to screen the promoter, 5’UTR, 3’UTR and first exons of 
CACNA1C, CACNB3 and CACNA1D using HRM for rare novel variants which may 
confer an increased susceptibility to BD. The data from ricopili as shown in Figure 
36, Figure 37 and Figure 38 from the PGC BD GWAS demonstrates that there is 
association between these genes and BD. Common variation in the regulatory 
regions of these genes do not appear to be associated with BD from the PGC BD 
GWAS. We used this data for selection of the calcium channels to follow up, with a 
specific focus on the regulatory regions and rare variants that may be present in 
the genes. On detection of a novel variant, genotyping would be undertaken in the 
full case-control cohort to investigate whether the variant was associated with BD 
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Figure 39. Exome sequencing coverage of regulatory regions in CACNA1D, 
CACNA1C and CACNB3. 
Exome capture over the 5’UTR, promoter region and the first exon of CACNA1D, 
CACNA1C and CACNB3 is relatively low in exome sequencing from the ExAC 
database (http://exac.broadinstitute.org/) 
4.4 HRM METHODS FOR SCREENING CACNA1C, CACNA1D, AND 
CACNB3 
The genetic sequence for each of the genes was retrieved using the UCSC genome 
browser (https://genome.ucsc.edu/). Primers for each genetic amplicon were 
designed using Primer 3 software as described previously (3.1.4). The list of 
primers used for HRM analysis of CACNA1C, CACNA1D and CACNB3 are listed in 
Appendix IIError! Reference source not found.. The regions screened by HRM 
were the 5’UTR and the promoter region, defined as 1000bp upstream of the 
transcriptional start site. 
CACNA1D 
CACNA1C 
CACNAB3 
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To assess the presence of variation in the regulatory regions of CACNA1C, 
CACNA1D, CACNB3 1,098 BD cases were utilised for HRM analysis. Following 
sample normalisation individuals who presented with aberrant curves were sent 
for Sanger sequencing to determine whether they were in fact real variants and not 
false-positives. Variants deemed to have potential aetiological effects, were 
followed up KASPar genotyping in 1098 BD research subjects and 1095 ancestrally 
matched controls.  
4.5 RESULTS 
4.5.1 HRM SCREENING OF GENES 
HRM analysis of the promoter region and the first exon of CACNA1C, CACNA1D and 
CACNB3 identified three novel variants and three previously annotated variants 
from dbSNP37 in the UCL1 and UCL2 cohort. These were validated using Sanger 
sequencing. The validated results are summarised in Table 22. The number of 
cases found with each variant through Sanger sequencing is also listed in Table 22. 
These numbers are not reflective of allele frequency as variants were chosen for 
sequencing based on aberrant curves. Novel variants are named by their 
chromosomal location and nucleotide change. The promoter region of CACNA1C 
harboured four variants rs538323756, rs11062091, rs112412740 and 
12:2162570 (C/G). All original SNV verification was conducted using 
GRCh37/hg19 build of the genome on the UCSC genome browser using the 
dbSNP137 release. Variant 12:2162217 (G/A) was not present on dbSNP137 but 
has been since given an ‘rs’ number, and so was considered a novel variant for this 
study. Variant rs312480 was detected in CACNA1D and 12:49212493 (C/G) was 
detected in CACNB3 in the promoter regions of both genes. Due to the extremely 
GC rich sequence and the presence of several repeat runs of sequence the second 
promoter amplicon in CACNA1D was not screened. This was because the PCR 
primers were unable to bind and amplify the regions efficiently due to the 
refractory nature of regions of high GC content and the presence of secondary 
structures. Secondary sets of primers were designed in an attempt to rectify this 
issue and several alternative PCR assay mixes were used that included deaza-7-
dGTP and/or Phusion high fidelity DNA polymerase (New England Biolabs) that  
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Gene Region SNV ID Chromosomal position (hg19) 
Variant 1000G MAF 
AA/Aa/aa 
CACNA1C Promoter  12:2162217 (G/A)* chr12:2162217 G/A - 38/2/0 
 
Promoter  rs11062091 chr12:2162369 G/A 0.148 19/14/7 
 
Promoter  rs112412740 chr12:2162548  G/A 0.0024 63/1/0 
 
Promoter  12:2162570 (C/G) chr12:2162570 C/G - 63/1/0 
CACNA1D Promoter  rs312480 chr3:53529140 A/T 0.1406 30/21/2 
CACNB3 Promoter  12:49212493 (G/C) chr12:49212493 G/C - 22/2/0 
Table 22. HRM variants from analysis in CACNA1C, CACNA1D and CACNB3.  
Some variants currently have dbSNP numbers but dbSNP137 was used for SNV 
validation. SNVs which are present on dbSNP138 or above are as following 
*rs538323756. MAF was obtained from the 1000G data set. 
had previously been shown to improve the amplification of GC-rich DNA sequences 
[427]. These strategies were not successful and it was not therefore possible to 
accurately identify variants in these regions using HRM analysis. 
4.5.2 INVESTIGATION OF THE EFFECTS OF VARIANTS  
Bioinformatic analysis was conducted on all variants to discern whether their 
presence had the potential to alter transcription factor binding sites in the 
promoter regions of each gene. This was done using Transcription Element Search 
System (TESS) which has been described in section 3.2.5 for variants located in 
non-coding regions of the genome. TESS scores the likelihood of transcription 
factor binding sites using positional weighted matrices against TFBS databases 
TRANSFAC 4.0, JASPAR, IMD and CBIL-GibbsMat databases. Positional weightings 
are calculated and the log-odds score is shown for the putative transcription factor 
binding site. The results for each variant are listed below.  
The CACNB3 variant 12:49212493 (G/C) is located in the promoter region of the 
first two isoforms of CACNB3, and in the intron of the secondary isoforms, 
transcript 3 and transcript 4. It is 221bps upstream of the start codon. The 
12:49212493 (G/C) variant results in the creation of a CDC5 TFBS. The CDC5 
transcription factor has been implicated in transduction of cytoplasmic signals to 
the nucleus following serum stimulation (Figure 40)[428].  
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Figure 40. TESS predictions for 12:49212493 (G/C) in the CACNB3 promoter. 
The TFBS highlighted in green indicate new TFBS which are gained in the presence 
of the variant. The 12:49212493 (G/C) variant in the promoter region of CACNB3 
results in the creation of the CDC5 TFBS. The final two TFBS’s ACE2 and SWI5 are 
not affected by the resulting base change suggesting that the G/C allele is not 
essential for the creation of this binding site. 
TESS results for rs538323756 are shown in Figure 41. It was predicted that when 
the wild type allele of rs538323756 was present an estrogen receptor (EsR) alpha 
Sp1 TFBS would be created. EsR-alpha SP1 is a member of a family of nuclear 
reporters and are ligand-activated transcription factors [429]. EsR-alpha activates 
transcription either directly or by activation of other transcription factors in a 
ligand dependent manner. EsR-alpha forms a complex with the SP1 transcription 
factor in a ligand activated manner [430]. The binding of ER-alpha SP1 to nuclear 
transcription factors is involved in activation of the cell cycle [431]. In the presence 
of the variant allele this transcription factor binding site appears to be lost, and the 
change results in the creation of two new TFBS. No information pertaining to the 
T-AG transcription factor could be found. The E2F family of transcription factors 
are involved in a number of cell cycle processes such as regulation of cellular 
differentiation, apoptosis and proliferation [432, 433]. The p107 transcription 
factor is a member of a tumour suppressor family and regulates E2F DNA binding 
activity and leads to repression of transcription through recruitment of repressor 
complexes to promoters [433].  
TESS results for 12:2162570 (C/G) in the CACNA1C promoter region also predicts 
changes to the TFBS sequence (Figure 41). When the wildtype C allele is present 
there are three TFBS which are lost in the presence of the variant G allele. These  
12:49212493 (G/C) 
Wild-type G  
ctcagccgcg ctcggggtgg gaccGgctgg gtttgggggg 
                          ====== = ACE2 (9.53) 
                          ====== == SWI5 (10.60) 
Mutation C  
ctcagccgcg ctcggggtgg gaccCgctgg gtttgggggg 
                        ======== === CDC5 (8.25) 
                          ====== = ACE2 (9.53) 
                          ====== == SWI5 (10.60) 
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Figure 41. TESS predictions for 12:2162217 (G/A) and 12:2162570 (C/G) in the 
CACNA1C promoter.  
The TFBS highlighted in red indicate ones which are lost in the presence of the 
mutated allele and the green TFBS are ones which are gained in the presence of the 
variant allele. The 12:2162217 (G/A) variant allele results in the creation of two 
new TFBS, T-AG and E2F+p107 and the loss of the ER-Alpha TFBS. The 
12:2162570 (C/G) variant results in the loss of three TFBS Prd, ICP4 and ABF1, 
and the addition of two new TFBS IPF1 and YY1. The numbers after the 
transcription factors in the diagrams are the log of the odds score for the 
conservation of the bases here for each TFBS and represent the strength of the 
prediction for the TFBS. 
12:2162217 (G/A) 
Wild-type G 
agcggcgctc ggcgcggcgc ggcgGgcccg gagcggcggc ggcggctctt 
              ======= = GCF (11.1281) 
                      ====== ER-Alpha (12.00) 
                                   ======= GCF (10.00) 
                                   ======== = WT1-KTS (18.00)  
Variant A 
agcggcgctc ggcgcggcgc ggcgAgcccg gagcggcggc ggcggctctt 
          ======= = GCF (11.1281) 
                   == === T-AG (6.4952)   
                  ==== E2F+p107 (8.00) 
                                   ======= GCF (10.00) 
                                   ======== = WT1-KTS (18.00) 
12:2162570 (C/G) 
  
Wild-type C  
gggaatcagg taatCgtcgg cggggaag 
  ====== GCN4 (12.00)  
     ===== == NF-GMb (13.00)  
           ====== Prd (9.4321) 
            ===== ICP4 (12.00) 
                ===== ====== ABF1(10.00) 
                 ==== RAF (8.00) 
Variant G 
gggaatcagg taatGgtcgg cggggaag 
  ====== GCN4 (12.00) 
     ===== == NF-GMb (13.00) 
         = ===== IPF1 (10.00) 
           ===== YYI (10.00) 
                 ==== RAF (8.00) 
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are PRD, ICP4 and ABF1. The PRD transcription factor controls transcriptional 
activation and anti-termination [434]. ICP4 is a regulator of viral gene expression 
associated with herpes simplex virus type 1 [435], it can act as both a promoter 
and inhibitor of transcription depending on its promoter structure. ABF1 is a 
member of the basic helix-loop-helix proteins. It contains a transcriptional 
repressor domain and it is purported to be involved in regulating cell 
differentiation [436]. The IPF1 (independent of pancreatic development 1) 
transcription factor is vital both during development and throughout later life for 
pancreatic development. It was originally thought that expression of this 
transcription factor was solely located to cells in the developing foregut [437], 
however other studies suggest that IPF1 transcription factor is also found in 
neuronal precursor cells in developing mice [438] and may play a role in the 
development of the CNS. Yin Yang I (YY1) is a ubiquitous transcription factor 
which plays a fundamental role in transcription regulation [439]. It has been linked 
to initiation of transcription in addition to activation and repression of 
transcription, giving it its name Yin Yang [439, 440]. 
4.5.3 GENOTYPING OF VARIANTS FROM HRM 
Variants selection for follow up genotyping was based on previously described 
criteria (see section 3.2.5). The variants were required to be novel and result in 
changes to transcription factor binding sites in the regulatory regions. Three 
variants from the HRM analysis of CACNA1C, CACNA1D and CACNB3 fitted these 
criteria. Two promoter region SNVs from CACNA1C, 12:2162217 (G/A) and 
12:2162570 (C/G), and 12:49212493 (G/C) in the promoter region of CACNB3. 
Optimization of assays for the genotyping of the SNV from the promoter region 
CACNB3 failed repeatedly. This variant was validated through Sanger sequencing 
from the stock DNA but due to the fact that the CACNB3 variant is located in a 
region of high GC content it was not possible to optimise an assay to genotype this 
variant in the case control cohort. 
The CACNA1C SNV 12:2162217 (G/A) was present as a heterozygote in 42 controls, 
and as a homozygote in two controls. This high frequency was reflected in the case 
population with 43 heterozygous cases confirmed through genotyping (p=0.79).  
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Gene SNP 
Eur 
MAF 
Cohort 
Sample 
number 
Genotype 
calls 
AA/Aa/aa 
MAF P 
Fishers 
Exact 
OR 
(95% 
CI) 
CACNA1C 
12:216221
7 (G/A) 
- BD 924 881/43/0 0.023 0.79 0.44 
1.06  
(0.7-1.6) 
   
Control 934 890/42/2 0.027 
   
CACNA1C 
12:216257
0 (C/G) 
- BD 938 930/1/0 0.001 0.31 1.00 NA 
   
Control 922 922/0/0 NA 
   
Table 23. Genotyping results for calcium channel variants detected by HRM. 
MAF, minor allele frequency, P, Chi Square p value, OR, Odds Ratio, CI, Confidence 
Interval, NA, Not Applicable.  
12:2162570 (C/G) was present in one BD sample, and not present in the control 
cohort (p=0.31). Neither of these variants were associated with BD in our sample 
(Table 23). 
4.6 DISCUSSION 
HRM failed to identify any genetic variants associated with BD in the regulatory 
regions and first exons of CACNB3, CACNA1C, and CACNA1D. This is typical in the 
field of complex genetics. Various disease models have been proposed for BD, 
including common genetic variants with small effect sizes and rare variants with 
large effect sizes. This is mirrored in the results that are coming from GWAS and 
next generation sequencing studies where large sample sizes are needed to detect 
association between BD and rare SNVs. There are a number of reasons why this 
may have occurred. Firstly the parameters set for SNV follow up genotyping in the 
complete UCL cohort limited the follow up variants to novel variants which had not 
been previously reported. This process led to the inclusion of three variants in the 
follow up analyses. The remaining variants may contribute susceptibility to BD but 
this cannot be determined given the original experimental parameters set for 
variant inclusion. 
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HRM analysis allowed for the verification of SNPs in regions which were GC rich. 
However these GC rich regions were refractory to the development of follow up 
genotyping assays because we were not able to design assays to adequately 
genotype these variants. 
In silico estimates of the predicted effect of the 12:2162570 (C/G) variant were 
that this change would lead to the loss of three TFBS and the creation of two new 
TFBS. This information does not provide enough detail to determine whether the 
variant may result in an increased or decreased expression of CACNA1C. All three 
of the transcription factors whose binding sites were lost are involved in 
transcriptional regulation, ABF1 was purported to play a role in cell differentiation, 
IPF1 involved in regulation of gene expression which can act as both an activator 
or repressor of gene transcription depending on the shape of the promoter 
structure and finally Prd that controls transcriptional activation and anti-
termination. IPF1 has been shown to be present in regions that generate neurons 
during the time of active neurogenesis, additionally the tethering of YY1 to the 
histone deacetylase protein, HDAC3 and HDAC2, result in transcription repression 
through histone deactylase activity [441, 442]. If the creation of the two new 
transcription factor binding sites were to lead to a repression of transcription of 
CACNA1C it could have knock on effects on transcriptional regulation and control 
of the CREB cycle. 
It is interesting that the 12:2162570 (C/G) variant was present in only one 
individual with BD in the approximate 1,000 individuals genotyped. With this data 
alone it is difficult to determine whether this variant may play a role in the 
aetiology of BD. Evolutionary theory holds that deleterious variants by default are 
likely to be rare due to purifying selection [443, 444]. The sample size of the 
original exploratory cohort used to detect variant present in the regulatory regions 
of CACNA1C, CACN1D and CACNB3 was of adequate size in which to find common 
and rare variation. The ability to detect an association between rare variants and a 
disease, is based on a number of factors, one is the relative risk of the variant, as 
estimated by 1+ λ, where λ is the excess relative risk of disease conferred by the 
allele [445]. The second is the sample size. Zuk et al have determined that to detect 
allele association with a 2-fold increase to disease risk, approximately 28,000 
samples are needed. For variants with larger relative risk scores, such as a 20-fold 
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increase in relative risk, 260 cases would be needed [445]. Our sample size is 
appropriate for variant identification and investigation of either common variants, 
or rare variants with larger effect sizes.  
The finding of a rare case-only variant suggests that replication of this variant in a 
larger sample size would be needed to determine whether it confers a relative risk 
to the development of BD. Previous reports have suggested that variants located in 
the promoter, 5’ and 3’UTR regions provide a stronger contribution to risk for BD 
than coding variants [292]. In general, regulatory regions are less conserved than 
coding regions of the genome which could account for the greater presence of rare 
variants here.  
It is clear to see from the above data that HRM provides a valuable resource for 
high throughput variant detection in specific regions of genes. Given adequate 
amplicon and sample sizes both common and rare novel variants were detected 
using this method. If known variants are present in a region, smaller amplicon 
regions can be utilised to genotype all variants. This could be used in future for 
variants, such as the CACNB3 12:49212493 (G/C), to screen for variants whose 
genotyping assay optimisation failed in the lab. 
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   High resolution melting Chapter 5
curve analysis of CACNG4 
5.1 INTRODUCTION 
Previous observations have indicated that several members of the calcium channel 
family of genes, including the TARP family of subunits, could potentially be 
implicated in BD susceptibility. TARPs consist of two subgroups, the canonical type 
I consisting of γ2, γ3, γ4 and γ8, and the atypical type II γ5 and γ7 [446]. Two 
members, γ1 and γ6, of this family of subunits are involved in interactions with the 
calcium channel pore and modifications of calcium influx into the cells through the 
α pore. These proteins play a vital role in trafficking and scaffolding of the AMPA-R 
to the postsynaptic density in neurons and are involved in promoting AMPA-R 
maturation [351, 356, 359, 388]. TARPs are expressed throughout the central 
nervous system (CNS) and display differing functions in their interactions with 
AMPA-Rs. The association of TARPs with AMPA-R have an important impact on 
AMPA-R function and induce AMPA-R modifications in function. This includes 
increasing single channel conductance, slowing their desensitization and 
deactivation and weakening blockage of calcium permeable AMPA-R by 
endogenous intracellular polyamines [362]. Each TARP differs in their influence on 
AMPA-R properties [351, 447]. Members of the TARP family can bind to a number 
of AMPA-R, but it is thought that only one TARP binds to the AMPA-R subunit in 
conjunction with their function at that given time [351, 359]. Additionally, TARPs 
play a role in canonical forms of synaptic plasticity through regulation of AMPA-R 
numbers in the hippocampus following long term potentiation (LTP) or depression 
(LTD) [351] and in Purkinje cells following LTD [448]. 
TARPs play a role in calcium entry into the cell through interaction with AMPA-R 
complexes that lack a GluR2 subunit. AMPA-Rs consisting of GluR-2 subunits are 
the most common receptors in the CNS and are calcium impermeable CI-AMPA-R 
[449, 450]. AMPA-R complexes lacking the GluR2 subunit are permeable to calcium  
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 (CP-AMPA-R) and demonstrate greater channel conductance than GluR2 
containing subunits [451, 452]. The interaction of TARP-γ2 with CP-AMPA-R 
results in increased calcium permeability through the attenuation of polyamine 
blocking [453, 454]. It has been previously demonstrated that AMPA-R 
desensitization and deactivation is prolonged through their interactions with 
TARPs [455]. This property is mediated by the first extracellular loop of the TARP 
protein [362]. 
As mentioned in section 1.3.2.4 members of the γ family of subunits have been 
associated with severe neurological phenotypes. In vivo studies into CACNG2 gene 
function, encoding TARP-γ2, demonstrate that in KO- γ2 mice demonstrate severe 
ataxia [272, 456]. This ataxia is a result of the absence of surface and synaptic 
expression of AMPA-R in cerebellar granule neurons. This is due to the role γ2 
plays in trafficking the AMPA-R to the PSD. Motifs in the γ2 protein have recently 
been found to interact with the Arc protein [457], which is transcriptionally 
upregulated in models of learning [458]. Arc functions at neural synapses and its 
transcription has been be linked to neural activity which is involved in information 
processing and storage [459]. Arc binds to γ2 amino acid Y229 through a unique 
hydrophobic pocket in the N-lobe domain of the Arc protein [457]. This binding of 
Arc to γ2 can mediate down regulation of AMPA-R receptors during synaptic 
scaling, and this regulation may be determined by TARP gene expression [457]. 
While γ2 does not show a genetic association with bipolar disorder or 
schizophrenia, the presence of the critical residue for Arc binding is of interest. 
Association between schizophrenia and genes encoding proteins containing an Arc 
N-lobe consensus sequence have been reported [411, 460]. The γ2 and γ4 share 
58.5% homology as determined by Uniprot (http://www.uniprot.org/) (Figure 42) 
. The consensus sequence for the Arc N-lobe protein appears to be present in the 
γ4 protein. This however is not indicative of binding to Arc N-lobe as the TARP γ3, 
which has 73.7% homology with TARP γ2, has evolved to avoid Arc binding in 
higher vertebrates [457]. 
A case-case analysis between BD and SCZ, in the UCL cohort conducted by Curtis et 
al, has shown an association in the 81kb intragenic region between CACNG4 and 
CACNG5 (see Figure 43 [271]). Both CACNG4 and CACNG5 are members of the 
voltage dependent calcium channel genes and encode a type-I TARP and a type-II  
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Figure 42. TARP γ2 and γ4 protein homology. 
The Arc binding domain at CACNG2 Y229 (orange square) is also conserved in 
CACNG4 at Y236. This is not a pre-requisite for binding at the Arc N-Lobe domain 
because the CACNG3 protein also has this domain and it doesn’t bind the Arc 
protein.  
TARP respectively. Data from the PGC-BD GWAS does not report any association 
signal arising in the CACNG4 gene as shown in Figure 44. The association signal 
seen in the case-case study between the SCZ cohort and the BD cohort could be 
driven by variants located in either of the genes. The properties of the TARP family 
of proteins, and their role in synaptic plasticity, make them an interesting gene 
family to study in the search for variants underlying genetic contribution to 
psychiatric disorders such as BD and SCZ.  
5.2 HYPOTHESIS 
While specific genes have been identified through GWAS or follow-on candidate 
gene studies, aside from the meta-analysis from Curtis et al there has been very 
little research of disease variant associations in the CACNG4 gene. This is due, in 
part to the limited power of GWAS studies with many rare variants not reaching 
the significant threshold levels due to their lower frequencies in BD cases. 
Therefore, we focused on the CACNG4, a member of the TARP family of genes 
which regulates AMPA-R trafficking to the PSD in an attempt to identify 
polymorphisms found in   
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Figure 43. Location of the associated variant from case-case analysis between 
CACNG4 and CACNG5. 
A case-case study between the UCL BD and SCZ cohort found an association 
between CACNG4 and CACNG5. The variant, rs17645023, is located 45kb CACNG4 
and 35kb from CACNG5 [271]. Image from https://genome.ucsc.edu/.  
 
 
Figure 44. Regional association plot of CACNG4. 
The plot is taken from the PCG BD GWAS. The plot is taken from the PCG BD GWAS. 
The x-axis shows the observed –logP value of each variant and the y-axis shows 
the chromosomal position. Variant rs3785599, in red, is associated with BD at 
p=0.031. The other SNPs coloured are in linkage disequilibrium with the 
associated SNP. The level of linkage disequilibrium is denoted by the colour of each 
variant. This variant does not pass the threshold level for genome wide 
significance The x-axis shows the observed PThe ricopili plot was obtained from 
http://www.broadinstitute.org/mpg/ricopili/. The data reflects the PGC-BD GWAS 
[270].  
CACNG4 
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BD cases and which were completely absent or present at lower frequencies in the 
ancestrally matched controls. 
Amino acid changing variants in specific regions of the gene could result in 
aberrant trafficking of the AMPA-R to the PSD. In addition to this, it is still 
undetermined if γ4 protein interaction with AMPA-R subunits is specific to one of 
the four, or if it binds to all GluR subunits. The presence of variants which effect 
trafficking of the AMPA-R to the PSD could have an effect on synaptic plasticity, 
and calcium entry to the cell, through the CP-AMPA-R GluR1, GluR3, GluR4. 
5.3 AIMS 
All regulatory regions and exons of CACNG4 were screened for variants using HRM 
analysis to establish whether the association signal seen in the BD vs SCZ analysis 
may be driven by a variant, or variants, harboured in these genetic regions. Further 
functional analysis was then undertaken to understand the biological effect of 
these variants. 
Previous work has been conducted into novel variation in CACNG5 using HRM 
analysis and this gene was not covered in the course of this PhD [390]. 
5.4 HRM SCREENING OF CACNG4 
Primers for CACNG4 are listed in Appendix II and were designed to cover the 
promoter region, the 5’UTR, all four exons and the 3’UTR. Full coverage of these 
regions was ensured by creating primers which overlapped with the amplicon 
before and after it, an example of which is shown in Figure 45. 
1,098 BD cases were utilised for HRM analysis. Following sample normalisation 
individuals who presented with aberrant melt curves were sent for Sanger 
sequencing to determine whether they were in fact real variants and not false-
positives. Variants deemed to have potential aetiological effects, were followed up 
KASPar genotyping in 1900 affected BD research subjects and 1350 ancestrally 
matched controls. The extra samples for genotyping came from newly extracted  
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Figure 45. An example of primer design for exon 4 and part of the 3'UTR of 
CACNG4. 
Each of the primer pairs are labelled in the same colour. Introns and the 3’UTR are 
denoted by lower case letters, and the exon of CACNG4 by the capital letters. Any 
base where common variation is reported is denoted through use of < > brackets. 
This is to ensure primers are not designed to fall on sequences containing common 
variation. All of the primer pairs overlap with each other ensuring full coverage of 
the genetic region of interest. 
 
taaagaggggaactgggggctgagagtgtgttttattgtatacctcatttgaactttgtactctatt
acccattcaacattaattactgaaaagaaaaattagcaaccagaataaagaaatactcatcaga
gaggggagtgtccacctgttccctacactgcccgtcccactgtgggtctaacctctgcctctctccc
tccctggccccgctccccgctccccgcttccctttcagGCCTCAGTAACATCATCGGTAT
CATCGTCTACATTTCCAGCAACACAGGTGACCCGAGTGACAAGCGGGAC
GAAGACAAAAAGAACCATTACAACTACGGCTGGTCTTTTTACTTTGGAG
CTCTGTCTTTCATTGTGGCTGAGACCGTGGGCGTCCTGGCTGTAAACAT
TTACATTGAGAAAAATAAAGAGTTGAGGTTTAAGACCAAACGGGAATT
CCTTAAGGCGTCTTCCTCTTCTCCTTATGCCAGGATGCCGAGCTACAGGT
ACCGGCGACGGCGCTCGAGGTCCAGCTCAAGGTCCACCGAGGCCTCGCC
CTCCAGGGACGTGTCGCCCATGGGCCTGAAGATCACAGGGGCCATCCCC
ATGGGGGAGCTGTCCATGTACACGCTGTCCAGGGAGCCCCTCAAGGTGA
CCACCGCAGCCAGCTACAGCCCCGACCAGGAGGCCAGCTTCCTGCAGGT
GCATGACTTTTTCCAGCAGGACCTGAA<G>GAAGGTTTCCA<C>GTCAG
CATGCTGAACCGAC<G>GACGACCCCTGTGTGAgccgcctgccctttctctccgct
ccagcctctccccagaa<c>ggctctttttgtcacacaggatggcatgtgatcctcaagacgacg
aacaatgaactaaagccaaat<g>cagccctccctggcctccagaggtggcgtgggctggcttt
gcacgaaggttgtgctgggagaccggacccggggctgcagaagaagctgaaggctgactttgtc
ccctccccg<a>aaaggggtgttttgatgcctcagggtctctgaaatctcc<c>gggaagcccc
agagctttcctgaggctgcctggccttgatcaacttgggaagacaaaattgagccattatctcctc
ttggaaacgaatcttgccagaaaaacgggatttcagggccttccctccctgcctgggtgtcgggc
caccagaaggctctgc 
 
Primer Pair 1 Primer Pair 2 
Primer Pair 3 Primer Pair 4  
Primer Pair 5 
CACNG4 Exon 4 & 3’UTR 
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DNA which had not been extracted prior to HRM screening. Given the sample size 
of the primary HRM analyses we deemed it large enough to determine variation at 
the genomic level. 
5.5 RESULTS 
5.5.1 HRM SCREENING OF GENES 
HRM analysis identified 22 variants in CACNG4 which are listed in Table 24. 
Thirteen of these variants have been annotated previously on dbSNP, and nine 
novel variants were identified and verified using HRM analysis and Sanger 
sequencing. Allele counts from the Sanger sequencing are shown in Table 24 but 
these are not representative of allele frequencies in the UCL cohort due to the 
selection criteria for samples. CACNG4 contains four exons which encode a 37kDa 
protein, 327 amino acids in length. HRM analysis identified two non-synonymous 
mutations located in the fourth exon of CACNAG4. In addition to these, HRM 
analysis found one variant in the 5’UTR, six synonymous mutations, four intronic 
variants and nine 3’UTR variants. Due to the nature of certain genomic regions the 
promoter region of CACNG4 were not screened. These regions were extremely GC 
rich and contained several repeat runs of sequence. This has previously been 
described in 4.5.1. 
5.5.2 INVESTIGATION OF VARIANT EFFECTS 
The potential functional impact of SNVs in CACNG4 was investigated using a 
number of different programmes depending on the type of variant found. SNVs 
found in coding regions of the genome were analysed using Polyphen2 and SIFT 
(section 3.2.5.1). There is a discrepancy between the scores predicted by both 
Polyphen2 and SIFT. Primarily Polyphen2 predicts that the two variants located in 
the fourth exon of CACNG4 are possibly damaging changes. In contrast SIFT predict 
low damage scores for each of the variants. This result potentially stems from the 
method by which the programmes investigate variant differences. SIFT uses PSI-
Blast to look at base conservation from a number of closely related sequences.  
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SNP ID 
Chromosomal 
position (hg19) 
Variant 
1000G 
MAF 
AA/Aa/aa Class of Variant 
rs34743848 chr17:65014360 C/T 0.0114 122/22/0 Synonymous variant 
rs186352782 chr17:65014366 C/T 0.0002 143/1/0 Synonymous variant 
17:65014414 (C/A) chr17:65014414 C/A - 129/15/0 Intronic variant 
17:65021046 (C/T)* chr17:65021046 C/T 0.002 127/2/0 Synonymous variant 
rs139952030 chr17:65021094 C/T 0.006 128/1/0 Synonymous variant 
17:65021126 (C/T) chr17:65021126 C/T - 125/4/0 Intronic variant  
rs187070398 chr17:65021132 G/A 0.001 127/2/0 Intronic variant 
17:65021173 (G/T) chr17:65021173 G/T - 128/1/0 Intronic variant 
rs2240648 chr17:65026515 A/G 0.4726 200/2/0 Intronic variant  
rs139092398 chr17:65026555 G/A 0.0088 200/2/0 Intronic variant 
chr17:65026648 
(G/A)** chr17:65026648  G/A - 102/1/0 
Non-Synonymous variant 
Arginine to Glutamine 
17:65026851 (C/T) chr17:65026851 C/T - 101/1/0 
Non-Synonymous variant 
Arginine to tryptophan 
rs11649752 chr17:65026886 C/T 0.0597 80/23/0 Synonymous variant 
rs138591032 chr17:65027293 G/A 0.0046 100/11/0 3'UTR variant  
17:65027367 (G/T) chr17:65027367 G/T - 150/2/0 3'UTR variant 
17:65027506 (C/T) chr17:65027506 C/T - 102/1/0 3'UTR variant 
rs201238001 chr17:65027556 A/G 0.001 162/3/0 3'UTR variant 
rs740555 chr17:65027740 G/C 0.3498 82/20/18 3'UTR variant 
17:65028637 (A/G) chr17:65028637 A/G - 102/2/0 3'UTR variant 
rs188250082 chr17:65028695 G/C 0.0002 152/6/0 3'UTR variant 
rs1051774 chr17:65029052 C/T 0.1703 68/34/0 3'UTR variant 
rs3803815 chr17:65029264 G/A 0.0727 134/14/0 3'UTR variant  
Table 24. Variants found using HRM analysis in CACNG4.  
MAF was obtained from the 1000G data set. Some variants currently have dbSNP 
numbers but dbSNP137 was used for SNV validation. SNPs which are present on 
dbSNP138 or above are as following *rs555971941, **rs371128228. Genotype 
counts come from the number of samples sequenced in each region following HRM 
analysis. These numbers are not representative of allele frequencies. 
Name Location Amino acid Polyphen2 SIFT 
rs371128228 chr17:65026648 R171Q 0.97 Probably Damaging 0.36 
17:65026851 (C/T) chr17:65026851 R239W 1.00 Probably Damaging 0.07 
Table 25. Polyphen2 and SIFT prediction effects for non-synonymous variants in 
CACNG4. 
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Polyphen2 on the other hand, in addition to calculating base conservation, 
measures the impact the amino acid change will have on both the secondary 
structure and tertiary protein structure. 
These variants were then analysed using Project Hope 
(http://www.cmbi.ru.nl/hope/method) [461] to determine the effect of the amino 
acid changes on protein structure. All predicted amino acid changes are shown in 
Figure 46. SNV rs371128228 results in an arginine to glutamine change at position 
171 in the amino acid chain. Arginine is a larger positively charged amino acid, 
while glutamine is smaller and is neutrally charged. The wildtype residue is not 
conserved at this position, however glutamine is not observed in other homologous 
sequences at this position. The loss of the positive charge and smaller size at 
position 171 may result in a loss of interactions with other molecules or residues, 
effecting protein folding or confirmation. SNV 17:65026851 (C/T) results in an 
arginine to tryptophan change at residue 239. The wildtype arginine residue is 
positively charged and smaller than tryptophan. Additionally tryptophan is 
hydrophobic in nature. Arginine is extremely conserved in this position of the 
sequence. While a few other amino acids do occur in homologous sequences to 
CACNG4, residues with properties similar to tryptophan are not observed. The loss 
of the positive charge and the change in hydrophobic nature could lead to a loss of 
hydrogen bonds and disturb correct folding of the resulting protein. 
NextProt beta (http://www.nextprot.org) was utilised to determine the specific 
location of all two variants in the native protein, these are shown in Figure 47. The 
R171Q variant is located in the second extracellular region. R239W is located 
directly upstream of the Protein Kinase C (PKC) domain and the nPIST domain. 
5.5.3 GENOTYPING OF VARIANTS DETECTED BY HRM 
The two non-synonymous SNVs from the fourth exon of CACNG4 were genotyped 
in the extended BD sample. Additionally, given the reasons for choosing CACNG4 as 
a candidate gene to investigate, the variants were genotyped in both the SCZ and 
ADS cohorts. SNV rs371128228 trended towards significance in the BD population 
and was present in five individuals p=0.0617, one individual with SCZ p=0.14, and 
three individuals with ADS p=0.725.  
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Figure 46. Amino acid changes in CACNG4.  
R171Q results in an arginine to glutamine change and R239W results in an 
arginine to tryptophan change. 
 
Figure 47. TARP γ4 structure.  
The CACNG4 protein contains four transmembrane domains. The amino acid 
residues shown here are the ones which are highly conserved between mouse, rat 
and human (Image based on [462]). The locations of the non-synonymous SNVs 
found using HRM are noted by the red circle in the second extracellular domain 
and just upstream of the PKC domain.  
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The variant was completely absent from the control cohort. The allele frequency of 
rs371128228 does not reach above 0.001 in any of the disease cohorts and is 
absent in the UCL control cohort. SNV 17:65026851 (C/T), was present in two 
individuals with BD p=0.7845, one individual with ADS p=0.9635, and one healthy 
volunteer. No association was seen in the UCL cohort. The variant was not present 
in the SCZ case cohort.  
Preliminary data from the UK10K SCZ cohort was additionally utilised for variant 
investigation and a Swedish schizophrenia cohort [411] comprising of 2,536 
individuals was also investigated for variant frequencies. Further control samples 
datasets from the exome variant server (EVS) 
(http://evs.gs.washington.edu/EVS/) European population and the 1000G’s 
(http://www.1000genomes.org/) Utah Residents with Northern and Western 
European Ancestry (CEU) population were investigated to ensure equal numbers 
of cases and controls were present (Table 28). The final publically available control 
database used was the Exome Aggregation Consortium (ExAC) 
(http://exac.broadinstitute.org) comprising 60,706 unrelated individuals. The 
European cohort in the ExAC consisted of 33,370 individuals [410]. This cohort 
contains data from Swedish SCZ and BD studies (12119); these include the 2453 
individuals from the previously mentioned Swedish exome cohort. These 2453 
individuals were removed from the overall control sample to ensure no overlap 
occurred as the genotype calls for each individual was previously known. In 
addition to the remaining 9576 Swedish SCZ and BD individuals, the ExAC cohort 
contains individuals from SCZ Trios from Taiwan (1505 individuals), SCZ Bulgarian 
Trios (461). The ExAC data does not currently have individual phenotypes 
available for each call and so it was impossible to remove these samples from the 
control cohort. As a result, the calculated p values are somewhat conservative in 
nature as we are unable to discern whether they are truly arising in the healthy 
control population or in the cohorts with psychiatric illness. The combined 
analysis for both CACNG4 variants is listed in Table 29. These results are calculated 
to show the combined association between the UCL psychosis cohort versus the 
UCL healthy volunteers, and the combined cohorts including the calls from the 
datasets mentioned above. In the combined analysis, two individuals from the 
UK10K SCZ cohort were heterozygous for the rs371128228 variant. This variant  
   
Gene Variant Location (hg19) 
Position 
in gene 
Change Eur MAF Cohort 
Sample 
number 
Genotype 
calls 
AA/Aa/aa 
MAF P 
Fishers 
Exact 
OR (95% CI) 
CACNG4 rs371128228 17:65026648 Exon G/A 0 BD 1885 1880/5/0 0.001 0.06 0.07 NA 
      
SCZ 604 603/1/0 0.001 0.19 0.38 NA 
      
ADS 1225 1221/3/0 0.001 0.11 0.16 NA 
      
Control 1315 1315/0/0 na 
  
 CACNG4 17:65026851 (C/T) 17:65026851 Exon C/T - BD 1876 1874/2/0 0.001 0.78 0.79 1.40 (0.13-15.4) 
      
SCZ 674 674/0/0 na - 
 
NA 
      
ADS 1227 1226/1/0 0.000 0.96 0.75 1.07 (0.7-17.1) 
      
Control 1309 1308/1/0 0.000 - 
 
  
Table 26. Results of SNVs genotyped from CACNG4. 
MAF, minor allele frequency, P, Chi Square p value, OR, Odds Ratio, CI, Confidence Interval, NA, Not Applicable. 
 
   
Variant Sample UCL UK10K SCZ Swedish SCZ 1000G Eur EVS Eur ExAC Eur 
  AA Aa AA Aa AA Aa AA Aa AA Aa AA Aa 
rs371128228  BD 1885 5 0 0 0 0 0 0 0 0 0 0 
  SCZ 604 1 1388 2 2543 0 0 0 0 0 0 0 
  ADS 1221 3 0 0 0 0 0 0 0 0 0 0 
  Control 1315 0 0 0 0 0 349 0 4228 1 30775 12 
              
17:65026851 (C/T)  BD 1876 2 0 0 0 0 0 0 0 0 0 0 
  SCZ 674 0 1390 0 2543 0 0 0 0 0 0 0 
  ADS 1227 1 0 0 0 0 0 0 0 0 0 0 
  Control 1309 1 0 0 0 0 349 0 4229 0 30826 1 
Table 27. Total variant counts for rs371128228 and 17:65026851 (C/T) in CACNG4. 
UCL, University College London Cohort; UK10K SCZ, UK 10K Schizophrenia cohort; Swedish SCZ, Swedish exome cohort; 1000G Eur, 1000 Genome 
Project European cohort; EVS, Exome Variant Server; ExAC Eur, Exome Aggregation Consortium European cohort. 
   
Variant 
 
AA Aa 
rs371128228 Case 7643 11 
 
Control 36665 13 
17:65026851 (C/T) Case 7710 4 
 
Control 36713 2 
Table 28. Total case control sample size for rs371128228 and 17:65026851 (C/T) CACNG4 variants. 
SNP Cohort Sample Calls MAF P Fishers Exact OR (95% CI) 
  
AA/Aa/aa 
    
rs371128228 BD+SCZ +ADS 3710/9/0 0.001 0.074 0.061 NA 
 
UCL control  1315/0/0 NA 
 
Combined Psychosis 
Cohort 
7643/11/0 6.9x10-4
 
1.05x10-4 NA 4.39 (1.94-9.96) 
 
Combined Control 
Cohort 
36665/13/0 8.5x10-5
 
17:65026851 (C/T) BD+SCZ +ADS 3777/3/0 7.93x10-4 
0.973 0.7096 1.04 (0.11-10) 
 
UCL control  1309/1/0 3.82x10-4 
 
Combined Psychosis 
Cohort 
7710/4/0 2.59x10-4 
0.001 0.0005 9.52 (1.74-51.99) 
 
Combined Control 
Cohort 
36713/2/0 2.72x10-5 
Table 29. Combined analysis of psychosis group versus Healthy Controls for CACNAG4 variants. 
rs371128228 from CACNG4 is significantly associated with the psychosis group including the samples from the UK10K SCZ samples. MAF, minor 
allele frequency, OR, Odds Ratio, CI, Confidence Interval, NA, not applicable.  
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was not present in the Swedish exome data set. Twelve healthy control individuals 
were heterozygous for this variant. Eleven of these individuals came from the ExAC 
cohort and one heterozygous individual was present in the EVS dataset. This 
variant was associated with the combined psychosis group (p=1.05x10-4, 
OR=4.39). Variant 17:65026851 (C/T) was absent in the additional SCZ databases. 
It was present in the one European individual from the EXaC cohort of 30826 
individuals.  Variant 17:65026851 (C/T) is associated with the combined psychosis 
group (Fishers Exact p=0.0005, OR=9.52). 
5.5.4 EFFECT OF RS371128228 ON AMPA-R TRAFFICKING 
Flow cytometry analysis was conducted to determine whether variant 
rs371128228 has an effect on trafficking of either of the AMPA-Rs, GluR1 or GluR2, 
to the cell surface. Hek293 cells were co-transfected with wild-type CACNG4 and 
GluR1 or GluR2. Additionally, cells were co-transfected with the CACNG4 pTAGRFP 
containing variant rs371128228 and GluR1 or GluR2. Both of the AMPA-R plasmids 
contain super ecliptic pHluorin tag (SEP) which is a modified pH sensitive GFP tag 
which has been described in the methods section previously (0). The SEP tag is 
located on the N-terminus of the plasmid and is essentially non-fluorescent under 
acidic conditions (pH>6.0). When SEP is in a neutral environment, such as at the 
cell surface, the fluorescent signal increases 100-fold [423-425]. To determine 
whether rs371128228 has an effect on surface expression of GluR1 or GluR2, 
fluorescence levels from the Alexa-488 channel of the LSRFortessa flow cytometer, 
which detects SEP signal, were collected. This data was normalised against a 
negative control of untransfected cells to determine the fluorescence range of SEP 
positive cells. This threshold or gate was set separately for each independent 
replication. An a priori minimum of 10000 events (or cells) was collected for each 
sample. The mean of the fluorescence intensity in each sample was calculated for 
three replicated independent experiments. 
Figure 48 shows the level of fluorescence for the negative control (A), the wild-
type CACNG4/GluR1 cells (B), and rs371128228 CACNG4/GluR1 (C). A decrease can 
be seen in the level of fluorescence in the experiments with the mutant allele 
versus the wild-type. The rs371128228 mutation significantly decreases the level  
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Figure 48. Histogram of the Fluorescence of SEP for CACNG4/GluR1. 
A. Untransfected negative controls were used to define the region where cells positive for SEP fluorescence would be detected. Cells above this 
range are the Alexa Fluor 488-A+ cohort and are located to the right of 103 on the x-axis of each histogram. B. Cells transfected with wild-type-
CACNG4 and GluR1. C. Cells transfected with rs371128228 CACNG4 and GluR1. 
  
Negative Wild-type CACNG4/GluR1 rs371128228 CACNG4/GluR1 
A B C 
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Figure 49. Histogram of the Fluorescence of SEP for CACNG4/GluR2. 
A. Untransfected negative controls were used to define the region where cells positive for SEP fluorescence would be detected. Cells above this 
range are the Alexa Fluor 488-A+ cohort and are located to the right of 103 the x-axis of on each histogram. B. Cells transfected with wild-type-
CACNG4 and GluR2. C. Cells transfected with rs371128228 CACNG4 and GluR2. 
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Sample 
Mean (Alexa Fluor 488-A) 
Mean  
Standard 
Deviation 
Standard 
Error 
T-test (paired, two tailed 
distribution) N1 N2 N3 
Wild-type 
CACNG4/GluR1 
4590 4633 4988 4737.00 218.43 126.11 
0.026 
Mutated 
CACNG4/GluR1 
4286 4348 4228 4287.33 60.01 34.65 
Wild-type 
CACNG4/GluR2 
5170 4106 5519 4931.67 736.03 424.95 
0.903 
Mutated 
CACNG4/GluR2 
4141 * 5523 4832.00 977.22 564.20 
Negative control 1656 1811 1985 1817.33 164.59 95.03 
 
Table 30. Mean Fluorescence from CACNG4/AMPA-R experiments. 
N1, Replication 1; N2, Replication 2; N3, Replication 3. *No reading for this sample in this replication. 
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Figure 50. Fluorescence intensity of SEP in HEK293 cells. 
The mean fluorescence for each transfection was calculated. Each bar graph represents three independent replicates (n=3). The value for the 
mutated rs371128228/GluR2 measurement represents the mean of data from two replicates (n=9). *p<0.05 
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of GluR1 at the cell surface (T-Test, p=0.026) (Table 30). Figure 49 shows the 
histograms of the same negative control, (A), the wild-type CACNG4/GluR2 
transfected cells (B), and rs371128228 CACNG4/GluR2 transfected cells (C). The 
rs371128228 does not show an effect on GluR2 surface expression (T-test, 
p=0.903). Figure 50 shows the averaged means of fluorescence intensity for all 
three replications. The second replication of rs371128228 CACNG4/GluR2 resulted 
in less than 10,000 events and is not included in the average. 
5.6 DISCUSSION 
The identification of variations which may confer an underlying susceptibility to 
the manifestation of psychiatric illness is crucial to understanding disease 
aetiology and may form the basis for pharmacotherapeutic intervention. The use of 
HRM analysis to investigate the presence of variation in the CACNG4 gene proved 
successful in identifying nine novel variants which were previously unreported at 
the time of study. Neither rs371128228 nor 17:65026851 (C/T) showed association 
in either the UCL BD cohort alone, or the combined UCL BD+SCZ+ADS cohort 
group. Upon addition of the extra datasets both the CACNG4 variants show an 
association with the combined psychosis group, (rs371128228, p=, OR=4.39, 
17:65026851 (C/T), Fishers Exact p=0.0005, OR=9.52). In the psychosis cohort 
both variants are extremely rare (rs371128228, MAF =6.9x10-4, 17:65026851 
(C/T) MAF=2.59x10-4), and less frequent in the control cohorts. Larger sample 
sizes are essential for investigating rare variants in disease aetiology. Previous 
work has supported the view that some genetic risk factors may be common to 
different psychiatric diagnoses and other illnesses comorbid with BD [39, 145, 
463]. Contribution of a single variant to the relative risk of BD, SCZ or ADS is 
important to delineate, aiding the construction of therapeutic targets designed to 
target molecular aberrations which may result in response to variation in the 
CACNG4 gene. This variant does not explain the signal arising between CACNG4 and 
CACNG5 as previously reported by Curtis et al. as there is no LD between the fourth 
exon of CACNG4 and the associated variant (Figure 51).  
Our criteria for SNV follow up excluded a number of potential variants which can 
have functional implications. HRM analysis detected the highest number of 
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variants in the 3’UTR region of CACNAG4. Seven exonic variants were reported in 
CACNG4, of these five were synonymous mutations and two were non-
synonymous. Six variants were located in the intronic region of the gene, and nine 
variants were located in the 3’UTR. There are a number of reasons for this 
apparent burden of variants in the 3’UTR. Firstly, the 3’UTR is not under as much 
selective pressure as the exonic gene regions and secondly, the 3’UTR is longer 
than most of the other regions covered by HRM in this gene. 3’UTR variants can 
affect the stability of mRNA and protein production [464]. mRNA abnormalities 
have been recently reported in a study using induced pluripotent stem cells (iPSC) 
to derive neural lines from four related individuals, two brothers with BD and their 
unaffected parents [465]. These variants additionally provide good follow up 
candidates for further genotyping in the CACNG4 gene in psychiatric illness. 
Eight novel variants have been identified in in the protein coding region of 
CACNG5; six of these are case-only variants which are associated with both BD and 
SCZ [390]. Both of the variants in CACNG4 are located in a region of the gene 
homologous to the region in CACNG5 which also harboured case only recurrent 
variation [390].  
Substance abuse is common in individuals with psychiatric disorders. ADS and BD 
are often co-morbid. Cassidy et al., studying substance abuse histories of 392 
patients hospitalised following manic or mixed episodes of BD, report comorbid 
rates of 14-60% for drug abuse, with a higher rate of substance abuse observed in 
males with BD versus females. The rate of alcohol abuse was 59.7% in males and 
37.8% in females with BD in this study [49]. The direction of this co-morbidity is 
still uncertain. Do individuals drink because they are depressed, or does their 
depression lead to drinking? Shared underlying genetic risk factors such as these 
CACNG4 variants may explain a part of the co-morbidity seen observed in both BD 
and ADS cohorts. ADS can be classified into two different types. Alcohol 
Dependence syndrome type-1 (ADS-I), which has an equal occurrence in both 
males and females, arises from a genetic predisposition combined with external 
environmental impacts. Alcohol Dependence syndrome type-2 occurs mainly in the 
sons of fathers with ADS and is influenced weakly by environmental factors  [466]. 
There are a number of differences between the two types in both severity and  
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Figure 51. Linkage disequilibrium between CACNG5 and CACNG4. 
HapMap project linkage disequilibrium analysis (r2) between CACNG5 and CACNG4 showing the position of the case-case associated variant 
(rs17645023). Image taken from UCSC genome browser hg18 
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control of drinking. ADS-I individuals are reported to commence drinking later in life 
compared to those with ADS-II. 
However, their dependence on alcohol increases rapidly throughout their lifetime, while 
the severity of alcohol dependence recorded in ADS-II individuals remains constant. 
Characteristic personality traits of individuals with ADS-I have shown they have a 
higher tendency for harm avoidance and low novelty seeking, and their drinking is often 
linked to anxiety relief. Characteristic traits of individuals with ADS-II individuals report 
higher novelty seeking and self-reported drinking to induce euphoria [466]. While these 
characteristic are not mutually exclusive and both ADS-I and ADS-II are not discrete 
diseases or separate entities, instead they mark opposite ends of the ADS spectrum. 
These characteristics are similar to those reported in individuals with BD, and 
potentially arise due to common variation present in common neurobiological 
pathways. 
AMPA receptors are the primary means through which the CNS mediates fast post-
synaptic signalling in the brain. Members of the TARP family of proteins play an integral 
role in regulating AMPA-R trafficking and anchoring to the PSD. Variations in TARPs 
have previously shown large detrimental phenotypic effects upon knock out in mice. 
Slight variation in these genes could lead to a resulting decrease in the level of AMPA-R 
expression on the PSD. Case-only recurrent variations in genes encoding for TARPs, 
which play an integral role in synaptic transmission, suggest a role for altered 
trafficking of AMPA-R to the post-synaptic density in disease susceptibility. CACNG4 has 
been implicated in controlling the timing of synaptic transmission, in response to 
glutamate. Alterations to the transport of these receptors could affect CNS plasticity 
resulting in abnormal synaptic connectivity.  
Flow cytometry analysis was used to determine whether the CACNG4 variant, 
rs371128228, effects cell surface of the AMPA-Rs GluR1 and GluR2. Wild-type CACNG4 
appears to traffic both GluR1 and GluR2 at a similar rate to the cell surface in Hek293 
cells as no significant difference was seen in the fluorescence intensities recorded. The 
rs371128228 variant decreases the level of GluR1 surface expression, but not GluR2. 
The exact same concentration of DNA was used to transfect the cells in each of the 
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experimental replicates. The overexpression of the receptors compared to the native 
TARP/AMPA concentration in the cell would suggest that the results seen would derive 
primarily from the transfected plasmids rather than the native protein. FACs analysis 
did not allow us to compare the intracellular concentration of GluR1/GluR2 to the 
concentration of the AMPA-Rs on the cell surface. The use of the SEP tag was our only 
indicator in this experiment as to the level of the level of GluR1 or GluR2 receptors at 
the cell surface. Use of confocal microscopy and the fluorescently labelled CACNG4-
pTAG-RFP and GluR1/GluR2-SEP would help to further quantify the number of 
CACNG4/GluR1 or CACNG4/GluR2 complexes at the cell surface.  
AMPA receptor trafficking plays an integral role in the regulation of synaptic plasticity 
in the CNS. Both lithium and sodium valproate have been shown to exert effect on 
signalling cascade pathways with are known to regulate AMPA-R trafficking [467, 468]. 
Previous studies have shown that both lithium and sodium valproate attenuate the 
levels of GluR1 on the membrane surface [469]. Expression arrays have reported a 
significant increase of GRIA1, which encodes GluR1, by lithium in a mouse model 
previously (T-test p=0.0212, increase in expression=1.18) [470]. This suggests that 
other proteins involved in the trafficking of AMPA-R, such as TARP-γ4, could be affected 
by commonly used BD treatments. 
Normalised molecular abundances profiles for AMPAR-R and TARPs predict that TARP 
γ4 plays a role in inner pore complexes of AMPA-R in the thalamus Figure 52 [471]. 
Research by Schwenk et al. provides further evidence for the presence of different 
AMPA-R/TARP complexes in different brain regions. In the thalamus, GluR2 is the most 
abundant AMPA-R receptor. GluR2 is the calcium impermeable AMPA-R and is found at 
highest concentrations in all brain regions studied aside from the cerebellum and brain 
stem. During development CACNG4 is widely expressed in neurons throughout 
neuroaxis [359] and in the adult thalamus, cerebellum and olfactory bulb. Studies 
focusing on the characteristics suggest that TARP-γ4/GluR1 channels may contribute to 
calcium entry and consequent synaptic plasticity [472]. Evidence has shown that co-
expression of TARPγ4/GluR1 and TARPγ2/GluR1 significantly increases calcium and 
monovalent cation permeability’s compared to GluR1 on its own [454]. 
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Figure 52. Normalised molecular abundance of GluR’s and CACNG proteins for the inner 
core architecture of GluR’s in different brain regions 
CACNG4  is found to contribute to the inner core of GluR complexes in the thalamus 
alongside CACNG3. Image taken from [471] 
The second mutation in CACNG4 is located near to the PDZ binding domain in the γ4 
protein. The atypical TARP proteins, γ2, γ3, γ4 and γ8, contain identical PDZ- binding 
motifs at the intracellular C-terminus [473]. This region is has been proposed as the 
essential binding domain for the targeting of the AMPA-Rs to the synapse [474]. 
Strikingly, given the identical nature of the domains in all type-I TARPs, deletions in the 
C termini at the PDZ domain of both γ2 and γ8 have differences in their impact on 
AMPA-R trafficking. Compared to wild-type trafficking, the frequency and expression of 
AMPAR-mediated miniature excitatory postsynaptic currents are reduced in the 
presence of the γ2 with C-terminus deletion. The γ8 C-terminus deletion result in a 
reduced frequency of AMPAR-mediated miniature excitatory postsynaptic currents but 
the amplitude of the current remains the same as that of the wild-type γ8 protein.  
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One must be cautious of proposing putative function which might arise based on 
evidence from homologous proteins. It is evident that while domains may be conserved, 
there are still other influencing factors which need to be considered. Evidence for this 
can be seen in the example of γ3 which does not bind the Arc protein in higher 
vertebrates. Until the protein structure, and additional functional work is conducted 
into the role γ4 may have on the trafficking of AMPA-Rs to the PSD one can merely 
postulate as to how variants in the C-terminus of the protein may impact on AMPA-R 
scaffolding, or expression at the PSD. 
HRM analysis identified two rare non-synonymous variants located in functional 
regions in the CACNG4 gene. These variants are associated with a combined mentally ill 
cohort involving BD and SCZ and a cohort of ADS individuals. The CACNG4 gene encodes 
for a transmembrane AMPA receptor regulator. AMPA receptors mediated the majority 
of fast synaptic currents in the central nervous system and are important for long term 
potentiation mechanisms and synaptic plasticity. Variants in the regulators of these 
receptors could have potential knock on effects, reducing the amount of AMPA-R on the 
post-synaptic density which has been shown in this thesis and have a downstream 
effect on decreasing or increasing synaptic transmissions. 
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  Investigation of Variants in Chapter 6
Calcium Channel Genes using 
Next Generation Sequencing 
Data 
6.1 EXONIC REGIONS 
6.1.1 INTRODUCTION 
The mechanisms through which variants in calcium channel genes increase an 
individual’s susceptibility to BD have yet to be elucidated. Many of the signals from BD 
GWAS studies implicate both individual members of the L-type voltage gated calcium 
channel gene family and the calcium signalling pathway in pathway analysis [232, 239]. 
To date there has been a lack of functional variation associated with BD. Variants 
located in exonic regions which results in changes to the amino acid code may 
contribute to disease risk by resulting in aberrant protein formation and folding. 
Advances in next generation sequencing technology are enabling researchers to conduct 
high throughput genomic analysis in a shorter time scale and in a more cost effective 
manner than was previously possible. Whole genome sequencing (WGS) allows for in-
depth screening of genetic regions that may not be covered by exome capture 
techniques. Additionally, variant detection in large genetic regions using techniques 
such as Sanger sequencing or HRM analysis proves costly and time consuming to 
investigate.  
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6.1.2 HYPOTHESIS 
Rare variation in protein coding regions of calcium channel genes may disrupt calcium 
influx into cells. These variants may disrupt the calcium signalling pathway or have an 
effect on membrane depolarisation in neurons. 
6.1.3 AIM 
WGS data from 99 individuals with BD selected from the extended UCL BD cohort was 
obtained. This data was used to screen all members of the L-type family of voltage 
dependent calcium channel genes for functional variants in exonic regions which may 
be associated with BD. Variant frequencies were classed using a minus log P (MLP) 
score of >0.7 generated from a comparison of allele frequency counts from the the 99 
BD individuals against the frequency of the variant in the 1000G European cohort. The 
predicted effects of the variants were investigated using a bioinformatics approach and 
changes that were classified as deleterious were genotyped in the UCL BD and control 
cohorts. 
6.1.4 RESULTS 
Twenty six functional variants were identified from the WGS data from 99 BD 
individuals in six calcium channel genes, CACNA1D, CACNA1S, CACNA2D4, CACNB1, and 
CACNB2 (Table 31 and Table 32 ). These genes have previously been implicated in some 
manner with BD (see section 1.3.2). Pathway analysis enrichment from the cross 
disorder PGC meta-analysis, investigating shared genetic variation between MDD, BD, 
SCZ, ADHD and ASD, implicated CACNA1D, CACNA1E, CACNA1S, CACNA2D2, CACNA2D4, 
and CACNB2 [268]. CACNB2 passed the threshold for genome-wide significant in the 
primary analysis of the five disorders. Additionally, rs11013860 is associated with BD, 
p=5.15x10-5, in a Han Chinese population [244]. CACNA1D was implicated in the 
pathway analysis in the PGC BD cohort [270] and signal is observed in this gene, in the 
PGC BD GWAS. A rare deletion in a CACNA2D4 has been found in two unrelated late 
onset bipolar I patients and one control. The break points of this deletion caused the 
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removal of cache domain in the CACNA2D4 protein which is involved in small molecule 
recognition in a wide range of proteins (see section 1.3.2.3) [385]. 
For a variant to qualify for follow up genotyping in the BD cohort it needed to have a 
minus log P value (MLP) of >0.7 for the Fisher’s exact test between 99 BD subjects and 
the 1000G control cohort [287]. An MLP that only used the European cohort from the 
1000G dataset was also calculated. Polyphen2 was utilised to determine the effect the 
variants may have on protein function. In order for the variants to be considered for 
further analysis they were required to have a Polyphen2 score of greater than 0.9, 
which was indicative that they were likely to be damaging. Variant frequencies in the 
exome variant server (EVS), 1000G dataset and the UK10K dataset gathered for each 
reported variant. Variant frequencies from the PGC BD GWAS study [270] were 
reported for each variant if available. Of these variants, only one, rs3850625 in 
CACNA1S, had been previously reported in the Hap Map data on the regional association 
plots.  
Seven variants met the criteria set out above of having an MLP > 0.7 and were denoted 
as probably damaging by Polyphen2. These are listed in Table 33. One variant, located 
in CACNA1D, rs115066564, did not have an MLP >1, but was predicted as having a 
PolyPhen2 score of 1, the most detrimental prediction, and so was included in the 
follow up genotyping assay. Six of these variants had been previously reported by 
dbSNP, and two, located in CACNA1D and CACNA2D4 respectively, were novel. All eight 
variants were analysed using Project Hope (http://www.cmbi.ru.nl/hope/method) 
[461] to determine the effect the amino acid changes may have in the protein structure 
in response to the mutation. 
The CACNA1D, variant rs370024486 was predicted to produce an arginine to 
tryptophan change at position 510. This change results in the loss of the wild-type 
residue charge. The mutated residue is larger than the wild-type residue which may 
lead to bumps in the protein folding. In addition to this tryptophan is more hydrophobic 
than arginine and this can result in the loss of hydrogen bonds and may disrupt correct 
protein folding. 
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A second CACNA1D variant rs115066564 was predicted to result in the change of an 
arginine to a histidine at position 930 (R930H). The variant is located in a repeat region 
of the CACNA1D protein sequence which is involved in multimer contact as denoted by 
the Proteins, Interfaces, Structures and Assemblies (PISA)-database. The histidine 
amino acid may have a reduced ability to make multimer contact due to its size.  
The third variant from the CACNA1D gene is chr3:53837454 (G/A). This variant was 
predicted to result in the change of an aspartic acid to an asparagine at position 1834. 
Aspartic acid residues are charged, and this is changed to asparagine, a polar amino 
acid. Amino acids with polar charges may participate in hydrogen bonding and this 
could result in increased interactions with other molecules and residues. 
The final variant to be genotyped in the UCL BD and control cohort was rs373663753. 
This variant was predicted to result in the change of an arginine to a tryptophan at 
position 2145. Both amino acid residues are polar in nature and therefore this 
substitution does not lead to a change in charge. Tryptophan is a larger residue and 
more hydrophobic than arginine, this can result in the loss of hydrogen bonds and 
disturb protein folding. 
The CACN2D4 variant, chr12:1963138 (G/T) results in an alanine to valine change at 
position 849 in the amino acid code. These two amino acids are very similar and do not 
result in a change to the charge of the amino acids. Valine is larger than alanine and 
could results in bumps in the protein structure. 
Workable genotyping assays could only be developed for four of the eight variants 
chosen for follow up genotyping. These variants were chr12:1963138 (G/T) from 
CACNA2D4 and chr3:53837454 (G/A), rs115066564 and rs373663753 from CACNA1D. 
Genotyping results are listed in Table 34. None of these variants were associated in the 
BD cohort, although three of the four genotyped variants were present in the case 
cohort only.  
The ExAC browser was used to determine variant frequency for variants which failed to 
genotype in the BD sample. The CACNA1D variant rs370024486 was present in three 
Europeans out of 4789 which had sequencing data in this region (MAF=0.0003132). It  
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Gene Name Location (hg19) 
Amino Acid 
Change 
WGS calls 
AA/Aa/aa 
MAF 
1000G 
MAF 
EUR AF MLP Eur MLP 
UK10K 
AF 
PGC 
freq 
PolyPhen2 
CACNA1D chr3:53752749 (T/G) chr3:53752749 S507A 98/1/0 0.005 0 0 1.08 0.7  0   Benign 0.219 
  rs370024486 chr3:53752758 R510W 98/1/0 0.005 0.000 0 1.08 0.7  0   Probably Damaging 0.963 
  rs115066564 chr3:53769508 R930H 98/1/0 0.005 0.001 0.003 0.63 0.31  0   Probably Damaging 1.0 
  rs146892408 chr3:53783341 I1121V 98/1/0 0.005 0 0 1.08 0.7  0   Benign 0.001 
  chr3:53837454 (G/A) chr3:53837454 D1834N 98/1/0 0.005 0 0 1.08 0.7  0   Possibly Damaging 0.903 
  rs141581705 chr3:53844126 T2018N 98/1/0 0.005 0 0 1.08 0.7 0.0011   Possibly Damaging 0.942 
  rs373663753 chr3:53845320 R2145W 98/1/0 0.005 0 0 1.08 0.7  0   Probably Damaging 0.990 
CACNA1S rs149547196 chr1:201009066 P1820S 98/1/0 0.005 0.001 0.001 0.63 0.44 0.005   Benign 0 
  rs13374149 chr1:201012484 R1639H 86/13/0 0.065 0.089 0.060 -0.61 0.11 0.043   Benign 0 
  rs3850625 chr1:201016296 R1520C 82/16/1 0.090 0.071 0.120 0.49 -0.64 0.124 0.1019 Possibly Damaging 0.85 
  rs145910245 chr1:201020165 T1335S 97/2/0 0.010 0.001 0.001 1.43 0.98 0.004   Benign 0.09 
  rs147112322 chr1:201042735 T700M 98/1/0 0.005 0 0.000 1.08 0.7 0.000   Benign 0.001 
  rs35534614 chr1:201058513 G258D 97/2/0 0.010 0.005 0.010 0.52 -0.2 0.016   Probably Damaging 0.992 
  rs12406479 chr1:201079344 A69G 89/9/1 0.055 0.023 0.050 2.23 0.1 0.052   Possibly Damaging 0.874 
  rs556751671 chr1:201081375 L31F 98/1/0 0.005 0 0 1.08 0.7 0.000   Probably Damaging 1.0 
Table 31. Non-synonymous SNVs in CACNA1S and CACNA1D from whole genome sequencing of 99 BD samples.  
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Gene Variant Location (hg19) 
Amino 
Acid 
Change 
WGS calls 
AA/Aa/aa 
MAF 
1000G 
MAF 
EUR AF MLP Eur MLP 
UK10K 
AF 
PGC 
freq 
PolyPhen2 
CACNA2D4 rs61741336 chr12:1906632 P117L 96/3/0 0.015 0 0 3.23 2.09  0   Benign 0.93 
  rs55971855 chr12:1908849 F143S 98/1/0 0.005 0.004 0.010 0.23 -0.37  0   
Possibly Damaging 
0.932 
  rs62621429 chr12:1910786 D223N 91/8/0 0.04 0.017 0.030 1.53 0.31 0.028   
Probably Damaging 
0.96 
  12:1949941(G/T) chr12:1949941 A300S 98/1/0 0.005 0 0 1.08 0.7 0   Benign 0.021 
  12:1963138 (C/T) chr12:1963138 A839V 98/1/0 0.005 0 0 1.08 0.7 0.001   
Possibly Damaging 
0.816 
  rs10735005 chr12:1995403 I813V 1/22/76 0.88 0.927 0.850 -1.79 0.54 0   Benign 0 
CACNAB1 rs199798694   chr17:37331645 G67V 97/2/0 0.01 0.002 0.01 0.96 -0.2 0.006   
Possibly Damaging 
0.838 
CACNB2 10:18789795 (G/A) chr10:18789795 G115R 98/1/0 0.005 0.000 0 1.08 0.7 0   Probably Damaging 1.0 
  rs143326262 chr10:18828181 T448I 98/1/0 0.005 0.001 0 0.63 0.7 0.004   Benign 0.36  
  rs61733968 chr10:18828486 R550G 92/7/0 0.035 0.007 0.02 2.28 0.78 0.019   
Probably Damaging 
0.958 
Table 32. Non-synonymous SNVs in CACNA2D4, CACNB1 and CACNB2 from whole genome sequencing of 99 BD samples.  
WGS, Whole Genome Sequencing; MAF, minor allele frequency; EUR, European; AF, Allele Frequency; MLP, Minus Log P. 
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Gene Variant Location (hg19) 
Amino Acid 
Change 
WGS calls 
AA/Aa/aa 
MAF 
1000G 
MAF 
EUR 
AF 
MLP 
Eur 
MLP 
UK10K 
AF 
PGC 
freq 
PolyPhen2 
CACNA1D  rs370024486 chr3:53752758 R510W 98/1/0 0.005 0 0 1.08 0.7     Probably Damaging 0.963 
  rs115066564 chr3:53769508 R931H 98/1/0 0.005 0.001 0.003 0.63 0.31     Probably Damaging 1.0 
  3:53837454 (G/A) chr3:53837454 D1834N 98/1/0 0.005 0 0 1.08 0.7     Possibly Damaging 0.903 
  rs373663753 chr3:53845320 R2145W 98/1/0 0.005 0 0 1.08 0.7     Probably Damaging 0.99 
 CACNA1S rs147112322 chr1:201042735 T700M 98/1/0 0.005 0 0 1.080 0.7 0   Probably Damaging 1.0 
  rs556751671 chr1:201081375 L31F 98/1/0 0.005 0 0 1.080 0.7 0   Probably Damaging 1.0 
 CACNA2D4 12:1963138 (G/T) chr12:1963138 A397V 98/1/0 0.005 0 0 1.080 0.7 0.001   Possibly Damaging 0.816 
 CACNB2 rs61733968 chr10:18828486 R550G 92/7/0 0.035 0.007 0.02 2.28 0.78 0.019   Probably Damaging 0.96 
Table 33. Variants from WGS for follow up genotyping.  
WGS, Whole Genome Sequencing, MAF, minor allele frequency, EUR, European, AF, Allele Frequency, MLP, Minus Log P. 
  
 
 
2
1
2
 
Gene Variant Location (hg19) Amino Acid 
Change 
EUR AF Cohort Sample 
number 
Genotype calls 
AA/Aa/aa 
MAF P Fishers 
Exact 
OR (95% CI) 
CACNA2D4 12:1963138 (G/T) chr12:1963138 A741V 0 BD 1900 1899/1/0 0.0003 0.80 0.65 0.703 (0.04-11.24) 
Control 1335 1334/1/0 0.0004 
CACNA1D rs115066564 chr3:53769508 R931H 0.001 BD 1894 1891/3/0 0.0008 0.51 0.47 2.1 (0.22-20.2) 
     Control 1321 1321/0/0 -    
 3:53837454 (G/A) chr3:53837454 D1837N 0 BD 1895 1894/1/0 0.0003 0.40 1.00 - 
 Control 1321 1321/0/0 - 
 rs373663753 chr3:53845320 R2145W 0 BD 1894 1893/1/0 0.0003 0.40 1.00 - 
 Control 1322 1321/0/0 - 
Table 34. Genotyping results for calcium channel variants detected by WGS. 
 WGS, Whole Genome Sequencing, MAF, minor allele frequency, EUR, European, AF, Allele Frequency, MLP, Minus Log P. 
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was additionally present in one individual from the Finnish European sample of 40 
individuals (MAF=0.012). The CACNA1S variant rs147112322 was present in 22 
individuals in the ExAC data. Thirteen of these were present in the European (Non- 
Finnish) population from 33370 individuals (MAF=0.0001948), five were present 
in the Latino population of 5789 individuals (MAF=0.0004319), and the remaining 
four individuals were spread amongst the remaining populations. The second 
CACNA1S variant which failed to genotype in our sample was present on the ExAC 
database in eight individuals. Seven of these were in the European (Non-Finnish) 
population of 33360 samples (MAF=0.0001049) and one individual in the Latino 
population of 5788 individuals (MAF=8.64x10-5). The CACNB2 variant was by far 
the most common variant it was present in 968 individuals in the European (Non-
Finnish) (MAF=0.01452) sample, 31, European (Finnish) (MAF=0.0047), 48 
Latinos (MAF=0.0041), 33 Africans (MAF=0.0032) and 30 South Asians 
(MAF=0.0018). 
6.1.5 DISCUSSION 
WGS identified twenty six variants in the L-type family of calcium channel genes in 
99 individuals with BD. Fifteen of these variants reached the cut off rate of an 
MLP>0.7. Seven variants were classified as deleterious by Polyphen2. A final 
variant, present in CACNA1D (Eur MLP= 0.31), was predicted to have a deleterious 
score of 1 by Polyphen2 and was included in the analysis. The most common 
variants found by WGS in the calcium channel gene protein coding regions were 
deleterious variants with MLP scores >0.7 (34.6%), the next common were benign 
variants with MLP scores >0.7 (26.9%). Deleterious variants with MLP<0.7 
comprised 23.1% of the total variants reported and benign variants were the least 
commonly reported variants (15.4%). 
None of the variants showed an association with BD in the UCL sample. The 
CACNA2D4 12:1963138 (G/T) variant had a lower MAF in the genotyped cohort 
than the WGS data as it was present in one individual with BD and one control 
sample. CACNA1D variant 3:53837454 (G/A) was not present in any of the healthy 
volunteers and was present in one individual with BD. rs115066564 was present in 
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three individuals with BD and present in one healthy control. Finally, variant 
rs373663753 was present in one individual with BD and no control individuals.  
There are a number of limitations which may influence the potential to infer 
association with rare variants in our sample. One of the main issues is the sample 
size here is underpowered for the detection of ultra-rare variants in the genome.  
It is apparent from this study that WGS is capable of identifying variants with low 
allele frequencies. All three of the variants in CACNA1D are case only variants and 
it may suggest a role for a burden of rare variants in this gene which may in turn 
increase an individual’s risk of BD. Four of the seven non-synonymous variants in 
the CACNA1D gene were predicted to be deleterious. Ament et al. [292] have 
reported the presence of 19 rare variants in the coding region of the CACNA1D 
gene [292]. This data came from WGS of 3,014 European individuals with BD and 
1,717 healthy controls. There was not a significant burden of rare variants in the 
coding region here. CACNA1D is a large gene, encoding a protein 2,161 amino acids 
long (http://www.uniprot.org/uniprot/Q01668). In contrast, six SNVs were 
reported for the coding regions of CACNA1C a protein of similar length (2,221 
amino acids) suggesting a higher prevalence of rare variation in the CACNA1D 
gene. No variants in CACNA1D have shown association with the UCL BD cohort in 
this study. 
In an attempt to refine allelic frequencies of each genotyped variant the EXac 
database was utilised (http://exac.broadinstitute.org/). The EXac database was 
used to determine variant frequency in other populations, as a comparison to the 
variants frequency found in the UCL BD cohort. The CACNA1D variant, 
rs115066564, was present in three individuals with BD and one healthy control in 
the UCL sample. In the EXac database this variant is present in 19 individuals of 
8255 (South Asian ancestry), 30 out of 33164 Europeans. This variant has a 
frequency of 4.5x10-4 in the European EXac cohort compared to 8x10-4 in the UCL 
BD cohort. The second variant 3:53837454 (G/A) has a frequency of 1.5x10-5 in the 
European EXac cohort compared to a frequency of 3x10-3 in the UCL BD cohort. 
Variant rs373663753 had a frequency of 1.5x10-5 in the European EXac cohort 
compared to 3x10-3 in the UCL BD cohort. The CACNA2D4 variant was present in 
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two individuals in the European cohort, an allelic frequency 3.312x10-5, compared 
to 3x10-4 in the UCL BD cases and 4x10-4 in the UCL controls 
Use of the ExAC database allows for the validation of variant calls in addition to 
comparison of variant frequencies. For example, while the variant rs115066564 
has a higher frequency in the UCL case cohort compared to the European control 
population, it also has a frequency of 1x10-3 in the South Asian cohort. Variants 
which failed to genotype in the UCL cohort were screened in the ExAC database to 
ensure their validity. All variants chosen for genotyping were present on this 
database.  
WGS provides a powerful tool for uncovering rare variation in the genome which 
has been previously missed by GWAS studies. Our model for variant investigation 
selected rare variants which were defined as deleterious in nature for a follow up 
in the UCL BD cohort. These variants did not show an association with BD. The use 
of the EXaC European cohort data have shown that three of the variants 
successfully genotyped here have higher frequencies in the BD cohort. This is in 
addition to the fact that there are cohorts of individuals with BD, SCZ and MDD 
included in the EXaC sample. The final variant from CACNA2D4 has a higher 
frequency in the UCL case cohort, but it is also present in the UCL control cohort. 
6.2 INTRONIC VARIANTS 
6.2.1 INTRODUCTION 
CACNA1C has been repeatedly implicated through GWAS as having an association 
with BD. In CACNA1C the strongest association signal is seen in the third intron of 
the gene with the markers rs1006737 (p=7.0×10-8) [232, 233], rs4765913 
(p=1.52×10-8) [232], rs4765914 (p=1.52x10-8) [268] and rs1024582 (p=1.7×10-7) 
[270]. The third intron of CACNA1C is approximately 300kb in length and contains 
a chromosomal region with high levels of linkage disequilibrium (LD), strong 
mammalian conservation and multiple ENCODE marked regions (Figure 53). These 
ENCODE designated sites are of particular importance as they are putative regions 
of gene expression regulation. The marker with the strongest association is  
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Figure 53. Linkage Disequilibrium in the third intron of CACNA1C. 
In the third intron of CACNA1C there exists a large region of LD, in which the 
rs1006737 BD associate variant lies. In this region there are high levels of histone 
marks, which indicate this region may be involved in gene expression regulation. 
(Image: UCSC genome browser hg18) 
rs1006737 (p=7.0×10-8) is located in this region in CACNA1C. The presence of this 
BD risk allele is associated with lower extraversion, trait anxiety, paranoid ideation 
and higher harm avoidance [372]. In addition to this the intronic BD risk variant 
rs1006737 may modulate amygdala function during emotional processing [373]. 
In the past, investigation of intronic variants has been hampered by the sheer size 
of genetic regions in which they are located. In addition to this, functional 
information pertaining to regulatory elements located in these areas was not 
widely available. This led to the arduous task of inferring functional effect for 
seemingly innocuous variants. The ENCODE consortium has provided researchers 
with a means to investigating specific effects of variants based on putative 
regulatory functions (see section 1.4.2) [475]. 
The National Human Genome Resources Institute (NHGRI) has a catalogue of all 
SNPs found by GWAS. Approximately 93% of SNP-phenotype associations lie in 
non-coding regions [399], making it difficult for researchers to imply biological 
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functioning. Novel SNPs found using the ENCODE methods show strong 
enrichment for GWAS disease associations. Maurano et al. have looked at the 
localisation of disease associated variants and their results show that 76.6% of 
these non-coding GWAS SNPs are present in DNAse I hypersensitivity sites (2931 
SNPs) or are in complete LD (r2=1) with SNPs in neighbouring DHS [399]. 
Individual analysis showed enrichment of GWAS variants in transcription factor 
binding sites modulated chromatin structure, as previously mentioned.  
The data from the ENCODE project can be used to define variants in intronic 
regions that may have an impact on the regulation of gene expression or 
transcription.  
6.2.2 AIMS 
The primary aim of this study was to interrogate whole genome sequencing (WGS) 
data from 99 individuals with BD to discern variants that may be involved in BD. 
The third intron of CACNA1C, chr12:2,230,353-2,559,413, was screened using WGS 
data, for variants located in conserved putative regulatory regions as denoted by 
ENCODE [392], which may also contribute to the risk of an individual developing 
BD during their lifetime. 
6.2.3 HYPOTHESIS 
The association signal in the third intron of CACNA1C may be arising from variants 
changing regulatory regions which exert control over gene expression. The 
chromosomal region displaying strong mammalian conservation may be indicative 
of a region which is important for gene transcription control as intronic regions do 
not contribute to the protein code, and are not normally under strong 
conservation. The other introns in CACNA1C do not display the same amount of 
conservation or contain as many ENCODE marks as intron three. Conserved 
intronic regions may be indicators of regions in the chromosome where regulatory 
elements are located. Changes to these regions may not have as detrimental an 
effect as those seen in protein coding regions, but may be strong enough to ensure 
that conservation of the base occurs. Alterations to the regulation of gene 
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expression may result in the excesses or reduced production of the native protein. 
These characteristics, combined with the evidence from previous BD GWAS 
studies, make this chromosomal region one of interest in the search for variants 
which may contribute to the onset of BD in patients. 
6.2.4 RESULTS 
Next generation sequencing identified a total of 133 variants located in the third 
intron of CACNA1C. The variants in the third intron of CACNA1C were selected for 
genotyping in the expanded BD case control cohort if they met the following four 
criteria as described in 3.3.3. From the 133 variants, eight variants met the 
specified criteria and these are listed in Table 35. The CACNA1C intron 3 variants 
rs146482058, rs79398153, rs191953785, rs112312080, rs35469670, 12:2329069 
(GG/TGG) and 12:2423175 (G/C) were present in the region of high LD between 
chr12:2,230,353-2,559,413 and each variant was in an ENCODE region [392]. All 
eight SNV regions are marked by H3K4me1, H3Kme3, and H3K27ac and active 
transcriptional enhancers with distinct chromatin signatures [401]. Enrichment 
for H3K4me1 and H3K27ac at a genetic level distinguishes active enhancers from 
inactive or poised enhancers [476, 477]. The presence of H3K4me1 and H3K27ac 
marked chromatin, with low levels of H3K4me3 and an absence of another histone 
marker, H3K27me3 represent putative human embryonic stem cell (hESC) 
enhancers and have been shown to localise proximally to genes that are expressed 
during development in hESCs and in epiblast cells [477]. Additionally, 
rs112312080 and 12:2423175 (G/C) were found to be present on (DHSs) as listed 
by the ENCODE project. 
Of the SNVs found in the intronic region, rs79398153 was found to be associated 
with BD (Fishers exact test p=0.015). Eighty-eight heterozygote and three 
homozygote cases and fourty-four heterozygote controls were detected for this 
variant. The excess of homozygotes may represent a recessive effect, since only 
one homozygote would be expected under HWE, but this excess is not statistically 
significant [478]. None of the other intronic CACNA1C SNPs were associated with 
BD. Imputation was used to determine for rs79398153 in UCL1 cohort using GWAS 
data showed that it was still significantly associated with BD (P=0.022) [239]. 
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rs79398153 is located in an ENCODE marked region for H3K4me1, H3K27ac and 
H3Kme3. GWAS data from the UCL cohort is only available for the first 506 BD-I 
samples recruited  
Pairwise linkage disequilibrium analysis of CACNA1C intron three SNP rs79398153 
with the top four BD GWAS associated variants, rs1006737 [232], rs4765913 
[232], rs476590 [479], and rs4765914 [268], were performed (Table 36). This 
analysis also found no evidence to suggest that the predicted alleles and 
haplotypes associated with BD in the previous GWAS were in the same haplotypes 
as the rare BD associated variant (Table 36). The D’ scores for each of the 
individual SNP comparisons seems to suggest high heritability between 
rs79398153 and each of the SNPs. However, the r2 estimates for each of the SNV LD 
analysis range from 0.014-0.032. This can be attributed to the fact that the MAF of 
rs79398153 in our cohort was 0.032 and therefore was considerably less common 
than the GWAS significant SNPs. Thus the risk allele of rs79398153 is unlikely to 
be a proxy for the risk alleles of the GWAS SNPs. 
 Another intronic variant, rs116947827, located 105bp upstream of rs79398153 
was in complete LD in the whole genome sequencing data from the 99 individuals 
with BD. This variant did not fit the criteria for genotyping in the BD sample as it 
was located in a repeat region and was not under conservation, having a negative 
GERP score of -6.69. The ENSEMBL (http://www.ensembl.org/index.html) 
database was used to calculate linkage disequilibrium scores for both rs79398153 
and rs116947827 and the 1000G calls. MAFs in the 1000G data differ in the 
summary analysis of all populations, rs79398153 (MAF=0.02), and rs116947827 
(MAF=0.01). Upon further investigation of the data however, the variants have the 
same MAF in all European populations. The T allele is not observed in the Finnish 
population however (Table 38). We postulated that the presence of these variants 
may have a detrimental effect on the regulation gene expression. 
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Variant 
Location 
(hg19) 
MLP 
Eur 
MLP 
GERP 
scores 
Indel/ 
CNV 
Repeat 
Region 
1000G 
MAF 
Encode Region 
rs146482058 chr12:2403077 10.85 7.03 0.61 - - 0 H3K4Me1, H3K4Me3 and H3K27Ac marks 
rs79398153 chr12:2295156 1.57 2.16 0.12 - - 0.01 
High H3K4Me1 marks and H3K4Me3 and 
H3K27Ac marks, Human mRNA 
12:2272007 (C/T) chr12:2272007 3.23 2.09 0.19 - - 0 H3K4Me1, H3K4Me3 and H3K27Ac marks 
rs191953785 chr12:2425097 2.29 2.09 2.32 - - 0 
H3K4Me1, H3K4Me3 and H3K27Ac marks, 
DNAse hypersensitivity cluster marks 
rs112312080 chr12:2354510 2.02 1.56 0.72 - - 0.001 
H3K4Me1, H3K4Me3 and H3K27Ac marks, 
Human mRNA 
rs35469670 chr12:2292743 2.15 1.39 0.45 - - 0 
H3K4Me1, H3K4Me3 and H3K27Ac marks, 
Human mRNA 
12: 2329069 
(GG/TGG) 
chr12:2329069 2.15 1.39 1.17 - - 0 
H3K4Me1, H3K4Me3 and H3K27Ac marks, 
Human mRNA 
12: 2423175 (G/C) chr12:2423175 2.15 1.39 1.98 - - 0 
H3K4Me1, H3K4Me3 and H3K27Ac marks, 
DNAse hypersensitivity cluster marks, Human 
mRNA 
Table 35. CACNA1C intronic variants matching study criteria. 
MLP, minus log P value; GERP, genomic rate profiling score; Indel, insertion/deletion; CNV, Copy Number Variation. 
Gene Marker 1 Marker 2 D' r
2
 LOD 
CACNA1C rs79398153 rs1006737 0.754 0.016 1.06 
 rs79398153 rs1024582 0.729 0.014 0.87 
 rs79398153 rs4765913 0.822 0.029 2.12 
 rs79398153 rs4765914 0.829 0.032 2.31 
Table 36. Pairwise linkage disequilibrium analysis between the BD associated SNP reported here and previous GWAS SNPs. 
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Gene Variant Location 
(hg19) 
Amino 
Acid 
Change 
Eur 
1000G 
MAF 
Cohort Sample 
number 
Genotype 
calls 
AA/Aa/aa 
MAF P Fishers 
Exact 
OR (95% CI) 
CACNA1C rs146482058 chr12:2403077 -/T 0 BD 1486 1322/134/3 0.048 0.642 0.306 0.94 (0.7-1.2) 
  Control 1022 922/96/4 0.051 
  rs79398153 chr12:2295156 C/T 0.016 BD 1498 1380/88/3 0.032 0.025 0.015 1.511 (1.1-2.1) 
  Control 1029 985/44/0/ 0.021 
  12:2272007 (C/T) chr12:2272007 C/T 0 BD 1503 1465/10/1 0.004 0.746 0.495 1.167 (0.5-2.9) 
  Control 1004 998/5/1 0.003 
  rs.191953785 chr12:2425097 C/T 0.009 BD 1475 1450/25/0 0.008 0.637 0.339 0.868 (0.5-1.6) 
  Control 1020 1005/20/0 0.010 
  rs112312080 chr12:2354510 C/T 0.0014 BD 1501 1439/35/0 0.012 0.474 0.298 1.223 (0.7-2.1) 
  Control 1023 1008/20/0 0.010 
  rs3546970 chr12:2292743 -/C 0 BD 1497 1394/76/0 0.026 0.317 0.194 1.211 (0.8-1.8) 
  Control 1026 982/44/0 0.021 
  12:2329069 (G/T) chr12:2329069 G/T 0 BD 1498 1457/14/0 0.005 0.642 0.428 1.229 (0.5-2.9) 
  Control 1033 1024/8/0 0.004 
  12:2423175 (-/T) chr12:2423175 -/T 0 BD 1502 1471/4/0 0.001 0.339 0.336 2.785 (.3-24.9) 
  Control 1026 1025/1/0 0.001 
Table 37. Tests of association with CACNA1C intronic variants with BD. 
EUR, European, MAF, minor allele frequency, AF, Allele Frequency, MLP, Minus Log P, OR, Odds Ratio. 
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Online software PROMO (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo) was 
used to determine whether the presence of either rs79398153 or rs116947827 
variants resulted in the gain or loss of any TFBS. This analysis was conducted on 
the region of the CACNA1C intron, chr12:2,295,005-chr12:2,295,733, which 
incorporates both variants. Each of the variants were analysed on their own and in 
the presence of the other variant. Neither of the variants causes the loss of a TFBS, 
but rather both SNVs result in the creation two new TFBS as shown in Figure 54. In 
the presence of rs116947827 alone, PROMO reports the creation of a Yin Yang 1 
(YY1) TFBS, and when rs79398153 is present for the analysis a c-Ets-168 TFBS is 
present. For rs79398153 the same two TFBS, XBP-1 and YY1, are reported for both 
the variant alone and in conjunction with rs116947827. PROMO predicted that in 
addition to the creation of four new TFBS, 103 other TFBS were reported from this 
region when both SNVs were analysed. The additional TFBS are not located in the 
region of the variants, but span the entire length of the genomic region and are 
listed in Table 39. This suggests that the genetic region where these variants are 
located could function as enhancers of gene transcription. Enhancers function 
through the binding of transcription factors such as YY1. 
The creation of the same YY1 TFBS approximately 100bp apart could influence the 
regulation of gene expression. The YY1 TF is a member of a zinc finger protein 
family, GLI-Kruppel, which is ubiquitously expressed throughout the human body 
YY1 TF play a role in both repression and activation of a wide variety of promoters. 
Tethering of YY1 to the histone deacetylase protein, HDAC3 and HDAC2, result in 
transcription repression through histone deactylase activity [441, 442].  
Changes to the mRNA secondary structure can impact the bio-synthesis of proteins 
produced through effects on translation [480-482]. A number of different studies 
have identified mRNA sequences in brain tissue with homology to the third intron 
of CACNA1C region (chr12:2295005-chr12:2295733) and these are described in 
Table 40. These mRNA sequences have been found in the cerebellum and 
hippocampus from both foetal and adult brain tissue. Changes to the mRNA 
structure can be a major factor in the regulation of gene expression. mRNA 
structure prediction software RNAfold (http://rna.tbi.univie.ac.at/cgi-
bin/RNAfold.cgi) was used to investigate whether rs79398153 and rs116947827 
induce spatial changes to the secondary structure of the mRNA strand.  
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Figure 54. PROMO transcription factor binding site predictions for CACNA1C 
intronic variants. 
The TFBS highlighted in green indicate new TFBS are predicted to occur in the 
presence of the new altered alleles by PROMO software. In the presence of mutant 
T alleles, rs79398153 and rs11947827, four new transcription factor binding sites 
are created. Two of these are YY1 transcription factor binding sites  
rs79398153 (C/T) 
Wildtype C 
cagccaggg caCggatcgt ttcctggccg 
  =====  GR-alpha [T00337] 
     ==== === Pax-5 [T00070] 
     ==== === p53 [T00671] 
            ====== TFII-I [T00824] 
  
                 
Mutation T 
cagccaggg caTggatcgt ttcctggccg 
  =====  GR-alpha [T00337] 
     ==== === Pax-5 [T00070] 
     ==== === p53 [T00671] 
     ==== == XBP-1 [T00902] 
          ==== YY1 [T00915] 
            ====== TFII-I [T00824] 
  
  
rs116947827 (C/T) 
Wildtype C 
tgcctccac taCgggctgt ggtttttgg 
====== AP-2alphaA [T00035] 
 ===== GR-alpha [T00337] 
            ======= Pax-5 [T00070] 
            ======= p53 [T00671] 
                     ======== NFI/CTF [T00094] 
  
  
Mutation T 
tgcctccac taTgggctgt ggtttttgg 
====== AP-2alphaA [T00035] 
 ===== GR-alpha [T00337] 
          ==== YY1 [T00915] 
            ======= Pax-5 [T00070] 
            ======= p53 [T00671] 
            ========= = c-Ets-16 8 [T00115] 
                     ======== NFI/CTF [T00094] 
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Population 
rs79398153 rs116947827 
Allele C Allele T Allele C Allele T 
All Populations 0.98 0.02 0.99 0.01 
     
All African 1.00 
 
1.00 
 
Americans with African 
ancestry 
1.00 
 
1.00 
 
Luhya 1.00 
 
1.00 
 
Yoruba 1.00 
 
1.00 
 
     
All American 0.95 0.05 0.99 0.01 
Colombian 0.98 0.02 0.99 0.01 
Mexian Ancestry 0.90 0.10 0.99 0.01 
Puerto Ricans 0.96 0.04 0.99 0.01 
     
All Asian 0.99 0.01 1.00 
 
Han Chinese 1.00 0.01 1.00 
 
Southern Han Chinese 0.99 0.02 1.00 
 
Japanese 0.99 0.01 1.00 
 
     
All European 0.99 0.01 0.99 0.01 
Utah Residents northern 
and western European 
ancestry 
0.99 0.01 0.99 0.01 
Finnish 1.00 
 
1.00 
 
British 0.98 0.02 0.98 0.02 
Iberian 0.93 0.07 0.93 0.07 
Tuscan 0.99 0.01 0.99 0.01 
Table 38. Allele frequencies from 1000G dataset for rs79398153 and 
rs116947827. 
 The 1000G data set has information regarding SNP frequencies from a number of 
different populations. For the European populations both SNPs are in complete LD. 
The variant is not present in the African population cohort and has different allele 
frequencies in the Asian and American Populations. 
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The prediction of mRNA structure is conducted using minimum free energy (MFE) 
modelling [483-485]. This is based on the theory that molecule will fold into the 
lowest energy state. RNAfold uses both MFE predictions (Figure 55) and centroid 
folding predictions (Figure 56) [486]. A mountain plot representation of the MFE 
structure, the centroid structure and the thermodynamic structure ensemble of the 
RNA structures alongside the entropy for each base pair is provided for the 
CACNA1C intron 3 variants (see Figure 57). MFE structure predictions show very 
little difference between the wild-type mRNA structure (MFE=-288.40), 
rs79398153 (MFE=-288.30) and rs116947827 (MFE=-288.80). The presence of 
rs79398153 results in the prediction of stronger binding and an extra loop in the 
top part of the mRNA structure compared to the wild-type. The predicted mRNA 
structure of rs116947827 shows additional branching occurring in addition to the 
loss of some of the RNA loops. While the structural changes are quite pronounced, 
there was not a reflective change in the MFE value. When both variants are 
present, there was a slightly higher predicted MFE value (MFE=-291.40). In the 
double mutant mRNA structure, rs79398153 branching patterns take precedent 
over the branching pattern from rs116947827. This is a result of the predicted 
binding strength for rs7938153 which is stronger than that predicted in the 
rs116947827 structure. 
Centroid structural predictions are RNA secondary structures which have minimal 
base pair distances to all secondary structures in the Boltzmann ensemble. 
Centroid structure predictions display greater structural changes, as shown in 
Figure 56, than the MFE structural prediction. Minimum free energy predictions 
are also provided by RNAfold for the wild-type (MFE=-221.80), rs79398153 
(MFE=234.40), rs116947827 (MFE=-206.20) and double mutant (MFE=-187.70) 
centroid structures. Distinct branch changes can be seen between rs7938153 and 
the wild-type. This reflects the change which is also observed in the MFE mRNA 
structures. Unlike the MFE mRNA predictions, the presence of both variants in the 
centroid structure predictions shows an entirely new loop structure. The double 
mutant structure has a much lower MFE value than that seen in the wild-type, 
rs79398153 or rs116947827. Subsequently the mountain plots and positional 
entropy for each position show differences for the double mutant structures Figure 
57. These changes to the mRNA structure predictions provide some evidence that 
the presence of these SNVs together may impact on gene expression.  
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TFBS Number 
 AP-2  2 
 C/EBPalpha  1 
 C/EBPalpha  2 
 C/EBPbeta  1 
 CAC-binding protein  6 
 c-Ets-1  2 
 c-Ets-1 68  3 
 c-Jun  7 
 c-Jun  3 
 Crx  1 
 Egr-1  1 
 Egr-3  1 
 Elk-1  1 
 GR  2 
 HNF-1A  8 
 HNF-4alpha  1 
 HNF-4alpha1  3 
 HNF-4alpha2  3 
 HOXD10  1 
 HOXD10  1 
 HOXD8  4 
 HOXD8  4 
 HOXD9  1 
 HOXD9  1 
 IRF-2  2 
 IRF-2  1 
 LXR-alpha:RXR-alpha  3 
 LyF-1  3 
 MyoD  3 
 NF-1  5 
 NF-AT1  3 
 NF-Y  3 
 POU1F1a  12 
 POU1F1b  3 
 POU1F1c  3 
 SREBP-1c  1 
 TFII-I  1 
Total 103 
Table 39. TFBS predicted by PROMO when both rs79398153 and rs116947827 are 
present. 
The presence of rs79398153 and rs116947827 results in the creation of 103 new 
putative TFBS throughout the genomic region used in CACNA1C experiments. 
These TFBS are in addition to the presence of the two YY1 TFBS which are created 
at the base position where the variants are altered. 
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Human 
mRNA 
Tissue Description Study 
AB209016 Brain Homo sapiens mRNA for Voltage-
dependent L-type calcium channel alpha-
1C subunit variant protein 
Totoki et al., Database 
Submission [487] 
BC146846 Brain, 
Cerebellum 
Homo sapiens calcium channel, voltage-
dependent, L type, alpha 1C subunit, 
mRNA (cDNA clone MGC:181949 
IMAGE:9056774), complete cds. 
Starusberg et al. [488]  
AJ224873 Brain, 
Hippocampus 
Homo sapiens (HLCC105) mRNA for 
voltage-dependent L-type calcium channel 
alpha-1C subunit (splice variant). 
Soldatov [489] 
Z34812 Brain, 
Hippocampus 
H. sapiens (HLCC73) mRNA for voltage-
dependent L-type Ca channel alpha 1 
subunit (splice variant). 
Soldatov [489] 
Z34813 Brain, 
Hippocampus 
H. sapiens (HLCC74) mRNA for voltage-
dependent L-type Ca channel alpha 1 
subunit (splice variant). 
Soldatov [489] 
Z34817 Brain, 
Hippocampus 
H. sapiens (HLCC86) mRNA for voltage-
dependent L-type Ca channel alpha 1 
subunit (splice variant). 
Soldatov [489] 
Z74996 Brain, 
Hippocampus 
H. sapiens mRNA for voltage-dependent L-
type calcium channel, alpha 1C subunit 
(splice variant). 
Soldatov [489] 
Table 40. Human mRNA from brain regions from the UCSC genome browser from 
the third intron of CACNA1C. 
 
 
Figure 55. mRNA secondary structures for rs79398153 and rs116947827 
This mRNA structure prediction is based on the minimum free energy (MFE) 
values which are list for each underneath each structure. 
Wildtype rs79398153 rs116947827 Double mutant 
-288.80 -291.40 -288.40 -288.30 
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Figure 56. mRNA centroid structural predictions of variants rs79398153 and 
rs116947827. 
 
Figure 57. mRNA secondary structures for rs79398153 and rs116947827. 
 
Wildtype rs79398153 rs116947827 Double mutant 
-206.20 -187.70 -221.80 -234.40 
Wildtype rs79398153 
rs116947827 Double mutant 
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6.2.4.1 EFFECT OF RS79398153 AND RS116947827 ON LUCIFERASE EXPRESSION 
The ability of rs79398153 and rs116947827 to modulate transcription regulation 
was tested using luciferase reporter gene constructs which are described in 
section 3.3.6 . Four different vectors containing the DNA sequence from the 
CACNA1C intron 3 (chr12:2295005-chr12:2295733) were created using the pgl3-
basic luciferase plasmid. The first plasmid construct contains the wild-type genetic 
sequence from this region. The second contained the mutated T allele of 
rs79398153. The third contains the mutated T allele of rs116947827 and a fourth 
plasmid, contains both mutated alleles from rs79398153 and rs116947827. The 
inserted DNA sequence was added 35bp upstream of the start codon of the 
luciferase gene. These clones tested the ability of the genetic sequence to act as a 
enhancer of luciferase reporter gene activity against the basal level of luciferase 
expression seen when no additional genetic sequence was inserted. Plasmids were 
transfected into HEK293 cells and luciferase readings were taken from lysed cells 
48 hours following transfection. A control plasmid containing no insert was also 
used to measure the basal level of luciferase expression seen in each transfection. 
No significant difference was observed in the level of luciferase expression with 
the pgl3-basic vector compared to expression levels in the wild-type and the rare T 
allele in rs79398153 and rs116947827 constructs. Additionally, no significant 
difference was observed between the wild-type sequence and the presence of the 
rare T alleles of rs79398153, and rs116947827 on their own (T-test, rs79398153 
p=0.339, rs116947827 p=0.362). A significant difference in luciferase expression 
was observed when both the rare T alleles of rs79398153 and rs116947827 were 
present in the pgl3-basic clone. There was a significant change to the level of 
luciferase expression in the presence of both allelic variants (double mutant 
p=0.002; see Figure 58). 
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Clone 
Ratio of Renilla to 
Firefly luciferase 
expression 
Standard 
Deviation 
Standard 
Error 
T-test (paired, two tailed 
distribution) 
pGL3-basic no insert 0.00051 0.00030 0.00010 0.476 
Wild-type CACNA1C 0.00057 0.00039 0.00013 NA 
rs79398153 T allele 0.00042 0.00023 0.00008 0.339 
rs116947827 T allele 0.00040 0.00034 0.00011 0.362 
Double Mutant 0.00006 0.00004 0.00001 0.002 
Table 41. Student T-test for changes in luciferase expression with CACNA1C intronic variants compared to the wild type control. 
No significant difference is observed when either of the allelic variants are present on their own. There is a significant change to the level of 
luciferase expression in the presence of both allelic variants. 
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Figure 58. Relative luciferase activity reporter gene assays for the experimental constructs in HEK293 cells.  
The Y-axis shows the mean of the renilla to firefly luciferase expression for all replications within an experiment and between experiments. Data 
expressed as mean SEM of three independent experiments performed in triplicate (n=9) **P< 0.005. 
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6.2.4.2 DNA-PROTEIN COMPLEX FORMATION BY RS79398153 AND RS116947827 VARIANTS 
PROMO analysis predicted the formation of two novel YY1 transcription factor 
binding sites 105bp from each other in the third intron of CACNA1C. Luciferase 
assay analysis showed that in the presence of both variants there was a 10-fold 
reduction in luciferase expression. The mRNA structural analysis provides 
evidence that the presence of both variants leads to changes which may influence 
gene expression through the creation of novel TFBS. Electromobility shift assay of 
the allelic variants rs79398153 (Figure 59) and rs116947827 (Figure 60) were 
conducted using nuclear cell lysate from HEK293 cells to determine whether the 
variants had a higher binding affinity or increased binding specificity to nuclear 
proteins (see section 3.3.8). 
For variant rs79398135 there was a single band in the presence of the wild type 
labelled probe and nuclear lysate (Lane 2). The band from the wild-type labelled 
probe disappeared in the presence of a 200x excess of unlabelled C probe. This was 
indicative of specific binding. In the presence of the mutated T labelled probe three 
bands were visible on the gel image (lane 5). The wild-type C unlabelled excess out 
competes the top band seen from the labelled probe at a 100x fold excess. In 
comparison the unlabelled T probe does not show as high an affinity for the 
proteins in the nuclear lysate and did not outcompete the band formed by the T-
labelled probe.  
The wild-type C allele of rs116947827 results in the formation of two bands, while 
the mutated T allele results in the formation of a stronger single band. This 
suggests that the mutated probe binds with greater affinity to one of more nuclear 
proteins. However, the 200x unlabelled T competitor probe does not result in the 
outcompeting of the labelled T probe. This may result from one of two things; 
either the binding of the labelled probe is unspecific and binds to indiscriminate 
proteins in the nuclear cell lysate which the unlabelled competitor probe may not 
target, or, the binding of the labelled competitor probe is too strong to be 
outcompeted at a concentration of 200x excess of the unlabelled competitor probe. 
This issue could be resolved by incrementally increasing the level of competitor 
probe from 200x excess up to 1000x excess. 
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This band was complete abolished in the presence of a 10x-200x excess of the 
mutated unlabelled rs116947827 T allele probe (Lane 6-10). In contrast the 
rs116947827 C allele unlabelled probe out competes the band formed by the 
labelled rs116947827 T allele probe at a 200x excess. This suggests the T allele of 
rs116947827 has a higher affinity for proteins in the nuclear cell lysate. Similar 
results were obtained in four independent experiments for each of the allelic 
variants.  
Online software PROMO (http://alggen.lsi.upc.es/cgi-bin/promo_v3/promo) 
predicted the formation of two YY1 transcription factor binding sites in the region 
of these variants. A super-shift assay was conducted which included the use of an 
antibody raised against YY1 as described in 3.3.9. These experiments were used to 
determine whether one or more of the EMSA bands was the result of probes 
binding to YY1. Binding of the antibody to the proposed transcription factor should 
result in a super shift of the observed labelled band because of the increased 
molecular weight of the antibody/transcription factor/probe complex (see Figure 
61). For rs79398153 the wild-type C allele appears to shift in the presence of the 
YY1 antibody (Lane 3). No band shift is apparent in the presence of the mutated 
allele (Lane 6). The wild-type C allele of rs116947827 shows a faint band shift in 
the presence of YY1 (lane 9); however the mutated T allele shows a stronger band 
formation and shift in the presence of YY1 (lane 12). An additional control of lane 
containing the YY1 antibody and probe for both wild-type and mutant alleles of 
rs79398153 and rs116947827 in the absence of nuclear cell lysate should have 
been added to ensure the results of these experiments were not as a result of 
artefact. Consistent results for the antibody binding were seen across four 
replicates of the each EMSA. 
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Figure 59. Electomobility shift assay for rs79398153. 
EMSAs performed with C (1-3) or T (4-15) labelled probes and HEK293 nuclear 
cell lysate. The wild-type labelled probe (C) which labels two bands (Lane 2). The 
200x excess of unlabelled C probe out competes the top band in the presence of 
the 200x unlabelled C probe (Lane 3). In contrast the T labelled probe binds three 
bands of proteins (Lane 5). The top band formed in the presence of the T labelled 
probe is not competed by the excess of T unlabelled probe suggesting unspecific 
binding or the need for a larger excess of unlabelled T probe. The top band formed 
by the T labelled probe is outcompeted by a 100x-200x excess of C-unlabelled 
probe (Lane 14-15)  
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Figure 60. Electromobility shift assay for rs116947827. 
EMSAs performed with C (1-3) or T (4-15) labelled probes and HEK293 nuclear 
cell lysate. The labelled T probe binds a single band of protein, as compared to the 
C labelled probe and nuclear cell lysate. The T labelled probe is out competed by 
the 10x unlabelled probe (lanes 6-10). The band formed in the presence of the T 
labelled probe is not competed out as effectively in the presence of the C-
unlabelled probe (lane11-15). In addition to this, the C-labelled band seen in lane 2 
is not outcompeted by the unlabelled 200x fold excess, suggesting that this binding 
is not specific.  
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Figure 61. Super shift EMSA assay of CACNA1C variants with a YY1 specfic 
antibody. 
In the presence of a YY1 specific antibody, a shift in band size is observed in lane 3, 
lane 9 and lane 12 suggesting that the anti-YY1 antibody is binding to proteins in 
the nuclear cell lysate that the labelled probe is binding to.   
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6.2.5 DISCUSSION 
Whole genome sequencing provides the ability to investigate, in depth, a wide 
range of variation present in an individual. We utilised whole genome data from 99 
individuals to investigate whether variants, located in the third region of CACNA1C 
increase an individual’s susceptibility to bipolar disorder. The presence of allelic 
changes in regulatory regions in the intron can have a downstream effect on gene 
expression and translation. The ENCODE data was utilised to define putative 
functional elements in this genetic region. 
Eight variants were selected for genotyping in the UCL cohort of BD samples and 
healthy control volunteers. Of the eight variants, one variant, rs79398153, was 
found to be associated with BD. Upon further investigation of the WGS data a 
variant 105bp upstream of rs79398153, rs116947827, was found to be in 
complete LD with rs79398153. In silico analysis using PROMO software indicates 
that these two variants individually created two YY1 TFBS.  
The ENCODE track on the UCSC genome browser shows rs79398153 as being 
located in a conserved region with high H3K4Me1 marks, H3K4Me3 and H3K27Ac 
marks. The presence of H3K4Me3 is often found close to active promoters. 
Enrichment for H3K4me1 and H3K27ac at a genetic level distinguishes active 
enhancers from inactive or poised enhancers [476, 477]. The presence of a 
combination of H3K4me1 and H3K27ac marked chromatin, with low levels of 
H3K4me3 and an absence of another histone marker, H3K27me3 is the hallmark of 
putative human embryonic stem cell (hESC) enhancers and these have been shown 
to localise proximally to genes that are expressed during development in human 
embryonic stem cells and in epiblast cells [477]. The presence of these marks 
indicates that this region may be involved in the regulation of gene expression.  
Gene expression reporter assays performed in HEK293 cells showed a significant 
decrease in the level of gene expression in the presence of both variants. It can be 
postulated that given the number of new TFBS created when both variants are 
present that transcription factors may have a higher affinity for binding this region 
and this in turn impact the regulation of CACNA1C gene expression. In addition to 
this, the presence of these variants are also purported to change mRNA structure. 
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HEK293 cells were co transfected with the pRL-SV40 and pgl3-basic vector, 
containing the region of interest, at a ratio of 1:2. Renilla expression for this assay 
is between 2000-5000 times greater than that of the firefly luciferase. As described 
in section 3.3.7 the pRL-SV40 vector contains the SV40 early enhancer and 
promoter element to ensure constitutive expression when co transfected in cells 
with any of the pGL3 vectors. The pGL3-basic vector in contrast does not contain 
any promoter elements, relying on the insertion of the potential promoter regions 
for expression of luciferase. The insertion of the CACNA1C region drives luciferase 
expression at a much lower level than that of Renilla, which is driven by the SV40 
early enhancer/promoter element.  
While the pGL3-basic vector is reported to be suitable for investigating the effect 
putative promoters and enhancer elements have on luciferase expression, the 
CACNA1C region may not be driving gene expression. Giannakis et al in 2003 have 
shown that the mere presence of a DNA insert in a reporter vector can elicit 
differences in expression compared to the empty control vector through the 
interaction of external features, such as androgens [490]. However, the reduction 
of luciferase expression in the presence of both variants was seen consistently over 
all experimental replicates. Intronic promoters have been previously described to 
drive expression of mRNA, and have been associated with diseases such as cancer 
[491]. A number of brain expressed transcripts are reported in this area of the 
CACNA1C gene (Table 40) which this sequence could be acting as a promoter of. 
The effects reported from these variants could be validated a number of ways, 
primarily through the use of an alternative reporter assay such as the pCAT3.  
Further work on the CACNA1C region should include the insertion of the genetic 
region into the pGL3-promoter vector to determine whether this region 
alternatively functions as an enhancer element. The pGL3-promoter vector 
contains the eukaryotic SV40 promoter which drives luciferase expression. The 
region of interest can then be placed either upstream or downstream of this 
promoter to determine the effect the region of interest has on enhancing 
transcription in the presence of an active promoter.  
The potential creation of new TFBSs in the presence of both BD associated variants 
was investigated using electromobility shift assays. The two variants appear to 
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have contrasting effects on binding of proteins in the nuclear cell lysate. For 
rs79398153, the wildtype C allele has a higher affinity for proteins in the nucleus 
than the rare T allele. Additionally, the rare T allele unlabelled probe fails to 
outcompete the labelled T probe, indicating less specific binding, or the need for a 
larger excess of unlabelled T probe. On the other hand, the rare T allele of 
rs116947827 has a higher affinity for binding of nuclear proteins than that of the 
wildtype C allele. The C allele does show specificity for protein binding, but a larger 
excess of unlabelled probe is needed to outcompete the band formed by the T 
labelled probe. The EMSA super shift assay shows a band super shift in the 
presence of the two alleles which have higher affinities for proteins in the nuclear 
cell lysate. These band shift, indicate that the labelled probes of the rs79398153 
wildtype C allele, and the rs116947827 rare T allele are binding to proteins tagged 
with the YY1 antibody. This is contradictory to the information provided by the 
PROMO in silico software that reports no YY1 TFBS in the wildtype CACNA1C 
intronic region. The band shifts observed in Figure 61 are quite faint, and not as 
intense as the band seen lower in the gel, or in the previous EMSA gels. It is 
possible that the YY1 antibody bound to TFBS in the nuclear proteins and that 
some of the labelled probe shared homologous sequence for this region, causing 
faint bands to be seen, rather than a total super shift of the entire band. Further 
analysis of this region is warranted to determine if there are novel TFBS formed in 
the presence of these variants. This could be done by using alternative 
programmes such as R Vista 2.0 which was not originally utilised in this study. 
This analysis has identified novel possible BD susceptibility variants in the third 
intron of CACNA1C. The rs79398153 variant appears to be acting independently of 
the allelic and haplotypic associations found in the previous BD association 
studies. Independent genetic replication and biological validation of intronic 
potentially aetiological variants would support the argument for carrying out 
whole genome sequencing as well as exome sequencing in BD. The biphasic nature 
of BD makes a compelling argument for the existence of DNA determined 
pathological switch mechanisms that may manifest themselves in the loss of 
control of gene expression. It is plausible that the creation of new transcription 
factor binding sites might lead to the manifestation of BD through environmental 
interactions with potential newly created TFBS in the intron of CACNA1C. These 
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hypothesis need to be further tested to delineate the exact manner in which these 
variants lead to an increased risk in developing BD. 
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  General Discussion Chapter 7
Bipolar disorder is a highly heritable disorder with a prevalence of 1% in the 
general population. Perturbation of Ca2+ metabolism has been strongly implicated 
in BD. Calcium channel associated genes have been repeatedly implicated in 
multiple GWAS studies and pathway analysis. At a physiological level, high levels of 
intracellular Ca2+ have been reported in a number of BD individuals in both 
platelets and lymphocytes [84, 492]. Variants in the anti-apoptotic protein B-cell 
CLL/lymphoma-2 (BCL-2) gene, which effect calcium homeostasis in the 
endoplasmic reticulum and the mitochondria, have also been associated with 
higher Ca2+ concentration levels in BD-1 lymphomas [493]. The Ca2+ signalling 
pathway is an integral cascade pathway and is the instigator of a variety of cellular 
mechanisms such as LTP in neurons and initiation of gene transcription. Many of 
these pathways are important for correct synaptic functioning. Ca2+ plays a central 
role in neurotransmitter release from the presynaptic density and several 
postsynaptic processes. Previous evidence shows that variants in the α pore of the 
calcium channel gene result in severe psychiatric illness such as Timothy 
Syndrome [363]. 
The L-type family of calcium channel genes and genes encoding other calcium 
channel subunits were investigated to determine whether DNA variation present 
in these genes contribute to the genetic risk of BD using HRM analysis and whole 
genome sequencing. This thesis focused on genetic variants which are present in 
the protein coding and regulatory region of the calcium channel genes. However, 
we also utilised whole genome sequencing data to investigate the third intron of 
CACNA1C for variants that may explain the replicated genome-wide association 
signal reported in this region [232, 261, 270]. 
Finding variants which contribute to disease risk for complex disorders is 
challenging. Common variants are likely to have small effect sizes, while variants 
with larger effect sizes are most likely to be rare in nature. Evolutionary theory 
holds that deleterious variants by default are likely to be rare due to purifying 
selection [443, 444]. The discovery sample used the HRM analysis identified both 
common and rare variants in the BD cohort. However the sample size for follow up 
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genotyping was not large enough to identify rare variants that may be associated 
with BD. 
The ability to detect an association between rare variants and a disease, is based 
on a number of factors, one is the relative risk of the variant, as estimated by 1+ λ, 
where λ is the excess relative risk of disease conferred by the allele [445]. The 
second is the sample size. Zuk et al, have determined that to detect allele 
association with a 2-fold increase to disease risk, approximately 28,000 samples 
are needed. For variants with larger relative risk scores, such as a 20-fold increase 
in relative risk, 260 cases would be needed [445]. Our study on BD was based on a 
relatively large sample size with approximately 1800 cases and 1300 controls. The 
initial sample size for the BD WGS included 99 case individuals. To identify more 
rare disease associated variants with large effect sizes larger sample sizes are 
needed. Results from studies such as the PGC-BD GWAS [270] emphasise the 
benefit of having large sample sizes, having identified eight loci passing genome-
wide significance. 
High-resolution melting curve analysis allowed for the rapid screening of the 
5’UTR, promoter region and first exon of the calcium channel genes CACNA1C, 
CACNA1D and CACNB3. This technique provided a way to screen the gene for both 
common and rare variants located in these regions. This technique did not find any 
variants associated with BD in these three genes. 
The functional and regulatory regions of the CACNG4 gene were screened in full 
using HRM analysis. This identified two non-synonymous variants, rs371128228 
which results in an arginine to glutamine change and 17:65026851 (C/T) which 
results in an arginine to tryptophan change. Both of these variants are located in 
the fourth exon of the gene. Neither variant was associated with BD alone 
(rs371128228, p=0.06, 17:65026851 (C/T) p=0.78). However, both variants were 
associated with psychiatric illness in a combined sample of approximately 37000 
controls and 8000 cases. The combined psychiatric illness sample comprised of 
1890 BD samples, 4538 SCZ samples, and 1221 individuals with ADS 
(rs371128228, p=1.05x10-4, OR=4.39, 17:65026851 (C/T) p=0.001, OR=9.52).  
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To date there have been no reports of associated variants within the CACNG4 gene. 
Variants in other members of this gene family, such as CACNG2 and CACNG5, have 
been reported to be associated with psychiatric illness. Case only variants in the 
CACNG5 gene are present in areas homologous to those harbouring the two rare 
variants in the CACNG4 gene [390]. Flow cytometry analysis into the effect of these 
variants on CACNG5 trafficking of AMPA-R to the cell surface demonstrate that 
some of the variants decrease GluR2 levels on the cell surface. 
The CACNG4 variant, rs371128228, disrupt the trafficking of GluR1 to the cell 
surface (p=0.02). Abnormal AMPA-R trafficking has been previously linked to 
several neurological disorders suggesting a possible pathogenic effect for these 
variants [494, 495]. While it is currently unclear exactly how TARPs and AMPA-R 
interact, studies suggest that TARPs interacts with AMPA-R in the ER to generate a 
facilitating receptor complex for AMPA-R exit from the ER [351, 496].  Changes in 
the TARP-γ4 protein structure could impact the efficiency or ability of the TARP to 
export the AMPA-R from the ER. Additionally the decrease of GluR1 subunits on 
the cell surface could result from an alteration to the ability of the TARP to anchor 
to the post-synaptic density. Further functional work to determine the mechanism 
of action of this variant is needed. 
Whole genome sequencing data was used to identify variants in the coding regions 
of all members of the L-Type family of calcium channel genes. This included 
CACNG4 to ensure that none of the variants had been missed using HRM analysis. 
This identified 26 non-synonymous mutations in the genes CACNA1D, CACNA1S, 
CACNA2D4, CACNB1, and CACNB2. Bioinformatic tools, PolyPhen2, and Project 
Hope, were used to determine whether these variants may be classed as 
deleterious for follow up genotyping in the UCL cohort. None of these variants 
showed an association with BD in the UCL samples. 
Our study designed an approach to investigate variants from WGS in the third 
intron of CACNA1C where the BD associated variant rs1006737 lies. We first 
examined the intron for any characteristic signatures which may indicate the 
reason for its repeated association with BD. We found there is strong LD present in 
this region in addition to high levels of conservation and high levels of histone 
marks. In general, intronic regions are not subjected to as much selective pressure 
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as that seen in exonic regions of gene. We then used the ENCODE data to determine 
whether there was a reason behind the conservation observed. For example, if this 
intronic region plays a role in regulation of gene transcription then it might explain 
the levels of conservation seen. Eight variants were identified that are located in 
putative regulatory regions as denoted by ENCODE, have allele frequencies larger 
than those seen in the 1000G European populations and in conserved regions. One 
of these variants, rs79398153, was associated in the UCL BD cohort (p=0.015, 
OR=1.511). Further investigation of the WGS data in this region identified a 
variant, rs116947827, which is in complete LD with the BD associated variants. 
Use of the ENCODE allowed for the identification of putative functional marks in 
which these variants are located.  
These variants, rs79398153 and rs116947827, decrease the level of luciferase 
expression significantly compared to the wild-type sequence (p=0.002). This 
further implicates their role in regulation of transcription. This could be through 
the creation of the YY1 transcription factor binding site. The use of the EMSA 
supershift assay shows support for binding of the YY1 antibody to proteins in the 
nuclear cell lysate. The YY1 transcription factor is ubiquitously expressed and is 
involved in either repression or activation of gene expression through the 
directing of histone deacetylases and histone acetyltransferases to promoters in 
the genome. Variants which result in the change of gene expression are hard to 
characterise. Regulatory effects can be far reaching and do not necessarily relate to 
the gene in which these regions are located. However, given the evidence for 
disrupted Ca2+ levels in individuals with BD, a decrease in the expression of the 
CACNA1C α pore may play a role in aberrant calcium influx. These variants are not 
in LD with rs1006737, and do not explain the replicated association signal 
observed at this locus. However our study shows the importance of designing 
novel approaches to characterising SNVs for genotyping and then functional follow 
up. The role these variants may have in the aetiology of BD, but perturbations to 
gene expression may have a detrimental knock-on effect further downstream. 
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7.1 STUDY  LIMITATIONS AND POTENTIAL CONFOUNDS 
HRM and whole genome sequencing methods were used for variant investigation 
both had their advantages and disadvantages. Of the 28 variants identified in 
CACNA1C, CACNA1D, CACNB3 and CACNG4 genes using HRM only five of them were 
A/T or C/G changes. The remaining 25 variants result in base changes which 
would result in the gain or loss of hydrogen bonds. These bonds play an integral 
role in the profile of the melt curve produced by the HRM software. Short genetic 
amplicon regions of 50bp or so would have increased sensitivity in detecting 
variant changes which do not result in the gain or loss of a hydrogen bond. In 
amplicons of up to 350bp in length it seems that the HRM software may not call the 
changes as accurately. HRM allowed for the screening of all BD samples in our 
cohort. The initial screening is fast and high throughput. These variants can then 
be validated through Sanger sequencing from the original DNA samples. 
The cost of HRM is significantly lower than that of WGS and allows for more 
individuals to be screened in addition to a shorter turnaround time from the 
beginning of an experiment to data collection. WGS is high throughput but cost 
implications often impede the screening of thousands of individuals. WGS allows 
for probing of the full genetic architecture underlying BD and the sequence depth 
allows for accurate quality control for base pair calls. In addition to this, regions of 
the genome which may be difficult to screen using PCR based methods can be 
investigated using WGS. 
Additionally the statistical power of single-variant based association tests for low-
frequency variants is reduced unless the sample sizes or variant effect sizes are 
very large [293]. The sample sizes for follow up genotyping in our study were not 
large enough to determine whether associations were present between rare 
variants and BD. 
The highest proportions of variants identified in the CACNG4 gene were present in 
the 3’UTR region. Variants located in the 3’UTR of CACNG4 may also play a role in 
disease susceptibility through their impact on mRNA stability in addition to the 
variants located in the fourth exon of CACNG4. These were not included in our 
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initial genotyping follow-up but could be potential candidates for further 
investigation into the role of CACNG4 in BD. 
7.2 FUTURE DIRECTIONS 
To further investigate our genetic association findings in the CACNA1C gene, 
genotyping of these variants in larger BD case-control samples is essential. 
Additionally WGS BD databases could be utilised to screen for these variants. Other 
variants in intron three of CACNA1C that did not meet the criteria in our discovery 
set could be further genotyped. The rs116947827 variant was present in a repeat 
region in the third intron of CACNA1C and did not fit the criteria for follow up 
genotyping in the UCL BD sample. However, the luciferase functional assay shows a 
decrease in gene expression only when both rs7938153 and rs116947827 are 
present.  Haplotype analysis may provide some insight into the LD structure in this 
region and further highlight variants located in functional regions.  
Further functional analysis needs to be conducted to determine how the variants 
cause the decrease in gene expression and the role of YY1 or other TFBS which are 
predicted to arise in this region. Recent reports have identified nine genes in the 
human brain which undergo recursive splicing [497]. Recursive splicing is 
reported to occurs in genes with long introns and removes the intron from the 
precursor mRNA through splicing which occurs in a step wise manner from the 5’ 
end of the intron to the 3’ end. In vertebrates long introns often contain a recursive 
splicing exon with 5’ and 3’ splice sites to aid the step wise splicing and ensuring it 
occurs in the correct step wise process. The third intron of CACNA1C is 
approximately 330kb in length which is extremely long. It is plausible that this 
intronic region contains recursive splicing exons which if variants located in these 
regions disrupted splicing in the precursor mRNA it could result in nonsense-
mediated RNA decay. 
Investigation of functional variants in CACNG4 was the first approach at identifying 
BD associated variants in this TARP in our study. Our criteria for follow up 
genotyping focused solely on protein coding variants which result in amino acid 
changes. The presence of multiple variants in the 3’UTR of the CACNG4 gene may 
247 
harbour some potential disease associated changes. Flow cytometry analysis was 
not conducted on the second BD associated variant in CACNG4. If this variant was 
to also disrupt trafficking of AMPA-Rs it would provide further evidence for the 
role of this gene in mental illness. This variant is extremely rare and would benefit 
from follow up analysis in a larger BD sample.  
There is a burden of rare case only variants in the CACNA1D gene. This gene has 
been implicated in BD through pathway and WGS sequencing analysis. Follow up 
of the variants identified in this study in larger cohorts may allow for an insight 
into the role, if any, these variants may have in risk of BD. 
Combined efforts from large consortiums in the field of psychiatric genetics have 
shown the impact collaborative efforts can have in the search for genetic variants 
contributing to BD. New analytical approaches to integrating genetic level pathway 
analysis with biological systems data is crucial in understanding the impact 
variants identified through GWAS and whole genome sequencing may have at a 
functional level. By increasing our understanding of the underlying biological 
mechanisms that lead to bipolar disorder we can provide a platform for the 
development of targeted personalised treatments, more accurate diagnosis and 
most importantly, improved quality of life for individuals suffering from bipolar 
disorder.  
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Appendix I 
  
The tables below outline the classifications of depression, mania, hypomania with 
and without psychosis as defined by the ICD-10 manual for clinical descriptions 
and diagnostic guidelines. In addition to the eight categories of bipolar disorder 
outlined below two more are present in the ICD-10, F31.8 other bipolar affective 
disorders and F31.9 Bipolar affective disorders, unspecified. These are not 
included in the table as there are no symptom guidelines for these subtypes. 
 
 
2
7
5
 
F30.0 Hypomania F30.1 Mania without psychotic symptoms F30.2 Mania with psychotic symptoms 
A.The mood is elevated or irritable to a 
degree that is definitely abnormal for the 
individual concerned and sustained for at 
least four consecutive days.  
A. A mood which is predominantly elevated, 
expansive or irritable and definitely abnormal for 
the individual concerned. This mood change must 
be prominent and sustained for at least a week 
(unless it is severe enough to require hospital 
admission).  
A. The episode meets the criteria for mania 
without psychotic symptoms (F30.1) 
B. The episode does not simultaneously 
meet the criteria for schizophrenia (F20) or 
schizo-affective disorder, manic type 
(F25.0).  
B. At least three of the following must be 
present, leading to some interference with 
personal functioning in daily living:  
B. At least three of the following must be present 
(four if the mood is merely irritable), leading to 
severe interference with personal functioning in 
daily living: 
C. Delusions or hallucinations are present, 
other than those listed as typical 
schizophrenic in F20 G1.1b, c and d in the 
ICD-10 (i.e. delusions other than those that 
are completely impossible or culturally 
inappropriate and hallucinations, that are 
not in the third person or giving a running 
commentary). The commonest examples are 
those with grandiose, self-referential, erotic 
or persecutory content. 
(1) increased activity or physical 
restlessness;  
(1) Increased activity or physical restlessness;  
(2) increased talkativeness;  (2) Increased talkativeness ('pressure of speech');  
(3) difficulty in concentration or 
distractibility;  
(3) Flight of ideas or the subjective experience of 
thoughts racing;  
(4) decreased need for sleep;  (4) Loss of normal social inhibitions resulting in 
behaviour which is inappropriate to the 
circumstances;  
(5) increased sexual energy;  (5) Decreased need for sleep;   
(6) mild spending sprees, or other types of 
reckless or irresponsible behaviour;  
(6) Inflated self-esteem or grandiosity;   
(7) Distractibility or constant changes in activity 
or plans;  
 
(7) increased sociability or over-familiarity.  (8) Behaviour which is foolhardy or reckless and 
whose risks the subject does not recognize e.g. 
spending sprees, foolish enterprises, reckless 
driving;  
 
  
 (9) Marked sexual energy or sexual indiscretions.   
Table 42. ICD-10 criteria for categorising a manic episode [7]. 
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F32 .0 Mild Depressive 
episodes 
F32.1 Moderate Depressive 
episodes 
F32.2 Severe Depressive 
episodes without 
psychotic symtpoms 
F32.3 Severe depressive episode with 
psychotic symptoms 
A. The depressive episode 
should last for at least 2 weeks, 
and meet the criteria set out in 
F32 for general depressive 
episode 
A. The general criteria for 
depressive episode (F32) must 
be met.  
The general criteria for 
depressive episode (F32) 
must be met.  
A. The general criteria for depressive 
episode (F32) must be met.  
B. At least two of the following 
three symptoms must be 
present:  
B. At least two of the three 
symptoms listed for F32.0, 
criterion B, must be present.  
B. All three of the symptoms 
in criterion B, F32.0, must be 
present.  
B. The criteria for severe depressive 
episode without psychotic symptoms 
(F32.2) must be met with the  
1)A depressed mood to a 
degree that is definitely 
abnormal for the individual, 
present for most of the day and 
almost every day, largely 
uninfluenced by circumstances, 
and sustained for at least 2 
weeks. 
C. Additional symptoms from 
F32.0, criterion C, must be 
present, to give a total of at least 
six.  
C. Additional symptoms 
from F32.0, criterion C, must 
be present, to give a total of 
at least eight.  
exception of criterion D.  
(2) loss of interest or pleasure 
in activities that are normally 
pleasurable;  
 D. There must be no 
hallucinations, delusions, or 
depressive stupor 
C. The criteria for schizophrenia (F20.-) 
or schizoaffective disorder, depressive 
type (F25.1) are not met.  
(3) decreased energy or 
increased fatigability.  
   
Table 43. ICD-10 criteria for categorising a depressive episode [7]. 
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F32 .0 Mild Depressive 
episodes 
F32.1 Moderate Depressive 
episodes 
F32.2 Severe Depressive 
episodes without 
psychotic symtpoms 
F32.3 Severe depressive episode with 
psychotic symptoms 
C. An additional symptom or 
symptoms from the following list 
should be present, to give a total 
of at least four:  
  D. Either of the following must be 
present:  
(1) loss of confidence and self-
esteem;  
  (1) delusions or hallucinations, other 
than those listed as typically 
schizophrenic in F20, criterion G1(1)b, c, 
and d (i.e. delusions other than those 
that completely impossible or culturally 
inappropriate and hallucinations that are 
not in the third person or giving a 
running commentary); the commonest 
examples are those with depressive, 
guilty, hypochondriacal, nihilistic, self-
referential, or persecutory content;  
(2) unreasonable feelings of self-
reproach or excessive and 
inappropriate guilt;  
  
(3) recurrent thoughts of death 
or suicide, or any suicidal 
behaviour;  
  
(4) complaints or evidence of 
diminished ability to think or 
concentrate, such as 
indecisiveness or vacillation;  
  
(5) change in psychomotor 
activity, with agitation or 
retardation (either subjective or 
objective);  
  (2) depressive stupor.  
(6) sleep disturbance of any type;    
Table 44. ICD-10 criteria for categorising a depressive episode [1]. 
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F31.0 Bipolar affective 
disorder, current episode 
hypomanic 
F31.1 Bipolar affective disorder, 
current episode manic without 
psychotic symptoms 
F31.2 Bipolar affective 
disorder, current episode 
manic with psychotic 
symptoms 
F31.3 Bipolar affective disorder, 
current episode moderate or mild 
depression 
A. The current episode 
meets the criteria for 
hypomania (F30.0).  
A. The current episode meets the 
criteria for mania without psychotic 
symptoms (F30.1).  
A. The current episode meets 
the criteria for mania with 
psychotic symptoms (F30.2).  
A. The current episode meets the 
criteria for a depressive episode of 
either mild (F32.0) or moderate 
severity (F32.1).  
B. There has been at least 
one other affective episode 
in the past, meeting the 
criteria for hypomanic or 
manic episode (F30.-), 
depressive episode (F32.-) 
or mixed affective episode 
(F38.00). 
B. There has been at least one other 
affective episode in the past, 
meeting the criteria for hypomanic 
or manic episode (F30.-), depressive 
episode (F32.-) or mixed affective 
episode (F38.00). 
B. There has been at least one 
other affective episode in the 
past, meeting the criteria for 
hypomanic or manic episode 
(F30.-), depressive episode 
(F32.-) or mixed affective 
episode (F38.00).  
B. There has been at least one other 
affective episode in the past, meeting 
the criteria for hypomanic or manic 
episode (F30.-), or mixed affective 
episode (F38.00).  
   A fifth character may be used 
to specify whether the 
psychotic symptoms are 
congruent or incongruent with 
the mood: F31.20 with mood 
congruent psychotic symptoms. 
F31.21 with mood incongruent 
psychotic symptoms 
 
Table 45. ICD-10 classifications of Bipolar Disorder. 
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31.4 Bipolar affective 
disorder, current episode 
severe depression 
without psychotic 
symptoms 
F31.5 Bipolar affective disorder, 
current episode severe 
depression with psychotic 
symptoms 
F31.6 Bipolar affective 
disorder, current episode 
mixed 
F31.7 Bipolar affective disorder, 
currently in remission 
A. The current episode 
meets the criteria for a 
severe depressive episode 
without psychotic 
symptoms (F32.2).  
A. The current episode meets the 
criteria for a severe depressive 
episode with psychotic symptoms 
(F32.3).  
A. The current episode is 
characterized by either a 
mixture or a rapid alternation 
(i.e. within a few hours) of 
hypomanic, manic and 
depressive symptoms.  
A. The current state does not meet the 
criteria for depressive or manic 
episode in any severity, or for any 
other mood disorder in F3 (possibly 
because of treatment to reduce the 
risk of future episodes).  
B. There has been at least 
one well authenticated 
hypomanic or manic 
episode (F30.-) or mixed 
affective episode (F38.00) 
in the past. 
B. There has been at least one well 
authenticated hypomanic or manic 
episode (F30.-) or mixed affective 
episode (F38.00) in the past.  
B. Both manic and depressive 
symptoms must be prominent 
most of the time during a 
period of at least two weeks.  
B. There has been at least one well 
authenticated hypomanic or manic 
episode  
  A fifth character may be used to 
specify whether the psychotic 
symptoms are congruent or 
incongruent with the mood: F31.50 
with mood congruent psychotic 
symptoms. F31.51 with mood 
incongruent psychotic symptoms 
C. There has been at least one 
well authenticated hypomanic 
or manic episode (F30.-), 
depressive (F32.-) or mixed 
affective episode (F38.00) in 
the past.  
(F30.-) in the past and in addition at 
least one other affective episode 
(hypomanic or manic (F30.-), 
depressive (F32.-), or mixed 
(F38.00)).  
Table 46. ICD-10 classifications of Bipolar Disorder. 
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F38.00 Mixed affective episode  
A. The episode is characterized by either a 
mixture or a rapid alternation (i.e. within a few 
hours) of hypomanic, manic and depressive 
symptoms.  
B. Both manic and depressive symptoms must 
be prominent most of the time during a period 
of at least two weeks. 
 C. No previous hypomanic, depressive or 
mixed episodes.  
Table 47. ICD-10 classification of mixed affective episode 
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Appendix II 
Buffers and Reagents for Materials and Methods Section 
II.I DNA EXTRACTION FROM BLOOD SAMPLES 
10X RBC Lysis Buffer: 100mM NaCl, 100mM EDTA. For 1 litre: 80.2g 
NH4Cl; 8.40g NaHCO3 3.7g EDTA. Make up to 1 litre. Store the RBC at 4°C 
for 6 months. 
 
Cell Lysis Solution: 10 mM Tris-HCl pH 8.0, 25 mM EDA, 0.5% SDS. For 1 
litre, 10 ml 1M Tris-HCL, 50 ml 0.5M EDTA, 25ml 4M 20% SDS and made up 
to one litre using deionised water. 
 
Proteinase K enzyme (20 mg/ml) (Sigma-Aldrich, UK) 
 
Proteinase K buffer: 50mM Tris.HCl (pH8.0), 50mM EDTA, 100mM NaCl. 
For one litre, 25ml 2M Tris, 100ml 0.5M EDTA, and 25ml 4M NaCl and made 
up to one litre using deionised water. 
 
Protein Precipitation solution: 5M Ammonium Acetate (pH5.2). For one 
litre, dissolve 385.4 g of ammonium acetate in one litre of deionised water. 
70% ethanol (Sigma-Aldrich, UK) 
 
Low EDTA TE: 10 mM Tris, 0.1 mM EDTA. For one litre add 20ml 0.5M Tris-
HCL, (pH8.0) and 200μl 0.5M EDTA (pH8.0) to 979.80ml of deionised water. 
II.II AGROSE GELS 
1% Agrose Gel: 0.9g of Agrose dissolved in 90ml of 1x TBE Buffer (Sigma-
Aldrich, UK) 
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Ethidium Bromide (Sigma-Aldrich, UK) 
 
Gel Buffer: 500ml of 1x TBE Buffer. 
 
Gel Combs 
II.III CELL CULTURE 
Complete growth medium: Dulbecco’s modified Eagle’s medium 
(DMEM, Sigma-Aldrich, UK) supplemented with 10% FBS (Sigma-Aldrich, 
UK) and 1% Penicllin – Streptomycin (Sigma-Aldrich, UK). 
 
Trypsin-EDTA solution (Sigma-Aldrich, UK) 
 
1 X Phosphate buffered saline (PBS) (Sigma-Aldrich, UK) 
 
Freezing medium: 1ml of DMEM supplemented with 20% FBS, 10% DMSO 
and 1% PenStrep 
II.IV TRANSIENT TRANSFECTION 
Lipofectamine 2000 (Invitrogen Life technologies, UK) 
 
Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich, UK) 
supplemented with 10% FBS (Sigma-Aldrich, UK) and 1% Penicllin–
Streptomycin (Sigma-Aldrich, UK). 
 
Opti-MEM® I Reduced Serum Medium (Thermo Fisher Scientific, UK) 
II.V PURIFICATION OF PCR PRODUCTS 
MicroCLEAN: 0.5 M NaCl, 1 mM Tris HCl pH 8.0, 0.1 mM EDTA, 20 % w/v 
PEG8000, 1.75 mM MgCl2. All the contents were added to 50 ml of PCR 
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water and the solution was heated gently for the contents to dissolve. The 
solution was filter sterilized using a 0.45 μM filter. 
II.VI MINI AND MIDI PREP 
Library Efficiency® DH5α™ Competent Cells (Life Technologies, UK) 
 
LB Broth: For one litre add 10g NaCL, 10g Trypton and 5g Yeast to 800ml 
of deionised water. Once all of the reagents have dissolved add deionised 
water up to 1 litre. Autoclave and store at 4°C. 
 
LB Agar: For one litre add 10g NaCL, 10g Trypton and 5g Yeast to 800ml of 
deionised water. Once all of the reagents have dissolved add deionised 
water up to 1 litre. Add 20g Agarose and autoclave. 
 
SOC Broth (Life Technologies, UK) 
 
Kanamycin (50μg/ml): Add 0.5g of sodium ampicillin in sufficient H2O to 
make a final volume of 10ml to make a stock solution of 100mg/ml. Sterilise 
using a 0.22μm filter and aliquot out. Aliquots should be stored at -20°C. 
Dilute this 1:100 when adding to LB Broth or Agar for a final concentration 
of 50μg/ml 
 
Ampicillin (100μg/ml): Add 1g of sodium ampicillin in sufficient H2O to 
make a final volume of 10ml to make a stock solution of 100mg/ml. Sterilise 
using a 0.22μm filter and aliquot out. Aliquots should be stored at -20°C. 
Dilute this 1:100 when adding to LB Broth or Agar for a final concentration 
of 100μg/ml 
II.VII EMSA 
Cytoplasmic Lysis buffer: 10mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) pH 7.6, 1 mM EDTA (ethylene 
diamine tetraacetic acid), 0.1 mM EGTA (ethylene glycol tetraacetic acid), 
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10 nM KCl, 1 mM dithiothreitol (DTT), 1 mM vanadate, 1 tablet of 'complete' 
protease inhibitor (Roche Diagnostics Ltd, UK). 
 
Nuclear Lysis buffer: 20mM HEPES pH 7.6, 0.2mM EDTA, 0.1mM EGTA, 
25% glycerol, 0.42M NaCl, 1mM DTT, 1mM vanadate and 1/2 tablet 
‘complete’ protease inhibitor. 
 
Nonidet P-40 (NP-40, Sigma-Aldrich, UK) 
 
1 X Phosphate buffered saline (PBS) (Sigma-Aldrich, UK) 
The cytoplasmic and the nuclear lysis buffers were filter sterilized using 0.2 
μm membrane filter and stored at 4°C. 
 
4% Polyacrylamide Gel: 5ml of 40% Acrylamide/Bis-acrylamide solution 
(Sigma-Aldrich, UK), 2.5ml 10X TBE, 80μl TEMED 
(Tetramethylethylenediamine), 300μl of 10 % APS (w/v) and 42.12ml of 
deionised water. 
 
Binding buffer: 2μl of 10x Parker Buffer (40mM HEPES (pH7.6), 100mM of 
KCL, 2mM EDTA, 1mM DTT, (pH 7.5) and deionised H20), 2μl 2.5mM DTT, 
1μl 50ng/μl of Poly(dI.dC) (Sigma-Aldrich, UK), 1μl of 5mM MgCl2, 1μl of 
0.05% NP-40. To this 1μl of each probe of interest was added and up to 2μg 
of nuclear proteins. 
 
Running Buffer: 0.5x TBE Buffer, 50ml of 10xTBE Buffer, 950ml of 
deionised water. 
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Appendix III 
Primers used for HRM analysis and genotyping of variants in CACNA1C, CACNA1D, 
CACNB3, and CACNG4 in Chapter 5 
Primer Primer Seq Amplicon Size  
CACNA1C Prom F1 gctccctttgacgtcatgc 313bp CACNA1C Prom R1 ctctggcaggagctgtttct 
CACNA1C 5'UTR F1 cctctgcagaaacagctcct 329bp CACNA1C 5'UTR R1 aaccccaaaaactgctcctt 
CACNA1C 5'UTR F2 ggtgctcagttcttggaagg 249bp CACNA1C 5'UTR R2 cattgaccatggaccaaaaa 
CACNA1C Exon1 F gggggtgttttcacatttctt 129bp CACNA1C Exon1 R aggaacccggtggaaaag 
  
 
Table 48. Primers used for HRM analysis of CACNA1C 
 
Primer Primer Seq Amplicon Size  
CACNA1D Prom F1 gatgtgagctccggctgcc 
129bp 
CACNA1D Prom R1 ctgcaaaggagaactggcttg 
CACNA1D Prom F2 cggatgtgagctccggctg 
391bp 
CACNA1D Prom R2 gtccctgcccttattctcgc 
CACNA1D Exon1 F ctgttatttgtccccgtccc 
247bp CACNA1D Exon1 R ctggaggaccatgacaggat 
  
 
Table 49. Primers used for HRM analysis of CACNA1D 
 
Primer Primer Seq Amplicon Size  
CACNB3 Prom F1 aatccttggcagggaagtg 359bp CACNB3 Prom R1 gaccgtgggagacagaagag 
CACNB3 Prom F2 agctgccgtcctgtcattag 396bp CACNB3 Prom R2 gatccaggcagggaggag 
CACNB3 5'UTR F1 gcggagtagttcctgggttg 238bp CACNB3 5'UTR R1 gccggctcctacaacaatag 
CACNB3 5'UTR F2 gcgggcactattgttgtagg 
257bp CACNB3 5'UTR R2 cgagagagcgcgaaggag 
CACNB3 Exon1 F ctcccccatgtatgacgac 66bp CACNB3 Exon1 R ggtgtcaccccaacttccc 
CACNAB3 M13 F cacgacgttgtaaaacgacgcggagtagttcctgggttg 339bp CACNAB3 M13 R ggataacaatttcacacaggggtgtcaccccaacttccc 
  
 
Table 50. Primers used for HRM analysis of CACNB3 
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Primer Primer Seq Amplicon Size  
CACNG4 5'UTR F1 agctcagaggagcgcacag 
202bp CACNG4 5'UTR R1 agcgctggggctcaaactc 
CACNG4 5'UTR F2 cctcggagtttgagccccag 
222bp CACNG4 5'UTR R2 tgagcgagaaggcggcgaag 
CACNG4 Exon1 F caccatggtgcgatgcgac 
260bp CACNG4 Exon1 R gcgcgcgcgtgtgtatatg 
CACNG4 Exon2 F acggatgagtgaacccagac 
148bp CACNG4 Exon2 R ccacagaaagagagtccagg 
CACNG4 Exon3 F ctcactgccctctgctttgtg 
209bp CACNG4 Exon3 R accacacgagacaggcactc 
CACNG4 Exon4 F1 tccacctgttccctacactg 
204bp CACNG4 Exon4 R1 gccacaatgaaagacagagc 
CACNG4 Exon4 F2 caggtgacccgagtgacaag 221bp CACNG4 Exon4 R2 gtggaccttgagctggacct 
CACNG4 Exon4 F3 cgtcttcctcttctccttatg 207bp CACNG4 Exon4 R3 aagtcatgcacctgcaggaag 
CACNG4 Exon4 F4 gaagatcacaggggccatc 237bp CACNG4 Exon4 R4 cttgaggatcacatgccatc 
CACNG4 3'UTR F1 
 
ctttctctccgctccagcctc 354bp 
CACNG4 3'UTR R1 ggcaagattcgtttccaaga 
CACNG4 3'UTR F2 gctgaaggctgactttgtc 262bp CACNG4 3'UTR R2 ctgacaagagcccagagacc 
CACNG4 3'UTR F3 cgaatcttgccagaaaaacg 272bp CACNG4 3'UTR R3 acagcgcaaaggccaaag 
CACNG4 3'UTR F4 catctctccctctctccaag 319bp CACNG4 3'UTR R4 tgctccttgggtctatgaca 
CACNG4 3'UTR F5 cttcagagtctggagggttc 285bp CACNG4 3'UTR R5 gcgttgatttgcaggaagtt 
CACNG4 3'UTR F6 ggagacctaagggtgaacag 388bp CACNG4 3'UTR R6 ttcttcttccaagcctgcac 
CACNG4 3'UTR F7 tccagccattcttttcttcc 271bp CACNG4 3'UTR R7 gacatcatcactaggccgaac 
CACNG4 3'UTR F8 ctcagctacctgctcacag 230bp CACNG4 3'UTR R8 gctgggcacacttggacatg 
CACNG4 3'UTR F9 catcagggttggcatcatct 272bp CACNG4 3'UTR R9 gtgttccaatgaatcctacc 
CACNG4 3'UTR F10 cccgctgccccagaagtttc 265bp CACNG4 3'UTR R10 gggagagaaggtgggcacag 
CACNG4 3'UTR F11 cccgctgcatctcagacctg 222bp CACNG4 3'UTR R11 ccctaactgcccacaaagac 
 
  
Table 51. Primers used for HRM analysis of CACNG4 
  
287 
 
Variant Primer 
CACNA1C Prom F1 GAAGGTGACCAAGTTCATGCTCGGCGCGGCGCGGCGG 
CACNA1C Prom F2 GAAGGTCGGAGTCAACGGATTCGGCGCGGCGCGGCGA 
CACNA1C Prom R CTGGGCGCGGAGGCAGGAA 
Table 52.Primers for Genotyping CACNA1C promoter SNP1 
Variant Primer 
CACNG4 rs371128228 
F1 
GAAGGTGACCAAGTTCATGCTCGAGCGCCGTCGCCG 
CACNG4  rs371128228 
F2 
GAAGGTGACCAAGTTCATGCTCGAGCGCCGTCGCCA 
CACNG4 rs371128228 R CTTCCTCTTCTCCTTATGCCSGGAT 
CACNG4 17:65026851 
(C/T) F1 
GAAGGTGACCAAGTTCATGCTAGGTGACCCGAGTGACAAGCA 
CACNG4  17:65026851 
(C/T) F2 
GAAGGTGACCAAGTTCATGCTAGGTGACCCGAGTGACAAGCT 
CACNG4 17:65026851 
(C/T) R 
CAAAGTAAAAAGACCAGCCGTAGTTGTA 
Table 53. Primers for Genotyping variants from the fourth exon of CACNG4 
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Appendix IV 
Primers used for genotyping variants in Chapter 6 
Primer Primer Sequence 
CACNA1C_rs146482058_F1 GAAGGTGACCAAGTTCATGCTAAGAGTTCTCTGTCACCTTAAGAAAAAAA 
CACNA1C_rs146482058_F2 GAAGGTCGGAGTCAACGGATTAAGAGTTCTCTGTCACCTTAAGAAAAAAT 
CACNA1C_rs146482058_R GTGTCTGCCAGTGCTTACACTATAATTTA 
CACNA1C_rs79398153_F2 GAAGGTGACCAAGTTCATGCTTGGTTTTCTCAGCCAGGGCAC 
CACNA1C_rs79398153_F2 GAAGGTCGGAGTCAACGGATTGGTTTTCTCAGCCAGGGCAT 
CACNA1C_rs79398153_R GAACCGAGTGAGGTGCCTGGAA 
CACNA1C_rs191953785_F1 GAAGGTGACCAAGTTCATGCTGTTGTTGTTCTCTTGCCCGATG 
CACNA1C_rs191953785_F2 GAAGGTCGGAGTCAACGGATTCTGTTGTTGTTCTCTTGCCCGATA 
CACNA1C_rs191953785_R GTCAAAGTCTCTTAATGTCACTGAAGCTT 
CACNA1C_rs112312080_F1 GAAGGTGACCAAGTTCATGCTGTCAATGAAAATTTAAACCCGGGTGG 
CACNA1C_rs112312080_F2 GAAGGTCGGAGTCAACGGATTAGTCAATGAAAATTTAAACCCGGGTGA 
CACNA1C_rs112312080_R CATTGAGAACCCTTCAGCACATGCAT 
CACNA1C_rs113414207 _F1 GAAGGTGACCAAGTTCATGCTGGACAGACCCCCCCCCG 
CACNA1C_rs113414207 _F2 GAAGGTCGGAGTCAACGGATTGGACAGACCCCCCCCCC 
CACNA1C_rs113414207 _R CTTCATTTGTGTGGGACCGTGACAT 
CACNA1C_12: 2329069 
(G/T)_F1 GAAGGTGACCAAGTTCATGCTGAAAGCCTCCCTCCTGGGC 
CACNA1C_12: 2329069 
(G/T)_F2 GAAGGTCGGAGTCAACGGATTGGAAAGCCTCCCTCCTGGGA 
CACNA1C_12: 2329069 
(G/T)_R AGTCTGGAGGCCTGGTGACCTA 
CACNA1C_12: 2423175 
(G/C)_F1 GAAGGTGACCAAGTTCATGCTGGAAAGGCCGTGTGCCC 
CACNA1C_12: 2423175 
(G/C)_F2 GAAGGTCGGAGTCAACGGATTCTGGAAAGGCCGTGTGCCG 
CACNA1C_12: 2423175 
(G/C)_R CCAGGGAGGCTCAGGAAAATATCAA 
Table 54. Primers for Genotyping CACNA1C intronic variants identified in WGS 
data 
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Primer Primer Sequence 
CACNA2D4_A741V_F1 GAAGGTGACCAAGTTCATGCTCATGGAAGCCTACTGGACAGC 
CACNA2D4_A741V_F2 GAAGGTCGGAGTCAACGGATTCCATGGAAGCCTACTGGACAGT 
CACNA2D4_A741V_R AACCTGGACCTACTCGGACATGTT 
CACNA1D_R931H_F1 GAAGGTGACCAAGTTCATGCTGTTCCGGAAGGAGTGGCTGC 
CACNA1D_R931H_F2 GAAGGTCGGAGTCAACGGATTGTTCCGGAAGGAGTGGCTGT 
CACNA1D_R931H_R GCCGCAGAGGACCCCATCC 
CACNA1D_D1837N_F1 GAAGGTGACCAAGTTCATGCTGGAGCTGTTCATCTCCTGAGTC 
CACNA1D_D1837N_F2 GAAGGTCGGAGTCAACGGATTGGGAGCTGTTCATCTCCTGAGTT 
CACNA1D_D1837N_R TCCTCTCTCCCAACTGCAGGTC 
CACNA1D_R2145W_F1 GAAGGTGACCAAGTTCATGCTGTAGCTCATAGTCCTGCCG 
CACNA1D_R2145W_F2 GAAGGTCGGAGTCAACGGATTCCTGTAGCTCATAGTCCTGCCA 
CACNA1D_R2145W_R GGGATGTGGGCCCCCTCTC 
Table 55. Primers for Genotyping CACNA2D4 and CACNA1D intronic variants 
identified in WGS data 
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